<?xml version="1.0" encoding="UTF-8" standalone="yes"?><Rowset rowCount='3204'><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2686">bromerguride</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of bromerguride in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="55739"/><TrialStartDate>1986-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacogenomic study of schizophrenia</ProtocolTitle><Sponsor>Ministry of Science and Technology of the People´s Republic of China, The Sixth Hospital of Peking University (Institute of Mental Health)</Sponsor><StudyType>Interventional</StudyType><Trial id="98482"/><TrialStartDate>2009-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Soonchunhyang University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="70175"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study evaluating the striatal and extrastriatal D2/3-receptor binding of ziprasidone using 18F-Fallypride PET scanning, in both schizophrenia patients and healthy volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53568"/><TrialStartDate>2008-06-16 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study evaluating the time course of 5-HT2 receptor occupancy (%RO) in healthy male volunteers after ziprasidone administration</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53500"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of iloperidone in schizophrenic patients</ProtocolTitle><Sponsor>Vanda Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42355"/><TrialStartDate>2005-12-12 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>HDZ</ProtocolAcronym><ProtocolTitle>High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Symptoms</ProtocolTitle><Sponsor>Massachusetts General Hospital, Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36301"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>12-Week, Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35031"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>MOZART</ProtocolAcronym><ProtocolTitle>A Study Comparing the Efficacy and Tolerability of Ziprasidone versus Clozapine for the Treatment of Schizophrenia in Patients Who Continue to Have Symptoms on or Cannot Tolerate Other Antipsychotic Drugs</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34991"/><TrialStartDate>2003-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Mozart Relapse Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34869"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)</ProtocolTitle><Sponsor>Sheba Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="33142"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Study to Assess the Effect of Iloperidone on QTc Interval Duration</ProtocolTitle><Sponsor>Novartis AG, Titan Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="148133"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Single-Blind, Parallel-Group Study To Evaluate The Effects of High-Dose Ziprasidone and Haloperidol on the QTC Interval after Intramuscular Administration in Patients with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc, Astellas Pharma US Inc, AstraZeneca Pharmaceuticals LP, BioTie Therapies Corp, Bristol-Myers Squibb Co, EPIX Pharmaceuticals Inc, Eisai Inc, Janssen Pharmaceuticals Inc, Merck &amp; Co Inc, Novartis Pharmaceuticals Corp, Otsuka America Pharmaceutical Inc, Pfizer Inc, Sanofi SA, Sention Inc, Takeda Pharmaceuticals North America Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="145156"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb/IV, multicenter, open-label extension study to evaluate the efficacy, safety and tolerability of oral ziprasidone in the treatment of schizophrenia or schizoaffective disorder patients who have successfully completed a previous ziprasidone study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="113446"/><TrialStartDate>1998-12-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Investigation of Sleep Architecture in Ziprasidone-Treated Bipolar Depression</ProtocolTitle><Sponsor>Queen's University at Kingston</Sponsor><StudyType>Interventional</StudyType><Trial id="45727"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Risperdal Consta for Bipolar Disorder</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="35003"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety Study of Ziprasidone (Geodon) for the Depressive Mixed State</ProtocolTitle><Sponsor>Tufts University</Sponsor><StudyType>Interventional</StudyType><Trial id="33942"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in the Treatment of Acute Mania: A 12-Week, Placebo-Controlled, Haloperidol-Referenced Study</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="145095"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, placebo-controlled, double-blind, double-dummy study to determine the safety and efficacy of oral ziprasidone compared to haloperidol in in-patients with an acute manic episode</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86706"/><TrialStartDate>2002-09-13 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A study of the efficacy and safety of intramuscular ziprasidone followed by oral ziprasidone for the treatment of psychosis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21413"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A One-Year Trial of Oral Ziprasidone in Bipolar I Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66020"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34468"/><TrialStartDate>2005-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33854"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 24-Week, Double-Blind, Placebo-Controlled Study to Determine if Patients with Bipolar I Disorder Achieve and Sustain Remission</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="154049"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, uncontrolled, open-label, efficacy study of gepirone in moderately depressed patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45060"/><TrialStartDate>1992-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, placebo-controlled, efficacy study of gepirone in patients with generalized anxiety disorder</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45085"/><TrialStartDate>1988-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel group, four perimenstrual period (PMP) to evaluate naratriptan as prophylactic treatment for menstrually-associated migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78584"/><TrialStartDate>1998-04-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled, four-period crossover, multi-attack, outpatient study to evaluate the safety and efficacy of oral naratriptan in the acute treatment of four migraine attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78527"/><TrialStartDate>1995-07-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, parallel group, ascending dose, randomized, placebo-controlled study to determine the blood pressure response to naratriptan in hypertensive subjects receiving anti-hypertensive therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78523"/><TrialStartDate>1994-07-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, cross-over, multi-attack, outpatient study to evaluate subject satisfaction with naratriptan compared with sumatriptan in subjects who had lapsed from their previous oral or subcutaneous sumatriptan because of lack of efficacy or tolerability</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77984"/><TrialStartDate>1997-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, double-dummy, randomized, placebo-controlled, four-way crossover study to assess the safety, tolerability and effect of naratriptan on psychomotor function</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77525"/><TrialStartDate>1994-09-27 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, two-period, crossover study followed by a double-blind, randomized, placebo-controlled, single-period, parallel study to evaluate the pharmacokinetics and pharmacodynamics of oral naratriptan in migraine subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77256"/><TrialStartDate>1996-01-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging, single attack, outpatient study to evaluate the efficacy, safety and tolerability of naratriptan in an adolescent migraine population</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77209"/><TrialStartDate>1995-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, four-way crossover study to evaluate the interaction of naratriptan and ergotamine in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77203"/><TrialStartDate>1995-10-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, single-dose, parallel group study to evaluate the pharmacokinetics of naratriptan in subjects with impaired hepatic function</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77201"/><TrialStartDate>1995-10-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Preference Trial with Naratriptan 2.5 mg and Paracetamol 1000 mg in Migraine Patients in the General Practice</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="133254"/><TrialStartDate>2005-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Crossover, Double-blind, Multicenter, Placebo-controlled, Randomized Study To Evaluate The Effect Of Naratriptan On Myocardial Blood Flow And Coronary Vasodilator Reserve In Migraineurs</ProtocolTitle><Sponsor>Imperial College School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="109370"/><TrialStartDate>2000-07-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A  multicenter study for evaluation of migraineurs' preferences for naratriptan over conventional first-line agents</ProtocolTitle><Sponsor>Headache Care Center</Sponsor><StudyType>Interventional</StudyType><Trial id="106787"/><TrialStartDate>2000-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety</ProtocolTitle><Sponsor>Chongqing Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="353222"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Prokinetics for functional dyspepsia</ProtocolTitle><Sponsor>Kawasaki Medical School</Sponsor><StudyType>Interventional</StudyType><Trial id="271387"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study to evaluate the efficacy of mosapride in the treatment of non-ulcer dyspepsia patients</ProtocolTitle><Sponsor>Dainippon Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19483"/><TrialStartDate>1992-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Mosapride on gastric accommodation</ProtocolTitle><Sponsor>National Center Of Neurology &amp; Psychiatry</Sponsor><StudyType>Interventional</StudyType><Trial id="190329"/><TrialStartDate>2011-11-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>18-Month Study of the Efficacy of Xaliproden (SR-57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="1358"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Sumatriptan 4 mg Statdose in the Acute Treatment of Cluster Headache</ProtocolTitle><Sponsor>Diamond Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="56654"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Compare PK and Bioavailability of Two NP-101 Patches With Oral Imitrex in Healthy Adults</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="178045"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Sumatriptan nasal spray in cluster headache</ProtocolTitle><Sponsor>Skåne University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="105756"/><TrialStartDate>1998-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, single-attack, parallel-group, outpatient study to  evaluate the efficacy and safety of sumatriptan (100 mg) tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="88123"/><TrialStartDate>2002-05-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, single-attack, parallel-group, two-phase study to evaluate efficacy and safety of sumatriptan 100 mg tablets versus placebo in the treatment of subjects who affirm tension, tension-type or stress headaches and who meet international headache society (IHS) criteria for migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="88119"/><TrialStartDate>2003-04-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, multicenter, open-label, out-patient, validation study to evaluate the safety and association between disability (as measured by the headache impact test, HIT-6) and IHS migraine classification (as determined by expert panel diary review) and to observe any changes in HIT-6 score following treatment with oral sumatriptan 50 mg</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="88102"/><TrialStartDate>2000-02-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, open-label, single-attack, parallel-group, outpatient study to compare the safety and efficacy of intake of sumatriptan 100 mg tablets at the first signs of migraine pain versus intake at moderate to severe headache during an acute migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87898"/><TrialStartDate>2002-06-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Ranging Study of a Drug for the Treatment of Acute Migraine</ProtocolTitle><Sponsor>BioHaven Pharmaceutical Holding Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="80591"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="54474"/><TrialStartDate>2009-06-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Study to Compare NP-101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53833"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Sumatriptan and Placebo on CGRP Induced Headache</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="341395"/><TrialStartDate>2018-02-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, single-center, randomized, three-way crossover study to evaluate the pharmacokinetics of sumatriptan in patients with migraine</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="302739"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Single, Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="290533"/><TrialStartDate>2017-03-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy of Subcutaneous GR-43175C (6 mg and Optional 6 mg) in the Acute Treatment of Menstrual Migraine – With Optional Open Follow-Up Treatment: Phase I</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="216819"/><TrialStartDate>1992-04-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Cupping and Serkangabin Versus Conventional Migraine Treatment</ProtocolTitle><Sponsor>Birjand University</Sponsor><StudyType>Interventional</StudyType><Trial id="192354"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="17975"/><TrialStartDate>2007-11-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Effect of GR-43175C on Blood Pressure in Hypertensive Migraine Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="160495"/><TrialStartDate>1989-03-13 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Effectiveness and the Tolerability of Paracetamol 1000 mg + Caffeine 130 mg in the Treatment of the Migraine. Phase IV, Randomized, Double-blind, Double-dummy, versus Sumatriptan 50 mg and Placebo</ProtocolTitle><Sponsor>Not Assigned</Sponsor><StudyType>Interventional</StudyType><Trial id="130402"/><TrialStartDate>2010-07-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Double-Dummy, Multicenter, Cross-Over, Controlled Trial Comparing Tolerability And Efficacy Of A Combination Of Paracetamol + Caffeine And Sumatriptan In The Treatment Of Migraine Attack</ProtocolTitle><Sponsor>Universita di Bari</Sponsor><StudyType>Interventional</StudyType><Trial id="102910"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Study to determine bioequivalence between two drugs for oral administration of zolmitriptan dispersible tablets 2.5 mg in healthy female volunteers under fasting conditions</ProtocolTitle><Sponsor>Productos Cientificos</Sponsor><StudyType>Interventional</StudyType><Trial id="215165"/><TrialStartDate>2015-02-12 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Determine Central 5-HT1B Receptor Occupancy of Zomig Rapimelt (Zolmitriptan) in Healthy Male Volunteers</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="64890"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label Trial to Evaluate the Effect of Zolmitriptan for the Treatment of Migraine in Adolescents</ProtocolTitle><Sponsor>Dallas Pediatric Neurology Associates</Sponsor><StudyType>Interventional</StudyType><Trial id="109753"/><TrialStartDate>2000-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="9">Aggression</Indication><ProtocolAcronym>Duphar</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo and baseline-controlled, multi-center,  parallel-group study of eltoprazine in demented elderly patients with disruptive behaviour</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="248440"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="73377"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Oral Eltoprazine for Treatment of Levodopa-Induced Dyskinesias (LID) in a Levodopa Challenge-Dose Setting in Parkinsons Disease</ProtocolTitle><Sponsor>PsychoGenics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="142028"/><TrialStartDate>2010-10-06 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term Exposure to Rizatriptan 5 and 10 mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029)</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="74324"/><TrialStartDate>1995-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long-Term Treatment of Acute Migraine in Children and Adolescents</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="61499"/><TrialStartDate>2009-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache</ProtocolTitle><Sponsor>Beth Israel Deaconess Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="23205"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to Test a Marketed Drug in the Treatment of Menstrual Migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13935"/><TrialStartDate>2005-05-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MATRIX(Migrainer Assess TRiptane eXamination)</ProtocolTitle><Sponsor>University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><Trial id="132785"/><TrialStartDate>2010-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled study to evaluate tolerability and efficacy of rizatriptan for the acute treatment of migraine in adolescents</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="112682"/><TrialStartDate>2002-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD</ProtocolTitle><Sponsor>Federal University of Rio Grande do Sul</Sponsor><StudyType>Interventional</StudyType><Trial id="32555"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="31824"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Non-control, Post-marketing, Genetic Association Study on Individual Difference of Therapeutic Effects of Antipsychotic Medication</ProtocolTitle><Sponsor>Ministry of Science and Technology of the People´s Republic of China, Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="98943"/><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Non-controlled, Post-marketing, Genetic Association Study on Individual Difference of Therapeutic Effects of Antipsychotic Medication</ProtocolTitle><Sponsor>Ministry of Health of the People's Republic of China, Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="98772"/><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacogenomic study of schizophrenia</ProtocolTitle><Sponsor>Ministry of Science and Technology of the People´s Republic of China, The Sixth Hospital of Peking University (Institute of Mental Health)</Sponsor><StudyType>Interventional</StudyType><Trial id="98482"/><TrialStartDate>2009-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in Non-Satisfied Patients With Previous Antipsychotic Drug</ProtocolTitle><Sponsor>Janssen Korea Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="87212"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three fixed doses of aripiprazole in the treatment of patients with acute schizophrenia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="82201"/><TrialStartDate>2000-01-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals</ProtocolTitle><Sponsor>General Hospital of Tianjin Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="365165"/><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><Trial id="36281"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment of Schizophrenia or Schizoaffective Disorder in Hospitalized Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35469"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Switch Study of BMS-337039 in Schizophrenic Out-Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35203"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Study of Aripiprazole and Olanzapine in the Treatment of Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34896"/><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="34854"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Evaluate the Short-term Safety and Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="303053"/><TrialStartDate>2017-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of the beginning of therapeutic response between different typical and atypical antipsychotics in acute psychosis</ProtocolTitle><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="302069"/><TrialStartDate>2016-10-16 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole effect in the treatment of residual symptoms in patients with schizophrenia</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="294183"/><TrialStartDate>2017-01-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week, randomized, open-label, comparative clinical trial</ProtocolTitle><Sponsor>XinXiang Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="255165"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="21671"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of effectiveness of Risperdal Consta compared to Abilify over a two-year period in patients with schizophrenia</ProtocolTitle><Sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="21111"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Oral Acceptability Trial</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19215"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>EULAST</ProtocolAcronym><ProtocolTitle>European Long-Acting Antipsychotics in Schizophrenia Trial</ProtocolTitle><Sponsor>The European Group for Research in Schizophrenia (EGRIS), Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><Trial id="191158"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PECANS</ProtocolAcronym><ProtocolTitle>Pan European Collaboration on Antipsychotic Naive Schizophrenia</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="186323"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Once-monthly in Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="157312"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APD</ProtocolAcronym><ProtocolTitle>Antipsychotic Effects On Brain Function In Schizophrenia</ProtocolTitle><Sponsor>University of California San Francisco</Sponsor><StudyType>Interventional</StudyType><Trial id="148717"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Pilot Study of Aripiprazole Augmentation in the Management of Residual Symptoms in Clozapine-Treated Outpatients With Chronic Schizophrenia</ProtocolTitle><Sponsor>University of Athens</Sponsor><StudyType>Interventional</StudyType><Trial id="146982"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Exploratory Open-Label Trial of Aripiprazole as an Adjuvant to Clozapine Therapy in Chronic Schizophrenia</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="146458"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lower Doses of Aripiprazole for the Treatment of Patients With Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>University of Florida</Sponsor><StudyType>Interventional</StudyType><Trial id="146339"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, 26-week, Parallel-Group Study to Evaluate the Effectiveness Of Switching To Aripiprazole From Atypical Antipsychotics In Patients With Schizophrenia</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="146290"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 26-Week Study of a Fixed Dose of Aripiprazole (15 mg) in the Treatment of Stabilized Patients with Chronic Schizophrenia</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="143844"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Schizophrenia with Aripiprazole. A One Year, Open-Label Study</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="139955"/><TrialStartDate>2005-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effects of Adjunctive Treatment With Aripiprazole on Body Weight, Metabolic Parameters, Clinical Efficacy, and Adverse Events in People With Psychotic Disorders on Treatment With Clozapine</ProtocolTitle><Sponsor>Christian Medical College, Vellore, India</Sponsor><StudyType>Interventional</StudyType><Trial id="131804"/><TrialStartDate>2013-02-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study to Compare the Efficacy of Ziprasidone (Zeldox) and Aripiprazole (Abilify) on Cognitive Functioning and Quality of Sleep in the Treatment of Schizophrenic Patients</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="129806"/><TrialStartDate>2007-12-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Observation of Aripiprazole in the Treatment of Autism</ProtocolTitle><Sponsor>Huazhong University of Science and Technology</Sponsor><StudyType>Interventional</StudyType><Trial id="163443"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Versus Risperidone for Treatment of Autism</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="122954"/><TrialStartDate>2011-08-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Methamphetamine Dependence: Double-Blind, Placebo Trial</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="23065"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 3-week, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of aripiprazole in patients with bipolar disorder experiencing an acute manic episode</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52061"/><TrialStartDate>2003-05-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Risperdal Consta for Bipolar Disorder</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="35003"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Trial of Aripiprazole in Children and Adolescents With Bipolar Disorder</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="34718"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Aripiprazole on Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="34597"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Associated With Methylphenidate in Children and Adolescents With Bipolar Disorder and ADHD</ProtocolTitle><Sponsor>Federal University of Rio Grande do Sul</Sponsor><StudyType>Interventional</StudyType><Trial id="32555"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>ALD</ProtocolAcronym><ProtocolTitle>Effect of Aripiperazole in Treatment of Psychotic Mania</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="221268"/><TrialStartDate>2014-04-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="30970"/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Patients With Acute Bipolar Mania</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19401"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="98380"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Subjects With Tourette's Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="353039"/><TrialStartDate>2018-09-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder</ProtocolTitle><Sponsor>New York University School of Medicine, US</Sponsor><StudyType>Interventional</StudyType><Trial id="20591"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="19006"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole (Abilify) as an Adjunctive Treatment for Inadequate Response in Major Depressive Disorder</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="93091"/><TrialStartDate>2012-02-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>VAST-D</ProtocolAcronym><ProtocolTitle>VA Augmentation and Switching Treatments for Improving Depression Outcomes</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="80741"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>ACES 257</ProtocolAcronym><ProtocolTitle>To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66414"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>ACES 263</ProtocolAcronym><ProtocolTitle>A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Covance Inc, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65947"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Prospective, Open-Label, Multicenter Study to Compare Aripiprazole Augmentation to Bupropion Combination Therapy in Older Patients with Major Depressive Disorder</ProtocolTitle><Sponsor>Youngnam University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="248370"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19213"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Dose-finding Study for SPM-962 in Advanced Parkinson's Disease Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88749"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the safety, tolerability and efficacy of rotigotine in patients with early Parkinson’s disease</ProtocolTitle><Sponsor>UCB Pharma GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="8758"/><TrialStartDate>1999-11-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled, dose-escalation, pharmacokinetic, safety and efficacy study of rotigotine patches in patients with early-stage Parkinson's disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8634"/><TrialStartDate>2004-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, single-arm, exploratory, 18-week, efficacy study of rotigotine in patients with advanced-stage Parkinson’s disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8627"/><TrialStartDate>2007-10-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>RECOVER</ProtocolAcronym><ProtocolTitle>Randomized Evaluation of the 24-h Coverage: Efficacy of Rotigotine</ProtocolTitle><Sponsor>Schwarz Pharma SpA, UCB BIOSCIENCES GmbH, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6996"/><TrialStartDate>2007-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>CLEOPATRA-PD</ProtocolAcronym><ProtocolTitle>Rotigotine Patch in Subjects With Advanced Stage, Idiopathic Parkinson’s Disease Who Are Not Well Controlled on Levodopa</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6652"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>BRIGHT</ProtocolAcronym><ProtocolTitle>Trial to Evaluate The Efficacy Of Rotigotine on Parkinson's Disease-Associated Motor Symptoms And Apathy</ProtocolTitle><Sponsor>UCB BIOSCIENCES GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="107751"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Study of SPM-962 in Patients With Restless Legs Syndrome (RLS)</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64749"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate Effect of Multi-Doses Flibans 100 mg Film-c Tablets on Single Dose PK of Digoxin 0.5 mg, Healthy Volunteers</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="66941"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym>HSDD</ProtocolAcronym><ProtocolTitle>Hypoactive Sexual Desire Disorder in Males</ProtocolTitle><Sponsor>Baylor College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="386577"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>RI-AME</ProtocolAcronym><ProtocolTitle>RI-AME Study OF (Isothiazolyl-3-14C)-Lurasidone</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64683"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>To study the difference in effect of various drug in patient suffering from Schizophrenia, a kind of mental disorder in which signs and symptoms are variable and include changes in perception, emotion, cognition, thinking, and behavior</ProtocolTitle><Sponsor>King George Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="328823"/><TrialStartDate>2016-11-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>To study effect of lurasidone in patients of schizophrenia in comparison with oplanzapine</ProtocolTitle><Sponsor>Government Medical College, Nagpur</Sponsor><StudyType>Interventional</StudyType><Trial id="326372"/><TrialStartDate>2016-12-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone HCl - A Long-Term Safety, Phase III Study of Patients With Clinically Stable Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="21178"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="200069"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pediatric Open-Label, Extension Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="148804"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, multicenter, placebo-controlled, randomized, double-blind, parallel-group study to determine the safety and efficacy of fixed-dose lurasidone for the treatment of schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="113438"/><TrialStartDate>2001-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone: A 24-Week Extension Study of Patients With Bipolar I Depression</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="49930"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>ELICE_BD</ProtocolAcronym><ProtocolTitle>Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients</ProtocolTitle><Sponsor>Japan National Institute Of Mental Health, National Center Of Neurology &amp; Psychiatry, University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="257654"/><TrialStartDate>2017-05-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone and Cognition in Bipolar I Disorder</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="191109"/><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="161759"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="62867"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>FRESH</ProtocolAcronym><ProtocolTitle>A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>SK Chemicals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="40985"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, double-blind, randomized, safety, efficacy, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine</ProtocolTitle><Sponsor>University of Palermo</Sponsor><StudyType>Interventional</StudyType><Trial id="187601"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, double-blind, placebo-controlled study of vilazodone's efficacy, safety, and biomarkers of response in major depressive disorder (MDD)</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="15425"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="9978">osemozotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa, safety and efficacy study of MN-305 (osemozotan) in patients with primary insomnia and sleep maintenance difficulties</ProtocolTitle><Sponsor>MediciNova Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7418"/><TrialStartDate>2007-01-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19752"/><TrialStartDate>2000-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym>ZENSAA</ProtocolAcronym><ProtocolTitle>A randomized, double-blinded, parallel-group, multi-center trial of tegaserod in female patients with irritable bowel syndrome and constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19640"/><TrialStartDate>2002-12-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, phase III trial of tegaserod in patients with constipation predominant irritable bowel syndrome (C-IBS)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19602"/><TrialStartDate>1999-10-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A trial of tegaserod in patients with irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19567"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, placebo-controlled study of tegaserod in patients with constipation-predominant irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19865"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A multinational, randomized, double-blind, placebo-controlled study of tegaserod in patients with chronic constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19585"/><TrialStartDate>2003-10-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Tegaserod Versus Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18705"/><TrialStartDate>2006-01-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Tegaserod on Orocecal Transit in Elderly Chronic Constipation Patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18699"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Tegaserod in Opioid-Induced Constipation in Patients With Non-Cancer Pain</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18690"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Tegaserod in Opioid-Induced Constipation in Patients With Non-Cancer Pain.</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18683"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Tegaserod in Opioid-Induced Constipation in Patients With Non-Cancer Pain</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18670"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, crossover design study of tegaserod in gastroesophageal reflux disease patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19779"/><TrialStartDate>2005-05-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, crossover study of tegaserod in patients with gastroesophageal reflux disease (GERD)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19817"/><TrialStartDate>1999-05-16 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Three Dosage Strengths of Almotriptan Malate (Axert) in the Treatment of Acute Migraine in Adolescents</ProtocolTitle><Sponsor>Janssen-Ortho Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13950"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, parallel-group trial to compare the single-dose and steady-state pharmacokinetics and safety of prucalopride in healthy young and elderly volunteers</ProtocolTitle><Sponsor>Janssen Pharmaceutica NV</Sponsor><StudyType>Interventional</StudyType><Trial id="66548"/><TrialStartDate>2010-05-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Long-term Prucalopride Treatment With Chronic Constipation in Subjects Aged &gt;/= 18 Years</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="80361"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride in Pediatric Subjects With Functional Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="76126"/><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Prucalopride in Combination With Polyethylene Glycol or Lactulose in Women With Chronic Constipation</ProtocolTitle><Sponsor>Xian-Janssen Pharmaceutical Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="209269"/><TrialStartDate>2014-10-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18410"/><TrialStartDate>1995-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Movicol (PEG 3350 + Electrolytes) or Prucalopride in the Treatment of Chronic Constipation: A Head-to-Head Comparison in a Controlled Environment</ProtocolTitle><Sponsor>Univ Witten / Herdecke</Sponsor><StudyType>Interventional</StudyType><Trial id="145125"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A crossover, double-blind, placebo-controlled, randomized trial to evaluate the efficacy of prucalopride on colonic transit, anorectal function and bowel habits in patients with chronic constipation</ProtocolTitle><Sponsor>Vrije Universiteit van Amsterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="112553"/><TrialStartDate>2002-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3119">Rett syndrome</Indication><ProtocolAcronym>STARS</ProtocolAcronym><ProtocolTitle>Evaluation of the Efficacy, Safety and Tolerability of Sarizotan in Rett Syndrome With Respiratory Symptoms</ProtocolTitle><Sponsor>Newron Pharmaceuticals SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="262664"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A short-term, phase III study to evaluate the efficacy and safety of bifeprunox versus placebo in the treatment of patients with acute exacerbations of schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S, Solvay Pharmaceuticals Inc, Wyeth Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="41537"/><TrialStartDate>2006-12-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Finding Study to Evaluate the Efficacy and Safety of Bifeprunox in Patients With an Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Oregon Health Sciences University</Sponsor><StudyType>Interventional</StudyType><Trial id="144243"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Bifeprunox in Bipolar Depression</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="33817"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Twice-Daily Titration Study of Bifeprunox in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34635"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>SLV-308 for Treatment of Patients With Early Parkinson's Disease</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6655"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-Dopa in the Treatment of Patients With Parkinsons Disease Experiencing Motor Fluctuations and Dyskinesia</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><StudyType>Interventional</StudyType><Trial id="55429"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, crossover study to assess the reduction of haloperidol-induced side effects by ACP-103</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7650"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6094"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Expanded Access of Pimavanserin for Patients With PD Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="260319"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled study to evaluate the ability of ACP-103 to reduce motor disturbances associated with haloperidol treatment in patients with schizophrenia</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="43965"/><TrialStartDate>2005-03-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Migraine Treatment Satisfaction With Treximet Versus Concomitant Two Aleve and Imitrex</ProtocolTitle><Sponsor>Wesley Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="81562"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treximet in the Treatment of Chronic Migraine</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="65054"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TEAM</ProtocolAcronym><ProtocolTitle>Treximet Early Intervention Adolescent Migraine</ProtocolTitle><Sponsor>Premiere Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="62076"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Trexima Versus Butalbital-Containing Combination Medications for the Acute Treatment of Migraine in Adults</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14072"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14052"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="13987"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>A drug-interaction study assessing the effects of CYP3A4 inhibition on the pharmacokinetics of Levadex (MAP-0004, orally inhaled DHE) in healthy subjects</ProtocolTitle><Sponsor>MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="78532"/><TrialStartDate>2011-06-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics And Tolerability Study of MAP-0004 Co-administered With Ketoconazole</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82218"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64984"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Bioavailability of DHE Administered by I-123 POD Device, IV Injection and Migranal Nasal Spray in Healthy Adults</ProtocolTitle><Sponsor>Clinical Network Services, Impel NeuroPharma</Sponsor><StudyType>Interventional</StudyType><Trial id="326056"/><TrialStartDate>2017-10-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study To Evaluate PRX-00023 In Patients With Generalized Anxiety Disorder (GAD)</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="32570"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of single and multiple doses of PRX-00023 in healthy subjects</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="57387"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>California Medical Clinic for Headache</Sponsor><StudyType>Interventional</StudyType><Trial id="74173"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLE</ProtocolTitle><Sponsor>IMPAX Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="312080"/><TrialStartDate>2017-12-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin for Preventing Weight Gain Among Smokers</ProtocolTitle><Sponsor>Mayo Clinic, Minnesota</Sponsor><StudyType>Interventional</StudyType><Trial id="224774"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="169745"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic properties of lorcaserin in obese or overweight elderly subjects</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42193"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic properties of lorcaserin in the fed and fasted state</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42126"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Lifestyle Modification and Lorcaserin for Weight Loss Maintenance</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><Trial id="225326"/><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>ViBiD</ProtocolAcronym><ProtocolTitle>Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="347676"/><TrialStartDate>2018-08-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Active-reference (Fluoxetine), Fixed-dose Study of Vortioxetine in Pediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="255832"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers</ProtocolTitle><Sponsor>University of Miami</Sponsor><StudyType>Interventional</StudyType><Trial id="249225"/><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="214821"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Vortioxetine Versus Escitalopram on Cognitive Function in Patients With Inadequate Response to Current Antidepressant Treatment of Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="214017"/><TrialStartDate>2014-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, multiple-ascending dose, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability and pharmacokinetics of naronapride in healthy volunteers</ProtocolTitle><Sponsor>ARYx Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77600"/><TrialStartDate>2011-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Safety and Tolerability of Vabicaserin in Patients With Sudden Worsening of Schizophrenia</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="35191"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese Male Subjects</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34607"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia</ProtocolTitle><Sponsor>Mitsubishi Tanabe Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="49109"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Cariprazine Capsules 6 mg in Schizophrenia or Bipolar disorder I patients who are receiving Cariprazine capsules 6 mg as stable dose</ProtocolTitle><Sponsor>AXIS Clinicals Limited, Aurobindo Pharma Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="378471"/><TrialStartDate>2019-05-13 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34531"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I, Open-label, Multiple-dose, Three-cohort Study to Determine the Occupancy of Cariprazine, an Anti-psychotic for Treating Schizophrenia, at the D2 and D3 Receptors Using [11C]-(+)-PHNO PET</ProtocolTitle><Sponsor>Columbia University</Sponsor><StudyType>Interventional</StudyType><Trial id="180307"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63803"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and efficacy study of APD-125 in patients with insomnia</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6851"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3064">Lewy body dementia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="255835"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan (LY-573144) in Children Aged 6 to 17 With Migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="384701"/><TrialStartDate>2019-06-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="284159"/><TrialStartDate>2017-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>GLADIATOR</ProtocolAcronym><ProtocolTitle>An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine</ProtocolTitle><Sponsor>CoLucid Pharmaceuticals Inc, Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="241950"/><TrialStartDate>2015-10-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>SAMURAI</ProtocolAcronym><ProtocolTitle>Lasmiditan Compared to Placebo in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="185649"/><TrialStartDate>2015-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55455">zonisamide + bupropion (obesity), Orexigen</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A single-center, randomized, double-blind, single-dose, phase I, safety and pharmacokinetics study comparing zonisamide SR with zonisamide IR for the potential treatment of obesity</ProtocolTitle><Sponsor>Orexigen Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="40175"/><TrialStartDate>2007-06-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57748">NXN-188 (oral), NeurAxon</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura</ProtocolTitle><Sponsor>NeurAxon Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="59645"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57748">NXN-188 (oral), NeurAxon</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of NXN-188 to Treatment Moderate to Severe Migraine With Aura</ProtocolTitle><Sponsor>NeurAxon Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="57852"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia</ProtocolTitle><Sponsor>Chung-Ang University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="196108"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="59234">RQ-00000010</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>RQ-00000010 for Gastroparesis and Constipation in Parkinsons Disease</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><Trial id="266107"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase Ib, placebo-controlled, multiple ascending dose (MAD) study to detremine the safety and efficacy of RP-5063 for the potential treatment of schizophrenia</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="84609"/><TrialStartDate>2011-09-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>REFRESH</ProtocolAcronym><ProtocolTitle>RP-5063 in Subjects With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc, Sristek Clinical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="83188"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="61221">AAT-009</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study of AAT-009 in patients with Alzheimer's disease</ProtocolTitle><Sponsor>RaQualia Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="277517"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="307430"/><TrialStartDate>2017-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC-34712) in Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="226592"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="164008"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study of brexpiprazole for the treatment of patients with posttraumatic stress disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="323090"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>STEP-D222</ProtocolAcronym><ProtocolTitle>Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63621"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="154643"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A study to compare the safety and efficacy of intranasal (IN) spray formulation of metoclopramide with oral tablet formulation of metoclopramide in patients with symptomatic diabetic gastroparesis</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="138073"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="63557">relenopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Double-blind, Randomized, Placebo-controlled, 12-Week, Dose-Range-Finding Trial of YKP-10811 Capsules Administered Once-Daily to Subjects With Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>SK Biopharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="161702"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64192">rizatriptan (VersaFilm oral quick release, migraine), IntelGenx</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, two-period, two-way crossover study in healthy male and female subjects to compare safety, pharmacokinetics and bioequivalence of rizatriptan with Maxalt-MLT</ProtocolTitle><Sponsor>IntelGenx Technologies Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="87945"/><TrialStartDate>2012-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study to Determine the Pharmacokinetics, Safety And Tolerability of Aripiprazole in Adults With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="298109"/><TrialStartDate>2017-06-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>EULAST</ProtocolAcronym><ProtocolTitle>European Long-Acting Antipsychotics in Schizophrenia Trial</ProtocolTitle><Sponsor>The European Group for Research in Schizophrenia (EGRIS), Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><Trial id="191158"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of ALKS-9072 in Subjects With Chronic Stable Schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="83320"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An interventional, randomized, blinded, phase I study on the safety, efficacy and pharmacokinetics of aripiprazole lauroxil nanocrystal dispersion in patients with schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="348436"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ALPINE</ProtocolAcronym><ProtocolTitle>A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="319953"/><TrialStartDate>2017-11-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>RESTAND</ProtocolAcronym><ProtocolTitle>PF-04995274 and Emotional Processing in Un-medicated Depression</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="338539"/><TrialStartDate>2018-05-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="67578">mosapride citrate (dyspepsia, sustained release), Daewoong</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of DWJ-1252 in the Treatment of Functional Dyspepsia (PART 2)</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="301316"/><TrialStartDate>2017-04-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="67578">mosapride citrate (dyspepsia, sustained release), Daewoong</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of DWJ-1252 in the Treatment of Functional Dyspepsia</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="285479"/><TrialStartDate>2016-12-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="69453">DA-6886</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="3862">Constipation predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Clinical Trial of DA-6886 in Healthy Male Subjects</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88900"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III trial to evaluate SEP-363856 for the treatment of patients with schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="371035"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the pharmacokinetics, safety and tolerability of SEP-363856, a novel oral drug with non-D2 mechanism of action, in healthy adult male subjects and in adult patients with schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="360949"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adults With Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="280004"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="154393"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="84360">testosterone + buspirone hydrochloride (oral, hypoactive sexual desire disorder), Emotional Brain</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym>@HOME</ProtocolAcronym><ProtocolTitle>A Study to Investigate the Subjective and Physiological Efficacy and Safety of Lybrido and Lybridos in the Domestic Setting in Healthy Female Subjects with Female Sexual Dysfunction and SSRI Usage</ProtocolTitle><Sponsor>Emotional Brain BV</Sponsor><StudyType>Interventional</StudyType><Trial id="270937"/><TrialStartDate>2010-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87714">dihydroergotamine (nasal, migraine), Satsuma Pharmaceuticals</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, pharmacokinetic study of STS-101 for the  treatment of acute migraine</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="371168"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="87714">dihydroergotamine (nasal, migraine), Satsuma Pharmaceuticals</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>EMERGE</ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS-101 in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="375771"/><TrialStartDate>2019-06-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90513">YL-0919</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Hydroxyzine piperazine povidone clinical trial of single-dose, phase I</ProtocolTitle><Sponsor>Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA, Zhejiang Huahai Pharmaceutical Group Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="271014"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="94639">zolmitriptan (inhalation powder, migraine), Acorda</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Pharmacokinetics (PK) Study of Single-Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults</ProtocolTitle><Sponsor>Acorda Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="246594"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="96279">sumatriptan (autoinjector, migraine), Promius Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="242710"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Mosapride on Glycemic Control and Incretin Secretion</ProtocolTitle><Sponsor>Yokohama City University</Sponsor><StudyType>Interventional</StudyType><Trial id="123156"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Patients With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33832"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Aripiprazole on Smoking Rate in Male Bipolar Mood Disorder I</ProtocolTitle><Sponsor>Tabriz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="308820"/><TrialStartDate>2017-01-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole in Patients with Bipolar I Disorder with a Major Depressive Episode</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="20242"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="145852"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical study to determine bioequivalence between two medications cinitapride oral administration of 1 mg tablets in healthy volunteers under fasting conditions</ProtocolTitle><Sponsor>Laboratorios Grisi</Sponsor><StudyType>Interventional</StudyType><Trial id="220299"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Cooperative Group for Clinical Research in G-POEM (POP), Jiangsu, China</ProtocolTitle><Sponsor>The Affiliated Zhongda Hospital of Southeast University</Sponsor><StudyType>Interventional</StudyType><Trial id="287483"/><TrialStartDate>2017-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym>AripipPTSD</ProtocolAcronym><ProtocolTitle>Aripiprazole in the Treatment of Post-Traumatic Stress Disorder Symptoms</ProtocolTitle><Sponsor>Universidade Federal de Sao Paulo - UNIFESP</Sponsor><StudyType>Interventional</StudyType><Trial id="21213"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety and Efficacy of Onzetra Xsail (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="319217"/><TrialStartDate>2017-11-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3063">Delirium</Indication><ProtocolAcronym/><ProtocolTitle>Effect of aripiprazole on prevention of delerium</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="300105"/><TrialStartDate>2017-01-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32273"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="15">Amnesia</Indication><ProtocolAcronym/><ProtocolTitle>Vilazodone for Corticosteroid-Induced Memory Impairment</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="120509"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp, Merck Sharp &amp; Dohme Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="13924"/><TrialStartDate>2007-02-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3063">Delirium</Indication><ProtocolAcronym>MIND-USA</ProtocolAcronym><ProtocolTitle>The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA Study</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="70993"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>PIMPARK</ProtocolAcronym><ProtocolTitle>Randomized, Placebo-Controlled Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5HT2A Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease</ProtocolTitle><Sponsor>Hopitaux Universitaires de Strasbourg</Sponsor><StudyType>Interventional</StudyType><Trial id="380442"/><TrialStartDate>2019-09-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An open, expanded study to assess the safety and tolerability of pimavanserin in the treatment of psychosis in Parkinson's disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="324885"/><TrialStartDate>2017-10-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="376">Gastric motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19752"/><TrialStartDate>2000-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, uncontrolled, 8 week, preliminary study to evaluate a combination of aripiprazole and topiramate in the treatment of opioid-dependent patients with schizoaffective disorder</ProtocolTitle><Sponsor>Universita' Degli Studi Di Messina</Sponsor><StudyType>Interventional</StudyType><Trial id="204521"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Acute Prucalopride Administration in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="372348"/><TrialStartDate>2017-02-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Phase I, Randomized, Double-Blind, Placebo-controlled, Crossover Study to Determine Whether Alcohol Has Any Effect on the Pharmacokinetics or Pharmacodynamics of GR-43175C Administered Orally</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153748"/><TrialStartDate>1989-08-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Double-blind, Randomised, Placebo-controlled, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Two Oral Doses of GR-43175C Separated by 2 h</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153747"/><TrialStartDate>1989-01-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Placebo-controlled, Crossover Study to Determine Whether Propranolol Has Any Effect on the Pharmacokinetics or Pharmacodynamics of Oral G-43175C in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153598"/><TrialStartDate>1989-02-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An Open-label Study to find the Efficacy of Sumatriptan in nitroglycerin-induced headache</ProtocolTitle><Sponsor>Millard Fillmore Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="107267"/><TrialStartDate>1999-01-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>An interventional study on impact of obesity, and implication of patient safety and sustained impairement of lurasidone clearance after discontinuation of posaconazole</ProtocolTitle><Sponsor>Tufts University</Sponsor><StudyType>Interventional</StudyType><Trial id="354884"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Eltoprazine on Cognitive Impairment Associated With Schizophrenia (CIAS) in Adults</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="73377"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vilazodone for the Treatment of Post-traumatic Stress Disorder</ProtocolTitle><Sponsor>Southern California Institute for Research and Education</Sponsor><StudyType>Interventional</StudyType><Trial id="96335"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym>APS</ProtocolAcronym><ProtocolTitle>Aripiprazole and Prolactin Study</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="64777"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia</ProtocolTitle><Sponsor>Tabriz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="308282"/><TrialStartDate>2012-11-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Supplementation in Risperidone Induced Hyperprolactinemia: a Randomized, Double-blind, Placebo-controlled Trial</ProtocolTitle><Sponsor>Indian Council of Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="129768"/><TrialStartDate>2011-03-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="445">Hypoglycemia</Indication><ProtocolAcronym/><ProtocolTitle>A Dose-Ranging Study of ATI-7505 in Patients With Postprandial Distress Syndrome</ProtocolTitle><Sponsor>The Procter &amp; Gamble Co</Sponsor><StudyType>Interventional</StudyType><Trial id="33519"/><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A three-way crossover, placebo-controlled, double-blind study to evaluate the pharmacodynamic effects of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19838"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in Bipolar Disorder With Co-morbid Lifetime Panic or Generalized Anxiety Disorder (GAD)</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="68728"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="32536"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Gene-by-Stress Interactions in Intervention Studies Significance</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="284338"/><TrialStartDate>2018-05-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="9">Aggression</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><Trial id="118457"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3283">Cannabis dependence</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Lorcaserin on Cannabis Withdrawal and Self-administration</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="309555"/><TrialStartDate>2017-09-05 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Geodon</ProtocolAcronym><ProtocolTitle>A 12-Week, Placebo-Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="34988"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone augmentation of SSRIs for patients with major depressive disorder (MDD) that do not sufficiently respond to treatment with SSRIs</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="20252"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Predictors of Response to Augmentation With Ziprasidone (Geodon) in Major Depressive Disorder</ProtocolTitle><Sponsor>Tufts Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="175892"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Extension Study of Lu-AA21004 in Participants With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="79285"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Vortioxetine (Lu-AA21004) for Treatment of Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="77438"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>Depression-Anx Trial</ProtocolAcronym><ProtocolTitle>An Antidepressant Medications from Treatment Initiation for Depressive Disorder with Anxiety Symptoms: A Prospective Comparative Study</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="282448"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3064">Lewy body dementia</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2940">Tic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole versus risperidone in the treatment of children and adolescents with tic disorders</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="306393"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2940">Tic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, 14-week, open-label naturalistic study to assess the efficacy of aripiprazole in short-term treatment of children and adolescents with tic disorder (TD)</ProtocolTitle><Sponsor>Mackay Memorial Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="190086"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1950">Conduct disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders</ProtocolTitle><Sponsor>Albert-Ludwigs-Universität Freiburg</Sponsor><StudyType>Interventional</StudyType><Trial id="31334"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate pharmacokinetics, safety and tolerability of Cariprazine in adolescent subjects with schizophrenia compared to adults</ProtocolTitle><Sponsor>Gedeon Richter Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="292530"/><TrialStartDate>2017-01-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Single-Blind, Placebo-Controlled, Non-Randomized, Cross-over, Single-Attack, Inpatient, Two-Part Study to Rechallenge With sc GR-43175C, Patients Who Had Previously Experienced an Adverse Event Involving Discomfort or Pain in the Chest Following GR-43175C Administration</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="202024"/><TrialStartDate>1990-12-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label Study Of Sumatriptan In Treating Migraine With Unilateral Cranial Autonomic Symptoms</ProtocolTitle><Sponsor>Universita degli Studi di Roma La Sapienza</Sponsor><StudyType>Interventional</StudyType><Trial id="113929"/><TrialStartDate>2003-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Effect of Mosapride on Gut Transit in Patients With Chronic Constipation or Constipated Irritable Bowel Syndrome and Healthy Subjects</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="228477"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym>ID_MotiReb_1302</ProtocolAcronym><ProtocolTitle>Prospective study in comparing the safety and the pharmacokinetics of Mosapride and Rebamipide having the effects on gastrointestinal diseases when administered as single drug or a complex in healthy korean male adults</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="192145"/><TrialStartDate>2014-04-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot study of comparative bioavailability between two drugs for oral administration of Lorcaserin Hydrochloride in prolonged-release tablets with 20 mg in healthy subjects under fasting conditions</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="337938"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A crossover, double-blind, placebo-controlled, randomized trial to evaluate the efficacy of the specific 5HT4 receptor agonist, prucalopride, on colonic motility in healthy volunteers</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><Trial id="112565"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of aripiprazole in comparision with haloperidol in patients with schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="48364"/><TrialStartDate>2003-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills</ProtocolTitle><Sponsor>University of Texas Health Science Center San Antonio</Sponsor><StudyType>Interventional</StudyType><Trial id="35461"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>ALFA</ProtocolAcronym><ProtocolTitle>A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34503"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PAFIP3_1Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: One-Year Follow-Up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238547"/><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PECANSII</ProtocolAcronym><ProtocolTitle>Pan European Collaboration on Antipsychotic Naive Schizophrenia II</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="220227"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 26-Week, Prospective Study to Evaluate the Long-Term Efficacy and Safety of Aripiprazole in Patients with Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder</ProtocolTitle><Sponsor>Seoul National University College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="144495"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>SPARTAN</ProtocolAcronym><ProtocolTitle>Three Doses of Lasmiditan (50, 100 and 200 mg) Compared to Placebo in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>CoLucid Pharmaceuticals Inc, Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="246340"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and  Depression</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="334705"/><TrialStartDate>2018-03-09 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, multicenter, parallel, longitudinal, open-label, active-controlled pilot study to determine the efficacy and safety of the combination of ziprasidone and sertraline compared to sertraline alone in treatment resistant depression without psychotic features</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86997"/><TrialStartDate>2001-05-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Major Depressive Disorder (MDD) With Ziprasidone</ProtocolTitle><Sponsor>Cedars-Sinai Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="35276"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="33855"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>MOMENTUM</ProtocolAcronym><ProtocolTitle>Maximizing Outcomes in Treating Acute Migraine</ProtocolTitle><Sponsor>Axsome Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="320888"/><TrialStartDate>2019-03-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Effects on Subjects With Chronic Non-Cancer Pain Suffering From Opioid Induced Constipation</ProtocolTitle><Sponsor>Shire plc, Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="66169"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Sumatriptan on the Post-operative Quality of Recovery After Elective Minimally Invasive Craniotomy</ProtocolTitle><Sponsor>The University Health Network</Sponsor><StudyType>Interventional</StudyType><Trial id="88895"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Effectiveness and the Tolerability of Paracetamol 1000 mg + Caffeine 130 mg in the Treatment of the Migraine. Phase IV, Randomized, Double-blind, Double-dummy, versus Sumatriptan 50 mg and Placebo</ProtocolTitle><Sponsor>Not Assigned</Sponsor><StudyType>Interventional</StudyType><Trial id="130402"/><TrialStartDate>2010-07-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Buspirone added to Typical Antipsychotics on Positive and Negative Symptoms in Schizophrenia</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="137579"/><TrialStartDate>2012-04-03 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study to assess pharmacokinetic parameters, tolerability and safety of aripiprazole in healthy volunteers</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52123"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Aripiprazole and Effexor XR Drug Interaction Study</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="43016"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym>TLC</ProtocolAcronym><ProtocolTitle>Treatment With Lorcaserin for Cocaine Use</ProtocolTitle><Sponsor>University of California San Francisco</Sponsor><StudyType>Interventional</StudyType><Trial id="302174"/><TrialStartDate>2018-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="224130"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Effects of Vortioxetine Versus Paroxetine on Polysomnography in Man: A Pharmacokinetic/pharmacodynamic Study</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="175375"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6 to 17 Years Old</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="152903"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, multi-center, single-arm, fixed dose titration, outpatient, phase II trial to evaluate the safety and tolerability of multiple doses of PRX-00023 in patients with moderate to severe generalized anxiety disorder (GAD)</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="57369"/><TrialStartDate>2005-03-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Study the PK and Safety of Single-Doses of STS-101, DHE Injection and Nasal Spray in Healthy Subjects</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373407"/><TrialStartDate>2018-09-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>BP2</ProtocolAcronym><ProtocolTitle>Bergen Psychosis Project 2 - The Best Intro Study</ProtocolTitle><Sponsor>Haukeland University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="81330"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>IMPACT</ProtocolAcronym><ProtocolTitle>Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (IMPACT)</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="38318"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>HAMLETT</ProtocolAcronym><ProtocolTitle>Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuation/dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="376186"/><TrialStartDate>2019-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Treatment of Prodromal Patients</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><Trial id="33981"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Antipsychotic to Treat Psychosis Syndrome</ProtocolTitle><Sponsor>Central South University</Sponsor><StudyType>Interventional</StudyType><Trial id="187160"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Psychosis, with Risperidone as Active-Control</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="145005"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III, Double-blind, Placebo-controlled Study of Aripiprazole in the Treatment of Psychosis</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="143592"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>On the question of Neuroleptic-Induced Metabolic Syndrome. Study 2: Fat Distribution and Specific Hormonal Parameters. Comparison between the metabolic syndrome of vulnerable and non-vulnerable patients from the schizophrenic group</ProtocolTitle><Sponsor>Medical University of Graz</Sponsor><StudyType>Interventional</StudyType><Trial id="132530"/><TrialStartDate>2006-01-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Aripiprazole on Psychiatric Symptoms in Patients With Parkinson Disease</ProtocolTitle><Sponsor>Japanese Ministry of Health, Labor and Welfare</Sponsor><StudyType>Interventional</StudyType><Trial id="126771"/><TrialStartDate>2012-03-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>25</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>NONSTOP</ProtocolAcronym><ProtocolTitle>Clinical Trial to Evaluate the Efficacy of Treatment versus Discontinuation in a First Episode of Non-affective Psychosis</ProtocolTitle><Sponsor>Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla</Sponsor><StudyType>Interventional</StudyType><Trial id="104352"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34459"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1279">Panic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-controlled, Double-blind Trial of Imipramine and Buspirone  in Patients with Panic Disorder</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><Trial id="113716"/><TrialStartDate>2003-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2085">Dysphagia</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone for Functional Dysphagia</ProtocolTitle><Sponsor>Cleveland Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="252576"/><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1936">Acute stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone, Stress, and Attentional Bias to Marijuana Cues</ProtocolTitle><Sponsor>University of Texas Health Science Center Houston</Sponsor><StudyType>Interventional</StudyType><Trial id="185685"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3020">motilide, Kitasato/Shimizu/Takeda</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="97">Diabetes mellitus</Indication><ProtocolAcronym/><ProtocolTitle>A pilot study to evaluate the effect of EM-523L on gastric emptying function and the change in plasma glucose levels after eating in patients with diabetic gastroparesis</ProtocolTitle><Sponsor>Kitasato Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="20108"/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="213">Multiple sclerosis</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Fluoxetine and 5-HT4 Serotonin Receptor Agonists on Cerebral Axonal Energy Metabolism and Glutamate Levels in Multiple Sclerosis</ProtocolTitle><Sponsor>Onderzoeks- En Ontwikkelingsfonds Rode Kruis-Vlaanderen</Sponsor><StudyType>Interventional</StudyType><Trial id="154919"/><TrialStartDate>2010-12-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1951">Delusional disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study of the efficacy and safety of intramuscular ziprasidone followed by oral ziprasidone for the treatment of psychosis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21413"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Controlled Trial To Compare The Effectiveness Of Intramuscular Olanzapine, Ziprasidone, Haloperidol Plus Promethazine, Haloperidol Plus Midazolam And Haloperidol Alone As The First Medication(S) Used To Treat Patients With Agitation Caused By Psychosis</ProtocolTitle><Sponsor>Universidade Federal do Tocantins</Sponsor><StudyType>Interventional</StudyType><Trial id="77462"/><TrialStartDate>2010-01-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>BPP</ProtocolAcronym><ProtocolTitle>Use, Effects and Side-Effects of Second-Generation Antipsychotics in a Naturalistic Setting</ProtocolTitle><Sponsor>University of Bergen</Sponsor><StudyType>Interventional</StudyType><Trial id="58531"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>IMPACT</ProtocolAcronym><ProtocolTitle>Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (IMPACT)</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="38318"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone Versus Standard Therapy for Agitated Patients in the ED</ProtocolTitle><Sponsor>George Washington University</Sponsor><StudyType>Interventional</StudyType><Trial id="34293"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study of the efficacy and safety of intramuscular ziprasidone followed by oral ziprasidone for the treatment of psychosis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21413"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>On the question of Neuroleptic-Induced Metabolic Syndrome. Study 2: Fat Distribution and Specific Hormonal Parameters. Comparison between the metabolic syndrome of vulnerable and non-vulnerable patients from the schizophrenic group</ProtocolTitle><Sponsor>Medical University of Graz</Sponsor><StudyType>Interventional</StudyType><Trial id="132530"/><TrialStartDate>2006-01-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="242">Esophageal disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of mosapride on oesophageal 24-h acid reflux variables in patients with gastro-esophageal reflux disease (GERD) symptoms</ProtocolTitle><Sponsor>Dainippon Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19373"/><TrialStartDate>1998-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84360">testosterone + buspirone hydrochloride (oral, hypoactive sexual desire disorder), Emotional Brain</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lybridos in Pre- and Postmenopausal Women With Hypoactive Sexual Desire Disorder Due to Maladaptive Activation of Sexual Inhibitory Systems</ProtocolTitle><Sponsor>Emotional Brain BV</Sponsor><StudyType>Interventional</StudyType><Trial id="100909"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="80">Coronary artery disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blinded, placebo-controlled study in patients with existing or suspected coronary artery disease was to investigate the effects of subcutaneous GR-43175C on the coronary vasculature</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="201477"/><TrialStartDate>1991-04-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="989">Colorectal tumor</Indication><ProtocolAcronym>XENON</ProtocolAcronym><ProtocolTitle>Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens</ProtocolTitle><Sponsor>Policlinico Universitario Agostino Gemelli, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="26207"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>ANODYNE-2</ProtocolAcronym><ProtocolTitle>Oral ALLOD-2 versus Oral Sumatriptan and versus Placebo in the Acute Treatment of Migraine With Associated Nausea</ProtocolTitle><Sponsor>Allodynic Therapeutics LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="301738"/><TrialStartDate>2017-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Functional MRI (fMRI) in CGRP Induced Migraine</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="173694"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Sumatriptan Suppositories in the Acute Treatment of Three Migraine Attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153847"/><TrialStartDate>1993-10-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Drug Interaction and Subjective Effects of Compounds for Opioid Use Disorder</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><Trial id="297792"/><TrialStartDate>2017-01-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Naratriptan Hydrochloride 2.5 mg Under Fasted Conditions</ProtocolTitle><Sponsor>West-Ward Columbus</Sponsor><StudyType>Interventional</StudyType><Trial id="185377"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3862">Constipation predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)</ProtocolTitle><Sponsor>Alizyme plc</Sponsor><StudyType>Interventional</StudyType><Trial id="18066"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1930">Paranoid schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1951">Delusional disorder</Indication><ProtocolAcronym>BP2</ProtocolAcronym><ProtocolTitle>Bergen Psychosis Project 2 - The Best Intro Study</ProtocolTitle><Sponsor>Haukeland University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="81330"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Cariprazine: Comparison of Slow- and Immediate-release Forms</ProtocolTitle><Sponsor>Gedeon Richter Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="197420"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Cognition and Tandospirone</ProtocolTitle><Sponsor>Toyama University</Sponsor><StudyType>Interventional</StudyType><Trial id="134476"/><TrialStartDate>2011-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label study to evaluate the effect of adjunctive treatment with serotonin-1A agonist tandospirone on memory functions in schizophrenia</ProtocolTitle><Sponsor>Toyama Medical and Pharmaceutical University</Sponsor><StudyType>Interventional</StudyType><Trial id="109279"/><TrialStartDate>2001-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Ziprasidone on Glucose and Plasma Lipids in Diabetes II and Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Manhattan Psychiatric Center</Sponsor><StudyType>Interventional</StudyType><Trial id="4761"/><TrialStartDate>2003-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym>Sirius</ProtocolAcronym><ProtocolTitle>Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="206263"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Effectiveness of Ziprasidone Using the Overlapped Switching Strategy in Patients with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Soonchunhyang University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="70175"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A safety and efficacy study of ziprasidone compared to haloperidol in patients with schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53556"/><TrialStartDate>1999-05-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="34910"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Compare PK and Bioavailability of Two NP-101 Patches With Oral Imitrex in Healthy Adults</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="178045"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Comparative, Crossover Study To Assess Efficacy Of Rizatriptan And Ergotamine In Healthy Volunteers</ProtocolTitle><Sponsor>Bispebjerg Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="111486"/><TrialStartDate>2002-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32883"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym>AAOFDIYWA</ProtocolAcronym><ProtocolTitle>Aripiprazole Added on for DMDD in Youths With ADHD</ProtocolTitle><Sponsor>Tri-Service General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="321219"/><TrialStartDate>2014-11-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym>MDGP</ProtocolAcronym><ProtocolTitle>Effects and Mechanism of Mosapride Citrate on Diabetic Gastroparesis</ProtocolTitle><Sponsor>Qingdao University</Sponsor><StudyType>Interventional</StudyType><Trial id="213680"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="259">Peripheral neuropathy</Indication><ProtocolAcronym/><ProtocolTitle>Comparing Lorcaserin Versus Duloxetine for the Treatment of Chemotherapy-Induced Peripheral Neuropathy</ProtocolTitle><Sponsor>Southeastern Regional Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="367426"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Response to 5HT4 Receptors Agonist (Prucalopride): Gastrocolic Reflex</ProtocolTitle><Sponsor>Hospital Clinico San Carlos</Sponsor><StudyType>Interventional</StudyType><Trial id="154909"/><TrialStartDate>2013-07-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym>PROGASS</ProtocolAcronym><ProtocolTitle>Prucalopride On the Gastreonteric Transit in Systemic Sclerosis</ProtocolTitle><Sponsor>Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico</Sponsor><StudyType>Interventional</StudyType><Trial id="149364"/><TrialStartDate>2013-02-19 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, open-label, non-randomized, 4-week flexible dose study to assess the safety and efficacy of adjunctive aripiprazole in Taiwanese patients with antidepressant-refractory major depressive disorder</ProtocolTitle><Sponsor>Buddhist Tzu Chi General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="85285"/><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the effect of aripiprazole on the steady-state pharmacokinetics of escitalopram or venlafaxine in subjects with depressive or anxiety disorders</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="77979"/><TrialStartDate>2007-05-02 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled, multicenter, 6-week study to evaluate the safety and efficacy of aripiprazole in patients with a primary diagnosis of major depressive disorder (MDD) who had an inadequate response to monotherapy with one or more antidepressant therapies</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52112"/><TrialStartDate>2007-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>ADAPT-A</ProtocolAcronym><ProtocolTitle>A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="35277"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Proposal to Investigate the Efficacy and Tolerability of Aripiprazole as an Add-on Therapy in Patients Not Responding to an Adequate Dose of an Antidepressant Therapy</ProtocolTitle><Sponsor>Manchester Mental Health and Social Care Trust</Sponsor><StudyType>Interventional</StudyType><Trial id="142057"/><TrialStartDate>2007-08-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>SBD-ASIB</ProtocolAcronym><ProtocolTitle>NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325308"/><TrialStartDate>2019-06-10 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="5111">lesopitron</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, bridging study to evaluate the pharmacokinetics, safety and tolerability of fixed doses of lesopitron in patients with generalized anxiety disorder (GAD)</ProtocolTitle><Sponsor>Laboratorios Dr Esteve SA</Sponsor><StudyType>Interventional</StudyType><Trial id="56286"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>RESOLVE2</ProtocolAcronym><ProtocolTitle>Major Depressive Disorder With Mixed Features</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80316"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine versus Sertraline in Mexicans</ProtocolTitle><Sponsor>Universidad Juarez Autonoma de Tabasco</Sponsor><StudyType>Interventional</StudyType><Trial id="383778"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open, randomized clinical trial to compare the effectiveness of low doses of haloperidol and regular doses of second generation antipsychotics in patients with first-episode schizophrenia and schizophreniform disorder</ProtocolTitle><Sponsor>AstraZeneca plc, Eli Lilly &amp; Co, Pfizer Inc, Sanofi-Synthelabo</Sponsor><StudyType>Interventional</StudyType><Trial id="62939"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of the beginning of therapeutic response between different typical and atypical antipsychotics in acute psychosis</ProtocolTitle><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="302069"/><TrialStartDate>2016-10-16 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>PAFIP3_3Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: Three-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="292671"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-controlled, Crossover, Polysomnographic Study to Evaluate the Effects of Lurasidone on Sleep in Healthy Subjects</ProtocolTitle><Sponsor>Duke University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="261848"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="199563"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to &lt; 13 Years Old) With Central Nervous System Disorders</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="313836"/><TrialStartDate>2017-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="626">Heart disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo- and active-controlled study to evaluate the effect of Lu-AA21004 on cardiac repolarization in healthy male volunteers</ProtocolTitle><Sponsor>H Lundbeck A/S, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="81480"/><TrialStartDate>2011-03-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1084">Psychomotor disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, crossover study to assess the reduction of haloperidol-induced side effects by ACP-103</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7650"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym>PADDY-2</ProtocolAcronym><ProtocolTitle>Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia</ProtocolTitle><Sponsor>EMD Serono Inc, Merck KGaA</Sponsor><StudyType>Interventional</StudyType><Trial id="6280"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 12-Week Open-Label Preliminary Study</ProtocolTitle><Sponsor>University of Turin</Sponsor><StudyType>Interventional</StudyType><Trial id="147070"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone Plus Omeprazole for Functional Dyspepsia</ProtocolTitle><Sponsor>Isfahan University of medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="330190"/><TrialStartDate>2016-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Aripiprazole on Smoking Rate in Schizophrenic Patients</ProtocolTitle><Sponsor>Clinical Psychiatry Research Center</Sponsor><StudyType>Interventional</StudyType><Trial id="137906"/><TrialStartDate>2013-04-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone HCl - A Long-Term Safety, Phase III Study of Patients With Clinically Stable Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="21178"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, active-controlled study of ziprasidone, compared to haloperidol in patients with acute exacerbation of schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53563"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, double-blind, active-controlled, safety and efficacy study of ziprasidone, compared to olanzapine in hospitalized patients with schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53560"/><TrialStartDate>2001-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ZEUS</ProtocolAcronym><ProtocolTitle>A 12-month, phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy study of ziprasidone in treating patients with schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53543"/><TrialStartDate>1997-09-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>8</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CATIE</ProtocolAcronym><ProtocolTitle>Schizophrenia Trial</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="36183"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>BIZET</ProtocolAcronym><ProtocolTitle>IM and Oral in Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36028"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36027"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="34910"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness</ProtocolTitle><Sponsor>Medical College of Wisconsin</Sponsor><StudyType>Interventional</StudyType><Trial id="32858"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Ziprasidone in Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21171"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Glulipid</ProtocolAcronym><ProtocolTitle>Glucose and Lipid Metabolism on Antipsychotic Medication</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="188758"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, placebo-controlled dose-escalation study to determine the central dopamine D2 receptor occupancy by ziprasidone in healthy male volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53506"/><TrialStartDate>1993-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study evaluating the time course of 5-HT2 receptor occupancy (%RO) in healthy male volunteers after ziprasidone administration</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53500"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Predictors of Response to Augmentation With Ziprasidone (Geodon) in Major Depressive Disorder</ProtocolTitle><Sponsor>Tufts Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="175892"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="174271"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Long-Term Safety and Efficacy of Ziprasidone in Subpopulations of Patients with Bipolar Mania</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="144707"/><TrialStartDate>1998-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 3-Week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33923"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33811"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="32695"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, ascending dose, double-blind, placebo-controlled, repeat dose, crossover study to evaluate safety, tolerability and pharmacokinetics of repeat dosing with oral GR-85548A for 5 days</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77531"/><TrialStartDate>1995-02-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, double-dummy, placebo-controlled, cross-over, comparator, outpatient study to compare the pharmacological effects of naratriptan, codeine and placebo in experienced psychoactive substance users</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77253"/><TrialStartDate>1995-10-27 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, multicenter, double-blind, randomized, parallel group, placebo-controlled, single-attack, inpatient study to evaluate the safety and efficacy of naratriptan following dosing during a migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77247"/><TrialStartDate>1993-12-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to evaluate the efficacy of naratriptan in the preventive treatment of refractory chronic migraine</ProtocolTitle><Sponsor>Columbia University College of Physicians &amp; Surgeons</Sponsor><StudyType>Interventional</StudyType><Trial id="115075"/><TrialStartDate>2003-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="265494"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Role of Mosapride in Patients With Gastroesophageal Reflux Disease</ProtocolTitle><Sponsor>Lotung Poh-Ai Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="23027"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Randomization of Sodium Alginate and Mosapride Citrate for Patients with Gastroesophageal Reflux Disease (GERD) Following Distal Gastrectomy with Billroth I Reconstruction - A Multicenter Comparative Study</ProtocolTitle><Sponsor>Kyosei Seiyaku Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="123244"/><TrialStartDate>2006-10-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A phase II clinical study to evaluate efficacy of renzapride in patients with diabetic gastroparesis</ProtocolTitle><Sponsor>EndoLogic LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="284097"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4274">roxindole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open-labelled trial to assess the efficacy of roxindole in acutely ill schizophrenic patients</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><Trial id="48835"/><TrialStartDate>1991-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, single-arm, open-label, outpatient, three attack study to evaluate the patient satisfaction with 100 mg sumatriptan tablets, administered at the first sign of pain for up to three migraines in subjects who were not satisfied with their current triptan therapy</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87308"/><TrialStartDate>2001-12-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, randomized, double-blind, placebo-controlled, parallel-group, single-attack study to determine the onset of efficacy of a new formulation of sumatriptan tablets 50 and 100 mg in treatment of subjects with acute migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87168"/><TrialStartDate>2003-10-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled study to evaluate the efficacy and tolerability of almotriptan in migraine patients who respond poorly to sumatriptan</ProtocolTitle><Sponsor>Universitat Duisburg Essen</Sponsor><StudyType>Interventional</StudyType><Trial id="69797"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>HEDNet2</ProtocolAcronym><ProtocolTitle>An RCT to Compare Naproxen to Sumatriptan for Headache Patients Discharged</ProtocolTitle><Sponsor>Montefiore Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="68607"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373929"/><TrialStartDate>2018-07-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A crossover study to determine the tolerability and pharmacokinetics of ZP-Triptan compared to subcutaneous injection of sumatriptan and oral administration of zolmitriptan treatments for migraine headaches</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="239395"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blinded, placebo-controlled, parallel group study to evaluate the efficacy of GR-43175C, for the acute treatment of menstrual migraine with optional open follow-up treatment</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="202328"/><TrialStartDate>1993-10-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blinded, randomized, single-dosed, placebo-controlled, crossover study to investigate the efficacy and safety of iv administered New Chemical Entity (NCE) and sc sumatriptan in acute migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="202042"/><TrialStartDate>2000-02-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Parallel Group Study of 6mg + Optional 6 Mg Subcutaneous GR43175C (Sumatriptan) Administered Using the Glaxo Autoinjector During the Aura Phase of a Migraine Attack With an Optional Open Six Month Extension</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="174767"/><TrialStartDate>1991-11-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open Design Study to Evaluate Repeat-Dose Oral Sumatriptan (100 mg Plus Optional 100 mg Plus Optional Further 100 mg for Recurrent Headache) in the Acute Treatment of Migraine Attacks During a 24-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="172576"/><TrialStartDate>1989-12-13 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>SNEB</ProtocolAcronym><ProtocolTitle>Sumatriptan Non-Responders: Evaluation of a Possible Biomarker</ProtocolTitle><Sponsor>Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="155125"/><TrialStartDate>2013-09-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label, Uncontrolled Study to Investigate the Single Dose Pharmacokinetics of Sumatriptan Nasal Spray in Adolescent Subjects With Migraine Outside of a Migraine Attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="154178"/><TrialStartDate>1998-07-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled Study to Assess the Efficacy/safety of Oral Sumatriptan (50 mg Film Coated Tablet) in the Acute Treatment of Migraine With an Optional Second Dose to Treat Recurrence</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152539"/><TrialStartDate>1994-05-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14062"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison Of Intravenous Sodium Valproate Versus Subcutaneous Sumatriptan And Intramuscular Metoclopramide For Treatment Of Acute Migraine Attacks</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="133438"/><TrialStartDate>2011-04-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Double-blind, Randomized Trial on Efficacy of Sumatriptan Versus Ketorolac in Migraine</ProtocolTitle><Sponsor>East Carolina University</Sponsor><StudyType>Interventional</StudyType><Trial id="112969"/><TrialStartDate>2002-03-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Crossover, Multicenter, Open-label, Randomized Trial to Compare Rizatriptan ODT 10 mg and Sumatriptan 50 mg for Treatment of Migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110404"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine in Emergency Department</ProtocolTitle><Sponsor>Pamukkale University</Sponsor><StudyType>Interventional</StudyType><Trial id="297870"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to determine bioequivalence between two drugs for oral administration of zolmitriptan dispersible tablets 2.5 mg in healthy female volunteers under fasting conditions</ProtocolTitle><Sponsor>Productos Cientificos</Sponsor><StudyType>Interventional</StudyType><Trial id="215165"/><TrialStartDate>2015-02-12 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative trial to evaluate the effect of zolmitriptan or sumatriptan for treatment of migraine</ProtocolTitle><Sponsor>Konstantopoulio GENERAL HOSPITAL OF NEA IONIA - PATISION</Sponsor><StudyType>Interventional</StudyType><Trial id="114816"/><TrialStartDate>2003-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Dose-Finding, Double-Blind, Placebo-Controlled, Multicenter Study To Assess Safety And Efficacy Of Zolmitriptan In Migraine</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><Trial id="113511"/><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MK-0462 in Treatment of Migraine With Recurrence</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="54671"/><TrialStartDate>1995-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A pharmacokinetic, randomized and parallel-group study to evaluate AXS-07 (MoSEIC meloxicam and rizatriptan) for the acute treatment of migraine</ProtocolTitle><Sponsor>Axsome Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="362250"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to Test a Marketed Product in the Treatment of Migraine-Associated Nausea</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="13995"/><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to Test a Marketed Drug in the Treatment of Menstrual Migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13936"/><TrialStartDate>2005-05-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to Test Rizatriptan in the Early Treatment of Acute Migraine</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="13920"/><TrialStartDate>2007-10-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, retrospective study of almotriptan versus rizatriptan in patients with migraine in Spain</ProtocolTitle><Sponsor>University of Valencia</Sponsor><StudyType>Interventional</StudyType><Trial id="113890"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label study to evaluate the efficacy of rizatriptan in patients with migraine</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><Trial id="113749"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to assess the safety and efficacy of rizatriptan in the treatment of migraine</ProtocolTitle><Sponsor>University of Kiel</Sponsor><StudyType>Interventional</StudyType><Trial id="110736"/><TrialStartDate>1998-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, placebo-controlled, randomized study on the efficacy of sumatriptan, rizatriptan and zolmitriptan in migraine</ProtocolTitle><Sponsor>Cardiovascular Research Institute Maastricht CARIM</Sponsor><StudyType>Interventional</StudyType><Trial id="109719"/><TrialStartDate>2000-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="1264"/><TrialStartDate>2000-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD</ProtocolTitle><Sponsor>Federal University of Rio Grande do Sul</Sponsor><StudyType>Interventional</StudyType><Trial id="31579"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of the Effects of Aripiprazole and Risperidone on the Pattern of Brain Activation in Schizophrenic Patients</ProtocolTitle><Sponsor>Qualissima</Sponsor><StudyType>Interventional</StudyType><Trial id="66873"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ATTAIN 267</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66370"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>GiSAS</ProtocolAcronym><ProtocolTitle>Pragmatic RCT Comparing Aripiprazole, Olanzapine and Haloperidol in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Istituto di Ricerche Farmacologiche Mario Negri</Sponsor><StudyType>Interventional</StudyType><Trial id="63527"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><StudyType>Interventional</StudyType><Trial id="62081"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, double-blind, multicenter, 4-week, placebo-controlled study to evaluate the safety and efficacy of aripiprazole and risperidone in hospitalized patients with a DSM-IV diagnosis of schizophrenia and schizoaffective disorder with acute relapse</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52038"/><TrialStartDate>2001-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="36310"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APLUS</ProtocolAcronym><ProtocolTitle>Acute Psychosis Treatment in the Long Term, Unitary Group Study</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35442"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="35268"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>STAR</ProtocolAcronym><ProtocolTitle>Schizophrenia Trial of Aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35148"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="351213"/><TrialStartDate>2018-06-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Treatment of the Prodrome</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="33984"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>11</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>LLS-ICP</ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="240159"/><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21173"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Dopaminergic Genotype of Schizophrenic Patients and the Benefit of Adjunctive Aripiprazole to Risperidone Treatment. the Effect on Hormonal and Metabolic Measures</ProtocolTitle><Sponsor>The Basque Foundation for Health Innovation and Research</Sponsor><StudyType>Interventional</StudyType><Trial id="173322"/><TrialStartDate>2013-10-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Alpha-PROGRESS trial</ProtocolAcronym><ProtocolTitle>An open-label study evaluating the effectiveness of aripiprazole for schizophrenia patients with dopamine supersensitivity psychosis</ProtocolTitle><Sponsor>Chiba University Graduate School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="164836"/><TrialStartDate>2013-11-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Neurocognitive Effects of Aripiprazole Compared with Risperidone in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Hiroshima University</Sponsor><StudyType>Interventional</StudyType><Trial id="153282"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Second-Generation Antipsychotics on Cognition in First-Episode Schizophrenia</ProtocolTitle><Sponsor>St Marianna University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="150321"/><TrialStartDate>2013-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Sub-Analysis of a Double-Blind Study of Intramuscular Aripiprazole or Haloperidol and Transition to Oral Therapy in Patients With Agitation Associated With Schizophrenia</ProtocolTitle><Sponsor>Riga Mental Health Care Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="146134"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial</ProtocolTitle><Sponsor>Yu-Li Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="13991"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Multiple-dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="137802"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="136610"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effects Of Atypical Antipsychotics On Cognitive Functioning In Schizophrenia</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><Trial id="125873"/><TrialStartDate>2011-03-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, multicenter, placebo-controlled, randomized to assess safety and efficacy of  aripiprazole versus haloperidol in schizophrenia</ProtocolTitle><Sponsor>The Zucker Hillside Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="113889"/><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19411"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind Clinical Trial To Evaluate The Safety And To Compare The Efficacy Of Aripiprazole And Risperidone For Treating Autistic Disorders</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="192415"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Treatment for Methamphetamine Dependence Among High-Risk Individuals</ProtocolTitle><Sponsor>National Institute on Drug Abuse, San Francisco Department of Public Health</Sponsor><StudyType>Interventional</StudyType><Trial id="14526"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Mood Stabilizer (MS) plus Antidepressant versus MS plus Placebo in Maintenance of Bipolar Disorder</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="59575"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="34910"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Preliminary Study of the Effectiveness and Tolerability of Aripiprazole in Bipolar Depression</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="33928"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Bipolar Depression</ProtocolTitle><Sponsor>Cambridge Health Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="33919"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized,Single-blind,Placebo-controlled Study To Assess the Efficacy of Aripiprazole Versus Placebo as Adjuncts to Lithium or Valproate in Relapse Prevention of Manic or Mixed Episodes in Bipolar I Patients Stratified by Index Manic or Mixed Episode</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="153358"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Beneficial Acute Anti-Depressant Effects of Aripiprazole as an Adjunctive Treatment or Monotherapy in Bipolar Patients Unresponsive to Mood Stabilizers: Results From a 16-Week, Open-Label Trial</ProtocolTitle><Sponsor>Catholic University of the Sacred Heart</Sponsor><StudyType>Interventional</StudyType><Trial id="146893"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym>APEX 241</ProtocolAcronym><ProtocolTitle>Aripiprazole Open-Label, Safety and Tolerability Study</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34106"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotical Mania</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="190612"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, multicenter, placebo-controlled, randomized study of aripiprazole in patients with acute bipolar mania</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="113141"/><TrialStartDate>2003-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals</ProtocolTitle><Sponsor>General Hospital of Tianjin Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="365165"/><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, efficacy study of rotigotine patches in patients with dopamine agonist-responsive Parkinson's disease</ProtocolTitle><Sponsor>Aderis Pharmaceuticals Inc, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8476"/><TrialStartDate>1997-03-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Placebo-controlled Study in Patients With Parkinson's Disease to Evaluate the Effect of Rotigotine on Non-motor Symptoms</ProtocolTitle><Sponsor>UCB Pharma SA, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="74990"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6803"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Parkinson's disease with a transdermal skin patch</ProtocolTitle><Sponsor>National Institute of Neurological Disorders and Stroke</Sponsor><StudyType>Interventional</StudyType><Trial id="6288"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Rotigotine Transdermal Patch in Early Parkinson's Disease: A Randomized, Double-Blind, Controlled Study Versus Placebo and Ropinirole</ProtocolTitle><Sponsor>Tel Aviv Sourasky Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="144222"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome</ProtocolTitle><Sponsor>UCB Biopharma SPRL</Sponsor><StudyType>Interventional</StudyType><Trial id="385279"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym>SNOWDROP</ProtocolAcronym><ProtocolTitle>Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH, Sprout Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="61161"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym>BEGONIA</ProtocolAcronym><ProtocolTitle>Fixed 100 mg Every Evening of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="61156"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Flibanserin Randomized Withdrawal Trial in Pre-Menopausal Women</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="33284"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Month Minimum Effective Dose of Flibanserin: 25 versus 50 mg bid versus 50 mg hs versus Placebo in Younger Women in North America</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="33306"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan Pharmacokinetics In Korean Males</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="78186"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="160203"/><TrialStartDate>1996-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A dose-finding, double-blind, multicenter, placebo-controlled, randomized study to evaluate the efficacy and safety of eletriptan in japanese migraineurs</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><Trial id="111703"/><TrialStartDate>2002-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Lithium Drug-Drug Interaction Study With Lurasidone HCl</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64602"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study to test the effectiveness and safety of a new medication in the treatment of schizophrenia</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34724"/><TrialStartDate>2004-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Lurasidone Versus Olanzapine on Neurotrophic Biomarkers in First Episode Untreated Schizophrenia</ProtocolTitle><Sponsor>All India Institute of Medical Sciences Bhubaneswar</Sponsor><StudyType>Interventional</StudyType><Trial id="315417"/><TrialStartDate>2017-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>31</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APIC</ProtocolAcronym><ProtocolTitle>Antipsychotic Induced Structural and Functional Brain Changes</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="228608"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><Trial id="160283"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Extended Use Study</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82983"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>PREVAIL3</ProtocolAcronym><ProtocolTitle>Lurasidone HCI - A 6-week, Phase III Study of Patients With Bipolar I Depression</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="74110"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, real world study to determine the efficacy of adjunct lurasidone for outpatients with treatment-resistant bipolar disorder (BP) of any type</ProtocolTitle><Sponsor>Sutter Health</Sponsor><StudyType>Interventional</StudyType><Trial id="149104"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A One-year, Open-label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35102"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>11</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Treatment on Decision-making in Major Depression</ProtocolTitle><Sponsor>Emory University</Sponsor><StudyType>Interventional</StudyType><Trial id="149219"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="9978">osemozotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="304">Sleep disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa, safety and efficacy study of MN-305 (osemozotan) in patients with primary insomnia and sleep maintenance difficulties</ProtocolTitle><Sponsor>MediciNova Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7418"/><TrialStartDate>2007-01-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A trial of tegaserod in patients with irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19717"/><TrialStartDate>1998-09-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, multicenter, placebo-controlled, randomized trial to evaluate the efficacy and safety of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms</ProtocolTitle><Sponsor>Hightop Medical Research Center</Sponsor><StudyType>Interventional</StudyType><Trial id="112873"/><TrialStartDate>2002-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, multicenter study of tegaserod in constipation-dominant irritable bowel syndrome in an Asian (Pakistan) population</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19669"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym>ZENSAA</ProtocolAcronym><ProtocolTitle>A randomized, double-blinded, parallel-group, multi-center trial of tegaserod in female patients with irritable bowel syndrome and constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19640"/><TrialStartDate>2002-12-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Preference of Tegaserod Versus PEG 3350 in Patients With Constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18711"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized Study to Assess the Efficacy of Movicol 1 Sachet Bid versus Tegaserod 6 mg Bid in Patients With Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>Queen Mary Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="128014"/><TrialStartDate>2006-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym>D2301E1</ProtocolAcronym><ProtocolTitle>Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42505"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Study the Effects of Almotriptan Oral Tablets in Patients With Migraine Headache</ProtocolTitle><Sponsor>MSN Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="133279"/><TrialStartDate>2010-12-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Prospective, Crossover, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Efficacy and Tolerability of Almotriptan 12.5 Mg in the Mild Pain Phase of Mestrual Migraine Followed by an Open Follow-Up Evaluation to Assess Consistency</ProtocolTitle><Sponsor>Almirall Prodesfarma SA</Sponsor><StudyType>Interventional</StudyType><Trial id="116717"/><TrialStartDate>2005-03-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, comparative study to assess the safety and efficacy of almotriptan versus sumatriptan in migraine patients</ProtocolTitle><Sponsor>Pharmacia Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="109741"/><TrialStartDate>2000-04-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="12980">repinotan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="65">Stroke</Indication><ProtocolAcronym>mRECT</ProtocolAcronym><ProtocolTitle>Repinotan in Patients With Acute Ischemic Stroke</ProtocolTitle><Sponsor>Bayer AG</Sponsor><StudyType>Interventional</StudyType><Trial id="6013"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>M-0001 Effects on Oral Contraceptive Plasma Levels</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="62869"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Effects on Subjects With Chronic Non-Cancer Pain Suffering From Opioid Induced Constipation</ProtocolTitle><Sponsor>Shire plc, Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="66169"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A reserach study to evaluate safety and efficacy of prucalopride tablet in patient having long term complain of constipation</ProtocolTitle><Sponsor>Torrent Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="256419"/><TrialStartDate>2016-08-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Trial in Healthy Volunteers, to Evaluate the Tolerability and Cardiac Safety of Prucalopride</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18994"/><TrialStartDate>2000-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride in patients with chronic idiopathic constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18427"/><TrialStartDate>1997-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Comparator Study of PEG 3350 Versus Prucalopride in Females With Chronic Constipation</ProtocolTitle><Sponsor>Norgine BV</Sponsor><StudyType>Interventional</StudyType><Trial id="133931"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>PADDY-2</ProtocolAcronym><ProtocolTitle>Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia</ProtocolTitle><Sponsor>EMD Serono Inc, Merck KGaA</Sponsor><StudyType>Interventional</StudyType><Trial id="6280"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym>PADDY 1</ProtocolAcronym><ProtocolTitle>Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment Associated Dyskinesia</ProtocolTitle><Sponsor>Merck KGaA, Merck Pharma SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="6134"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-month, placebo-controlled, phase III study to evaluate the metabolic effects and long-term efficacy of bifeprunox in patients with stable schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S, Solvay Pharmaceuticals Inc, Wyeth Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="41526"/><TrialStartDate>2006-12-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36060"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Bifeprunox in Bipolar Depression</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33911"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, pilot phase I study to evaluate dopamine D2 receptor occupancy after multiple oral administration of DU-127090 to healthy male volunteers, using 11C-raclopride by means of position emission tomography (PET)</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41463"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Switch Study of Existing Atypical Antipsychotics to Bifeprunox</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35593"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, SLV-308 Safety Extension to Study S308.3.002 in Patients With Parkinsons Disease Experiencing Motor Fluctuations</ProtocolTitle><Sponsor>Abbott Laboratories</Sponsor><StudyType>Interventional</StudyType><Trial id="8243"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="68790"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>CLARITY-2</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="382842"/><TrialStartDate>2019-04-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14054"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="35978">PRX-00933 (oral, obesity/diabetes), Proximagen</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa, double-blind, placebo-controlled study to evaluate the efficacy of BVT-933 in obese patients</ProtocolTitle><Sponsor>Swedish Orphan Biovitrum AB</Sponsor><StudyType>Interventional</StudyType><Trial id="54146"/><TrialStartDate>2002-02-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64984"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="129680"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Adult ADHD With Atomoxetine or Atomoxetine and Buspar</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="31591"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, multicenter, randomized study of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine</ProtocolTitle><Sponsor>CENTRE ANTI-DOULEUR</Sponsor><StudyType>Interventional</StudyType><Trial id="107130"/><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of single and multiple doses of PRX-00023 in healthy subjects</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="57387"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to compare the bioavailability, pharmacokinetics, safety and tolerability of zolmitriptan (TRZ) with marketed zolmitriptan tablet and marketed zolmitriptan nasal spray in healthy adult volunteers</ProtocolTitle><Sponsor>Shin Nippon Biomedical Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="86427"/><TrialStartDate>2011-03-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>ZAP</ProtocolAcronym><ProtocolTitle>ZAP, US Zomig for Appropriate for Primary Care</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14109"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Zolmitriptan Nasal Spray</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14078"/><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Zomig in the Treatment of Migraines in Adolescents</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14069"/><TrialStartDate>2003-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym>LorNic</ProtocolAcronym><ProtocolTitle>Combination Nicotine Patch/Lorcaserin for Smoking Cessation</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="272364"/><TrialStartDate>2016-11-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of APD356 in the Treatment of Obesity</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38680"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin in Obesity: Identification of CNS Targets Using fMRI</ProtocolTitle><Sponsor>Beth Israel Deaconess Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="225419"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Relapse-Prevention Study With Lu-AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="34949"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Efficacy and Safety of Lu-AA21004 in Treating Generalized Anxiety Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="23030"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu-AA21004) in Acute Treatment of Major Depressive Disorder in Adults</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="44556"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Vortioxetine (Lu-AA21004) in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34985"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Cognitive Dysfunction in MDD Patients</ProtocolTitle><Sponsor>Zaporizhzhya Medical Academy of Postgraduate Education</Sponsor><StudyType>Interventional</StudyType><Trial id="301563"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="294442"/><TrialStartDate>2017-03-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Multi-country, Multi-site, Non-Interventional Study on Vortioxetine in Major Depression patients In South East Asia</ProtocolTitle><Sponsor>A/S Lundbeck Overseas (Singapore)</Sponsor><StudyType>Interventional</StudyType><Trial id="267158"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine for the Treatment of Major Depression and Co-morbidities After Traumatic Brain Injury (TBI)</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="266640"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Safety, Tolerability and Pharmacokinetic Study of PRX-03140 for the Treatment of Alzheimer's Disease</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="3888"/><TrialStartDate>2004-12-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study of PRX-03140 to Assess Safety for Use in Adult Subjects With Post Traumatic Stress Disorder</ProtocolTitle><Sponsor>Ology Bioservices Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="83297"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, multiple-ascending dose, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability and pharmacokinetics of naronapride in healthy volunteers</ProtocolTitle><Sponsor>ARYx Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77600"/><TrialStartDate>2011-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Study of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65697"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With Schizophrenia</ProtocolTitle><Sponsor>Allergan Singapore PTE Ltd, Allergan plc, Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="347207"/><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine for Bipolar I Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63809"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features</ProtocolTitle><Sponsor>Allergan Singapore PTE Ltd, Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="344918"/><TrialStartDate>2018-06-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="29374"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="79318"/><TrialStartDate>2011-07-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Cariprazine Capsules 6 mg in Schizophrenia or Bipolar Disorder I Patients</ProtocolTitle><Sponsor>AXIS Clinicals Limited, Aurobindo Pharma Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="354246"/><TrialStartDate>2018-09-21 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features</ProtocolTitle><Sponsor>Allergan Singapore PTE Ltd, Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="344918"/><TrialStartDate>2018-06-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study on the Efficacy, Safety and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="252177"/><TrialStartDate>2016-03-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="359769"/><TrialStartDate>2018-11-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study on the Efficacy, Safety and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="252177"/><TrialStartDate>2016-03-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="304">Sleep disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="268946"/><TrialStartDate>2016-10-20 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1050">Hallucination</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="249583"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3064">Lewy body dementia</Indication><ProtocolAcronym/><ProtocolTitle>Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="268946"/><TrialStartDate>2016-10-20 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="52893">clavulanic acid (extended-release, depression/Parkinson's disease), Rexahn</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Rexahn Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="44571"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53651">ATHX-105</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A three-way crossover, phase I trial to evaluate the pharmacokinetics of ATHX-105 for potential treatment of obesity</ProtocolTitle><Sponsor>Athersys Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36255"/><TrialStartDate>2008-09-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82214"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82214"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54699">temanogrel</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3258">Acute coronary syndrome</Indication><ProtocolAcronym>PR1C</ProtocolAcronym><ProtocolTitle>Safety Study of APD-791 With Aspirin and/or Clopidogrel</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="167386"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan in Participants With Migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="308816"/><TrialStartDate>2017-08-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Single, Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="290533"/><TrialStartDate>2017-03-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57473">revexepride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>An Exploratory, Double-Blind, Randomized, Stratified, Placebo-Controlled, Repeated Dose Trial to Investigate the Efficacy of M0003 on Symptoms Suggestive for Gastroparesis, to Assess the Pharmacodynamic Effects on Gastric Emptying, and to Assess the Safety, Tolerability and Pharmacokinetics of M0003</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="143168"/><TrialStartDate>2007-11-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym>ReCOGNITION</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="246850"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="90337"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Study on the Effects of DA-9701 on Gastrointestinal Motility on Healthy Adult Volunteers</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="90337"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><Trial id="178376"/><TrialStartDate>2013-08-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3510">Pulmonary artery hypertension</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study of RP-5063 for the treatment of pulmonary arterial hypertension</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="316349"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Intravenous TAK-954 for the Prophylaxis and Treatment of Postoperative Gastrointestinal Dysfunction in Participants Undergoing Large- and Small-Bowel Resection</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><Trial id="368821"/><TrialStartDate>2019-03-07 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, single-center, randomized, three-way crossover study to evaluate the pharmacokinetics of sumatriptan in patients with migraine</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="302739"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>EQUATOR</ProtocolAcronym><ProtocolTitle>Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="90312"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ZENITH</ProtocolAcronym><ProtocolTitle>Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="79423"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Positron emission tomagraphy (PET) study following a single oral dose of OPC-34712</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="38179"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="171461"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1929">Borderline personality disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole in Borderline Personality Disorder</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><Trial id="327857"/><TrialStartDate>2018-11-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes, Associated With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="309883"/><TrialStartDate>2017-10-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="342247"/><TrialStartDate>2018-05-16 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A phase III study of brexpiprazole for the treatment of agitation in patients with dementia of the Alzheimer's type</ProtocolTitle><Sponsor>H Lundbeck A/S, Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="317701"/><TrialStartDate>2018-06-30 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Delphinus</ProtocolAcronym><ProtocolTitle>A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="98372"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Pyxis</ProtocolAcronym><ProtocolTitle>Study of the Safety and Efficacy of Fixed-Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77610"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Safety and Efficacy of Brexpiprazole as Adjunctive Therapy in the Treatment of Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute, Otsuka Pharmaceutical Co Ltd, Sharp Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="335179"/><TrialStartDate>2018-05-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="164112"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="164016"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="63311">tandospirone (eye-drop formulation), Alcon</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1226">Age related macular degeneration</Indication><ProtocolAcronym>GATE</ProtocolAcronym><ProtocolTitle>Geographic Atrophy Treatment Evaluation (GATE)</ProtocolTitle><Sponsor>Alcon Research Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="54196"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pharmocokinetic Study of Aripiprazole Extended Release Injectable Suspension in patients with Schizophrenia</ProtocolTitle><Sponsor>Mylan Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="363837"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole IM Depot in the Acute Treatment of Adults With Schizophrenia</ProtocolTitle><Sponsor>China Otsuka Pharmaceutical Co Ltd, Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="300706"/><TrialStartDate>2017-05-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ASPIRE</ProtocolAcronym><ProtocolTitle>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23078"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, parallel-group, comparison trial of aripiprazole IM depot in patients with schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="101289"/><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64364">zolmitriptan (nasal, migraine), SNBL</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to compare the bioavailability, pharmacokinetics, safety and tolerability of zolmitriptan (TRZ) with marketed zolmitriptan tablet and marketed zolmitriptan nasal spray in healthy adult volunteers</ProtocolTitle><Sponsor>Shin Nippon Biomedical Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="86427"/><TrialStartDate>2011-03-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77576"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="67509">SUVN-D4010</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects</ProtocolTitle><Sponsor>Suven Life Sciences Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="243083"/><TrialStartDate>2015-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="279887"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="82058">YH-12852</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Evaluate the Efficacy and Safety of YH-12852 in Patients With Functional Dyspepsia</ProtocolTitle><Sponsor>Yuhan Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="242031"/><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87742">aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blinded, single-dose, randomized, placebo-controlled, 7 day study to determine the safety and bioavailability of AQS-1301 in healthy volunteers</ProtocolTitle><Sponsor>Aequus Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="246123"/><TrialStartDate>2015-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym>SBD-ASIB</ProtocolAcronym><ProtocolTitle>NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325308"/><TrialStartDate>2019-06-10 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="102298">litoxetine, Ixaltis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="187">Urinary incontinence</Indication><ProtocolAcronym>DBPC Trial</ProtocolAcronym><ProtocolTitle>To Evaluate the Safety, Tolerability and Efficacy of Oral Litoxetine in Subjects With Urinary Incontinence</ProtocolTitle><Sponsor>Ixaltis SA</Sponsor><StudyType>Interventional</StudyType><Trial id="325453"/><TrialStartDate>2018-04-03 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="109472">sumatriptan (migraine, ZENEO), Crossject</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A bioequivalence study of sumatriptan in the treatment of facial algia and acute migraine</ProtocolTitle><Sponsor>Crossject</Sponsor><StudyType>Interventional</StudyType><Trial id="330220"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="113329">sumatriptan (oral spray, OroMist, migraine), Suda Pharmaceuticals/ Strides Pharma Science</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A pilot, first-in-human clinical trial SUD-001H for the potential treatment of migraine</ProtocolTitle><Sponsor>Suda Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="360559"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, open-label, long-term study to evaluate the safety, tolerability and efficacy of aripiprazole in the maintenance treatment of patients with bipolar I disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="80180"/><TrialStartDate>2000-08-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, double-blind, multicenter, controlled clinical trial to compare the safety and efficacy of aripiprazole versus haloperidol for the treatment of patients with bipolar disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="70615"/><TrialStartDate>2004-06-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>ATTAIN 267</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66370"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="351213"/><TrialStartDate>2018-06-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A head to head comparison of aripiprazole versus olanzapine as adjuvants to lithium for treating manic or mixed episodes in bipolar disorder</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="216294"/><TrialStartDate>2013-09-12 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19426"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Patients With Acute Mania</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19400"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot bioequivalence study between granules containing 1.0 mg of cinitapride (drug test) developed by Ultra Laboratories, SA de CV and Pemix ​​granulate containing 1.0 mg of cinitapride (Drug Reference) manufactured by Almirall Pharmaceutical Industries Ltd. for Pharmaceutical Andromaco , SA de CV 2.0 mg dose administration</ProtocolTitle><Sponsor>Ultra Laboratories, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="163576"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot Study to Evaluate Bioavailability of eletriptan 80 mg Tablets in Healthy Volunteers, eletriptan versus Relpax (Pfizer) and Establish the Best Conditions For Study Bioequlvalence</ProtocolTitle><Sponsor>Landsteiner Scientific Sa De Cv</Sponsor><StudyType>Interventional</StudyType><Trial id="163943"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="701">Personality disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to evaluate the efficacy of sumatriptan in serotonergic functioning in children with oppositional defiant disorder</ProtocolTitle><Sponsor>Universiteit Utrecht</Sponsor><StudyType>Interventional</StudyType><Trial id="111371"/><TrialStartDate>2002-02-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence study between the test drug zolmitriptan (Ultra laboratories SA de CV) and Zomig Rapimelt (Astrazeneca, SA de CV) as reference medicine</ProtocolTitle><Sponsor>Ultra Laboratories, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="302697"/><TrialStartDate>2014-10-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of drugs Migrepam tablets, film-coated, 2.5 mg (ZAO "Pharmaceutical Company" Obolensky ", Russia) and Zomig tablets, film-coated, 2.5 mg (AstraZeneca UK Limited, UK)</ProtocolTitle><Sponsor>Obolensky</Sponsor><StudyType>Interventional</StudyType><Trial id="224199"/><TrialStartDate>2015-03-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3063">Delirium</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Delirium in Cancer Patients With Aripiprazole</ProtocolTitle><Sponsor>University of Fukui</Sponsor><StudyType>Interventional</StudyType><Trial id="123466"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47204">sumatriptan (sublingual, migraine, NovaMist), Suda</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A pilot study to compare the pharmacokinetics of sumatriptan oral spray with Imitrex in healthy volunteers</ProtocolTitle><Sponsor>NovaDel Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="60305"/><TrialStartDate>2004-05-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Reducing the Abuse of Opioids in Drug Users</ProtocolTitle><Sponsor>University of Texas Health Science Center San Antonio</Sponsor><StudyType>Interventional</StudyType><Trial id="369937"/><TrialStartDate>2019-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="84">Crohns disease</Indication><ProtocolAcronym>IMPULSE</ProtocolAcronym><ProtocolTitle>The Investigations for Improving Successful Judgment Rate With PillCam Patency Capsule and Differential Diagnosis in Crohns Disease Patients With Following Capsule Endoscopy</ProtocolTitle><Sponsor>Osaka City University</Sponsor><StudyType>Interventional</StudyType><Trial id="118707"/><TrialStartDate>2012-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Frovatriptan Versus Zolmitriptan in the Treatment of Migraine With or Without Aura, a Patient Preference Study</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="117172"/><TrialStartDate>2007-03-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3063">Delirium</Indication><ProtocolAcronym>MIND Study</ProtocolAcronym><ProtocolTitle>Modifying the Incidence of Delirium</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="197371"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="201">Liver disease</Indication><ProtocolAcronym/><ProtocolTitle>Clinical observation of Pingwei capsule in treating functional dyspepsia with liver stagnation and spleen deficiency and its effect on CCK, ghrelin</ProtocolTitle><Sponsor>Affiliated Hospital of Gansu University of Chinese Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="372403"/><TrialStartDate>2014-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase Ib/II, placebo-controlled, double-blind, safety and tolerability follow-on study of ACP-103 in patients with Parkinson's disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7656"/><TrialStartDate>2004-06-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7126"/><TrialStartDate>2007-06-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Efficacy of Pimavanserin in Patients with Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="68790"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="376">Gastric motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, open-label, two-phase, five-period crossover study to evaluate the pharmacokinetics of tegaserod in healthy subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19860"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response</ProtocolTitle><Sponsor>Genaissance Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34541"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of 7 Day Prucalopride Administration in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="344627"/><TrialStartDate>2018-06-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, non-randomized, within-subject, one-sequence, crossover, drug-interaction study to evaluate the safety and potential pharmacokinetic interaction of sumatriptan and an oral contraceptive when co-administered to healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87863"/><TrialStartDate>2000-08-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, single-dose, open-label, randomized, three-period crossover study to evaluate the bioequivalence of fast disintegrating sumatriptan 100 mg tablet administered in the fasted and fed states compared to the currently marketed sumatriptan 100 mg tablet administered immediately after food to healthy male and female subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87677"/><TrialStartDate>2002-07-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-label, Crossover Study to Evaluate the Bioequivalence of 50 and 100 mg Sumatriptan Tablets</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="154192"/><TrialStartDate>1993-07-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Phase I, Randomized, Double-Blind, Crossover Study to Investigate the Pharmacokinetics of GR-43175C After Four Different Oral Doses</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="154186"/><TrialStartDate>1989-04-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Placebo-controlled, Crossover Pilot Study to Evaluate the Effect of GR-43175C on Gastric Emptying in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153745"/><TrialStartDate>1989-03-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An Open-label Study of Evaluation of the Anatomic Site of Absorption of Sumatriptan (GR-43175)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153596"/><TrialStartDate>1992-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Crossover, Dose-finding, Double-blind, Placebo-controlled, Randomized Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of Sumatriptan In Healthy Subjects ,following Ascending Single Intranasal Doses And Multiple Intranasal Doses</ProtocolTitle><Sponsor>RTI International</Sponsor><StudyType>Interventional</StudyType><Trial id="108077"/><TrialStartDate>1997-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="96279">sumatriptan (autoinjector, migraine), Promius Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study of DFN-11 Injection in Medication Overuse Headache</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="243746"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="9978">osemozotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II/III clinical study of MN-305 (osemozotan), for the potential treatment of general anxiety disorder</ProtocolTitle><Sponsor>MediciNova Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7420"/><TrialStartDate>2005-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, open-Label, prospective study on effectiveness and safety of the addition of and switching to aripiprazole for resolving antipsychotic-induced hyperprolactinemia</ProtocolTitle><Sponsor>NHIC Ilsan hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="283175"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Improving Driving In Young People With Autism Spectrum Disorders</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="340951"/><TrialStartDate>2018-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Early Pharmacotherapy Aimed at Neuroplasticity in Autism : Safety and Efficacy</ProtocolTitle><Sponsor>Wayne State University</Sponsor><StudyType>Interventional</StudyType><Trial id="171961"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety and pharmacokinetics of single and multiple doses of PRX-00023 in healthy subjects</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="57387"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="836">Insulin dependent diabetes</Indication><ProtocolAcronym>SMEAC</ProtocolAcronym><ProtocolTitle>Metabolic Effects of Antipsychotic Substitution in Children</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="56972"/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="167385"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="89983">aripiprazole + sertraline (oral, major depressive disorder), Otsuka Pharmaceutical</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="319613"/><TrialStartDate>2017-11-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1585">Syndrome X</Indication><ProtocolAcronym/><ProtocolTitle>One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33782"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr Reddy's Under Fed Conditions</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="197622"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Ziprasidone Decreases Cortisol Excretion in Healthy Subjects</ProtocolTitle><Sponsor>University of Gottingen</Sponsor><StudyType>Interventional</StudyType><Trial id="145366"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3283">Cannabis dependence</Indication><ProtocolAcronym>SToP-C</ProtocolAcronym><ProtocolTitle>Substance Misuse To Psychiatric Disorders for Cannabis</ProtocolTitle><Sponsor>The University of Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="334943"/><TrialStartDate>2018-07-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, comparative study of aripiprazole versus naltrexone in treatment of patients with alcohol dependence</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="61755"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Subjects With Alcoholism</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23519"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Small Dose Aripiprazole for the Treatment of Alcohol Use Disorders: A Randomized, Double-Blind, Placebo-Controlled Study</ProtocolTitle><Sponsor>Chiba University Graduate School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="155298"/><TrialStartDate>2013-09-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1943">Psychiatric symptom</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="349386"/><TrialStartDate>2018-07-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, multicenter, randomized, double-blind, placebo-controlled, cross-over, two-attack, outpatient study to determine the efficacy, safety and tolerability of sumatriptan nasal spray (10 or 20 mg) in the treatment of patients with acute migraine with and without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87128"/><TrialStartDate>2001-01-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Double-blind, Placebo-controlled, Parallel Study To Evaluate the Safety and Efficacy of 25, 50 and 100 mg Sumatriptan and Placebo in Subjects with Acute Migraine Attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="202177"/><TrialStartDate>1989-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Safety and Efficacy of Sumatriptan Suppositories in the Acute Treatment of Three Migraine Attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153847"/><TrialStartDate>1993-10-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, double-blind, placebo-controlled study to evaluate intranasal GR-43175N (1, 5, 10, 20 and 40 mg) in the acute treatment of migraine (one nostril application)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="105600"/><TrialStartDate>1990-09-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open =-Label, Randomized, Two-way Crossover, Two-sequence, Two-period, Two-treatment Study of Mosapride Tablet in Healthy Thai Volunteers</ProtocolTitle><Sponsor>Mahidol University</Sponsor><StudyType>Interventional</StudyType><Trial id="280549"/><TrialStartDate>2017-02-25 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A study to evaluate the pharmacokinetics and dose proportionality of single and multiple oral doses of mosapride in healthy male volunteers</ProtocolTitle><Sponsor>Dainippon Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19597"/><TrialStartDate>1993-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, double-blind, cross-over study to evaluate the prokinetic effect of AS-4370 on gastric emptying in healthy adult volunteers using 99mTc-DTPA</ProtocolTitle><Sponsor>Dainippon Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19363"/><TrialStartDate>1991-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic properties of lorcaserin in subjects with hepatic impairment</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42194"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot study of comparative bioavailability between two drugs for oral administration of Lorcaserin Hydrochloride in prolonged-release tablets with 20 mg in healthy subjects under feeding conditions</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="338193"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers</ProtocolTitle><Sponsor>Shire Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="115035"/><TrialStartDate>2013-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="90513">YL-0919</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>To Explore the Safety and Efficacy of Hypidone Hydrochloride Tablets in Treatment of Patients With MDD</ProtocolTitle><Sponsor>Chinese Academy of Medical Military Sciences, Shanghai Synergy Pharmaceutical Sciences Co Ltd, Zhejiang Huahai Pharmaceutical Group Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="326171"/><TrialStartDate>2018-01-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>CAMP</ProtocolAcronym><ProtocolTitle>Comparison of Antipsychotics for Metabolic Problems Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="36367"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>HEALTH</ProtocolAcronym><ProtocolTitle>Health Evaluation of Abilify Long-Term Therapy</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="36302"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>APLUS</ProtocolAcronym><ProtocolTitle>Acute Psychosis Treatment in the Long Term, Unitary Group Study</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35442"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="35268"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Aripiprazole on Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="34597"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized Open-label Study of the Effects of Aripiprazole in Overweight and Obstructive Sleep Apnea Subjects With Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotic Drugs</ProtocolTitle><Sponsor>Biwako Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="136397"/><TrialStartDate>2011-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym/><ProtocolTitle>The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial</ProtocolTitle><Sponsor>Yu-Li Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="13991"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Study of Velusetrag in Diabetic or Idiopathic Gastroparesis</ProtocolTitle><Sponsor>Theravance Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="96663"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym>DIGEST</ProtocolAcronym><ProtocolTitle>The Diabetic and Idiopathic Gastroparesis Efficacy, Safety and Tolerability study</ProtocolTitle><Sponsor>Theravance Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="213523"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>IMPACT</ProtocolAcronym><ProtocolTitle>Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (IMPACT)</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="38318"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="673">Narcotic dependence</Indication><ProtocolAcronym/><ProtocolTitle>Psychopharmacology for Cocaine Dependence - Buspirone</ProtocolTitle><Sponsor>University of Texas Health Science Center Houston</Sponsor><StudyType>Interventional</StudyType><Trial id="116067"/><TrialStartDate>2011-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Study of Two Fixed-Doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="134389"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Study of Geodon in Non-Rapid Cycling Bipolar II Patients With Major Depression</ProtocolTitle><Sponsor>The Medical Research Network</Sponsor><StudyType>Interventional</StudyType><Trial id="34452"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym>STABIL-B</ProtocolAcronym><ProtocolTitle>Sequential Therapy for the Treatment of Severe Bipolar Depression</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="280467"/><TrialStartDate>2018-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin in the Treatment of Cocaine Use Disorder</ProtocolTitle><Sponsor>National Institute on Drug Abuse</Sponsor><StudyType>Interventional</StudyType><Trial id="284356"/><TrialStartDate>2017-06-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin</ProtocolTitle><Sponsor>National Institute on Drug Abuse</Sponsor><StudyType>Interventional</StudyType><Trial id="225012"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Study of Telcagepant (MK-0974) in Participants With Moderate to Severe Acute Migraine With or Without Aura</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp, Merck Sharp &amp; Dohme Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="13924"/><TrialStartDate>2007-02-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness</ProtocolTitle><Sponsor>Medical College of Wisconsin</Sponsor><StudyType>Interventional</StudyType><Trial id="32858"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Role of Antidepressants or Antipsychotics in Preventing Psychosis</ProtocolTitle><Sponsor>St Lukes Roosevelt Hospital Center</Sponsor><StudyType>Interventional</StudyType><Trial id="97635"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>TEA</ProtocolAcronym><ProtocolTitle>Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="66210"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Aripiprazole in First Episode Psychosis</ProtocolTitle><Sponsor>Chonbuk National University</Sponsor><StudyType>Interventional</StudyType><Trial id="62420"/><TrialStartDate>2009-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>REMEDY</ProtocolAcronym><ProtocolTitle>Assessing approaches aimed at improving sexual functioning</ProtocolTitle><Sponsor>Imperial College Healthcare NHS trust</Sponsor><StudyType>Interventional</StudyType><Trial id="336942"/><TrialStartDate>2018-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP3_1Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: One-Year Follow-Up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238547"/><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>CONSTATRE</ProtocolAcronym><ProtocolTitle>A Study of Relapse Prevention and the Effectiveness of Long-Acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schiozaffective Disorder</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><Trial id="20998"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Double-blind, Randomized, Controlled Trial of Aripiprazole versus Risperidone for the Treatment of Amphetamine-induced Psychosis</ProtocolTitle><Sponsor>Kermanshah University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="171709"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>ZAC</ProtocolAcronym><ProtocolTitle>Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="170060"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>On the question of neuroleptic-induced metabolic syndrome.Study 1: Fat distribution and specific hormonal parameters. A prospective comparative study of five atypical antipsychotics</ProtocolTitle><Sponsor>Medical University of Graz</Sponsor><StudyType>Interventional</StudyType><Trial id="139210"/><TrialStartDate>2006-09-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65374">PF-03382792</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1005">Unidentified indication</Indication><ProtocolAcronym/><ProtocolTitle>A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64961"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="24">Anorexia nervosa</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="31351"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="304">Sleep disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for treating patients with delayed sleep phase syndrome and hypersomnolence disorder</ProtocolTitle><Sponsor>Akita University</Sponsor><StudyType>Interventional</StudyType><Trial id="314591"/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym>HEDNet2</ProtocolAcronym><ProtocolTitle>An RCT to Compare Naproxen to Sumatriptan for Headache Patients Discharged</ProtocolTitle><Sponsor>Montefiore Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="68607"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="36247"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Pretreatment With Sumatriptan on Cilostazol-Induced Headache in Healthy Volunteers</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="298350"/><TrialStartDate>2017-05-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, controlled study to evaluate the pharmacokinetics and efficacy of velusetrag in patients with chronic constipation (CC) compared with healthy volunteers</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="58969"/><TrialStartDate>2009-06-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym>Depression-Cog Trial</ProtocolAcronym><ProtocolTitle>An Antidepressant Medications from Treatment Initiation for Depressive Disorder with Cognitive Impairment: A Prospective Comparative Study</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="282235"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2520">Insulin resistance</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes</ProtocolTitle><Sponsor>Veterans Medical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="18217"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Absorption, Disposition, Metabolic Fate, and Elimination of The Dopamine Agonist Rotigotine in Man: Administration by Intravenous Infusion or Transdermal Delivery</ProtocolTitle><Sponsor>UCB BIOSCIENCES GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="144116"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="106">Eating disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single-Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance</ProtocolTitle><Sponsor>Theravance Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="156147"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 4-week, randomized, single-blind, open-label, parallel study to compare the efficacy and safety of ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86610"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, randomized, double-blind, 24-h study to assess the safety and efficacy of ziprasidone in the acute control and short-term management of agitated psychotic patients</ProtocolTitle><Sponsor>Comprehensive NeuroScience Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="75666"/><TrialStartDate>2001-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety And Efficacy Study Of Ziprasidone In Pediatric Psychotic Illness</ProtocolTitle><Sponsor>Medical College of Wisconsin</Sponsor><StudyType>Interventional</StudyType><Trial id="32858"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study of ziprasidone for the treatment of psychosis in patients who had already had benefits from ziprasidone treatment in a previous study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21407"/><TrialStartDate>2003-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>On the question of neuroleptic-induced metabolic syndrome.Study 1: Fat distribution and specific hormonal parameters. A prospective comparative study of five atypical antipsychotics</ProtocolTitle><Sponsor>Medical University of Graz</Sponsor><StudyType>Interventional</StudyType><Trial id="139210"/><TrialStartDate>2006-09-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A prospective controlled study to evaluate the safety and efficacy of acupuncture versus valproic acid in the prophylaxis of migraine without aura</ProtocolTitle><Sponsor>University of Padova</Sponsor><StudyType>Interventional</StudyType><Trial id="157130"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="242">Esophageal disease</Indication><ProtocolAcronym/><ProtocolTitle>Effect of mosapride on UES</ProtocolTitle><Sponsor>Shimane University</Sponsor><StudyType>Interventional</StudyType><Trial id="271396"/><TrialStartDate>2016-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Aripiprazole on Cocaine Craving and Self-Administration</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="34067"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1931">Hebephrenic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65680"/><TrialStartDate>2010-04-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A crossover, open-label, randomized trial to assess the safety and pharmacokinetics of propranolol plus frovatriptan in healthy volunteers</ProtocolTitle><Sponsor>Vernalis plc</Sponsor><StudyType>Interventional</StudyType><Trial id="109726"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, crossover trial to assess the safety of frovatriptan plus ergotamine in healthy volunteers</ProtocolTitle><Sponsor>Vernalis plc</Sponsor><StudyType>Interventional</StudyType><Trial id="109717"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="304">Sleep disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Effectiveness of Mosapride for GERD Patients With Sleep Disorders</ProtocolTitle><Sponsor>Shimane University</Sponsor><StudyType>Interventional</StudyType><Trial id="162155"/><TrialStartDate>2013-11-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Single-Attack and Inpatient Study to Evaluate the Efficacy and Safety of Five Dose Levels of Sumatriptan Suppositories (6, 12.5, 25, 50 and 100 mg) in the Acute Treatment of Migraine With and Without Aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="206851"/><TrialStartDate>1992-10-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Single-Blind, Placebo-Controlled, Non-Randomized, Cross-over, Single-Attack, Inpatient, Two-Part Study to Rechallenge With sc GR-43175C, Patients Who Had Previously Experienced an Adverse Event Involving Discomfort or Pain in the Chest Following GR-43175C Administration</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="202024"/><TrialStartDate>1990-12-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalency Study of Naratriptan Hydrochloride 2.5 mg Under Fed Conditions</ProtocolTitle><Sponsor>West-Ward Columbus</Sponsor><StudyType>Interventional</StudyType><Trial id="178286"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Treximet (Formerly Known as Trexima) for the Acute Treatment of Probable Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14049"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan versus Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161688"/><TrialStartDate>1996-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="250">Pancreatitis</Indication><ProtocolAcronym/><ProtocolTitle>The Clinical Study of Acute Pancreatitis Treated by TongFuSan</ProtocolTitle><Sponsor>Beijing Friendship Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="206981"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A compassionate protocol of ziprasidone for patients who had successfully completed a previous ziprasidone study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="89310"/><TrialStartDate>2000-07-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, multicenter, 6-week, open-label, non-comparative, flexible-dose study to evaluate the efficacy, safety and tolerability of oral ziprasidone in the treatment of acute exacerbation of schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86402"/><TrialStartDate>2002-09-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, multi-center, randomized, double-blind, placebo-controlled, safety and efficacy study of ziprasidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53484"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36202"/><TrialStartDate>2003-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect and safety of ziprasidone compared to other atypical anti-psychotic drug in schizophrenic patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21120"/><TrialStartDate>2001-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1948">Asperger syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="30970"/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1258">Spinal cord injury</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (Spinalon) in Patients With Chronic Spinal Cord Injury</ProtocolTitle><Sponsor>Nordic Life Science Pipeline Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="83109"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Multiple Doses of Lasmiditan in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="309530"/><TrialStartDate>2017-08-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="301294"/><TrialStartDate>2017-06-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Treatment for Refractory Gastroesophageal Reflux Disease</ProtocolTitle><Sponsor>Universitaire Ziekenhuizen Leuven</Sponsor><StudyType>Interventional</StudyType><Trial id="353800"/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="31">Asthma</Indication><ProtocolAcronym/><ProtocolTitle>Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="263970"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Compare the Efficacy and Tolerability of the Combination of Aripiprazole and Selective Serotonin Reuptake Inhibitors (SSRIs) Used in Major Depression</ProtocolTitle><Sponsor>Chi-Mei Medical Center Of Taiwan</Sponsor><StudyType>Interventional</StudyType><Trial id="50660"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>OPTIMUM</ProtocolAcronym><ProtocolTitle>Optimizing Outcomes of Treatment-Resistant Depression in Older Adults</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="278829"/><TrialStartDate>2017-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="54699">temanogrel</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1076">Thrombosis</Indication><ProtocolAcronym/><ProtocolTitle>Single-Dose, Safety Study of APD-791 in Healthy Volunteers</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36541"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>STABIL-B</ProtocolAcronym><ProtocolTitle>Sequential Therapy for the Treatment of Severe Bipolar Depression</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="280467"/><TrialStartDate>2018-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Therapy for Reducing Comorbid Substance Abuse</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="33105"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A multi-centre, placebo-control, single blind trial was to evaluate the efficacy, tolerability and safety of ATL-1251 in constipation-predominant irritable bowel syndrome patients</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><Trial id="20294"/><TrialStartDate>2000-03-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-control, dose-ranging study was to assess the pharmacokinetics and pharmacodynamics of renzapride in constipation-predominant IBS patients</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><Trial id="20277"/><TrialStartDate>2002-04-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="73740">sumatriptan (intranasal, migraine), Promius Pharma</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A three-way, single-dose, randomized, cross-over study on the pharmacokinetic characterization and dose selection of a novel sumatriptan nasal spray formulation, DFN-02</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="326535"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3797">Gastrointestinal motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>Timing of administration of mosapride on feeding intolerance in TBI patients</ProtocolTitle><Sponsor>Third Military Medical University of the Chinese PLA</Sponsor><StudyType>Interventional</StudyType><Trial id="371313"/><TrialStartDate>2019-02-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3150">Social phobia</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder</ProtocolTitle><Sponsor>The Medical Research Network</Sponsor><StudyType>Interventional</StudyType><Trial id="216250"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Detoxification and Treatment of Subjects With Medication Overuse Headache</ProtocolTitle><Sponsor>New England Center for Headache, P.C.</Sponsor><StudyType>Interventional</StudyType><Trial id="14472"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A cardiac safety trial of renzapride in patients with gastroparesis</ProtocolTitle><Sponsor>EndoLogic LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="339700"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="35268"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 26-Week, Prospective Study to Evaluate the Long-Term Efficacy and Safety of Aripiprazole in Patients with Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder</ProtocolTitle><Sponsor>Seoul National University College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="144495"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="97">Diabetes mellitus</Indication><ProtocolAcronym/><ProtocolTitle>Effect of tegaserod on gastric emptying in patients with diabetic gastroparesis</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="9410"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="226">Nausea</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="94639">zolmitriptan (inhalation powder, migraine), Acorda</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="31">Asthma</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder</ProtocolTitle><Sponsor>Acorda Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="271888"/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1634">Vascular dementia</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2520">Insulin resistance</Indication><ProtocolAcronym/><ProtocolTitle>Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics</ProtocolTitle><Sponsor>Veterans Medical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="192142"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A pilot, randomized study to evaluate the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression</ProtocolTitle><Sponsor>AstraZeneca plc, Ministry of Science and Technology of the People´s Republic of China, National Alliance for Research on Schizophrenia and Depression, National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality</Sponsor><StudyType>Interventional</StudyType><Trial id="81089"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90560">lorcaserin hydrochloride (extended-release, obesity), Arena/Eisai</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot study of single-dose oral bioequivalence, randomized, balanced, open, two-treatments, two-sequences, two-periods, crossed of Lorcaserin Hydrochloride of 20 mg in extended release tablets of Lupine Limited, India compared with the administration of Belviq XR (Lorcaserin Hydrochloride) of 20 mg in extended release tablets from Arena Pharmaceuticals Gmbh, in healthy male subjects of the male gender in the postprandial state</ProtocolTitle><Sponsor>Laboratorios Grin, Lupin Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="347689"/><TrialStartDate>2017-02-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess the Safety and Efficacy of Onzetra Xsail (Sumatriptan Nasal Powder) for the Acute Treatment of Episodic Migraine With or Without Aura in Adolescents</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="319217"/><TrialStartDate>2017-11-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>High-Dose Lurasidone for Patients With Treatment-Resistant Schizophrenia</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><Trial id="86206"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Non-controlled, Post-marketing, Genetic Association Study on Individual Difference of Therapeutic Effects of Antipsychotic Medication</ProtocolTitle><Sponsor>Ministry of Health of the People's Republic of China, Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="98772"/><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-month, prospective, open-label study to evaluate the comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Cephalon Inc, Eli Lilly &amp; Co, Johnson &amp; Johnson, Merck &amp; Co Inc, National Alliance for Research on Schizophrenia and Depression, Otsuka Pharmaceutical Co Ltd, Pfizer Inc, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="97114"/><TrialStartDate>2012-01-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, multicenter, parallel, double-blind, double-dummy, active-control study to compare the effects of ziprasidone and olanzapine in patients with schizophrenia or schizophrenic disorder, previously treated with a typical neuroleptic drug (fluphenazine)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86687"/><TrialStartDate>2000-04-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, prospective, multicenter, non-comparative, open-label study to determine the tolerability, safety and efficacy of ziprasidone in pre-treated or untreated subjects with schizophrenia or schizoaffective disorders, over 12 weeks with an extension phase of up to 6 months for tolerability and safety</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86059"/><TrialStartDate>2001-07-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An 8-week, randomized, double-blind, active-controlled, head-to-head, safety and efficacy study of ziprasidone, compared to risperidone in patients with schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53572"/><TrialStartDate>1995-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label, Multicenter Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35764"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34897"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="33855"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>5</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment</ProtocolTitle><Sponsor>Shanxi Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="250546"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of metabolic side-effect of olanzapine or ziprasidone monotherapy, ziprasidone replacement and ziprasidone joint olanzapine treatment on schizophrenia or schizophrenia like patients - an open, controlled study</ProtocolTitle><Sponsor>Xijing Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="248305"/><TrialStartDate>2015-10-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study of the efficacy and safety of intramuscular ziprasidone followed by oral ziprasidone for the treatment of psychosis</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21413"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Kahn</ProtocolAcronym><ProtocolTitle>Investigation of the efficacy of ziprasidone versus olanzapine in the management of recent-onset psychosis; A flexible-dose, parallel-group, double-blind study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="20969"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled Study to Evaluate the Effects Of Donepezil Adjunctive Treatment To Ziprasidone On Cognitive Deficits In Schizophrenia</ProtocolTitle><Sponsor>Bispebjerg Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="147542"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Brain Activation During Memory Tasks in Patients with Schizophrenia Under Treatment of Risperidone or Ziprasidone. A FMRT Investigation</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen, University Hospital, Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="131623"/><TrialStartDate>2006-01-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study to Compare the Efficacy of Ziprasidone (Zeldox) and Aripiprazole (Abilify) on Cognitive Functioning and Quality of Sleep in the Treatment of Schizophrenic Patients</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="129806"/><TrialStartDate>2007-12-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 21-day, randomized, double-blind, placebo-controlled replication trial of ziprasidone in acute bipolar mania</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><Trial id="70352"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="32459"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Prospective, Open-Label Treatment Trial of Ziprasidone Monotherapy in Children and Adolescents with Bipolar Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="145507"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A 21-day, phase III, multicenter, in-patient, randomized, double-blind, placebo-controlled, safety and efficacy study of ziprasidone in patients with acute bipolar mania</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53553"/><TrialStartDate>2002-04-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A 3-Week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33923"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66454"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Geodon in Weight Loss Study for Bipolar Disorders</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><Trial id="35111"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, double-blind, multi-center, randomized, placebo-controlled study to evaluate the safety and efficacy of gepirone in patients with moderate depression</ProtocolTitle><Sponsor>Fabre Kramer Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="45942"/><TrialStartDate>2005-06-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label, randomized, placebo-controlled, efficacy study of gepirone in patients with major depressive disorder</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45919"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>An 8-week, placebo-controlled, safety and efficacy study of gepirone for the treatment of depression</ProtocolTitle><Sponsor>GlaxoSmithKline plc, Summit Research Network, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="45929"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, uncontrolled, open-label multi-attack outpatient study to evaluate the long-term safety of oral naratriptan as short-term prophylactic treatment for menstrually-associated migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78620"/><TrialStartDate>2000-03-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, open-label, non-comparative, pilot, multi-attack, outpatient study to evaluate the efficacy and tolerability of naratriptan in prophylactic treatment of pure menstrual migraine attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78543"/><TrialStartDate>2000-10-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, randomized, double-blind, placebo-controlled, parallel group, multi-attack, outpatient study to evaluate the effects of naratriptan in the conversion of a chronic daily headache pattern consistent with transformed migraine to an episodic migraine pattern</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77297"/><TrialStartDate>1998-04-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, parallel-group, double-blind, placebo-controlled, dose-ranging, outpatient, single-attack study to evaluate the efficacy and safety of four doses of naratriptan in the acute treatment of a single migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77259"/><TrialStartDate>1995-07-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, placebo-controlled, two-way crossover study to evaluate the ocular effects of naratriptan in healthy female subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77244"/><TrialStartDate>1996-02-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Preference for Triptans in Migraine Patients: A Randomized, Open-Label, Crossover Prospective Study</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><Trial id="125981"/><TrialStartDate>2010-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, comparative study to assess the efficacy and safety of eletriptan versus naratriptan in migraine patients</ProtocolTitle><Sponsor>Glaxo Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="116170"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Crossover, Double-blind, Comparative Study of Naratriptan and Naproxen in the Treatment of Migraine</ProtocolTitle><Sponsor>Erasmus University Medical Center Rotterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="114438"/><TrialStartDate>2003-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Dose-finding, Double-blind, Multicenter, Placebo-controlled, Randomized Study To Evaluate Safety, Efficacy And Early Clinical Experience With Subcutaneous Naratriptan In The Acute Treatment Of Migraine</ProtocolTitle><Sponsor>Glaxo Wellcome Research and Development Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="107426"/><TrialStartDate>1998-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, single-blind, 2-week proof of concept study to compare the quality of life in subjects receiving DA-9701 and mosapride</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="17642"/><TrialStartDate>2008-03-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Cooperative Group for Clinical Research in G-POEM (POP), Jiangsu, China</ProtocolTitle><Sponsor>The Affiliated Zhongda Hospital of Southeast University</Sponsor><StudyType>Interventional</StudyType><Trial id="287483"/><TrialStartDate>2017-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled trial to assess the effect of mosapride with esomeprazole in improving esophageal peristaltic function in patients with gastroesophageal reflux disease</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="139373"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="678">Neuropathy</Indication><ProtocolAcronym/><ProtocolTitle>An exploratory study to evaluate the efficacy of xaliproden in eliminating chemotherapy-induced neuropathy in patients with colorectal cancer</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45808"/><TrialStartDate>2007-02-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Pre-Emptive Oral GR-43175C Treatment During a Cluster Headache Period – (100 mg tid for 7 Days) – a Double-Blind, Parallel-Group, Placebo-Controlled Study</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="158781"/><TrialStartDate>1991-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study in Subjects With Acute Migraines Headaches</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="93927"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, outpatient, single attack study to evaluate the safety and efficacy of sumatriptan tablets 50 and 100 mg versus placebo during a migraine headache at the first sign of pain</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87876"/><TrialStartDate>2000-07-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled, parallel-group, single-attack, in-clinic, pilot study to investigate the efficacy and tolerability of 100 mg sumatriptan administered as a film-coated, fast disintegrating tablet in subjects with moderate or severe migraine pain</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87718"/><TrialStartDate>2002-08-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, pilot, open-label, randomized, crossover, stratified, multiattack study to evaluate the efficacy and tolerability between sumatriptan suppository 25 mg and sumatriptan tablet 50 mg in the treatment of acute migraine (with and without aura) associated with the menstrual cycle</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87679"/><TrialStartDate>2000-05-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, cross-over, multi-attack, outpatient study to evaluate subject satisfaction with naratriptan compared with sumatriptan in subjects who had lapsed from their previous oral or subcutaneous sumatriptan because of lack of efficacy or tolerability</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77984"/><TrialStartDate>1997-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Sumatriptan With Naprosyn in Migraine With Aura</ProtocolTitle><Sponsor>Dent Neurologic Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="54220"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="36247"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase IIIB, Double-Blind, Multicenter, Parallel-Group, General Practice Study to Compare Sumatriptan With Migraleve (Pfizer) in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="207540"/><TrialStartDate>1990-01-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Study to Evaluate Repeat-Dose Oral Sumatriptan 100 mg in the Acute Treatment of Adolescent Migraine During a Six Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="169729"/><TrialStartDate>1995-05-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Open, Pilot Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Sumatriptan Oral (50 mg) + Oral Metoclopramide (10 mg) + Oral Aspirin (900 mg) in the Treatment of a Single Migraine Attack in Patients Not Usually Pain Free During Previous Attacks, With the Following Molecules, Taken by Oral Route as Monotherapy: Triptan and Aspirin</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152315"/><TrialStartDate>1999-09-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open Design, Multiple Treatment Study to Evaluate Subcutaneous Sumatriptan (6 mg) in the Acute Treatment of Cluster Headache Attacks During a 3-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="149351"/><TrialStartDate>1991-09-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Sodium Valproate and Sumatriptan in Acute Migraine Attack</ProtocolTitle><Sponsor>Shahid Sadoughi University of Medical Sciences and Health Services</Sponsor><StudyType>Interventional</StudyType><Trial id="132889"/><TrialStartDate>2011-10-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison the Effect of Propofol with Subcutaneous Sumatriptane in Treatment of Acute Migraine Headache</ProtocolTitle><Sponsor>Shahid Sadoughi University of Medical Sciences and Health Services</Sponsor><StudyType>Interventional</StudyType><Trial id="127509"/><TrialStartDate>2012-03-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="116531"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, multicenter, placebo-controlled, parallel group, randomized study to assess the efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine</ProtocolTitle><Sponsor>Universitatsklinikum Essen</Sponsor><StudyType>Interventional</StudyType><Trial id="108656"/><TrialStartDate>1999-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Comparative, Cross-over, Double-blind, Multicenter, Placebo-controlled Study to assess Rizatriptan versus sumatriptan in migraine</ProtocolTitle><Sponsor>San Francisco (Calif) Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="107557"/><TrialStartDate>1998-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, multicenter, randomized study of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine</ProtocolTitle><Sponsor>CENTRE ANTI-DOULEUR</Sponsor><StudyType>Interventional</StudyType><Trial id="107130"/><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Zolmitriptan by Sublingual Administration</ProtocolTitle><Sponsor>Xijing Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="323316"/><TrialStartDate>2018-01-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, placebo-controlled trial to compare the safety and efficacy of rizatriptan and ibuprofen in migraine patients</ProtocolTitle><Sponsor>Sanjay Gandhi Postgraduate Institute of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="67470"/><TrialStartDate>2007-04-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="54474"/><TrialStartDate>2009-06-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Dose-Finding Study of MK-0974 in Acute Migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13993"/><TrialStartDate>2005-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>BP2</ProtocolAcronym><ProtocolTitle>Bergen Psychosis Project 2 - The Best Intro Study</ProtocolTitle><Sponsor>Haukeland University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="81330"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, randomized, double-blind, placebo-controlled study of mirtazapine for the treatment of positive and negative symptoms of schizophrenia</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="62890"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="61723"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, 4-week, placebo- and haloperidol-controlled, phase II study to evaluate the safety and efficacy of aripiprazole in acutely relapsing schizophrenic patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="51218"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>COATS</ProtocolAcronym><ProtocolTitle>Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="37845"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="373398"/><TrialStartDate>2019-05-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>STAR-1</ProtocolAcronym><ProtocolTitle>Use of Galantamine and CDP-Choline (Citicoline) to Treat Adults with Schizophrenia</ProtocolTitle><Sponsor>Georgetown University</Sponsor><StudyType>Interventional</StudyType><Trial id="36353"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PROACTIVE</ProtocolAcronym><ProtocolTitle>Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36294"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>SFBRI</ProtocolAcronym><ProtocolTitle>Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia</ProtocolTitle><Sponsor>Louisiana State University</Sponsor><StudyType>Interventional</StudyType><Trial id="36222"/><TrialStartDate>2003-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>BEST</ProtocolAcronym><ProtocolTitle>Best Event Schizophrenia Trial-A Randomized, Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia</ProtocolTitle><Sponsor>Kettering Health Network</Sponsor><StudyType>Interventional</StudyType><Trial id="35766"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Olanzapine Versus Aripiprazole in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="34852"/><TrialStartDate>2003-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ALFA</ProtocolAcronym><ProtocolTitle>A Study of Aripiprazole in Patients With Schizophrenia in General Psychiatric Practices</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34503"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic</ProtocolTitle><Sponsor>Centre Hospitalier Universitaire De Nice</Sponsor><StudyType>Interventional</StudyType><Trial id="336664"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A preliminary open-label study to evaluate the effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia</ProtocolTitle><Sponsor>Ministry of Education, Culture, Sports, Science and Technology of Japan</Sponsor><StudyType>Interventional</StudyType><Trial id="308859"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>QUAIL</ProtocolAcronym><ProtocolTitle>QUAIL-Study</ProtocolTitle><Sponsor>Kansai Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="275473"/><TrialStartDate>2016-08-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film versus Abilify 10 mg Tablet in Healthy Volunteers</ProtocolTitle><Sponsor>CMG Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="235115"/><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>9</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>DREaM</ProtocolAcronym><ProtocolTitle>A Study to Compare Disease Progression and Modification Following Treatment with Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's with Recent-Onset Schizophrenia or Schizophreniform</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="228891"/><TrialStartDate>2015-07-08 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>31</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APIC</ProtocolAcronym><ProtocolTitle>Antipsychotic Induced Structural and Functional Brain Changes</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="228608"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PREVENT</ProtocolAcronym><ProtocolTitle>Secondary Prevention of Schizophrenia. A randomized, controlled trial</ProtocolTitle><Sponsor>University of Cologne</Sponsor><StudyType>Interventional</StudyType><Trial id="228171"/><TrialStartDate>2007-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Phase IV Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19419"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study on Cognitive Dysfunction Improvement of Aripiprazole for Japanese Schizophrenia Patients</ProtocolTitle><Sponsor>Tottori University</Sponsor><StudyType>Interventional</StudyType><Trial id="184586"/><TrialStartDate>2014-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Study to Evaluate the Effects of the DRD3 Ser9Gly and HTR2A A-1438G/T102C Polymorphisms on Aripiprazole Efficacy in Schizophrenic Patients as Modified By Clinical Factors</ProtocolTitle><Sponsor>National Dong-Hwa University</Sponsor><StudyType>Interventional</StudyType><Trial id="148596"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An [18F]fallypride PET study to evaluate the brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="147568"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Single-Group Trial to Evaluate the Efficacy and Tolerability of Aripiprazole in First-Episode Drug-Naive Patients With Schizophrenia</ProtocolTitle><Sponsor>Tokyo Women's Medical College</Sponsor><StudyType>Interventional</StudyType><Trial id="144540"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aripiprazole in Patients With Schizophrenia and Schizoaffective Disorders</ProtocolTitle><Sponsor>Ranbaxy Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="144391"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Dose Ranging Study of the Efficacy and Tolerability of Aripiprazole in Acutely Relapsing Hospitalized Schizophrenic Patients</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="144020"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized Open-label Study of the Effects of Aripiprazole in Overweight and Obstructive Sleep Apnea Subjects With Schizophrenia or Schizoaffective Disorder Switched From Other Antipsychotic Drugs</ProtocolTitle><Sponsor>Biwako Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="136397"/><TrialStartDate>2011-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Aripiprazole on Swallowing Function</ProtocolTitle><Sponsor>Tohoku University</Sponsor><StudyType>Interventional</StudyType><Trial id="120663"/><TrialStartDate>2012-05-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>A Short Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88278"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><Trial id="31138"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Combination Treatment for Augmenting Language in Children With ASD</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><StudyType>Interventional</StudyType><Trial id="243092"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Aripiprazole</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><Trial id="174686"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Therapy for Reducing Comorbid Substance Abuse</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="33105"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-month, prospective, open-label study to evaluate the comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Cephalon Inc, Eli Lilly &amp; Co, Johnson &amp; Johnson, Merck &amp; Co Inc, National Alliance for Research on Schizophrenia and Depression, Otsuka Pharmaceutical Co Ltd, Pfizer Inc, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="97114"/><TrialStartDate>2012-01-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Patients With Acute Symptoms of Bipolar Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34506"/><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="174271"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette's Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="98391"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="34199"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Bipolar Disorder and Alcohol Use Disorder</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="273220"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Measure the Difference in All-cause Hospitalizations for Patients Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="351213"/><TrialStartDate>2018-06-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>ASCERTAINTRD</ProtocolAcronym><ProtocolTitle>Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="280824"/><TrialStartDate>2017-05-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="256985"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>PRADA</ProtocolAcronym><ProtocolTitle>Prediction of Response to Anti-depressant</ProtocolTitle><Sponsor>University of Occupational &amp; Environmental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="219145"/><TrialStartDate>2014-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Versus Duloxetine in Combination With Mirtazapine for Treatment-Resistant Major Depressive Disorder: A Rater-Masked, Randomized Trial</ProtocolTitle><Sponsor>Fujita Health University</Sponsor><StudyType>Interventional</StudyType><Trial id="154722"/><TrialStartDate>2013-08-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo- and Ropinirole-Controlled Study for SPM-962 in Advanced Parkinson's Disease Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88752"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-stage, Idiopathic Parkinson's Disease</ProtocolTitle><Sponsor>Schwarz Pharma SpA, UCB BIOSCIENCES GmbH, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6651"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson's Subject Symptoms Management</ProtocolTitle><Sponsor>UCB Biopharma SPRL</Sponsor><StudyType>Interventional</StudyType><Trial id="293374"/><TrialStartDate>2017-03-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>Honeymoon</ProtocolAcronym><ProtocolTitle>Non Motors Aspects in De Novo Parkinson's Disease</ProtocolTitle><Sponsor>University Hospital, Grenoble</Sponsor><StudyType>Interventional</StudyType><Trial id="262627"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Profile of Neupro Patch Administrated at 2, 4, 6 and 8 mg/day Weekly in Patients With Early-stage Parkinson's Disease</ProtocolTitle><Sponsor>Luye Pharma Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="257516"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Phase III Open-Label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects</ProtocolTitle><Sponsor>UCB Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6634"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled Study for SPM-962 in Restless Legs Syndrome (RLS) Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="16945"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="63710"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>An interventional, randomized, cross-over study to investigate the effect of steady-state exposure to flibanserin on the single-dose pharmacokinetics of the contraceptive steroids ethinylestradiol and levonorgestrel in healthy premenopausal women</ProtocolTitle><Sponsor>Bausch Health Companies Inc, Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="334732"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym>VIOLET</ProtocolAcronym><ProtocolTitle>24-Week, Placebo-Controlled Trial of Flibanserin Once-Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="33366"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym>DAISY</ProtocolAcronym><ProtocolTitle>Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="33283"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MATRIX(Migrainer Assess TRiptane eXamination)</ProtocolTitle><Sponsor>University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><Trial id="132785"/><TrialStartDate>2010-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, comparative study to assess the efficacy and safety of eletriptan versus naratriptan in migraine patients</ProtocolTitle><Sponsor>Glaxo Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="116170"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, placebo-controlled, randomized study for the comparison of the effectiveness of oral eletriptan (40 to 80 mg) and oral sumatriptan (50 to 100 mg) in reducing the time loss and overall impact of migraine attacks</ProtocolTitle><Sponsor>Pfizer Central Research</Sponsor><StudyType>Interventional</StudyType><Trial id="109739"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>Illuminate</ProtocolAcronym><ProtocolTitle>Lurasidone Pediatric Bipolar Study</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="169879"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PASTEL</ProtocolAcronym><ProtocolTitle>A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88214"/><TrialStartDate>2012-07-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Digoxin Drug-Drug Interaction With Lurasidone HCl</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64678"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of lurasidone hydrochloride</ProtocolTitle><Sponsor>Jiang Su Guodan Biological Pharmaceutical Co Ltd, Nanjing Huawe Medicine Technology Development Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="361206"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>FUNDACION ESPANOLA PARA EL DESARROLLO DE LA NEUROMETRIA, Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34722"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Effects on Tissue Glutamate in Schizophrenia</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="206465"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>NMDA Antagonists in Bipolar Depression</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="121831"/><TrialStartDate>2013-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Biosignatures of Latuda for Bipolar Depression</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="210316"/><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study to Compare Frovatriptan versus Topiramate for Prevention of Migraine</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="46325"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Controlled Trial to Investigate the Efficacy and Safety of Frovatriptan to Prevent Menstrual Migraine</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14085"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, non-randomized, comparison, pilot study of frovatriptan versus naproxen sodium versus no therapy for the symptomatic or prophylactic treatment of weekend migraine</ProtocolTitle><Sponsor>Valduce Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="135054"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Crossover, Patient Preference Study of Frovatriptan Versus Rizatriptan for The Acute Treatment Of Migraine</ProtocolTitle><Sponsor>The Menarini Group</Sponsor><StudyType>Interventional</StudyType><Trial id="117052"/><TrialStartDate>2007-04-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="2529">Hot flashes</Indication><ProtocolAcronym/><ProtocolTitle>Vilazodone for Menopausal Hot Flashes</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><Trial id="91010"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of efficacy and safety of vilazodone, escitalopram and amitriptyline in patients of depression</ProtocolTitle><Sponsor>Government Medical College, Nagpur</Sponsor><StudyType>Interventional</StudyType><Trial id="317685"/><TrialStartDate>2016-02-08 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Vilazodone on Glutamate in the Anterior Cingulate Cortex in Anxious Unipolar Depressives</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="166237"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Switching From Generic Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) to Three Different Dose Initiation Strategies With Vilazodone</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="164445"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, placebo-controlled study of tegaserod in patients with constipation-predominant irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19865"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A study of tegaserod in patients with alternating irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19744"/><TrialStartDate>2000-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study of tegaserod in Asian-Pacific patients with non-diarrhea irritable bowel syndrome (non-D-IBS)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19719"/><TrialStartDate>2002-10-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study of tegaserod in constipation-predominant irritable bowel syndrome patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19715"/><TrialStartDate>1998-09-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, multicenter study of tegaserod in constipation-dominant irritable bowel syndrome in an Asian (Pakistan) population</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19669"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18192"/><TrialStartDate>2007-08-03 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18054"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19752"/><TrialStartDate>2000-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled study of tegaserod in patients with chronic constipation</ProtocolTitle><Sponsor>University of Illinois</Sponsor><StudyType>Interventional</StudyType><Trial id="19656"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Polyethyleneglycol-3350 Versus Tegaserod In Treatment Of Patients With Chronic Constipation</ProtocolTitle><Sponsor>Braintree Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="101402"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym>D2301E1</ProtocolAcronym><ProtocolTitle>Extension Study to Assess the Long-Term Safety of Tegaserod in Women With Symptoms of Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42504"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, cross-over trial of tegaserod in gastroesophageal reflux disease patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19788"/><TrialStartDate>2005-05-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to assess the efficacy and safety of almotriptan in migraine patients</ProtocolTitle><Sponsor>Almirall Prodesfarma SA</Sponsor><StudyType>Interventional</StudyType><Trial id="109669"/><TrialStartDate>2000-04-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="11201">elopiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I crossover, randomized, placebo-controlled study comparing the pharmacokinetics of two doses of DU-29894 with flesinoxan, sulpride, haloperidol and placebo in healthy volunteers</ProtocolTitle><Sponsor>Abbott Healthcare Products BV</Sponsor><StudyType>Interventional</StudyType><Trial id="50117"/><TrialStartDate>1995-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effects of prucalpride  on small bowel and colonic transit in patients with functional constipation or constipation-predominant irritable bowel syndrome</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19090"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Prucalopride in Patients With Severe Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18425"/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of the Effect of Dose-titration of Prucalopride for The Treatment of Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18424"/><TrialStartDate>1998-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Prucalopride for the Re-Treatment of Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18413"/><TrialStartDate>1999-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Prucalopride for the Treatment of Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18412"/><TrialStartDate>1995-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Safety and Tolerability of Prucalopride in Constipated Elderly Subjects Living in a Nursing Facility</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18411"/><TrialStartDate>1999-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Sarizotan in Parkinson Patients With L-Dopa-Induced Dyskinesia</ProtocolTitle><Sponsor>EMD Serono Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7031"/><TrialStartDate>2002-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym>PADDY-O</ProtocolAcronym><ProtocolTitle>An Open-Label, Multicenter, Multinational, Phase III Follow-Up Study to Investigate the Long-Term Safety and Efficacy of Sarizotan HCl 1 mg bid in Patients With Parkinsons Disease Suffering From Treatment-Associated Dyskinesia</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><Trial id="143076"/><TrialStartDate>2005-09-08 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, pilot phase I study to evaluate dopamine D2 receptor occupancy after multiple oral administration of DU-127090 to healthy male volunteers, using 11C-raclopride by means of position emission tomography (PET)</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41463"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34636"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Abatacept as GVHD Prophylaxis Phase 2</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34500"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34459"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="22806">piclozotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="65">Stroke</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of SUN-N4057 in Subjects With Acute ischemic stroke and measurable penumbra on magnetic resonance imaging (MRI)</ProtocolTitle><Sponsor>Daiichi Sankyo Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="5474"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6117"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>CLARITY</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="285071"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="27819">capeserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, double-blind, placebo-controlled study to evaluate the efficacy of capeserod in patients with mild-to-moderate Alzheimers disease</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="54170"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="29493">adoprazine</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="36604"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Pharmacokinetic Study to Evaluate Treximet in Adolescents With Migraine and Healthy Subjects Administered at Three Doses</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="60838"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, crossover study to evaluate the pain-free response to early-intervention with Treximet in patients with episodic migraine</ProtocolTitle><Sponsor>Carolina Headache Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="178258"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea</ProtocolTitle><Sponsor>GlaxoSmithKline Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14027"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics And Tolerability Study of MAP-0004 Co-administered With Ketoconazole</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82218"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics And Tolerability Study of MAP-0004 Co-administered With Ketoconazole</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82218"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A drug-interaction study assessing the effects of CYP3A4 inhibition on the pharmacokinetics of Levadex (MAP-0004, orally inhaled DHE) in healthy subjects</ProtocolTitle><Sponsor>MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="78532"/><TrialStartDate>2011-06-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Tolerability Study of MAP-0004 in Smoking and Non-Smoking Adult Volunteers</ProtocolTitle><Sponsor>Allergan Inc, MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="70494"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Double-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="79337"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate safety and pharmacokinetics of buspirone once-a-day transdermal spray when compared to oral buspirone in healthy volunteers for the treatment of anxiety disorder</ProtocolTitle><Sponsor>Acrux Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="55157"/><TrialStartDate>2003-08-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Determine the Pharmacokinetics of Buspirone from a Metered Dose Transdermal System (MDTS) in anxiety</ProtocolTitle><Sponsor>Acrux Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="260786"/><TrialStartDate>2002-10-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="14038"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Pharmacokinetics (PK) Study of Single-Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults</ProtocolTitle><Sponsor>Acorda Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="246594"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Safety and efficacy of APD-356 in the treatment of obesity</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38679"/><TrialStartDate>2005-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study on the Usability of the Needle-Free Intraject System in Adult Patients During Acute Migraine Attack</ProtocolTitle><Sponsor>Zogenix Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14101"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>CONNECT</ProtocolAcronym><ProtocolTitle>Efficacy of Lu-AA21004 on Cognitive Dysfunction in Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="86033"/><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Lu-AA21004 for Treatment of Major Depressive Disorder</ProtocolTitle><Sponsor>ICON Clinical Research, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="72879"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Vortioxetine (Lu-AA21004) in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="69058"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-label, Safety, Extension Study of 5 and 10 mg of Vortioxetine (Lu-AA21004) in Long-term Treatment of Major Depressive Disorder in Adults</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="34799"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>THINC-it Vortioxetine - Sensitivity to Change</ProtocolTitle><Sponsor>Brain and Cognition Discovery Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="288325"/><TrialStartDate>2017-05-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>VOR-IISR</ProtocolAcronym><ProtocolTitle>Pattern Separation, Brain Derived Neurotrophic Factors, and Mechanisms of Vortioxetine</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="279907"/><TrialStartDate>2017-08-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine iv With 10 mg/Day Vortioxetine po in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="273437"/><TrialStartDate>2016-09-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 18 Years of Age</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="268938"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Active Reference (Fluoxetine) Fixed-Dose Study of Vortioxetine in Pediatric Patients Aged 7 to 11 Years With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="255928"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III Study of Lu-AA21004 in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="225186"/><TrialStartDate>2015-04-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine 5, 10 and 20 mg, Relapse Prevention Study in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="222918"/><TrialStartDate>2015-02-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>AtWoRC</ProtocolAcronym><ProtocolTitle>Assessment in Work Productivity and the Relationship with Cognitive Symptoms in Patients With MDD Taking Vortioxetine</ProtocolTitle><Sponsor>Lundbeck Canada Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="219593"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic study of PRX-03140 for the Treatment of Alzheimer's Disease</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="3893"/><TrialStartDate>2005-03-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Short Term Effects of PRX-03140 in Patients With Mild Alzheimer's Disease Being Treated With Aricept</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="1029"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia</ProtocolTitle><Sponsor>Mitsubishi Tanabe Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="88625"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of MP-214 in Patients With Schizophrenia</ProtocolTitle><Sponsor>Mitsubishi Tanabe Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="88569"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia</ProtocolTitle><Sponsor>Allergan plc</Sponsor><StudyType>Interventional</StudyType><Trial id="367946"/><TrialStartDate>2019-06-06 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Efficacy of a Fixed-Dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="252333"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="79318"/><TrialStartDate>2011-07-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Object of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="359783"/><TrialStartDate>2018-11-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1269">Functional bowel disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Placebo-controlled, Multiple Dose Phase I Study To Assess The Safety, Tolerability And Pharmacokinetics Of TD-5108 For The Potential Treatment Of Gastrointestinal (GI) Motility Disorders In Healthy Volunteers</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17993"/><TrialStartDate>2006-04-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="54699">temanogrel</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym/><ProtocolTitle>Single-Dose, Safety Study of APD-791 in Healthy Volunteers</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36541"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic, Single-Dose Study of Oral Lasmiditan in Subjects With Normal and Impaired Hepatic Function</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="287110"/><TrialStartDate>2017-03-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="240">Ocular hypertension</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of piromelatine in patients with ocular hypertension or primary open angle glaucoma</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="327251"/><TrialStartDate>2016-09-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase I study to assess the safety, tolerability and pharmacokinetics of Neu-P11 in healthy volunteers</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="68682"/><TrialStartDate>2010-06-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59015">ATI-9242</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, randomized, double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability and pharmacokinetics (PK) of ATI-9242 in healthy subjects</ProtocolTitle><Sponsor>ARYx Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36597"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Motilitone to Treat Functional Dyspepsia</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="222412"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Motilitone on Gastric Emptying in Patients With Functional Dyspepsia: Evaluation Using MRI Method</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><Trial id="192850"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Multicenter Clinical Study of RP-5063</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="154091"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="60372">clavulanic acid (immediate-release, male sexual disorders), Rexahn</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="186">Erectile dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)</ProtocolTitle><Sponsor>Rexahn Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="16685"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60663">buspirone + melatonin (depression), BrainCells</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of a Combination Product (BCI-024 and BCI-049) to Treat Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="23056"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to &lt; 13 Years Old) With Central Nervous System Disorders</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="313836"/><TrialStartDate>2017-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Trial of OPC-34712 in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="81754"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>VECTOR</ProtocolAcronym><ProtocolTitle>Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="79322"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for acute schizophrenia</ProtocolTitle><Sponsor>Fujita Health University</Sponsor><StudyType>Interventional</StudyType><Trial id="337006"/><TrialStartDate>2018-04-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I, Safety and Pharmacokinetic Study of Multiple Dose Brexpiprazole in Japanese Patients with Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="331948"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>TAILWIND</ProtocolAcronym><ProtocolTitle>Comparison of the Effectiveness of Brexpiprazole With That of Risperidone</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="259887"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Lighthouse</ProtocolAcronym><ProtocolTitle>Brexpiprazole in Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="115865"/><TrialStartDate>2013-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Flexible Dose Brexpiprazole as Monotherapy or Combination Therapy in the Treatment of Adults With Post-traumatic Stress Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="286321"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="358334"/><TrialStartDate>2018-11-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="347113"/><TrialStartDate>2018-10-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="150606"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Study of Two Fixed-Doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="134389"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Study of Brexpiprazole in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="359639"/><TrialStartDate>2018-10-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label trial to assess the long-term safety and efficacy of brexpiprazole as adjunctive therapy in patients with major depressive disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="352654"/><TrialStartDate>2018-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="298103"/><TrialStartDate>2017-09-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="163929"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Safety and Tolerability Study of Brexpiprazole as Adjunct Treatment in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="155051"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="154647"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A study to compare pharmacokinetic (PK) exposure of Gimoti versus Reglan in healthy subjects for the relief of symptoms associated with acute and recurrent diabetic gastroparesis</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="308767"/><TrialStartDate>2017-08-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym>TQT</ProtocolAcronym><ProtocolTitle>A double-blind, double-dummy, four-way, crossover study to evaluate the effect of EVK-001 on cardiac ventricular repolarization (QT interval) in male and female healthy volunteers</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="210158"/><TrialStartDate>2014-08-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="165690"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="63557">relenopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of YKP-10811 in Subjects With Irritable Bowel Syndrome With Constipation</ProtocolTitle><Sponsor>SK Chemicals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="177029"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Aripiprazole Intramuscular Depot (OPC-14597, Lu-AF41155) in the Acute Treatment of Adults With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="90119"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="89655"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Aripiprazole Long-acting Injection in Recent Onset and Chronic Schizophrenia Patients</ProtocolTitle><Sponsor>Chonbuk National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="370358"/><TrialStartDate>2018-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole IM Depot for Chinese Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="313265"/><TrialStartDate>2017-06-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole, Abilify Maintena Collaborative Clinical Protocol</ProtocolTitle><Sponsor>Florida Atlantic University</Sponsor><StudyType>Interventional</StudyType><Trial id="256499"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ASPIRE</ProtocolAcronym><ProtocolTitle>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="21267"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>QUALIFY</ProtocolAcronym><ProtocolTitle>Aripiprazole Once-Monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="111564"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy, Safety and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86120"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>BD-CAEL</ProtocolAcronym><ProtocolTitle>CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="327471"/><TrialStartDate>2018-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-blind study to evaluate the  pharmacokinetics of PF-04995274 in healthy subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80412"/><TrialStartDate>2011-07-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72849">minesapride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Effects of DSP-6952 on the QT/QTc in Healthy Male and Female Volunteers</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="324767"/><TrialStartDate>2017-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="72849">minesapride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3862">Constipation predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Dose-finding Study of DSP-6952 in Patients with Irritable Bowel Syndrome with Constipation</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="283814"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="72849">minesapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3862">Constipation predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-controlled, Double-blind, Parallel-group, Exploratory Study of DSP-6952 in Patients with Irritable Bowel Syndrome with Constipation</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="104455"/><TrialStartDate>2012-12-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Four-way Crossover Study of Three Formulations of M-207 with Intranasal zolmitriptan in Healthy Volunteers</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="383718"/><TrialStartDate>2019-05-29 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A crossover study to determine the tolerability and pharmacokinetics of ZP-Triptan compared to subcutaneous injection of sumatriptan and oral administration of zolmitriptan treatments for migraine headaches</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="239395"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="82058">YH-12852</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Investigation of the Absorption, Metabolism, and Excretion and the Absolute Bioavailability of YH-12852</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="323541"/><TrialStartDate>2017-03-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="82058">YH-12852</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Phase I/IIa Trial of YH-12852 in Healthy Subjects and Patients With Functional Constipation</ProtocolTitle><Sponsor>Yuhan Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="239544"/><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="97555">dihydroergotamine (aerosol nasal, migraine), Impel NeuroPharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>STOP-301</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of POD DHE (INP-104) in Migraine</ProtocolTitle><Sponsor>Impel NeuroPharma</Sponsor><StudyType>Interventional</StudyType><Trial id="343029"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>NMDA Antagonists in Bipolar Depression</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="121831"/><TrialStartDate>2013-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="102298">litoxetine, Ixaltis</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="2379">Mixed urinary incontinence</Indication><ProtocolAcronym/><ProtocolTitle>Safety and efficacy of litoxetine in women with urinary incontinence</ProtocolTitle><Sponsor>Ixaltis SA</Sponsor><StudyType>Interventional</StudyType><Trial id="336277"/><TrialStartDate>2017-03-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 52-week, long-term, randomized, double-blind study to compare the safety, tolerability and efficacy of aripiprazole and lithium in patients with bipolar I disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="87138"/><TrialStartDate>2011-02-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Low-Dose Adjunctive Aripiprazole in the Treatment of Bipolar Depression: Double-Blind, Placebo-Controlled, Pilot Study</ProtocolTitle><Sponsor>Douglas Mental Health University Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="84355"/><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>PAMS</ProtocolAcronym><ProtocolTitle>Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder</ProtocolTitle><Sponsor>University of Maryland</Sponsor><StudyType>Interventional</StudyType><Trial id="34878"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment and Outcome of Early Onset Bipolar Disorder</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System, The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="34477"/><TrialStartDate>2002-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Drug-Drug Interaction Study of Aripiprazole and Lamotrigine in Patients With Bipolar Type I Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34455"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depression Episode</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19205"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Comparison of Two Fixed Doses of Aripiprazole With Placebo in Acutely Relapsed, Hospitalized Patients With Bipolar Disorder I (Manic or Mixed) In Subpopulations</ProtocolTitle><Sponsor>University of Louisville</Sponsor><StudyType>Interventional</StudyType><Trial id="144026"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, open-label, single- and multiple-dose study to evaluate the pharmacokinetics and tolerability of cinitapride (CIN) in healthy Chinese subjects</ProtocolTitle><Sponsor>Almirall Prodesfarma SA</Sponsor><StudyType>Interventional</StudyType><Trial id="374392"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Safety,Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical study to determine the bioequivalence of two drugs for oral administration of cinitapride 1 mg tablets in healthy volunteers under fasting conditions</ProtocolTitle><Sponsor>Ultra Laboratories, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="197217"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Controlled, Multicenter Study in Patients With Functional Dyspepsia to Compare the Safety and Efficacy of DA-9701 and Itopride Hydrochloride</ProtocolTitle><Sponsor>Catholic University of Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="237213"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="153">Hepatitis C virus infection</Indication><ProtocolAcronym/><ProtocolTitle>Gastroparesis During Pegylated Interferon Therapy for Chronic Hepatitis C: Effects of Mosapride</ProtocolTitle><Sponsor>Osaka University</Sponsor><StudyType>Interventional</StudyType><Trial id="140880"/><TrialStartDate>2006-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1933">Undifferentiated schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65680"/><TrialStartDate>2010-04-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A crossover, double-blind, placebo-controlled, randomized trial to compare the pharmacokinetics and efficacy of zolmitriptan (Zomig) with dexfenfluramine on central serotonergic neurotransmission as assessed by active oddball auditory event-related potentials in healthy volunteers without migraine</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="108589"/><TrialStartDate>1999-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled study assessing the efficacy of oral lornoxicam in the treatment of acute migraine attack</ProtocolTitle><Sponsor>Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul University</Sponsor><StudyType>Interventional</StudyType><Trial id="201173"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan versus Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161688"/><TrialStartDate>1996-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>MBRP + Vortioxetine versus MBRP on Preventing Relapse in Chronic MA Users</ProtocolTitle><Sponsor>Central South University</Sponsor><StudyType>Interventional</StudyType><Trial id="369154"/><TrialStartDate>2019-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3063">Delirium</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone Versus Standard Therapy for Agitated Patients in the ED</ProtocolTitle><Sponsor>George Washington University</Sponsor><StudyType>Interventional</StudyType><Trial id="34293"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Versus Placebo in Diabetic Gastroparesis</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><Trial id="166924"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1279">Panic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Refractory Anxiety</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="31331"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="369">Male sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, open-label study to investigate the effect of switching to aripiprazole on sexual dysfunction and the hypothalamic-pituitary-gonadal axis in male patients with schizophrenia treated with atypical antipsychotics</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="89004"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, double-blind, placebo-controlled, safety and efficacy study of ACP-103 in patients with Parkinson's disease and treatment-induced motor dysfunction</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7687"/><TrialStartDate>2004-08-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="376">Gastric motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, parallel-group, placebo-controlled, ascending-dose study to evaluate the tolerability, pharmacokinetics and pharmacodynamics of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19849"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Bioavailability</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, three-period crossover study to evaluate the bioequivalence of sumatriptan 4 mg STATdose to sumatriptan 6 mg STATdose after dose-normalization, and to assess the relative bioavailability of 4 mg sumatriptan injected using the STATdose device compared to 4 mg sumatriptan injected manually</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87751"/><TrialStartDate>2004-09-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, single-dose, open-label, randomized, four-period crossover study to evaluate the bioequivalence of fast disintegrating sumatriptan tablets (50 and 100 mg tablets) compared with the currently marketed sumatriptan tablets (50 and 100 mg Imitrex /Imigran tablets), in healthy male and female volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87649"/><TrialStartDate>2002-05-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, single dose, three-way crossover study to evaluate the bioequivalence and taste acceptability of two different 20 mg/100 microl sumatriptan nasal spray formulations compared to the current 20 mg/100 microl sumatriptan nasal spray market formulation in healthy subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87620"/><TrialStartDate>2000-07-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open, randomized, crossover, two-period study of comparative pharmacokinetics and bioequivalence of Sumatriptan-LekT film-coated tablets, 100 mg (OJSC Tyumen Chemical-Pharmaceutical Plant, Russia) and Imigran tablets, coated with 100 mg (GlaxoSmithKline Trading, Russia) with the participation of healthy volunteers on an empty stomach</ProtocolTitle><Sponsor>JSC "Patent Farm"</Sponsor><StudyType>Interventional</StudyType><Trial id="325623"/><TrialStartDate>2017-12-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan</ProtocolTitle><Sponsor>Amgen Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="258466"/><TrialStartDate>2016-02-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Assess Triptan-Induced Disruption Of Trigemino-Cortical Connectivity</ProtocolTitle><Sponsor>University of Hamburg</Sponsor><StudyType>Interventional</StudyType><Trial id="231593"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Investigate Intra-Subject Variability and Sex Differences in the Pharmacokinetics of 100 mg Sumatriptan Following Oral Dosing</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="159579"/><TrialStartDate>1993-05-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Pharmacokinetics and Tolerability of Two Single Treximet (Formerly Known as Trexima) Ta Blets (Administered Two Hours Apart) in Healthy Volunteers.</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153675"/><TrialStartDate>2004-10-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Pharmacokinetic and Pharmacodynamic Profile of Intranasal Sumatriptan at Doses of 5, 10 and 20 Mg</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152477"/><TrialStartDate>1993-09-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, single-dose, double-blind, two-parallel-group, four-period crossover study to evaluate the safety, pharmacokinetics and pharmacodynamics of Lu-AA21004 in healthy adult volunteers</ProtocolTitle><Sponsor>H Lundbeck A/S, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="81626"/><TrialStartDate>2011-03-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Lu-AA21004 on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="74871"/><TrialStartDate>2011-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="349230"/><TrialStartDate>2018-08-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>BUSPARK</ProtocolAcronym><ProtocolTitle>Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson Disease</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><Trial id="247246"/><TrialStartDate>2016-06-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym>DAAMSEL</ProtocolAcronym><ProtocolTitle>Double-Blind, Placebo-Controlled Study of Adjunctive Aripiprazole for Symptomatic Hyperprolactinemia In Premenopausal Women With Schizophrenia</ProtocolTitle><Sponsor>University of Maryland</Sponsor><StudyType>Interventional</StudyType><Trial id="76584"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>Research of the variance on patients with schizophrenia treated with low dose aripiprazole on hyperprolactinemia induced by the second generation antipsychotics</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="311136"/><TrialStartDate>2013-07-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week, randomized, open-label, comparative clinical trial</ProtocolTitle><Sponsor>XinXiang Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="255165"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="19955">VML-670</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy of VML-670 in patients with sexual dysfunction</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="55878"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled clinical trial of buspirone for treating autism spectrum disorders</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="186656"/><TrialStartDate>2012-12-05 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Proton Pump Inhibitor With Prokinetics or Placebo in Patients With Laryngopharyngeal Reflux Disease</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><Trial id="238651"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3038">Appetite loss</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3283">Cannabis dependence</Indication><ProtocolAcronym/><ProtocolTitle>Use of a Mobile Health Sensor in an Open-Label Trial of Lorcaserin for the Treatment of Cannabis Use Disorder</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="275339"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="63544"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="69">Renal failure</Indication><ProtocolAcronym/><ProtocolTitle>Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="74435"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53257">aripiprazole (intramuscular), Otsuka/BMS</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="1345"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="226">Nausea</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Exploratory Study of the Effects of Vortioxetine (Lu-AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="87881"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, single-dose, double-blind, two-parallel-group, four-period crossover study to evaluate the safety, pharmacokinetics and pharmacodynamics of Lu-AA21004 in healthy adult volunteers</ProtocolTitle><Sponsor>H Lundbeck A/S, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="81626"/><TrialStartDate>2011-03-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Lu-AA21004 on the Concentrations of Selected Neurotransmitters in Healthy Male Subjects</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="74871"/><TrialStartDate>2011-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="105">Dysmenorrhea</Indication><ProtocolAcronym/><ProtocolTitle>Menstrual Migraine Treatment With Treximet (Formerly Known as Trexima)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14015"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A single-center, randomized, double-blind, placebo-controlled, crossover study to investigate the effects of ziprasidone on polysomnographic sleep structure and subjective sleep quality in healthy male subjects</ProtocolTitle><Sponsor>University of Gottingen</Sponsor><StudyType>Interventional</StudyType><Trial id="69555"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2940">Tic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="19006"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym>NCT03525808</ProtocolAcronym><ProtocolTitle>Brexpiprazole Study</ProtocolTitle><Sponsor>University of Massachusetts</Sponsor><StudyType>Interventional</StudyType><Trial id="339688"/><TrialStartDate>2018-03-19 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="172841"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Gepirone Versus Placebo in Treatment of Cocaine Dependence - 3</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><Trial id="33696"/><TrialStartDate>1990-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1490">Sleep apnea</Indication><ProtocolAcronym>BREATH</ProtocolAcronym><ProtocolTitle>Buspiron for chemoreflex modulation and central Apnea treatment in Heart failure patients</ProtocolTitle><Sponsor>Fondazione Toscana Gabriele Monasterio</Sponsor><StudyType>Interventional</StudyType><Trial id="365992"/><TrialStartDate>2016-05-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A post-marketing surveillance, phase IV study to assess the safety and efficacy of Imigran (sumatriptan) administered in Korean subjects with acute migraine with or without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="99672"/><TrialStartDate>1997-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="90303"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan versus Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161688"/><TrialStartDate>1996-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym>TDM-VIGIL</ProtocolAcronym><ProtocolTitle>Multicenter trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescents</ProtocolTitle><Sponsor>Wuerzburg University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="375478"/><TrialStartDate>2017-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3454">Dizziness</Indication><ProtocolAcronym/><ProtocolTitle>Rizatriptan for Episodic Dizziness in Vestibular Migraine</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><StudyType>Interventional</StudyType><Trial id="230238"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42195"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot study of comparative bioavailability between two drugs for oral administration of Lorcaserin Hydrochloride in prolonged-release tablets with 20 mg in healthy subjects under fasting conditions</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="336721"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A balanced, two-way, cross-over randomization study to investigate the effect of concomitant food intake on the oral bioavailability of prucalopride in healthy subjects</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="58960"/><TrialStartDate>2009-06-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym/><ProtocolTitle>Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="174271"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32883"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>BETA</ProtocolAcronym><ProtocolTitle>Broad effectiveness: Study with aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19395"/><TrialStartDate>2002-05-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>Alpha-PROGRESS trial</ProtocolAcronym><ProtocolTitle>An open-label study evaluating the effectiveness of aripiprazole for schizophrenia patients with dopamine supersensitivity psychosis</ProtocolTitle><Sponsor>Chiba University Graduate School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="164836"/><TrialStartDate>2013-11-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3150">Social phobia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, open-label study to evaluate the efficacy and safety of tandospirone versus sertraline monotherapy for social anxiety disorder</ProtocolTitle><Sponsor>Fudan University</Sponsor><StudyType>Interventional</StudyType><Trial id="178044"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="31">Asthma</Indication><ProtocolAcronym/><ProtocolTitle>Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="263970"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the striatal D2 receptor occupancy of pardoprunox, a potential treatment for Parkinson's disease</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="42706"/><TrialStartDate>2002-11-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2085">Dysphagia</Indication><ProtocolAcronym>IEMPru</ProtocolAcronym><ProtocolTitle>Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><Trial id="308271"/><TrialStartDate>2017-10-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="84859">UI05MSP015CT</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym>MARS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia</ProtocolTitle><Sponsor>Korea United Pharm Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="306090"/><TrialStartDate>2014-11-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Pharmacokinetics and Tolerability of Two Single Treximet (Formerly Known as Trexima) Ta Blets (Administered Two Hours Apart) in Healthy Volunteers.</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153675"/><TrialStartDate>2004-10-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Single-Dose, Two-Period, Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a Trexima (Sumatriptan 85 mg and Naproxen Sodium 500 mg) Tablet Compared With an Imitrex (Sumatriptan) 100 mg Tablet</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152012"/><TrialStartDate>2006-02-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="347113"/><TrialStartDate>2018-10-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Drug Use Investigation for Imigran Injection (Sumatriptan)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="149353"/><TrialStartDate>2000-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Serotonin 1A Agonists and Cognition in Schizophrenia</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><Trial id="35790"/><TrialStartDate>2003-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Aripiprazole and Lexapro Drug Interaction Study</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19228"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><Trial id="297959"/><TrialStartDate>2015-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="4232"/><TrialStartDate>2004-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym/><ProtocolTitle>Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="93597"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3020">motilide, Kitasato/Shimizu/Takeda</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A pilot study to evaluate the effect of EM-523L on gastric emptying function and the change in plasma glucose levels after eating in patients with diabetic gastroparesis</ProtocolTitle><Sponsor>Kitasato Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="20108"/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="181875"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><StudyType>Interventional</StudyType><Trial id="83013"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 26-week, open-label study to evaluate the neurocognitive efficacy of aripiprazole when compared with olanzapine in stable outpatients with stable psychosis</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52127"/><TrialStartDate>2001-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Treatment of the Prodrome</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="33984"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of the beginning of therapeutic response between different typical and atypical antipsychotics in acute psychosis</ProtocolTitle><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="302069"/><TrialStartDate>2016-10-16 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Parallel-Group, Multiple-Dose, Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="177903"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57473">revexepride</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>SSP-002358 Drug Interaction Study With Omeprazole</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="79954"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="38094">ibipinabant</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>BMS-646256 in obese and overweight type 2 Diabetics</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="5138"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled phase I study to evaluate the pharmacokinetics of velusetrag as a potential treatment of chronic constipation, in healthy volunteers</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="58967"/><TrialStartDate>2009-06-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="108460">meloxicam + rizatriptan (fixed-dose combination/oral, migraine), Axsome</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>MOMENTUM</ProtocolAcronym><ProtocolTitle>Maximizing Outcomes in Treating Acute Migraine</ProtocolTitle><Sponsor>Axsome Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="320888"/><TrialStartDate>2019-03-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, open-label, non-comparative study to determine the safety, tolerability and efficacy of oral ziprasidone for the early treatment of subjects with psychotic sisorders</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86145"/><TrialStartDate>2002-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Ziprasidone Study for Psychosis Treatment in Adolescents</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="33934"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>25</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>NONSTOP</ProtocolAcronym><ProtocolTitle>Clinical Trial to Evaluate the Efficacy of Treatment versus Discontinuation in a First Episode of Non-affective Psychosis</ProtocolTitle><Sponsor>Fundación Pública Andaluza Para La Gestión De La Investigación En Salud De Sevilla</Sponsor><StudyType>Interventional</StudyType><Trial id="104352"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53257">aripiprazole (intramuscular), Otsuka/BMS</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Intramuscular Aripiprazole in Acutely Agitated Patients Diagnosed With Dementia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="1345"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients</ProtocolTitle><Sponsor>National Institute on Drug Abuse</Sponsor><StudyType>Interventional</StudyType><Trial id="32101"/><TrialStartDate>2008-05-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Frovatriptan Versus Zolmitriptan in the Treatment of Migraine With or Without Aura, a Patient Preference Study</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="117172"/><TrialStartDate>2007-03-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="805">Stomach ulcer</Indication><ProtocolAcronym/><ProtocolTitle>The Open Study for the Effects of Mosapride Citrate on Gastric Ulcer Healing after Endoscopic Submucosal Disection</ProtocolTitle><Sponsor>Kyoto Prefectural University</Sponsor><StudyType>Interventional</StudyType><Trial id="134808"/><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Buspirone and Motivational Enhancement Therapy for the Treatment of Marijuana Dependence - 1</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32273"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>SBD-ASIB</ProtocolAcronym><ProtocolTitle>NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325308"/><TrialStartDate>2019-06-10 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>MBD</ProtocolAcronym><ProtocolTitle>NRX-101 for Moderate Bipolar Depression and Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325291"/><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Biosignatures of Latuda for Bipolar Depression</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="210316"/><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, multicenter, randomized, double-blind, placebo-controlled, cross-over, two-attack, outpatient study to determine the efficacy, safety and tolerability of sumatriptan nasal spray (10 or 20 mg) in the treatment of patients with acute migraine with and without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87128"/><TrialStartDate>2001-01-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1519">Ileus</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride for Post-operative Ileus in Patients Undergoing Gastrointestinal Surgery</ProtocolTitle><Sponsor>Jinling Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="163150"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>ADAM</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Long-Term Safety of M-207 in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="312554"/><TrialStartDate>2017-11-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open-label, phase I, single dose study to investigate the pharmacokinetics of GR-85548 in subjects with impaired renal function</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78275"/><TrialStartDate>1994-11-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="97">Diabetes mellitus</Indication><ProtocolAcronym/><ProtocolTitle>Antipsychotics and Gene Expression in Soft Tissues</ProtocolTitle><Sponsor>Medical University of Vienna</Sponsor><StudyType>Interventional</StudyType><Trial id="192590"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Phase III Efficacy Trial of Buspirone with Comparison to Sertraline in Treatment of General Anxiety Disorder</ProtocolTitle><Sponsor>Libbs Farmaceutica Ltda</Sponsor><StudyType>Interventional</StudyType><Trial id="124461"/><TrialStartDate>2012-06-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Effects of 7 Day Prucalopride Administration in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="344627"/><TrialStartDate>2018-06-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Assess Safety And Efficacy Of Ziprasidone In Tourette's Syndrome</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110086"/><TrialStartDate>1999-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1585">Syndrome X</Indication><ProtocolAcronym/><ProtocolTitle>Identification and Treatment Response Prediction of Antipsychotic-Related Metabolic Syndrome</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="59511"/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1585">Syndrome X</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Aripiprazole on Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="34597"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1585">Syndrome X</Indication><ProtocolAcronym/><ProtocolTitle>A Phase IV Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophrenic Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19419"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="259">Peripheral neuropathy</Indication><ProtocolAcronym>XENON</ProtocolAcronym><ProtocolTitle>Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens</ProtocolTitle><Sponsor>Policlinico Universitario Agostino Gemelli, Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="26207"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Augmentation Therapy With Tandospirone on Cognition and Social Function in Schizophrenia</ProtocolTitle><Sponsor>Hizen Psychiatric Center, Jikei University, Kanazawa Medical University, Kansai Medical University, Okayama University, Osaka University, St Marianna University School of Medicine, Toyama University</Sponsor><StudyType>Interventional</StudyType><Trial id="118216"/><TrialStartDate>2012-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><StudyType>Interventional</StudyType><Trial id="62081"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>An 8-week, randomized, double-blind, active-controlled, head-to-head, safety and efficacy study of ziprasidone, compared to risperidone in patients with schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53572"/><TrialStartDate>1995-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>HDZ</ProtocolAcronym><ProtocolTitle>High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Symptoms</ProtocolTitle><Sponsor>Massachusetts General Hospital, Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36301"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35810"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial</ProtocolTitle><Sponsor>Central Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="35792"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>AP Project</ProtocolAcronym><ProtocolTitle>Dose reduction or switch to ziprasidone followed by clozapine therapy: what works better in a long stay schizophrenia group?</ProtocolTitle><Sponsor>Universiteit Utrecht</Sponsor><StudyType>Interventional</StudyType><Trial id="270203"/><TrialStartDate>2007-07-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62606">CL-H1T</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym/><ProtocolTitle>Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="174271"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone</ProtocolTitle><Sponsor>North Dakota State University</Sponsor><StudyType>Interventional</StudyType><Trial id="233987"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting and Fed Conditions</ProtocolTitle><Sponsor>Par Pharmaceutical Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="198404"/><TrialStartDate>1998-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioavailability Study of (Buspar) Buspirone HCl Tablets Under Fasting Conditions</ProtocolTitle><Sponsor>Par Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="191808"/><TrialStartDate>1998-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3774">Sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="132075"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to evaluate the pharmacokinetics, safety and efficacy of aripiprazole as an add-on medication in patients with major depressive disorder resistant to clomipramine treatment</ProtocolTitle><Sponsor>Universita degli Studi di Napoli Federico II</Sponsor><StudyType>Interventional</StudyType><Trial id="85592"/><TrialStartDate>2011-03-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="59550"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Augmentation of SSRI Therapy in Treatment Refractory Depression</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="35106"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A 4-Week, Open-Label, Parallel-Group Study To Compare Mirtazapine Monotherapy Versus Combination Therapy With Mirtazapine and Aripiprazole in Depressed Patients Without Psychotic Features</ProtocolTitle><Sponsor>Ludwig-Maximilians University of Munich</Sponsor><StudyType>Interventional</StudyType><Trial id="145764"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="201">Liver disease</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics, Safety and Tolerability of Vortioxetine in Normal Hepatic Function or Severe Hepatic Impairment</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="198836"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features</ProtocolTitle><Sponsor>Allergan Singapore PTE Ltd, Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="344918"/><TrialStartDate>2018-06-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym>Depression-Anx Trial</ProtocolAcronym><ProtocolTitle>An Antidepressant Medications from Treatment Initiation for Depressive Disorder with Anxiety Symptoms: A Prospective Comparative Study</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="282448"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="212">Motor neurone disease</Indication><ProtocolAcronym/><ProtocolTitle>Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="11086"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, placebo-Controlled pilot study of augmentation therapy to evaluate ziprasidone augmentation of SSRIs in patients with post traumatic stress disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd, Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="374746"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Palcebo-Controlled, Parallel Assignment, Phase IV Study to Evaluate The Efficacy of Ziprasidone (Geodon) in The Treatment of Civilian Men And Women With Severe Post Traumatic Stress Disorder (PTSD)</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="21074"/><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Clinical Study of Acute Pancreatitis Treated by TongFuSan</ProtocolTitle><Sponsor>Beijing Friendship Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="206981"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36285"/><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32883"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>PAFIP3_1Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: One-Year Follow-Up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238547"/><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>9</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>DREaM</ProtocolAcronym><ProtocolTitle>A Study to Compare Disease Progression and Modification Following Treatment with Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's with Recent-Onset Schizophrenia or Schizophreniform</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="228891"/><TrialStartDate>2015-07-08 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2954">Weight gain</Indication><ProtocolAcronym/><ProtocolTitle>Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia</ProtocolTitle><Sponsor>Genovate Biotechnology Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="14198"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="480">Premenstrual syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Single-center, Single-Blind, Randomized Trial To Compare The Efficacy Of Buspirone Versus Fluoxetine In The Treatment Of Premenstrual Syndrome</ProtocolTitle><Sponsor>Lorestan University</Sponsor><StudyType>Interventional</StudyType><Trial id="118984"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of a Combination Product (BCI-024 and BCI-049) to Treat Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="23056"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy of buspirone for treatment of patients with severe depression</ProtocolTitle><Sponsor>University of Helsinki</Sponsor><StudyType>Interventional</StudyType><Trial id="110788"/><TrialStartDate>2001-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2954">Weight gain</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin for Weight Loss Management in Patients on Antipsychotics: A Pilot Study</ProtocolTitle><Sponsor>Southern California Institute for Research and Education</Sponsor><StudyType>Interventional</StudyType><Trial id="158344"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym>NordLOTS step 3</ProtocolAcronym><ProtocolTitle>Nordic Long-Term Obsessive Compulsive Disorder (OCD) Treatment Study</ProtocolTitle><Sponsor>Centre for Child and Adolescent Mental Health, Eastern and Southern Norway</Sponsor><StudyType>Interventional</StudyType><Trial id="148024"/><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: A 10-Week, Open-Label Study</ProtocolTitle><Sponsor>Gulhane School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="144676"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym>ROCAAS</ProtocolAcronym><ProtocolTitle>Randomized, controlled trial for OCD of Aripiprazole Augmentation to SSRI</ProtocolTitle><Sponsor>Kyushu University</Sponsor><StudyType>Interventional</StudyType><Trial id="138039"/><TrialStartDate>2013-10-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="90303"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Buspirone, a Fundus-Relaxing Drug, in Patients with Functional Dyspepsia</ProtocolTitle><Sponsor>Katholieke Universiteit Leuven</Sponsor><StudyType>Interventional</StudyType><Trial id="146103"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II, Multicenter, Open-Label Study Of Clinical Pharmacology, Safety, And Tolerability Of Ziprasidone In Patients With Schizophrenia</ProtocolTitle><Sponsor>Meiji Seika Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="98811"/><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Week, Randomized, Open-Label, Flexible-Dose, Parallel-Design, Controlled Study To Compare Efficacy And Tolerability Of Ziprasidone Versus Olanzapine In Naive First-Episode Schizophrenia</ProtocolTitle><Sponsor>Xiangya Hospital Of Central South University</Sponsor><StudyType>Interventional</StudyType><Trial id="94354"/><TrialStartDate>2012-01-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, phase IIIb, multicenter, open-label, randomized, parallel-group, flexible-dose study to evaluate the efficacy of im/oral ziprasidone compared to haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86719"/><TrialStartDate>2002-03-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, placebo-controlled dose-escalation study to determine the central dopamine D2 receptor occupancy by ziprasidone in healthy male volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53506"/><TrialStartDate>1993-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, multi-center, randomized, double-blind, placebo-controlled, safety and efficacy study of ziprasidone in patients with acute exacerbation of schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53484"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia</ProtocolTitle><Sponsor>University of Arizona</Sponsor><StudyType>Interventional</StudyType><Trial id="363985"/><TrialStartDate>2017-11-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CAMPUS</ProtocolAcronym><ProtocolTitle>The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia</ProtocolTitle><Sponsor>Bispebjerg Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="36280"/><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Efficacy and Safety of Ziprasidone for the Treatment of Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36202"/><TrialStartDate>2003-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pfizer/IVGTT/Ziprasidone/Olanzapine</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="3580"/><TrialStartDate>2000-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study Comparing the Safety and Efficacy of Ziprasidone and Risperidone for the Treatment of Chronic Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35474"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment of Schizophrenia or Schizoaffective Disorder in Hospitalized Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35469"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics</ProtocolTitle><Sponsor>Bronx Psychiatric Center</Sponsor><StudyType>Interventional</StudyType><Trial id="35153"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>31</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APIC</ProtocolAcronym><ProtocolTitle>Antipsychotic Induced Structural and Functional Brain Changes</ProtocolTitle><Sponsor>Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="228608"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical effect of cross titration of anti-psychotics with ziprasidone in schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="20968"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 24-Week, Open-Label Study on Ziprasidone's Efficacy and Influence on Glucolipid Metabolism in Patients With Schizophrenia and Metabolic Disorder</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="157372"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Switching Patients With Schizophrenia to Ziprasidone From Conventional or Other Atypical Antipsychotics</ProtocolTitle><Sponsor>Jahn Ferenc Del-pesti Korhaz</Sponsor><StudyType>Interventional</StudyType><Trial id="146998"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 28-Week Trial To Compare Ziprasidone and Haloperidol in Outpatients With Stable Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="145193"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-month, prospective, open-label study to evaluate the comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Cephalon Inc, Eli Lilly &amp; Co, Johnson &amp; Johnson, Merck &amp; Co Inc, National Alliance for Research on Schizophrenia and Depression, Otsuka Pharmaceutical Co Ltd, Pfizer Inc, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="97114"/><TrialStartDate>2012-01-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, open-label, six-way crossover study to evaluate the impact of calories and fat content of meals on oral ziprasidone absorption in patients with schizophrenia schizoaffective disorder, bipolar disorder, or psychotic disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="62998"/><TrialStartDate>2006-07-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Mood Stabilizer (MS) plus Antidepressant versus MS plus Placebo in Maintenance of Bipolar Disorder</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="59575"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="36526"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Geodon in Weight Loss Study for Bipolar Disorders</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><Trial id="35111"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="34910"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34753"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33844"/><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>An 8-Week, Multicenter, Open-Label Study of Efficacy and Safety of Switching to Ziprasidone from Olanzapine in Patients with Bipolar I Disorder</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="159750"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone With Adjunctive Mood Stabilizer in the Maintenance Treatment of Bipolar I Disorder: Long-Term Changes in Weight and Metabolic Profiles</ProtocolTitle><Sponsor>Case Western Reserve University</Sponsor><StudyType>Interventional</StudyType><Trial id="146179"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, double-blind, randomized, placebo-controlled, efficacy study of gepirone in patients with atypical depression</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45071"/><TrialStartDate>1994-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>Copernico</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine</ProtocolTitle><Sponsor>Ache Laboratorios Farmaceuticos SA</Sponsor><StudyType>Interventional</StudyType><Trial id="98196"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of naratriptan as prophylactic treatment for menstrually-associated migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78594"/><TrialStartDate>1999-12-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, ascending dose, double-blind, placebo-controlled, four-way crossover study to evaluate the safety, tolerability, pharmacodynamic and pharmacokinetic response to two doses of oral GR-85548A separated by 4 h</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77982"/><TrialStartDate>1993-10-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, randomized, double-blind, double-dummy, active-, placebo-controlled, parallel group, multi-attack, outpatient study to evaluate the effect of naratriptan compared with naproxen sodium on migraine-related quality of life</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77205"/><TrialStartDate>1997-10-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, double-blind, two-attack, cross-over outpatient study to compare the efficacy, safety and tolerability of oral naratriptan with oral sumatriptan in the acute treatment of migraine in patients susceptible to headache recurrence</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77197"/><TrialStartDate>1995-09-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label study to assess the effect of subcutaneous naratriptan on cardiac hemodynamics in patient-volunteers with existing or suspected coronary artery disease</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77173"/><TrialStartDate>1995-09-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, double-dummy, randomized, placebo-controlled, four-way crossover study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77167"/><TrialStartDate>1996-02-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, phase III study to evaluate the long-term safety and efficacy of naratriptan in patients with acute migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77122"/><TrialStartDate>1995-06-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MATRIX(Migrainer Assess TRiptane eXamination)</ProtocolTitle><Sponsor>University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><Trial id="132785"/><TrialStartDate>2010-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A dose-ranging, late phase II study to evaluate the safety and efficacy of tandospirone for the treatment of neurosis</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="50252"/><TrialStartDate>1992-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, randomized, placebo-controlled study to evaluate the efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety</ProtocolTitle><Sponsor>The First Affiliated Hospital of Zhengzhou University</Sponsor><StudyType>Interventional</StudyType><Trial id="239721"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Investigation Of Relationships Among Upper Abdominal Symptoms, Findings Of Esophagogastroduodenoscopy (EGD) And Quality Of Life (QOL) And Comparing Study Of Therapeutic Effects Of Various Gastrointestinal Drugs On Upper Abdominal Symptoms Of Patients With Functional Dyspepsia (FD) Or Non-Erosive Reflux Disease (NERD) By Using Questionnaires To Evaluate Upper Abdominal Symptoms (GOS) And QOL (SF-8)</ProtocolTitle><Sponsor>Miyagi Cancer Society</Sponsor><StudyType>Interventional</StudyType><Trial id="136364"/><TrialStartDate>2009-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Dose-Comparison, Crossover Study  of Subcutaneous GR-43175c (6 and 12 mg) for The Acute Treatment of Cluster Headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="182900"/><TrialStartDate>1990-10-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>An Open Design, Multiple Treatment Study to Evaluate Subcutaneous Sumatriptan (6 mg) in the Acute Treatment of Cluster Headache Attacks During a 3-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="149351"/><TrialStartDate>1991-09-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A crossover, double-blind, placebo-controlled, randomized study on the safety and efficacy of sumatriptan in cluster headache</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="116276"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, single-attack, outpatient study to compare the safety and efficacy of sumatriptan 50 and 100 mg versus placebo during a migraine headache at the first sign of pain</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87849"/><TrialStartDate>2001-02-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Rizatriptan 5 and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54675"/><TrialStartDate>1995-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of BGG-492 in the Treatment of Migraine</ProtocolTitle><Sponsor>Novartis AG, Novartis Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="53804"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Sofusa System With Sumatriptan (KC-5010) Phase I, Dose-Escalation and Safety Study</ProtocolTitle><Sponsor>Kimberly-Clark Worldwide Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="306601"/><TrialStartDate>2018-01-17 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Compare PK and Bioavailability of Two NP-101 Patches With Oral Imitrex in Healthy Adults</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="178045"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, multicenter, doulble-blind, randomized, parallel-group, active-controlled study to assess the safety and efficacy sumatripan or Migril for the treatment of migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="158932"/><TrialStartDate>1990-10-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14060"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled, outpatient, four-period, crossover, four-attack study to evaluate the safety and efficacy of 25, 50 and 100 mg po sumatriptan in adolescent migraine subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="128817"/><TrialStartDate>1995-03-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, open-label study to compare the efficacy and tolerability of intravenous valproic acid (iVPA) with intramuscular metoclopramide and subcutaneous (sc) sumatriptan for prolonged acute migraine</ProtocolTitle><Sponsor>Guilan University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="128806"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Prospective, Open, Multi-attack Study of Patient Preference and Efficacy between Zolmitriptan Nasal Spray 5 mg and Sumatriptan RDT 100 mg in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Gothenburg Migraine Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="117173"/><TrialStartDate>2007-10-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, comparative study to assess the safety and efficacy of almotriptan versus sumatriptan in migraine patients</ProtocolTitle><Sponsor>Pharmacia Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="109741"/><TrialStartDate>2000-04-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, placebo-controlled, randomized study for the comparison of the effectiveness of oral eletriptan (40 to 80 mg) and oral sumatriptan (50 to 100 mg) in reducing the time loss and overall impact of migraine attacks</ProtocolTitle><Sponsor>Pfizer Central Research</Sponsor><StudyType>Interventional</StudyType><Trial id="109739"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled, dose-finding study to assess the efficacy and safety of sumatriptan in migraine patients</ProtocolTitle><Sponsor>Glaxo Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="108854"/><TrialStartDate>1999-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Open-Labeled to Assess Sumatriptan in Migraine</ProtocolTitle><Sponsor>Gothenburg Migraine Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="107774"/><TrialStartDate>1998-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Pharmacokinetics (PK) Study of Single-Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults</ProtocolTitle><Sponsor>Acorda Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="246594"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, multicenter, placebo-controlled, randomized study on the safety and efficacy of eletriptan versus zolmitriptan in migraine</ProtocolTitle><Sponsor>Imperial College London</Sponsor><StudyType>Interventional</StudyType><Trial id="115191"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, multicenter, placebo-controlled, randomized to evaluate the efficacy of zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine</ProtocolTitle><Sponsor>Kings College Hospital NHS Trust</Sponsor><StudyType>Interventional</StudyType><Trial id="112851"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Multicenter Study To Assess Safety And Efficacy Of Zolmitriptan In Migraine</ProtocolTitle><Sponsor>Gothenburg Migraine Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="107255"/><TrialStartDate>1998-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of Rizatriptan in the Treatment of Acute Attacks of Post-Traumatic Headache in US Military Troops (Maxalt)</ProtocolTitle><Sponsor>Henry M Jackson Foundation for the Advancement of Military Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="75139"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="7069"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, three-way crossover trial to examine the efficacy of rizatriptan and the consistency of treatment response in migraine attacks of children and adolescents</ProtocolTitle><Sponsor>University of Helsinki</Sponsor><StudyType>Interventional</StudyType><Trial id="68462"/><TrialStartDate>2005-11-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, multicenter, open-label, crossover trial to assess patient preference for almotriptan or rizatriptan for the treatment of moderate/severe migraine attacks</ProtocolTitle><Sponsor>Hospital General Yagüe</Sponsor><StudyType>Interventional</StudyType><Trial id="66613"/><TrialStartDate>2006-03-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="61390"/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Drug Study in Pediatric Subjects With Migraines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="14081"/><TrialStartDate>2007-12-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TAME1</ProtocolAcronym><ProtocolTitle>Study to Test an Approved Product in the Early Treatment of Migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13874"/><TrialStartDate>2004-08-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym>TREAT</ProtocolAcronym><ProtocolTitle>Treatment of Children With ADHD Who Do Not Fully Respond to Stimulants</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="32552"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym>AAOFDIYWA</ProtocolAcronym><ProtocolTitle>Aripiprazole Added on for DMDD in Youths With ADHD</ProtocolTitle><Sponsor>Tri-Service General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="321219"/><TrialStartDate>2014-11-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Aripiprazole and Risperidone on ADHD</ProtocolTitle><Sponsor>Gorgan University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="302127"/><TrialStartDate>2016-05-03 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparing risperidone and aripiprazole in ADHD</ProtocolTitle><Sponsor>Shahrekord University of Medical Sciences and Health Services</Sponsor><StudyType>Interventional</StudyType><Trial id="201025"/><TrialStartDate>2012-03-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-month, prospective, open-label study to evaluate the comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Cephalon Inc, Eli Lilly &amp; Co, Johnson &amp; Johnson, Merck &amp; Co Inc, National Alliance for Research on Schizophrenia and Depression, Otsuka Pharmaceutical Co Ltd, Pfizer Inc, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="97114"/><TrialStartDate>2012-01-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>NeSSy</ProtocolAcronym><ProtocolTitle>Clinical Effectiveness of Newer Anti-Psychotics in Comparison With Conventional Anti-Psychotics in Schizophrenia</ProtocolTitle><Sponsor>Universitaet Bremen</Sponsor><StudyType>Interventional</StudyType><Trial id="68296"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PROSIPAL</ProtocolAcronym><ProtocolTitle>Prevention of Relapse With Oral Antipsychotics Versus Injectable Paliperidone Palmitate</ProtocolTitle><Sponsor>Janssen-Cilag Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64771"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the safety and efficacy of aripiprazole in patients with schizophrenia who were switched from olanzapine, risperidone or haloperidol</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="51180"/><TrialStartDate>2002-05-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>HEALTH</ProtocolAcronym><ProtocolTitle>Health Evaluation of Abilify Long-Term Therapy</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="36302"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>11</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication</ProtocolTitle><Sponsor>Janssen-Cilag Ltd, Janssen-Ortho Inc (Canada)</Sponsor><StudyType>Interventional</StudyType><Trial id="36288"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Patients With Schizophrenia - Effects on Glucose Metabolism</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35603"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Switch Study of Existing Atypical Antipsychotics to Bifeprunox</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35593"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>SWAT</ProtocolAcronym><ProtocolTitle>SWitching to Abilify Trial</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35439"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35145"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study</ProtocolTitle><Sponsor>Veterans Medical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="35032"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacologic Treatment of Acute Episode of Schizophrenia: a Real World Study</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="313440"/><TrialStartDate>2017-09-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction of High-dose Antipsychotic Therapy</ProtocolTitle><Sponsor>Juntendo University</Sponsor><StudyType>Interventional</StudyType><Trial id="285098"/><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ASPIRE</ProtocolAcronym><ProtocolTitle>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23078"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PECANSII</ProtocolAcronym><ProtocolTitle>Pan European Collaboration on Antipsychotic Naive Schizophrenia II</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="220227"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Open-label Study to Assess Usability of the Medical Information Device-1 (MIND-1) System in Adults With Schizophrenia On Oral Aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="208736"/><TrialStartDate>2014-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="174271"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label, randomized, phase III trial to study the therapeutic equivalence and safety of the drug Aripiprazole OD-Teva, lozenges 15 mg (Teva) and the drug Abilify 15 mg tablets (Bristol-Myers Squibb ) in patients with acute exacerbations of schizophrenia</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="169056"/><TrialStartDate>2012-07-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A non-randomized, open-label, single-group study to evaluate the spontaneous brain magnetic activity in schizophrenia patients treated with aripiprazole</ProtocolTitle><Sponsor>University of New Mexico</Sponsor><StudyType>Interventional</StudyType><Trial id="148498"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Aripiprazole Augmentation of Clozapine in Schizophrenia</ProtocolTitle><Sponsor>Universita' Degli Studi Di Messina</Sponsor><StudyType>Interventional</StudyType><Trial id="146151"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Intramuscular Aripiprazole in the Acute Management of Psychomotor Agitation</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="145852"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic Schizophrenia</ProtocolTitle><Sponsor>University of Florida</Sponsor><StudyType>Interventional</StudyType><Trial id="144906"/><TrialStartDate>2000-12-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Non-Randomized, Open-Label, Multicenter Naturalistic Study of Schizophrenic Patients Treated With Aripiprazole</ProtocolTitle><Sponsor>Vejle General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="144488"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Open, Randomized Trial Of The Effect Of Aripiprazole Versus Risperidone On Social Cognition In Schizophrenia</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><Trial id="142289"/><TrialStartDate>2005-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Aripiprazole on Cognition and Psychomotor Function in Schizophrenia: An Open-Study</ProtocolTitle><Sponsor>Minamihanno Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="142066"/><TrialStartDate>2011-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>EArS Study</ProtocolTitle><Sponsor>Gifu University</Sponsor><StudyType>Interventional</StudyType><Trial id="135317"/><TrialStartDate>2011-10-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym>AripfMRI</ProtocolAcronym><ProtocolTitle>Pilot Study of the Effect of Aripiprazole Treatment in Autism Spectrum Disorders on Functional Magnetic Resonance Imaging (fMRI) Activation Patterns and Symptoms</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="62565"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Aripiprazole Versus Placebo in the Reduction of Aggressive and Aberrant Behavior in Autistic Children</ProtocolTitle><Sponsor>University of Medicine and Dentistry of New Jersey</Sponsor><StudyType>Interventional</StudyType><Trial id="45459"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="23292"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym>SToP-S</ProtocolAcronym><ProtocolTitle>Substance Misuse To Psychosis for Stimulants</ProtocolTitle><Sponsor>Li Ka Shing Faculty of Medicine, The University of Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="335058"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, multicenter, randomized, double-blind study to evaluate the safety and efficacy of aripiprazole in in- and out-patients with acute mania</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52062"/><TrialStartDate>2003-05-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="36526"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole (Abilify) in Children With Symptoms of Mania</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="34590"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>PLACID</ProtocolAcronym><ProtocolTitle>Comparison of treatment with inhaled loxapine and an injected drug to treat patients with schizophrenia or bipolar disorder and who are seriously agitated</ProtocolTitle><Sponsor>Ferrer Internacional SA</Sponsor><StudyType>Interventional</StudyType><Trial id="226539"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Omega-3 Fatty Acid Adjunctive to Open-Label Aripiprazole for the Treatment of Bipolar Disorder in Children and Adolescents</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="177082"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="172452"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>CIBA</ProtocolAcronym><ProtocolTitle>Cognitive Impairment in Bipolar Disorder Treated with Aripiprazole</ProtocolTitle><Sponsor>Bristol-Myers Squibb GmbH, Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><Trial id="139995"/><TrialStartDate>2011-01-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, multicenter, placebo-controlled, randomized study of aripiprazole in patients with acute bipolar mania</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="113141"/><TrialStartDate>2003-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>RUPP PI PDD: Drug and Behavioral Therapy for Children With Pervasive Developmental Disorders</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><Trial id="31343"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Tourette Syndrome</ProtocolTitle><Sponsor>University of Florida</Sponsor><StudyType>Interventional</StudyType><Trial id="6416"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A pragmatic, double-blind, randomized study to evaluate and compare the effectiveness and adverse effects of intramuscular olanzapine and aripiprazole for the treatment of agitated patients with schizophrenia</ProtocolTitle><Sponsor>Nakhonsawan Psychiatric Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="275273"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="198402"/><TrialStartDate>2014-06-11 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled Study of Intramuscular Aripiprazole In Comparison With Intramuscular Haloperidol for the Treatment of Acute Agitation in Patients With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Riga Mental Health Care Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="143734"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>ADMIRE</ProtocolAcronym><ProtocolTitle>Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="50894"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Abilify as an Adjunctive Treatment for Refractory Depression</ProtocolTitle><Sponsor>St Lukes Roosevelt Hospital Center</Sponsor><StudyType>Interventional</StudyType><Trial id="35378"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>APOLLO</ProtocolAcronym><ProtocolTitle>A Study of Abilify Tablet (Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="328310"/><TrialStartDate>2018-02-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>CANBIND6</ProtocolAcronym><ProtocolTitle>Personalized Indications for CBT and Antidepressants in Treating Depression</ProtocolTitle><Sponsor>Nova Scotia Health Authority</Sponsor><StudyType>Interventional</StudyType><Trial id="259491"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19212"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Naturalistic Study Of Aripiprazole Augmentation, Antidepressant Combination Or Switching Therapy In Patients With Major Depressive Disorder Who Are Partial- Or Non-Responsive To Current Antidepressants</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="189186"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Continuation Electroconvulsive Therapy (C-ECT) for Relapse Prevention in Major Depression</ProtocolTitle><Sponsor>Hospital Universitari de Bellvitge</Sponsor><StudyType>Interventional</StudyType><Trial id="187786"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Comparison of Medication Augmentation and PST in the Treatment of Depression in Older Adults</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="154541"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Rotigotine Versus Placebo, A Study To Evaluate The Efficacy In Advanced Stage Idiopathic Parkinson's Disease Subjects</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="89435"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>NEUPOS</ProtocolAcronym><ProtocolTitle>A Trial of Neupro (Rotigotine Transdermal Patch) in Patients With Parkinson's Disease Undergoing Surgery</ProtocolTitle><Sponsor>UCB Pharma GmbH, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8390"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Safety Study of LY-03003 in Patients With Early-stage Parkinson's Disease</ProtocolTitle><Sponsor>Luye Pharma Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="171611"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Flibanserin Versus Placebo in Premenopausal Women With HSDD</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="33112"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>BI-44370 TA in Acute Migraine Attack</ProtocolTitle><Sponsor>Boehringer Ingelheim International GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="42951"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Midazolam Drug-Drug Interaction Study With Lurasidone HCl</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64676"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PEARL 2</ProtocolAcronym><ProtocolTitle>Lurasidone HCl A Phase III Study of Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35542"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, Extension Study Looking at the Effects of Lurasidone (SM-13496) in Subjects with Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="264215"/><TrialStartDate>2017-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Impact of Aripiprazole (Abilify) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><Trial id="210228"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Bioequivalence Of Two Different Lurasidone Formulations In Patients</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="170924"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>RI-AME</ProtocolAcronym><ProtocolTitle>RI-AME Study OF (Isothiazolyl-3-14C)-Lurasidone</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64683"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open preliminary trial to evaluate the effect of frovatriptan plus dexketoprofen in the treatment of menstrually related migraine</ProtocolTitle><Sponsor>University of Turin</Sponsor><StudyType>Interventional</StudyType><Trial id="189631"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the effect of frovatriptan in the treatment of migraine</ProtocolTitle><Sponsor>San Francisco Clinical Research Center</Sponsor><StudyType>Interventional</StudyType><Trial id="112647"/><TrialStartDate>2002-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized Anxiety Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="126543"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Efficacy and Tolerability of Vilazodone in Patients With Generalized Anxiety Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="104461"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3150">Social phobia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Vilazodone to Treat Social Anxiety Disorder</ProtocolTitle><Sponsor>The Medical Research Network</Sponsor><StudyType>Interventional</StudyType><Trial id="95701"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Vilazodone in Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82479"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Does Vilazodone Help With Antidepressant-associated Sexual Dysfunction?</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="132075"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, double-blind study of tegaserod in female patients with irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19590"/><TrialStartDate>2001-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>An Evaluation of the Efficacy and Safety of Tegaserod 6 mg Bid Given Orally to Chinese Patients With Chronic Constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18715"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety and Tolerability of Tegaserod 2 mg Bid versus Placebo in Patients With Chronic Constipation</ProtocolTitle><Sponsor>Hospital Authority,Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="18429"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of the Role of Tegaserod Therapy in the Management of Gastroesophageal Reflux Disease (GERD) Symptoms in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18800"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>ACTMigraine</ProtocolAcronym><ProtocolTitle>ACT Therapy for HF Migraine</ProtocolTitle><Sponsor>Fondazione IRCCS Istituto Neurologico Carlo Besta</Sponsor><StudyType>Interventional</StudyType><Trial id="332221"/><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Acute Migraine When Pain Is Mild Versus When Pain Is Moderate to Severe: an Almotriptan, Parallel, Placebo-controlled, Clinical Trial 'act When Mild?'</ProtocolTitle><Sponsor>Almirall Prodesfarma SA</Sponsor><StudyType>Interventional</StudyType><Trial id="326754"/><TrialStartDate>2005-12-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, double-blind, randomized, safety, efficacy, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine</ProtocolTitle><Sponsor>University of Palermo</Sponsor><StudyType>Interventional</StudyType><Trial id="187601"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>EVA-Almogran</ProtocolAcronym><ProtocolTitle>Assessed by a Visual Analog Scale for Satisfaction Migraine Patients After Treatment for three Consecutive Crises with Almogran</ProtocolTitle><Sponsor>Almirall Prodesfarma SA</Sponsor><StudyType>Interventional</StudyType><Trial id="130553"/><TrialStartDate>2006-10-10 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety Study of Prucalopride in Healty Volunteers</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="36414"/><TrialStartDate>2008-11-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride in Pediatric Subjects, With Functional Fecal Retention</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="90371"/><TrialStartDate>1998-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Prucalopride in Male Subjects With Chronic Constipation</ProtocolTitle><Sponsor>Shire plc, Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="67516"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, parallel-group trial to compare the single-dose and steady-state pharmacokinetics and safety of prucalopride in healthy young and elderly volunteers</ProtocolTitle><Sponsor>Janssen Pharmaceutica NV</Sponsor><StudyType>Interventional</StudyType><Trial id="66548"/><TrialStartDate>2010-05-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury: A double-blind, placebo-controlled study</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19065"/><TrialStartDate>2000-03-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym>PROGASS</ProtocolAcronym><ProtocolTitle>Prucalopride On the Gastreonteric Transit in Systemic Sclerosis</ProtocolTitle><Sponsor>Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico</Sponsor><StudyType>Interventional</StudyType><Trial id="149364"/><TrialStartDate>2013-02-19 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Prucalopride on Gastroesophageal Reflux, Esophageal Motility and Gastric Emptying in Healthy Volunteers</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="122160"/><TrialStartDate>2011-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="40911"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Switch Study of Existing Atypical Antipsychotics to Bifeprunox</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35593"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Open Label Extension Study of Bifeprunox</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34835"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6 Months, Double-Blind, Risperidone-Referenced, Flexible-Dose, Parallel-Group Extension Study of Bifeprunox in Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="161290"/><TrialStartDate>2004-10-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label SLV-308 Safety Extension to Study S308.3.003 in Early PD Patients</ProtocolTitle><Sponsor>Abbott Laboratories, Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="7000"/><TrialStartDate>2007-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label SLV-308 Safety, Extension to Study S308.3.001 in Early PD Patients</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6999"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>Van Gogh Study</ProtocolAcronym><ProtocolTitle>A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV-308 as Adjunct Therapy to L-Dopa in Patients With Parkinson's Disease Experiencing Motor Fluctuations</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="143594"/><TrialStartDate>2008-03-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7126"/><TrialStartDate>2007-06-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="167385"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ADVANCE</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="279982"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, crossover study to assess the reduction of haloperidol-induced side effects by ACP-103</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7650"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="295506"/><TrialStartDate>2017-02-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym>SERENE</ProtocolAcronym><ProtocolTitle>Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="282172"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14094"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14062"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14060"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="35978">PRX-00933 (oral, obesity/diabetes), Proximagen</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIb, Swedish, multicenter, placebo-controlled, double-blind trial to evaluate the safety and efficacy of BVT-933 in obese patients</ProtocolTitle><Sponsor>Swedish Orphan Biovitrum AB</Sponsor><StudyType>Interventional</StudyType><Trial id="54134"/><TrialStartDate>2004-04-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone in Parkinson's Disease</ProtocolTitle><Sponsor>University of Rochester</Sponsor><StudyType>Interventional</StudyType><Trial id="263515"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open study of the safety and efficacy of buspirone in anxiety</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="110911"/><TrialStartDate>2001-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44760">FK-962</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized Study to Evaluate FK-962 in Subjects With Mild to Moderate Alzheimer's Disease</ProtocolTitle><Sponsor>Astellas Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="2462"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A Study of PRX-00023 in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34391"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym>BLOSSOM</ProtocolAcronym><ProtocolTitle>Behavioral Modification and Lorcaserin Second Study for Obesity Management</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38930"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of APD356 in the Treatment of Obesity</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38680"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym>OBC-01</ProtocolAcronym><ProtocolTitle>A 48 weeks, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of obesity medication on morbid obese and obese patients</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="274758"/><TrialStartDate>2016-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Treatment Satisfaction and Preference for Sumavel DosePro in the Treatment of Migraine</ProtocolTitle><Sponsor>Zogenix Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="76404"/><TrialStartDate>2009-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1909">Binge eating disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine for Binge Eating Disorder</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><Trial id="238022"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Study of Lu-AA21004 in Treating Generalized Anxiety Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23317"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-blind, multiple-dose, single-sequence study to evaluate the effect of Lu-AA21004, on the steady-state pharmacokinetics, safety and tolerability of lithium, in healthy male subjects, for the potential treatment of major depressive disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="95293"/><TrialStartDate>2012-03-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>SOLUTION</ProtocolAcronym><ProtocolTitle>Study of Vortioxetine (Lu-AA21004) in Major Depressive Disorder in Asian Countries</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="86275"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Vortioxetine (Lu-AA21004) in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="68240"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of rapastinel as monotherapy in major depressive disorder (MDD)</ProtocolTitle><Sponsor>Naurex Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="371575"/><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Placebo-Controlled, Duloxetine-Referenced, Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu-AA21004) in Acute Treatment of Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="34977"/><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-label, Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu-AA21004) in Long-term Treatment of Major Depressive Disorder in Adults</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="34793"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="16688"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Comparing Bioavailability of Oral Formulations of Vabicaserin</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="36217"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Vabicaserin in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="36214"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34669"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="79871"/><TrialStartDate>2011-09-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Parallel-group Study to Investigate the Efficacy, Safety and Tolerability of Cariprazine in Patients with Predominant Negative Symptoms of Schizophrenia</ProtocolTitle><Sponsor>Gedeon Richter Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="138552"/><TrialStartDate>2013-04-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="47297"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Cariprazine Capsules 6 mg in Schizophrenia or Bipolar disorder I patients who are receiving Cariprazine capsules 6 mg as stable dose</ProtocolTitle><Sponsor>AXIS Clinicals Limited, Aurobindo Pharma Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="378471"/><TrialStartDate>2019-05-13 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="96390"/><TrialStartDate>2012-11-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="124197"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, placebo-controlled, double-blind study to evaluate the safety, pharmacodynamics and efficacy of APD-125, a potential treatment for insomnia</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7334"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="255835"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="56250">PSN-602</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa efficacy study to compare PSN-602 to sibutramine for treatment of obesity</ProtocolTitle><Sponsor>OSI Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54992"/><TrialStartDate>2009-05-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym>MAD</ProtocolAcronym><ProtocolTitle>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Neu-P11 in Subjects With Primary Insomnia</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="66015"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="96772"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>BEACON</ProtocolAcronym><ProtocolTitle>Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="79197"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>NCT03525808</ProtocolAcronym><ProtocolTitle>Brexpiprazole Study</ProtocolTitle><Sponsor>University of Massachusetts</Sponsor><StudyType>Interventional</StudyType><Trial id="339688"/><TrialStartDate>2018-03-19 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Brexpiprazole in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="355608"/><TrialStartDate>2018-07-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled, parallel group-comparison trial to assess the efficacy and safety of brexpiprazole as adjunctive therapy in patients with major depressive disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="352653"/><TrialStartDate>2018-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="123583"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64192">rizatriptan (VersaFilm oral quick release, migraine), IntelGenx</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A single-dose, randomized, open-label, three-way crossover, pivotal study to compare the bioavailability of Rizaport with Maxalt-MLT (US reference) and Maxalt lingua (European reference) in healthy subjects for the treatment of acute migraines</ProtocolTitle><Sponsor>IntelGenx Technologies Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="354520"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="214972"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Multiple-dose Safety, Tolerability and Pharmacokinetics Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="137802"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72849">minesapride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A single-dose ascending study and a multiple-dose study in healthy male subjects and a multiple-dose study in subjects who have no more than 3 spontaneous bowel movements per week to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of DSP-6952, and a single-dose study in healthy male subjects to examine the effect of food</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="324766"/><TrialStartDate>2011-08-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of M-207 at Two App Sites With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="357027"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>Zotrip</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="258736"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in Two Parts (Part 1 and 2)</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="322358"/><TrialStartDate>2017-11-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Assessing the Safety, Tolerability and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161862"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87714">dihydroergotamine (nasal, migraine), Satsuma Pharmaceuticals</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Study the PK and Safety of Single-Doses of STS-101, DHE Injection and Nasal Spray in Healthy Subjects</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373407"/><TrialStartDate>2018-09-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="87714">dihydroergotamine (nasal, migraine), Satsuma Pharmaceuticals</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>EMERGE</ProtocolAcronym><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS-101 in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="375771"/><TrialStartDate>2019-06-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89741">cinitapride + omeprazole (extended release, capsule, dyspepsia/GERD), Cadila Healthcare</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial To Study The Effects Of Two Drugs, Fixed Dose Combination Capsules Of Omeprazole and Cinitapride ER And Omeprazole Capsules In Patients With Non-Ulcer Dyspepsia (NUD) Or Gastroesophageal Reflux Disease (GERD)</ProtocolTitle><Sponsor>Cadila Pharmaceuticals (EA) Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="160046"/><TrialStartDate>2009-04-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89983">aripiprazole + sertraline (oral, major depressive disorder), Otsuka Pharmaceutical</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="170215"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="94639">zolmitriptan (inhalation powder, migraine), Acorda</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder</ProtocolTitle><Sponsor>Acorda Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="271888"/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>NRX-GLX</ProtocolAcronym><ProtocolTitle>NRX101 Glx Biomarker Validation Study</ProtocolTitle><Sponsor>NeuroRx Inc, New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="326023"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym>MBD</ProtocolAcronym><ProtocolTitle>NRX-101 for Moderate Bipolar Depression and Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325291"/><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym/><ProtocolTitle>NMDA Antagonists in Bipolar Depression</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="121831"/><TrialStartDate>2013-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="102889">mosapride + rebamipide (functional dyspepsia), Il Dong</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial to Assess the Efficacy and Safety of Combination Therapy of Motireb 5/100 mg in Functional Dyspepsia Patients</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="265494"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="107748">aripiprazole oral soluble film (STARFILM), CMG Pharmaceutical</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Bioavailability Study of Aripiprazole 10 mg Oral Soluble Film versus Abilify 10 mg Tablet in Healthy Volunteers</ProtocolTitle><Sponsor>CMG Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="235115"/><TrialStartDate>2015-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Effect of ATI-7505 on Gastrointestinal Transit in Healthy Volunteers</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="65175"/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>ARIQUELI</ProtocolAcronym><ProtocolTitle>Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar I Non-responders Patients</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><StudyType>Interventional</StudyType><Trial id="95366"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Placebo-Controlled, Double-Blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="31464"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Investigative Study of the Safety and Efficacy of Extended Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="31461"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="256985"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase IV Study of the Safety and Efficacy of Aripiprazole in Combination With Lamotrigine in the Long-Term Maintenance Treatment of Patients With Bipolar I Disorder With A Recent Manic or Mixed Episode</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19407"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device 1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161124"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>ADAM</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Long-Term Safety of M-207 in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="312554"/><TrialStartDate>2017-11-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Pilot Study of Aripiprazole for Male and Female Veterans With Chronic Post-Traumatic Stress Disorder Who Respond Suboptimally to Antidepressants</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="153202"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3010">Colonoscopy</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride + Prucalopride Booster versus Prucalopride + Picosalax Booster for the Colon Capsule</ProtocolTitle><Sponsor>Queen's University</Sponsor><StudyType>Interventional</StudyType><Trial id="136440"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="90303"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1933">Undifferentiated schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34895"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="47297"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Study of Oral Eletriptan (40 and 80 mg), Oral Sumatriptan (25 and 50 mg) and Placebo</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161722"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161569"/><TrialStartDate>1999-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym>ANXPD</ProtocolAcronym><ProtocolTitle>Anxiety in Parkinson's: Use of Quantitative Methods to Guide Rational Treatment</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="222563"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3194">Delusion</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="233">Neurodegenerative disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase I/II, placebo-controlled study to evaluate the efficacy of xaliproden in patients with neurodegenerative diseases</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45811"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="298650"/><TrialStartDate>2017-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3294">Metabolic syndrome X</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled trial to assess the efficacy of switching from olanzapine, quetiapine,and risperidone to aripiprazole on ten years coronary heart disease risk and metabolic syndrome status</ProtocolTitle><Sponsor>National Institutes of Health, The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="133978"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="478">Raynauds disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance Patients</ProtocolTitle><Sponsor>National Institute on Drug Abuse</Sponsor><StudyType>Interventional</StudyType><Trial id="32101"/><TrialStartDate>2008-05-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="149">Helicobacter pylori infection</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy Between Helicobacter Pylori Eradication Therapy and Motilitone in Functional Dyspepsia</ProtocolTitle><Sponsor>Chung-Ang University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="196108"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Cerebral Pharmacodynamic Effects of 5-HT1B Receptor Stimulation</ProtocolTitle><Sponsor>Rigshospitalet, Denmark</Sponsor><StudyType>Interventional</StudyType><Trial id="275175"/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Sumatriptan Succinate 100 mg Tablets Under Fasting Conditions</ProtocolTitle><Sponsor>Teva Pharmaceuticals USA Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="178266"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Sumatriptan Succinate 100 mg Tablets Under Non-Fasting Conditions</ProtocolTitle><Sponsor>Teva Pharmaceuticals USA Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="177963"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, placebo-controlled, double-blind, parallel-group study to assess the safety of of daily sc dose of GR-43175C</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="156308"/><TrialStartDate>1989-06-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Tolerance of Subcutaneous Injection With GR43175C at Concentrations of 12, 16 and 24 mg/ml</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="154097"/><TrialStartDate>1989-04-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A double-blind, crossover study to investigate response of healthy volunteers to electrical stimuli after sumatriptan injection</ProtocolTitle><Sponsor>National Natural Science Foundation of China</Sponsor><StudyType>Interventional</StudyType><Trial id="137652"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Food Study of Sumatriptan Succinate Tablets 100 mg to Imitrex Tablets 100 mg</ProtocolTitle><Sponsor>Mylan Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="105406"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym>ReCOGNITION</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="246850"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="150606"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="26590">ergotamine (inhaled, Tempo), Sheffield</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, crossover trial to assess the safety of frovatriptan plus ergotamine in healthy volunteers</ProtocolTitle><Sponsor>Vernalis plc</Sponsor><StudyType>Interventional</StudyType><Trial id="109717"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3863">Diarrhea predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, randomized, placebo-controlled study to evaluate the efficacy of tandospirone in patients with irritable bowel syndrome-diarrhea and anxiety</ProtocolTitle><Sponsor>The First Affiliated Hospital of Zhengzhou University</Sponsor><StudyType>Interventional</StudyType><Trial id="239721"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym/><ProtocolTitle>Gene-by-Stress Interactions in Intervention Studies Significance</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="284338"/><TrialStartDate>2018-05-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym>CAMELLIA-TIMI</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Effect of Long-term Treatment With Belviq (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors</ProtocolTitle><Sponsor>Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="165000"/><TrialStartDate>2014-01-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="63544"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Lu-AA21004 for Treatment of Major Depressive Disorder</ProtocolTitle><Sponsor>ICON Clinical Research, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="72879"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg Under Fasting Conditions</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="199781"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>AVIS</ProtocolAcronym><ProtocolTitle>Adjunctive Vortioxetine in Schizophrenia</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="221347"/><TrialStartDate>2016-02-29 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Association Between Anxiety and Bipolar I Disorder in Randomized, Placebo-Controlled, Maintenance Study of Ziprasidone Combined With Mood Stabilizer</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="147988"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Effects on Alcohol Reactivity and Consumption</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="57159"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1490">Sleep apnea</Indication><ProtocolAcronym>CSA treatment</ProtocolAcronym><ProtocolTitle>Buspirone as a Potential Treatment for Recurrent Central Apnea</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="45870"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1490">Sleep apnea</Indication><ProtocolAcronym>REST-SCI</ProtocolAcronym><ProtocolTitle>Role of Enhancing Serotonin Receptors Activity for Sleep Apnea Treatment in Patients With SCI</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="230887"/><TrialStartDate>2015-05-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="59826"/><TrialStartDate>2009-09-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Multi-Center Evaluation of the Safety and Efficacy of sc GR-43175C in Patients With Acute Migraine Attacks – Using a Two-Dose Regimen</ProtocolTitle><Sponsor>GlaxoSmithKline plc, Shealy Institute for Comprehensive Health Care</Sponsor><StudyType>Interventional</StudyType><Trial id="153676"/><TrialStartDate>1989-03-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Effects of Mosapride on Esophageal Motor Activity and Esophagogastric Junction Compliance in Healthy Volunteers</ProtocolTitle><Sponsor>Shimane University</Sponsor><StudyType>Interventional</StudyType><Trial id="155447"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Two-Way, Crossover Study To Assess The Safety, Tolerability, Pharmacokinetics, Bioequivalence of an Investigational Once-daily Extended-release Formulation of Lorcaserin, as Compared to the Twice-daily Immediate-release Formulation</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc, Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="226748"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of APD-356 (lorcaserin) in Healthy Japanese Adult Subjects</ProtocolTitle><Sponsor>Eisai Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="204673"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Prospective, open, randomized, crossover study on the comparative pharmacokinetics and bioequivalence of the drug prucalopride, tablets, film-coated 2 mg (JSC "Obninsk chemical and pharmaceutical company", Russia) in comparison with the preparation Resolor, tablets, film-coated 2 mg ("Janssen-Cilag SpA ", Italy)</ProtocolTitle><Sponsor>OOO "Obninsky Tsentr Nauki I Tekhnology"</Sponsor><StudyType>Interventional</StudyType><Trial id="219574"/><TrialStartDate>2014-12-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>REFRESH</ProtocolAcronym><ProtocolTitle>RP-5063 in Subjects With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc, Sristek Clinical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="83188"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><StudyType>Interventional</StudyType><Trial id="62081"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 4-week, double-blind, multicenter, Active- and placebo-controlled, phase III study to evaluate the safety and efficacy of aripiprazole when compared with either haloperidol or placebo in hospitalized patients with a DSM-IV diagnosis of acute relapse, schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="51215"/><TrialStartDate>2000-05-16 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>DIMES</ProtocolAcronym><ProtocolTitle>Digital Medicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373941"/><TrialStartDate>2019-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Acutely Relapsed Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35145"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33453"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, uncontrolled, 8 week, preliminary study to evaluate a combination of aripiprazole and topiramate in the treatment of opioid-dependent patients with schizoaffective disorder</ProtocolTitle><Sponsor>Universita' Degli Studi Di Messina</Sponsor><StudyType>Interventional</StudyType><Trial id="204521"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Switching Outpatients with Bipolar or Schizoaffective Disorders and Substance Abuse from Their Current Antipsychotic to Aripiprazole</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="147788"/><TrialStartDate>2003-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3733">Traumatic brain injury</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone for the Treatment of Traumatic Brain Injury (TBI) Irritability and Aggression</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><Trial id="118457"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="106">Eating disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="31351"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1102">Atopic dermatitis</Indication><ProtocolAcronym/><ProtocolTitle>Study to evaluate the efficacy of tandospirone citrate (5-HT1a receptor agonist) in pateints with atopic dermatitis</ProtocolTitle><Sponsor>Nippon Medical School Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="155928"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Phase I, Open-label, Randomized, Three-way, Incomplete Crossover Study to Evaluate the Bioavailability of Different Dose Combinations of Sumatriptan Succinate and Naproxen Sodium 500 mg in Healthy Volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="183618"/><TrialStartDate>2004-01-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="16">Amphetamine dependence</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of Interactions Between Methamphetamine and Aripiprazole-1</ProtocolTitle><Sponsor>National Institute on Drug Abuse</Sponsor><StudyType>Interventional</StudyType><Trial id="31151"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="349230"/><TrialStartDate>2018-08-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The effect of added buspiron to atypical antipsychotic drugs in the treatment of negative symptoms in patients with schizophrenia</ProtocolTitle><Sponsor>Ahvaz Jundishapur University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="295354"/><TrialStartDate>2017-02-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3399">ipsapirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized Trial To Evaluate The Effects of Lamotrigine on the 5-HT1A Receptor Function in Healthy Human Males</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="144006"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1930">Paranoid schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym>SBD-ASIB</ProtocolAcronym><ProtocolTitle>NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325308"/><TrialStartDate>2019-06-10 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical study to determine bioequivalence of two oral medications aripiprazole 10 mg tablets in healthy volunteers under fasting conditions</ProtocolTitle><Sponsor>Laboratorio Torrent</Sponsor><StudyType>Interventional</StudyType><Trial id="237967"/><TrialStartDate>2015-10-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical study to determine bioequivalence of two oral medicinal tablets aripiprazole 10 mg in healthy volunteers under fasting conditions</ProtocolTitle><Sponsor>Accord Farma, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="220112"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open, randomized, crossover study of comparative pharmacokinetics, bioequivalence and safety of drugs Ariprizol, tablet, 10 mg (Belupo, medicines and cosmetics dd, Croatia) and Abilify, tablets, 10 mg (Bristol-Myers Squibb Company Manufacturing, Puerto Rico) in healthy volunteers</ProtocolTitle><Sponsor>Belupo</Sponsor><StudyType>Interventional</StudyType><Trial id="178327"/><TrialStartDate>2014-03-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym>LIVE</ProtocolAcronym><ProtocolTitle>Lorcaserin Intra Venous Cocaine Effects</ProtocolTitle><Sponsor>Midwest Biomedical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="253188"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2955">Weight loss</Indication><ProtocolAcronym>MELT</ProtocolAcronym><ProtocolTitle>Metformin and Lorcaserin for Weight Loss in Schizophrenia</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="262940"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open-label, single-dose, three-period, cross-over trial to evaluate the effect of food and formulation on the pharmacokinetics (PK) of LuAA-21004, for the potential treatment of major depressive disorder in healthy subjects</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="95305"/><TrialStartDate>2012-03-16 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Effect of Vortioxetine, Paroxetine and Placebo on Sexual Functioning in Healthy Volunteers</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="275332"/><TrialStartDate>2016-11-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PREVENT</ProtocolAcronym><ProtocolTitle>A second-generation, randomized, double-blind, placebo-controlled study to evaluate cognitive behavioral therapy (CBT), aripiprazole, and clinical management (CM) for the prevention of psychosis</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Deutsche Forschungsgemeinschaft (DFG)</Sponsor><StudyType>Interventional</StudyType><Trial id="81422"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, open-label extension study to evaluate the long-term safety and efficacy of aripiprazole in patients who completed the 10-week acute phase of the study CN138005 ST and for whom continued treatment was indicated for psychotic symptoms associated with dementia of the Alzheimer’s type</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="79709"/><TrialStartDate>2000-08-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP3_nc3Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-Episode Non-Affective Psychosis: Three-Years Follow-Up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="374274"/><TrialStartDate>2015-01-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP3_3Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: Three-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="292671"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>SIP</ProtocolAcronym><ProtocolTitle>Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole</ProtocolTitle><Sponsor>Feinstein Institute for Medical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="203397"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="84108">NLX-112</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>[18F]-F13640 as a New Brain Radiopharmaceutical</ProtocolTitle><Sponsor>Hospices Civils De Lyon</Sponsor><StudyType>Interventional</StudyType><Trial id="320123"/><TrialStartDate>2017-12-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65374">PF-03382792</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1005">Unidentified indication</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63311"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="24">Anorexia nervosa</Indication><ProtocolAcronym>ARIANE</ProtocolAcronym><ProtocolTitle>Aripiprazole in Anorexia Nervosa</ProtocolTitle><Sponsor>Hospital Clinic of Barcelona</Sponsor><StudyType>Interventional</StudyType><Trial id="64675"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym>SAMS</ProtocolAcronym><ProtocolTitle>A prospective, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of sumatriptan for the prevention of acute mountain sickness (AMS)</ProtocolTitle><Sponsor>University of Tehran</Sponsor><StudyType>Interventional</StudyType><Trial id="66340"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Control, Crossover, Dose-Comparison Study of Subcutaneous GR-43175C, for the Treatment of Chronic Tension-Type Headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc, University Hospital Gentofte</Sponsor><StudyType>Interventional</StudyType><Trial id="207940"/><TrialStartDate>1989-02-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="214821"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3774">Sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A preliminary open-label study to evaluate the effect of adjunctive aripiprazole on sexual dysfunction in schizophrenia</ProtocolTitle><Sponsor>Ministry of Education, Culture, Sports, Science and Technology of Japan</Sponsor><StudyType>Interventional</StudyType><Trial id="308859"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Rotigotine Transdermal Patch in Healthy Chinese Subjects</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="90603"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics (PK) of a Single Intravenous (IV) TAK-954</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="314324"/><TrialStartDate>2017-11-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="279887"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Abuse Potential of Lasmiditan in Participants Who Are Recreational Drug Users</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="313232"/><TrialStartDate>2017-09-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>ZIP</ProtocolAcronym><ProtocolTitle>Ziprasidone in the Psychosis Prodrome</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><Trial id="33973"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="275883"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Telcagepant (MK-0974) Long-term, Safety Study in Adult Participants With Acute Migraine</ProtocolTitle><Sponsor>Laboratoires Merck Sharp &amp; Dohme Chibret SA, Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp, Merck Sharp &amp; Dohme SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="13922"/><TrialStartDate>2007-02-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84360">testosterone + buspirone hydrochloride (oral, hypoactive sexual desire disorder), Emotional Brain</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Placebo-Controlled, Crossover, Lybridos Dose-Finding Study to Validate the Predictive Power of the Diagnostic Model for Lybrido and Lybridos Efficacy and to Identify and Evaluate Additional Psychometric and Biological Markers Which Increase the Predictive Power of the Diagnostic Model, in Women With Hypoactive Sexual Desire Disorder With or Without Sexual Arousal Disorder And/or Female Orgasmic Disorder or SSRI Induced Sexual Dysfunction, in the Domestic Situation</ProtocolTitle><Sponsor>Companion Diagnostics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="178585"/><TrialStartDate>2014-01-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32280"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>STABIL-B</ProtocolAcronym><ProtocolTitle>Sequential Therapy for the Treatment of Severe Bipolar Depression</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="280467"/><TrialStartDate>2018-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Pediatric Open-Label, Extension Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="148804"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A post-marketing surveillance, phase IV study to assess the safety and efficacy of Imigran (sumatriptan) administered in Korean subjects with acute migraine with or without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="99672"/><TrialStartDate>1997-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, General Practice Study to Compare GR-43175 With Paracetamol and Metoclopramide in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153845"/><TrialStartDate>1991-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, placebo-controlled, randomized study for the comparison of eletriptan (40 to 80 mg) and oral sumatriptan (50 to 100 mg) for the treatment of acute migraine in sumatriptan-naive patients</ProtocolTitle><Sponsor>Memorial University</Sponsor><StudyType>Interventional</StudyType><Trial id="109744"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, double-blind, placebo-controlled study to evaluate intranasal GR-43175N (1, 5, 10, 20 and 40 mg) in the acute treatment of migraine (one nostril application)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="105600"/><TrialStartDate>1990-09-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1519">Ileus</Indication><ProtocolAcronym/><ProtocolTitle>Anti-inflammatory Effect of Pre-operative Stimulation of the Cholinergic Anti-inflammatory Pathway</ProtocolTitle><Sponsor>KU Leuven R&amp;D</Sponsor><StudyType>Interventional</StudyType><Trial id="227707"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Status Migrainosus - Differentiating Between Responders and Non-responders</ProtocolTitle><Sponsor>Hartford Healthcare</Sponsor><StudyType>Interventional</StudyType><Trial id="289638"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym>TDM-VIGIL</ProtocolAcronym><ProtocolTitle>Multicenter trial in to investigate the usage of antidepressant and antipsychotics (with / without approval) in patients at the age of children and adolescents</ProtocolTitle><Sponsor>Wuerzburg University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="375478"/><TrialStartDate>2017-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="304">Sleep disorder</Indication><ProtocolAcronym/><ProtocolTitle>Proof-of-concept trial of ACP-103, for the treatment of sleep disturbances related to Parkinson's disease and schizophrenia</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="144837"/><TrialStartDate>2006-04-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="175">Hyperlipidemia</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="8781"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Acute Prucalopride Administration in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="372348"/><TrialStartDate>2017-02-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2434">Vertigo</Indication><ProtocolAcronym/><ProtocolTitle>A cross-over, double-blind, placebo-controlled, randomized, pilot study to assess the efficacy of zolmitriptan in the treatment of patients with migrainous vertigo</ProtocolTitle><Sponsor>Humboldt University of Berlin</Sponsor><StudyType>Interventional</StudyType><Trial id="114148"/><TrialStartDate>2003-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62624">FKB01MD</Drug><Endpoint>Safety,Bioavailability</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I pharmacokinetic study of FKB01MD</ProtocolTitle><Sponsor>Fabre Kramer Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="272328"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="133586"/><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, placebo-controlled, randomized study for the comparison of eletriptan (40 to 80 mg) and oral sumatriptan (50 to 100 mg) for the treatment of acute migraine in sumatriptan-naive patients</ProtocolTitle><Sponsor>Memorial University</Sponsor><StudyType>Interventional</StudyType><Trial id="109744"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="4324">alnespirone</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A pharmacokinetic study of examining the effect of food on the pharmacokinetics of alnespirone in humans</ProtocolTitle><Sponsor>Servier</Sponsor><StudyType>Interventional</StudyType><Trial id="55397"/><TrialStartDate>1995-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Gene-by-Stress Interactions in Intervention Studies Significance</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="284338"/><TrialStartDate>2018-05-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, open-label, randomized, multicenter, parallel-group, 3-months pilot study to determine the best option for transitioning from amisulpride to ziprasidone therapy in subjects receiving amisulpride for chronic or subchronic schizophrenia or schizoaffective disorders</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86319"/><TrialStartDate>2001-04-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, dose-ranging, haloperidol-controlled, exploratory study evaluating safety and efficacy of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53489"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="33855"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="233">Neurodegenerative disease</Indication><ProtocolAcronym/><ProtocolTitle>A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="344862"/><TrialStartDate>2018-05-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>NRX-GLX</ProtocolAcronym><ProtocolTitle>NRX101 Glx Biomarker Validation Study</ProtocolTitle><Sponsor>NeuroRx Inc, New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="326023"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Evaluation Study of the Bioavailability of Brexpiprazole Orally Disintegrating Tablets in Healthy Male Subjects</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="269136"/><TrialStartDate>2016-09-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="316099"/><TrialStartDate>2017-10-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Absorption, Metabolism and Excretion of (14C)-Lasmiditan - Single Oral Dose Administration</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="287153"/><TrialStartDate>2017-04-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="5614">Dravet syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Clinical study to evaluate safety and efficacy of lorcaserin in children with dravet syndrome</ProtocolTitle><Sponsor>National Institutes of Health</Sponsor><StudyType>Interventional</StudyType><Trial id="287969"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Buspirone Hydrochloride 30 mg Tablets, Fasting</ProtocolTitle><Sponsor>Teva Pharmaceuticals USA Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="176056"/><TrialStartDate>2001-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>10</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Augmentation Versus Switching to Different Class of Antidepressants in Major Depressive Disorder</ProtocolTitle><Sponsor>Korea University</Sponsor><StudyType>Interventional</StudyType><Trial id="83129"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="33974"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole as Augmentation for TRD</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, State University of New York</Sponsor><StudyType>Interventional</StudyType><Trial id="33900"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Phase Ib Trial of PRX-00023 in Healthy Subjects</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="148095"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals</ProtocolTitle><Sponsor>General Hospital of Tianjin Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="365165"/><TrialStartDate>2018-09-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-control, parallel-group, dose-ranging study was to evaluate three doses of renzapride</ProtocolTitle><Sponsor>SmithKline Beecham plc</Sponsor><StudyType>Interventional</StudyType><Trial id="20238"/><TrialStartDate>2002-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Anti-depressant Discontinuation in Treatment Resistant Depression</ProtocolTitle><Sponsor>University of Louisville</Sponsor><StudyType>Interventional</StudyType><Trial id="365306"/><TrialStartDate>2019-02-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3771">Idiopathic pulmonary fibrosis</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study of RP-5063 for the treatment of idiopathic pulmonary fibrosis (IPF)</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="335622"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3010">Colonoscopy</Indication><ProtocolAcronym/><ProtocolTitle>Study of efficacy and tolerability of combination therapy with low-volume polyethylene glycol (Moviprep), sodium picosulfate hydrate (Pursennid), mosapride citrate hydrate (Gasmotin) on bowel preparation</ProtocolTitle><Sponsor>Juntendo University</Sponsor><StudyType>Interventional</StudyType><Trial id="248043"/><TrialStartDate>2013-08-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="707">Psychosexual disorder</Indication><ProtocolAcronym/><ProtocolTitle>A One-Year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="33305"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="707">Psychosexual disorder</Indication><ProtocolAcronym/><ProtocolTitle>Flibanserin Randomized Withdrawal Trial in Pre-Menopausal Women</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="33284"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regimen</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="337764"/><TrialStartDate>2018-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled trial of blonanserin versus aripiprazole in psychotic disorder</ProtocolTitle><Sponsor>Fujita Health University, Hospital of St Cross, The Jindai Hospital, The Okehazama Hospital, Toyota Memorial Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="156063"/><TrialStartDate>2013-07-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>The Effect of Varying Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetic Profile of Orally Administered Lurasidone: A Phase I Study</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="154992"/><TrialStartDate>2008-11-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3150">Social phobia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety</ProtocolTitle><Sponsor>University of Medicine and Dentistry of New Jersey</Sponsor><StudyType>Interventional</StudyType><Trial id="31470"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3774">Sexual dysfunction</Indication><ProtocolAcronym>KISS</ProtocolAcronym><ProtocolTitle>Aripiprazole, Abilify Maintena Collaborative Clinical Protocol</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="232572"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2520">Insulin resistance</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="18219"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym>PEARL 3</ProtocolAcronym><ProtocolTitle>Lurasidone HCL - A 6-Week, Phase III Study of Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35671"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym>The role of buspirone in LIDs in patients with Parkinson's disease.</ProtocolAcronym><ProtocolTitle>The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease</ProtocolTitle><Sponsor>Imperial College London</Sponsor><StudyType>Interventional</StudyType><Trial id="375494"/><TrialStartDate>2015-05-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="80">Coronary artery disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled trial to assess the efficacy of switching from olanzapine, quetiapine,and risperidone to aripiprazole on ten years coronary heart disease risk and metabolic syndrome status</ProtocolTitle><Sponsor>National Institutes of Health, The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="133978"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)</ProtocolTitle><Sponsor>Jamaica Hospital Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="33315"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Acceptance and Commitment Therapy in SSRI-Resistant Obsessive Compulsive Disorder</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="278251"/><TrialStartDate>2017-09-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1938">Dissociative disorder</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of Adverse Events in a Naive Pediatric Population Treated With an Antipsychotic</ProtocolTitle><Sponsor>Centre Hospitalier Universitaire De Nice</Sponsor><StudyType>Interventional</StudyType><Trial id="336664"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Effects on Tissue Glutamate in Schizophrenia</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="206465"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2686">bromerguride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, 6-week, open-label study to evaluate the efficacy of bromerguride in schizophrenic patients</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="55729"/><TrialStartDate>1988-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, open-label, six-way crossover study to evaluate the impact of calories and fat content of meals on oral ziprasidone absorption in patients with schizophrenia schizoaffective disorder, bipolar disorder, or psychotic disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="62998"/><TrialStartDate>2006-07-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open, randomized clinical trial to compare the effectiveness of low doses of haloperidol and regular doses of second generation antipsychotics in patients with first-episode schizophrenia and schizophreniform disorder</ProtocolTitle><Sponsor>AstraZeneca plc, Eli Lilly &amp; Co, Pfizer Inc, Sanofi-Synthelabo</Sponsor><StudyType>Interventional</StudyType><Trial id="62939"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ZEOSS</ProtocolAcronym><ProtocolTitle>Ziprasidone in Early Onset Schizophrenia Spectrum Disorders</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="61606"/><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study evaluating the cardiovascular safety of ziprasidone</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53571"/><TrialStartDate>2001-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 24-h Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="45729"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="40981"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus</ProtocolTitle><Sponsor>North Suffolk Mental Health Association</Sponsor><StudyType>Interventional</StudyType><Trial id="36033"/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone Versus Olanzapine In The Treatment Of Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35142"/><TrialStartDate>2003-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>ME-2112 Phase III</ProtocolTitle><Sponsor>Meiji Seika Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="224197"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect and safety of ziprasidone compared to other atypical anti-psychotic drug in schizophrenic patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21120"/><TrialStartDate>2001-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="174271"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Week, Randomized, Blinded-Assessment Study To Compare Intramuscular and Oral Formulations Ziprasidone and Haloperidol in the Treatment of Acute Exacerbation of Schizophrenia and Schizoaffective Disorder</ProtocolTitle><Sponsor>Sterkfontein Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="146251"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 44-Week, Double-Blind, Continuation Study To Compare Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><Trial id="144394"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy And Tolerability Of Ziprasidone Versus Clozapine In The Treatment Of Dually Diagnosed (DD-) Patients With Schizophrenia And Cannabis Use Disorder: a Randomized Study</ProtocolTitle><Sponsor>University of Cologne</Sponsor><StudyType>Interventional</StudyType><Trial id="141023"/><TrialStartDate>2006-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in Bipolar Disorder With Co-morbid Lifetime Panic or Generalized Anxiety Disorder (GAD)</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="68728"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="275883"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, placebo-controlled, double-blind, double-dummy study to determine the safety and efficacy of oral ziprasidone compared to haloperidol in in-patients with an acute manic episode</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86706"/><TrialStartDate>2002-09-13 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, double-blind, multi-center, randomized, placebo-controlled, safety and efficacy study of gepirone in patients with moderate depression</ProtocolTitle><Sponsor>Fabre Kramer Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="45940"/><TrialStartDate>2005-06-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled, comparison study to evaluate the safety and efficacy of gepirone and imipramine for the treatment of major depression</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45079"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, double-blind, randomized, parallel group design, placebo-controlled single-attack outpatient study to evaluate the efficacy of naratriptan for mild menstrually associated migraine (MAM) when treatment was administered during the mild pain phase</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77524"/><TrialStartDate>2001-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, ascending-dose, double-blind, randomized, placebo-controlled study to compare the safety, tolerability, pharmacodynamics and pharmacokinetics of two doses of oral naratriptan in young and elderly subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77288"/><TrialStartDate>1995-08-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, comparative, double-blind, multicenter, placebo-controlled study to assess the safety and efficacy of rizatriptan and naratriptan in patients with  moderate/severe migraine headache</ProtocolTitle><Sponsor>Ignatius Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="107809"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of DWJ-1252 in the Treatment of Functional Dyspepsia</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="285479"/><TrialStartDate>2016-12-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Randomized, Controlled, Prospective Trial: Combizym in the Prevention of Aged Functional Dyspepsia</ProtocolTitle><Sponsor>The General Hospital of the People's Liberation Army</Sponsor><StudyType>Interventional</StudyType><Trial id="257472"/><TrialStartDate>2016-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Mosapride for Functional Dyspepsia</ProtocolTitle><Sponsor>Hyogo College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="236927"/><TrialStartDate>2013-05-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Proton Pump Inhibitor and Mosapride on Acid Pocket in Gastroesophageal Reflux Disease</ProtocolTitle><Sponsor>Gangnam Severance Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="281451"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Effectiveness of Mosapride for GERD Patients With Sleep Disorders</ProtocolTitle><Sponsor>Shimane University</Sponsor><StudyType>Interventional</StudyType><Trial id="162155"/><TrialStartDate>2013-11-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, phase III trial, to compare the efficacy of xaliproden (0.5 mg/day po) against placebo in 2400 patients with Alzheimer's disease</ProtocolTitle><Sponsor>Sanofi-Synthelabo</Sponsor><StudyType>Interventional</StudyType><Trial id="3953"/><TrialStartDate>2003-09-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1089">Neurotoxicity drug-induced</Indication><ProtocolAcronym>XENOX</ProtocolAcronym><ProtocolTitle>XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45807"/><TrialStartDate>2002-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14043"/><TrialStartDate>2006-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, single-attack outpatient study to evaluate the efficacy and safety of sc sumatriptan (6 mg) versus placebo in the acute treatment of a migraine that was moderate or severe upon awakening</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="88027"/><TrialStartDate>2001-09-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, single-attack outpatient study to evaluate the efficacy and safety of sc sumatriptan 6 mg versus placebo in the acute treatment of a migraine that was moderate or severe upon awakening</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="88018"/><TrialStartDate>2001-09-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, single attack, out patient study to evaluate the safety and efficacy of sumatriptan 50 and 100 mg tablets administered during the mild pain phase of a menstrually-associated migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87895"/><TrialStartDate>2001-06-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel group, single attack, out patient study to evaluate the safety and efficacy of sumatriptan 50 and 100 mg tablets administered during the mild pain phase of a menstrually-associated migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87830"/><TrialStartDate>2001-07-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Bioavailability Study to Compare OptiNose Sumatriptan With Imitrex in Healthy Subjects</ProtocolTitle><Sponsor>OptiNose AS</Sponsor><StudyType>Interventional</StudyType><Trial id="83918"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, double-dummy, randomized, placebo-controlled, four-way crossover study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77167"/><TrialStartDate>1996-02-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treximet in the Treatment of Chronic Migraine</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="65054"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Comprehensive Migraine Intervention</ProtocolTitle><Sponsor>Montefiore Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="64373"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MK-0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54664"/><TrialStartDate>1995-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Migraine Treatment in ED</ProtocolTitle><Sponsor>New York University School of Medicine, US</Sponsor><StudyType>Interventional</StudyType><Trial id="249999"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="233467"/><TrialStartDate>2015-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind Study to Compare the Efficacy and Safety or Oral Sumatriptan (50mg or 100mg) With Placebo for the Acute Treatment of Migraine in Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="174772"/><TrialStartDate>1991-10-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Single-Attack Evaluation of the Efficacy and Tolerability of TREXIMA™ (Sumatriptan 85mg/Naproxen Sodium 500mg)* Tablets vs Placebo When Administered During the Mild Pain Phase of a Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="174770"/><TrialStartDate>2004-10-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Single Dose Pharmacokinetics of Sumatriptan Nasal Spray in Pediatric Subjects Outside a Migraine Attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152704"/><TrialStartDate>1999-06-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III, Randomized, Double-blind, Parallel- Assignment Study to Assess Safety and Efficacy of Two Oral Doses of Sumatriptan (100 mg) Following Acute Treatment of Migraine With Subcutaneous Sumatriptan (6 mg)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="149354"/><TrialStartDate>1990-11-13 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Crossover, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Effect of Sumatriptan for Migraine Attacks in Children</ProtocolTitle><Sponsor>Hospital District of Helsinki and Uusimaa</Sponsor><StudyType>Interventional</StudyType><Trial id="110727"/><TrialStartDate>1997-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open study designed to study the effects of the anti-migraine drug sumatriptan on muscle energy metabolism and relationship to the side-effects</ProtocolTitle><Sponsor>Henry Ford Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="110177"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-blind, Placebo-controlled, Randomized Study To Evaluate The Effectiveness Of Sumatriptan In Reducing Productivity Loss Due To Migraine</ProtocolTitle><Sponsor>Headache Care Center, Springfield</Sponsor><StudyType>Interventional</StudyType><Trial id="109360"/><TrialStartDate>2000-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, crossover, double-blind, placebo-controlled study to assess the safety and efficacy of sumatriptan nasal spray in children with migraine</ProtocolTitle><Sponsor>University Hospital for Children and Adolescents</Sponsor><StudyType>Interventional</StudyType><Trial id="108074"/><TrialStartDate>1998-04-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to compare the bioavailability, pharmacokinetics, safety and tolerability of zolmitriptan (TRZ) with marketed zolmitriptan tablet and marketed zolmitriptan nasal spray in healthy adult volunteers</ProtocolTitle><Sponsor>Shin Nippon Biomedical Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="86427"/><TrialStartDate>2011-03-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A cross-over, double-blind, placebo-controlled, randomized, pilot study to assess the efficacy of zolmitriptan in the treatment of patients with migrainous vertigo</ProtocolTitle><Sponsor>Humboldt University of Berlin</Sponsor><StudyType>Interventional</StudyType><Trial id="114148"/><TrialStartDate>2003-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Double-blind, Multicenter, Placebo-controlled, Randomized Study to Evaluate the Efficacy of Zolmitriptan and Sumatriptan in Patients with Migraine</ProtocolTitle><Sponsor>Centre Hospitalier Universitaire de Rangueil</Sponsor><StudyType>Interventional</StudyType><Trial id="110125"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A clinical trial to evaluate efficacy and safety of zolmitriptan 5 mg nasal spray in acute treatment of migraine</ProtocolTitle><Sponsor>Cipla Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="103579"/><TrialStartDate>2007-12-06 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="5111">lesopitron</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, balanced, cross-over study to evaluate the effect of lesopitron on pupil diameter and oral temperature compared to buspirone in healthy male subjects</ProtocolTitle><Sponsor>Laboratorios Dr Esteve SA</Sponsor><StudyType>Interventional</StudyType><Trial id="56274"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Native American Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of Rizatriptan in the Treatment of Acute Attacks of Post-Traumatic Headache in US Military Troops (Maxalt)</ProtocolTitle><Sponsor>Henry M Jackson Foundation for the Advancement of Military Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="75139"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MK-0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54664"/><TrialStartDate>1995-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Combination therapy of triptan agent and anti-epileptic drug in migraine</ProtocolTitle><Sponsor>Teikyo Heisei University, Tokyo Women's Medical College</Sponsor><StudyType>Interventional</StudyType><Trial id="318262"/><TrialStartDate>2017-11-13 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Parallel-Group Study to Compare The Efficacy of Rizatriptan 10 Mg Iyophilized Wafer in The Acute Treatment of Migraine in Patients with Unilateral Trigeminal Autonomic Symptoms</ProtocolTitle><Sponsor>IRCCS San Raffaele</Sponsor><StudyType>Interventional</StudyType><Trial id="116938"/><TrialStartDate>2009-06-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>USMAP</ProtocolAcronym><ProtocolTitle>A multicenter, open-label, comparative study to evaluate the effect of rizatriptan Rizatriptan in migraine: The USMAP (US Migraine Assessment Protocol) study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="112669"/><TrialStartDate>2002-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label, Randomized, Pilot Study Of Rizatriptan Combined With Rofecoxib Versus Rizatriptan For The Acute Treatment Of Migraine</ProtocolTitle><Sponsor>Universidade Federal Fluminense</Sponsor><StudyType>Interventional</StudyType><Trial id="111841"/><TrialStartDate>2002-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Crossover, Multicenter, Open-label, Randomized Trial to Compare Rizatriptan ODT 10 mg and Sumatriptan 50 mg for Treatment of Migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110404"/><TrialStartDate>2001-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Comparative, Cross-over, Double-blind, Multicenter, Placebo-controlled Study to assess Rizatriptan versus sumatriptan in migraine</ProtocolTitle><Sponsor>San Francisco (Calif) Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="107557"/><TrialStartDate>1998-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Drug Interaction Study Between AZD-3480 and Aripiprazole in Healthy Subjects</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="20438"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="1252"/><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Tolerability and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia</ProtocolTitle><Sponsor>FORUM Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="85742"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, multicenter, randomized, open-label, parallel-group study to evaluate the acceptability of aripiprazole oral disintegrating tablets in the treatment of stable patients with schizophrenia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="83140"/><TrialStartDate>2003-07-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, active-controlled, double-blind, placebo-controlled study to compare the safety, efficacy, and tolerability of aripiprazole with olanzapine in patients with schizophrenia who were in acute relapse and required hospitalization</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82417"/><TrialStartDate>2000-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ATTAIN 266</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Covance Services Malaysia Sdn Bhd, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="67570"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>H8Y-MC-HBBO</ProtocolAcronym><ProtocolTitle>A Long-Term, Open-Label Study on Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="66662"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 26-week, randomized, placebo-controlled study to evaluate the safety and efficacy of aripiprazole in patients with stable, chronic schizophrenia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="51173"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, double-blind, multicenter, placebo-controlled study to evaluate the safety and efficacy of aripiprazole in comparision with haloperidol in patients with schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="48364"/><TrialStartDate>2003-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Safety Study Comparing LY-2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="46131"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CAMP</ProtocolAcronym><ProtocolTitle>Comparison of Antipsychotics for Metabolic Problems Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="36367"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)</ProtocolTitle><Sponsor>Louisiana State University</Sponsor><StudyType>Interventional</StudyType><Trial id="35138"/><TrialStartDate>2003-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia</ProtocolTitle><Sponsor>University of Colorado at Denver and Health Sciences Center</Sponsor><StudyType>Interventional</StudyType><Trial id="34865"/><TrialStartDate>2005-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APEX 239</ProtocolAcronym><ProtocolTitle>Aripiprazole in Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34496"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study on individualized optimal treatment for antipsychotic drugs</ProtocolTitle><Sponsor>The Sixth Hospital of Peking University (Institute of Mental Health)</Sponsor><StudyType>Interventional</StudyType><Trial id="328278"/><TrialStartDate>2016-07-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, double-blind, controlled study of Shizhen’anshen granules therapy for individuals at high risk of schizophrenia</ProtocolTitle><Sponsor>Beijing Anding Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="320576"/><TrialStartDate>2017-12-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>TAILOR</ProtocolAcronym><ProtocolTitle>An experimental study comparing discontinuation with maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophrenia-like psychosis without psychotic symptoms</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="298863"/><TrialStartDate>2017-03-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PAFIP3_3Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: Three-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="292671"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine System</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="256985"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: a prospective, open-label study</ProtocolTitle><Sponsor>University of Miyazaki</Sponsor><StudyType>Interventional</StudyType><Trial id="256170"/><TrialStartDate>2010-08-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="234013"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Follow-on Study of the Long-term Safety of Aripiprazole in Patients With Chronic Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="228682"/><TrialStartDate>1998-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19208"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label Comparison of two Switching Strategies to Aripiprazole Treatment in Schizophrenic Patients: Add-On, Wait, and Tapering of Previous Antipsychotics Versus Add-on and Simultaneous Tapering</ProtocolTitle><Sponsor>Oizumi Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="148249"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Non-Randomized Study to Evaluate the Effectiveness, Acceptability, and Risks in the Inner-City Hospital Setting of Aripiprazole in the Acute Treatment of Male Patients with Schizophrenia</ProtocolTitle><Sponsor>Guy's Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="146635"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-Week, Open-Label, Naturalistic Switch Study of the Efficacy and Tolerability of Aripiprazole in Stable Outpatients with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="146003"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Pilot Study of Using Aripiprazole to Resolve Antipsychotic-Induced Symptomatic Hyperprolactinemia</ProtocolTitle><Sponsor>Korea University</Sponsor><StudyType>Interventional</StudyType><Trial id="145449"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Observation of Aripiprazole Augmentation of Clozapine in Treatment-resistant Schizophrenia</ProtocolTitle><Sponsor>Hannover Medical School</Sponsor><StudyType>Interventional</StudyType><Trial id="145129"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Chiba-BETA</ProtocolAcronym><ProtocolTitle>Chiba Broad Effectiveness Trial With  Aripiprazole</ProtocolTitle><Sponsor>Chiba University Graduate School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="139953"/><TrialStartDate>2009-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical and Neuropsychological Factors Associated With Second Generation Antipsychotic Response in Patients Diagnosed With First Episode of Early Onset Schizophrenia Spectrum Disorders</ProtocolTitle><Sponsor>Fundació Sant Joan de Déu</Sponsor><StudyType>Interventional</StudyType><Trial id="137063"/><TrialStartDate>2012-01-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation Of Efficacy, Safety, Quality Of Life (QOL), And Tolerability In Patients With Schizophrenia Who Are Switched From Prior Antipsychotics To Aripiprazole</ProtocolTitle><Sponsor>Kyoto University</Sponsor><StudyType>Interventional</StudyType><Trial id="125339"/><TrialStartDate>2011-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label, randomized study of aripiprazole in schizophrenia</ProtocolTitle><Sponsor>VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="113131"/><TrialStartDate>2003-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Autistic Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88306"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym>Aripiprazole in Autism</ProtocolAcronym><ProtocolTitle>Phase IV Long-term Maintenance Study of Aripiprazole in the Treatment of Irritability Associated With Autistic Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="71639"/><TrialStartDate>2011-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Children With Autism: A Pilot Study</ProtocolTitle><Sponsor>Drexel University College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="42540"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>HeartAriQue</ProtocolAcronym><ProtocolTitle>Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine</ProtocolTitle><Sponsor>Taichung Veterans General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="63409"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="47136"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Switching Outpatients with Bipolar or Schizoaffective Disorders and Substance Abuse from Their Current Antipsychotic to Aripiprazole</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="147788"/><TrialStartDate>2003-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Aripiprazole Prescribing Patterns and Side Effects in Elderly Psychiatric Inpatients</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="144790"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>Switching to Aripiprazole in Subjects with Pervasive Developmental Disorders Showing Tolerability Issues with Risperidone</ProtocolTitle><Sponsor>University of Fukui</Sponsor><StudyType>Interventional</StudyType><Trial id="152237"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>An 8-week, single-blind, randomized, controlled study to evaluate efficacy and safety of aripiprazole as an adjunct to valproic acid (Ari + Val), compared with haloperidol plus valproic acid (Hal + Val), for the treatment of patients with acute mania</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88732"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Aripiprazole Administered With Lithium or Valproate Over 12 Weeks in the Treatment of Mania in Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19426"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym>AWARE 273</ProtocolAcronym><ProtocolTitle>Efficacy and Safety Study of Once-Weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="80098"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A prospective open-label study to investigate the potential effectiveness of aripiprazole for tics, social adjustment, and parental stress in children and adolescents with Tourette's disorder</ProtocolTitle><Sponsor>Chang Gung Memorial Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="264425"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>APOLLO</ProtocolAcronym><ProtocolTitle>A Study of Abilify Tablet (Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="328310"/><TrialStartDate>2018-02-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3514">Postnatal depression</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Week, Prospective, Open-Label, Multicenter Study to Evaluate the Augmentation of Aripiprazole for Depressed Patients With an Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>Hallym University</Sponsor><StudyType>Interventional</StudyType><Trial id="156233"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>CAN-BIND-1</ProtocolAcronym><ProtocolTitle>Canadian Biomarker Integration Network for Depression Study</ProtocolTitle><Sponsor>The University Health Network</Sponsor><StudyType>Interventional</StudyType><Trial id="100372"/><TrialStartDate>2012-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinsons Disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8389"/><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>RECOVER extension study</ProtocolAcronym><ProtocolTitle>Long-Term Extension of Recover Long-Term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="8373"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>SP715</ProtocolAcronym><ProtocolTitle>An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="7118"/><TrialStartDate>2002-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease</ProtocolTitle><Sponsor>Schwarz Pharma SpA, UCB BIOSCIENCES GmbH, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6815"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A 6-month, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of rotigotine in patients with advanced-stage parkinson's disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="57891"/><TrialStartDate>2009-06-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study designed to evaluate the safety and efficacy of rotigotine in the treatment of Parkinson's disease (PD)</ProtocolTitle><Sponsor>Aderis Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="51535"/><TrialStartDate>1988-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A 6-Month Minimum Effective Dose of Flibanserin: 25 versus 50 mg bid versus 50 mg hs versus Placebo in Younger Women in North America</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="33306"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A One-Year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD)</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="33305"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>Flibanserin (Addyi) versus Flibanserin and Sex Therapy</ProtocolTitle><Sponsor>San Diego Sexual Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="256372"/><TrialStartDate>2017-01-25 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Eletriptan for the Treatment of Migraine in Patients Not Satisfied With Rizatriptan Therapy</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14082"/><TrialStartDate>2003-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Trexima and Relpax Gastric Scintigraphy Inside and Outside a Migraine</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14046"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Prospective Survey of Menstrual Migraine and Prevention With Eletriptan</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="14001"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A dose-finding, double-blind, multicenter, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine</ProtocolTitle><Sponsor>New England Center for Headache, P.C.</Sponsor><StudyType>Interventional</StudyType><Trial id="114107"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>High-Dose Lurasidone for Patients With Treatment-Resistant Schizophrenia</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><Trial id="86206"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Switch Ext</ProtocolAcronym><ProtocolTitle>A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="67269"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>SWITCHCore</ProtocolAcronym><ProtocolTitle>A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="67260"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of SM-13496 (lurasidone HCl) in patients with schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35470"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Active-Control, Open-label, Comparative, Randomized, Three-arm, Parallel-group, Multicenter, Phase-III Clinical Study to Evaluate The Efficacy And Safety Of Two Doses Of Lurasidone Compared With Quetiapine In Newly Diagnosed Patients Of Acute Schizophrenia</ProtocolTitle><Sponsor>MSN Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="180757"/><TrialStartDate>2014-04-07 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="172841"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Short-Term (6-Week) Phase II, Lurasidone Double-Blind, Randomized Trial in Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="143840"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>PERSISTExt</ProtocolAcronym><ProtocolTitle>This is an Open-label, Multicenter, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86412"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>PREVAIL 1</ProtocolAcronym><ProtocolTitle>Lurasidone - A 6-Week Study of Patients With Bipolar I Depression (Add-on)</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="49909"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>Illuminate</ProtocolAcronym><ProtocolTitle>Lurasidone Pediatric Bipolar Study</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="169879"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Frovatriptan as a Transitional Therapy in Medication Overuse Headache</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><Trial id="63280"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Research Study To Evaluate If Frovatriptan Is Safe And Effective In Preventing Migraine Headache After Fasting</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="14073"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Cross-over, Patient Preference Study of Frovatriptan Versus Zolmitriptan for the Acute Treatment of Migraine</ProtocolTitle><Sponsor>The Menarini Group</Sponsor><StudyType>Interventional</StudyType><Trial id="117269"/><TrialStartDate>2007-06-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Efficacy and Tolerability of Vilazodone in Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82482"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="140215"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10003">SDZ-MAR-327</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, maximum tolerated dose study of SDZ-MAR-327 in hospitalized schizophrenic patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="49977"/><TrialStartDate>1995-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter trial of tegaserod in women with irritable bowel syndrome (IBS) with constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19583"/><TrialStartDate>2004-11-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, open-label, two-phase, five-period crossover study to evaluate the pharmacokinetics of tegaserod in healthy subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19860"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of Efficacy and Safety of Tegaserod in Male Patients With Chronic Constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18714"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18192"/><TrialStartDate>2007-08-03 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18054"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42499"/><TrialStartDate>2004-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42634"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-dose, double-blind, multicenter study to evaluate the efficacy and safety of almotriptan in patients with migraine</ProtocolTitle><Sponsor>King's College London</Sponsor><StudyType>Interventional</StudyType><Trial id="74142"/><TrialStartDate>2002-07-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Effectiveness of Almotriptan Malate (AXERT) 12.5 mgs When Taken at the Onset of Migraine Pain</ProtocolTitle><Sponsor>Ortho-McNeil Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13843"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15073">FK-960</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II efficacy study of FK-960 for the potential treatment of cognitive disorder</ProtocolTitle><Sponsor>Fujisawa Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52010"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Long-Term Tolerability and Safety of Oral Prucalopride in Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="64336"/><TrialStartDate>1998-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="60792"/><TrialStartDate>1998-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>The Application of Lactulose and Prucalopride in Intestine Preparation in Chronic Constipation Patients before Colonoscopy</ProtocolTitle><Sponsor>Jingjiang People's Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="305386"/><TrialStartDate>2017-03-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effects of prucalpride  on colonic transit in patients with slow and normal transit constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19099"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym/><ProtocolTitle>Sarizotan in the Treatment of Neuroleptic-Induced Tardive Dyskinesia</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="6402"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Bifeprunox Extension to Extension Study in Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="48742"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, dose-finding, phase IIb study to evaluate the efficacy and tolerability of bifeprunox in patients with schizophrenia</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41453"/><TrialStartDate>2003-03-09 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, dose-escalation, safety and pharmacokinetic study of ACP-103 in healthy volunteers</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7649"/><TrialStartDate>2003-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="295386"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="386317"/><TrialStartDate>2019-07-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>CLARITY 3</ProtocolAcronym><ProtocolTitle>A phase III, 6-week, parallel-designed, randomized, double-blind, placebo-controlled, multicenter study to assess safety and efficacy of pimavanserin as an adjunctive treatment for major depressive disorder (MDD)</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="378238"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>CGRP, Estrogen, Cortisol, VIP, a-Amylase, PGE2, PG12 and Beta-Endorphin Levels in Menstrual Migraine Before and After Treximet</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="76259"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="34783">R-137696</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, parallel assignment study to evaluate the safety and efficacy of R-137696 in functional dyspepsia patients with visceral hypersensitivity (VH) or impaired accommodation</ProtocolTitle><Sponsor>Johnson &amp; Johnson</Sponsor><StudyType>Interventional</StudyType><Trial id="19806"/><TrialStartDate>2004-05-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="38094">ibipinabant</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Multiple-Dose Study to Evaluate the Efficacy, Safety and Pharmacokinetics of BMS-646256 in Obese Subjects</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="38239"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Tolerability Study of MAP-0004 in Smoking and Non-Smoking Adult Volunteers</ProtocolTitle><Sponsor>Allergan Inc, MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="70494"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>A 12-month, open-label study to assess overall safety (including pulmonary and cardiovascular) of dihydroergotamine at 6 and 12 months</ProtocolTitle><Sponsor>MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66346"/><TrialStartDate>2010-05-11 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A long-term, open-label study assessing the safety and tolerability of Levadex orally inhaled dihydroergotamine in adult migraineurs</ProtocolTitle><Sponsor>MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="78528"/><TrialStartDate>2011-06-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [(11)C]-(+)-PHNO PET Study in Humans</ProtocolTitle><Sponsor>University of Toronto</Sponsor><StudyType>Interventional</StudyType><Trial id="249480"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Pharmacokinetics and Safety of Dihydroergotamine Administered via Two Intranasal Delivery Devices</ProtocolTitle><Sponsor>IMPAX Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="190691"/><TrialStartDate>2014-05-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="46420">buspirone (transdermal spray, MDTS/ACROSS), Acrux</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate safety and pharmacokinetics of buspirone once-a-day transdermal spray when compared to oral buspirone in healthy volunteers for the treatment of anxiety disorder</ProtocolTitle><Sponsor>Acrux Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="55157"/><TrialStartDate>2003-08-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TEENZ</ProtocolAcronym><ProtocolTitle>Zomig - Treatment of Acute Migraine Headache in Adolescents</ProtocolTitle><Sponsor>AstraZeneca AB, AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="70801"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Four-way Crossover Study of Three Formulations of M-207 with Intranasal zolmitriptan in Healthy Volunteers</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="383718"/><TrialStartDate>2019-05-29 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Prospective, Open, Multi-attack Study of Patient Preference and Efficacy between Zolmitriptan Nasal Spray 5 mg and Sumatriptan RDT 100 mg in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Gothenburg Migraine Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="117173"/><TrialStartDate>2007-10-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym/><ProtocolTitle>Addressing Post Cessation Weight Gain</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="226533"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym>BLOOM-DM</ProtocolAcronym><ProtocolTitle>Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7401"/><TrialStartDate>2007-12-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A phase Ia, safety and pharmacokinetic clinical study of lorcaserin, in healthy volunteers</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42247"/><TrialStartDate>2004-07-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>African Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Safety and efficacy of APD-356 in the treatment of obesity</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38679"/><TrialStartDate>2005-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Predictors of Lorcaserin-Induced Weight Loss</ProtocolTitle><Sponsor>Columbia University</Sponsor><StudyType>Interventional</StudyType><Trial id="320592"/><TrialStartDate>2018-01-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A clinical Study to Study the Effect of Lorcaserin Tablets in the Treatment of Obesity</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="299785"/><TrialStartDate>2017-06-08 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Single-Dose Study to Determine the Safety, Tolerability, and Pharmacokinetic Properties of Lorcaserin Hydrochloride (Belviq) in Obese Adolescents From 12 to 17 Years of Age</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="165876"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47759">sumatriptan (needleless delivery, Intraject), Endo</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered via the intraject system</ProtocolTitle><Sponsor>Zogenix Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="18493"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Investigating the Effect of Vortioxetine in Adult ADHD Patients</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="219077"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Vortioxetine (Lu-AA21004) for Treatment of Generalized Anxiety Disorder in Adults</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="32522"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>ViBiD</ProtocolAcronym><ProtocolTitle>Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="347676"/><TrialStartDate>2018-08-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, multicenter, single-blind, placebo-controlled, single- and multiple-dose, parallel group pharmacokinetic (PK) study to evaluate the intrinsic factors influencing the drug disposition of LuAA-21004  for the potential treatment of major depressive disorder in healthy subjects</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="95301"/><TrialStartDate>2012-03-16 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Vortioxetine (Lu-AA21004): Open-Label Extension Study</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="67817"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Vortioxetine (Lu-AA21004) in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="67698"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study With Vortioxetine on Emotional Functioning in Patients With Depression</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="369666"/><TrialStartDate>2019-02-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Relationship Among Changes in Brain Network Activation in Adult Outpatients With Major Depressive Disorder</ProtocolTitle><Sponsor>Psychiatric Medicine Associates LLC, Rush University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="259209"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of PRX-03140 Monotherapy in Subjects With Alzheimer's Disease Receiving a Stable Dose of Donepezil</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="12453"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="376">Gastric motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, multiple-ascending dose, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability and pharmacokinetics of naronapride in healthy volunteers</ProtocolTitle><Sponsor>ARYx Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77600"/><TrialStartDate>2011-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="376">Gastric motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy of ATI-7505 in healthy volunteers</ProtocolTitle><Sponsor>Procter &amp; Gamble Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17613"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, parallel-group, double-blind, placebo-controlled, study to evaluate the efficacy of ATI-7505 in healthy volunteers</ProtocolTitle><Sponsor>Procter &amp; Gamble Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17613"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term Study of MP-214 in Patients With Schizophrenia</ProtocolTitle><Sponsor>Mitsubishi Tanabe Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="88661"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia</ProtocolTitle><Sponsor>Mitsubishi Tanabe Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="88655"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine for Mania</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63704"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63803"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="304">Sleep disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="255835"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="52634">TD-2749</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1269">Functional bowel disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, safety, tolerability and pharmacokinetic, single-dose study of TD-2749, in healthy volunteers</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17540"/><TrialStartDate>2005-01-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1269">Functional bowel disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Phase I Study To Assess The Safety, Tolerability And Pharmacokinetics Of TD-5108 For The Potential Treatment Of Gastrointestinal (GI) Motility Disorders In Healthy Volunteers</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17990"/><TrialStartDate>2005-12-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Ranging Study of Oral COL-144 in Acute Migraine Treatment</ProtocolTitle><Sponsor>CoLucid Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="52511"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="56250">PSN-602</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A first-in-human, safety, tolerability and pharmacokinetics study of PSN-602 in healthy lean and overweight/obese subjects</ProtocolTitle><Sponsor>OSI Pharmaceuticals Inc, Prosidion Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="36111"/><TrialStartDate>2008-06-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57473">revexepride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A Prospective Phase I, Single-Dose, Open-Label, Multicenter Clinical Trial to Evaluate the Pharmacokinetics and Safety of M-0003 in Young Children Aged Between 1 and 36 Months</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="138647"/><TrialStartDate>2008-09-22 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57748">NXN-188 (oral), NeurAxon</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, dose-escalation study of NXN-188 in healthy volunteers, for potential treatment of migraine</ProtocolTitle><Sponsor>NeurAxon Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="25745"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59015">ATI-9242</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate D2 Receptor Occupancy Following Single Intravenous Administration of ATI-9242</ProtocolTitle><Sponsor>Braeburn Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="265137"/><TrialStartDate>2016-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Motilitone on Gastric Accommodation in Healthy Adult Patients: Evaluation Using MRI Method</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><Trial id="178376"/><TrialStartDate>2013-08-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="59234">RQ-00000010</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>RQ-00000010 for Gastroparesis and Constipation in Parkinsons Disease</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><Trial id="266107"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="312466"/><TrialStartDate>2018-01-02 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled, safety, tolerability, pharmacokinetics and efficacy study of intranasal sumatriptan, delivered using an OptiNose device, for the potential treatment of acute migraine</ProtocolTitle><Sponsor>OptiNose AS</Sponsor><StudyType>Interventional</StudyType><Trial id="64437"/><TrialStartDate>2007-11-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym>STEP-A</ProtocolAcronym><ProtocolTitle>Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64408"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Brexpiprazole Plus Ketamine in Treatment-Resistant Depression (TRD)</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="298103"/><TrialStartDate>2017-09-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Genomics Analysis - Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="330573"/><TrialStartDate>2018-02-19 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Schizophrenia With Impulsivity</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="206172"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Lighthouse extension</ProtocolAcronym><ProtocolTitle>Brexpiprazole in Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="116246"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="310103"/><TrialStartDate>2017-10-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to &lt; 13 Years Old) With Central Nervous System Disorders</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="313836"/><TrialStartDate>2017-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, 12-week, randomized, double-blind, placebo-controlled trial of  brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type</ProtocolTitle><Sponsor>H Lundbeck A/S, Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="340571"/><TrialStartDate>2018-06-30 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Safety and Tolerability of OPC-34712 as Adjunctive Therapy in the Treatment of Adult Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="81321"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>8</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Polaris</ProtocolAcronym><ProtocolTitle>Study of the Safety and Efficacy of Two Fixed Doses of OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="77633"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>8+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Evaluate the Efficacy, Safety and Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="341006"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="225442"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the pharmacokinetics of an optimized formula of EVK-001 for treatment of diabetic gastroparesis</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54345"/><TrialStartDate>2008-06-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="85624"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ASPIRE</ProtocolAcronym><ProtocolTitle>An Open-Label, Multicenter, Rollover, Long-Term Study of Aripiprazole Intramuscular Depot in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66658"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ARILAI</ProtocolAcronym><ProtocolTitle>Effects of Aripiprazole (LAI) on Psychosocial/Cognitive Functioning, Patient Reported Acceptability of Treatment in Schizophrenia</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="255017"/><TrialStartDate>2017-01-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety And Tolerability Study Of Aripiprazole im Depot In Adult Subjects With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="147873"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, parallel-group, comparison trial of aripiprazole IM depot in patients with schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="101289"/><TrialStartDate>2010-07-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, dose-ranging study of safety of aripiprazole lauroxil (Aristada) in patients with schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="334592"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, non-inferiority study to evaluate the efficacy and safety of aripiprazole once-monthly-an extended-release injectable suspension versus oral aripiprazole (ARI) for the treatment of schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="151650"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole Lauroxil in Subjects with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="249326"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Study In Healthy Subjects To Evaluate The Changes In The Protein sAPP-Alpha In Cerebrospinal Fluid Following A Single Oral Dose Of PF-04995274</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="69840"/><TrialStartDate>2010-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study To Evaluate The Safety, Tolerability And Plasma Drug Levels Following A Single-Dose Of PF-04995274 In Healthy Adult Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65137"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="72849">minesapride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3862">Constipation predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Effects of DSP-6952 on the QT/QTc in Healthy Male and Female Volunteers</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="324767"/><TrialStartDate>2017-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="73740">sumatriptan (intranasal, migraine), Promius Pharma</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>DFN-02 Open-Label, Safety Study in Patients With Acute Migraine</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="214607"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="84360">testosterone + buspirone hydrochloride (oral, hypoactive sexual desire disorder), Emotional Brain</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Lybridos Food effect study Voedsel effect onderzoek naar Lybridos</ProtocolTitle><Sponsor>Emotional Brain BV</Sponsor><StudyType>Interventional</StudyType><Trial id="216539"/><TrialStartDate>2015-01-26 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84360">testosterone + buspirone hydrochloride (oral, hypoactive sexual desire disorder), Emotional Brain</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Lybridos in Pre and Postmenopausal Women With Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Emotional Brain BV</Sponsor><StudyType>Interventional</StudyType><Trial id="180253"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="97555">dihydroergotamine (aerosol nasal, migraine), Impel NeuroPharma</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Bioavailability of DHE Administered by I-123 POD Device, IV Injection and Migranal Nasal Spray in Healthy Adults</ProtocolTitle><Sponsor>Clinical Network Services, Impel NeuroPharma</Sponsor><StudyType>Interventional</StudyType><Trial id="326056"/><TrialStartDate>2017-10-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="109472">sumatriptan (migraine, ZENEO), Crossject</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A clinical study of sumatriptan for the treatment of severe migraine</ProtocolTitle><Sponsor>Crossject</Sponsor><StudyType>Interventional</StudyType><Trial id="330217"/><TrialStartDate>2017-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Mosapride Citrate in Type 2 Diabetic Patient's GLP-1</ProtocolTitle><Sponsor>Chiba University</Sponsor><StudyType>Interventional</StudyType><Trial id="224957"/><TrialStartDate>2015-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="102889">mosapride + rebamipide (functional dyspepsia), Il Dong</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym>ID_MotiReb_1302</ProtocolAcronym><ProtocolTitle>Prospective study in comparing the safety and the pharmacokinetics of Mosapride and Rebamipide having the effects on gastrointestinal diseases when administered as single drug or a complex in healthy korean male adults</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="192145"/><TrialStartDate>2014-04-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="102889">mosapride + rebamipide (functional dyspepsia), Il Dong</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Drug Interaction Study of Mosapride and Rebamipide</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="181099"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Impact of Buspirone Maintenance on the Reinforcing Effects of Cocaine</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><Trial id="89613"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole (Abilify) in Patients With Bipolar Mania</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="81216"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Assessing the Effectiveness of Treatment by Aripiprazole and Placebo for Control of Obsession in Patients With Bipolar Mood Disorder</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="302425"/><TrialStartDate>2016-05-14 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole effect in the treatment of mania</ProtocolTitle><Sponsor>University of Social Welfare and Rehabilitation Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="301904"/><TrialStartDate>2015-10-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="133586"/><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, placebo-controlled, randomized study for the comparison of eletriptan (40 to 80 mg) and oral sumatriptan (50 to 100 mg) for the treatment of acute migraine in sumatriptan-naive patients</ProtocolTitle><Sponsor>Memorial University</Sponsor><StudyType>Interventional</StudyType><Trial id="109744"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Frovatriptan Versus Zolmitriptan in the Treatment of Migraine With or Without Aura, a Patient Preference Study</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="117172"/><TrialStartDate>2007-03-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62606">CL-H1T</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1050">Hallucination</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6094"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62606">CL-H1T</Drug><Endpoint>Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Phase I study to Evaluate Bioavailability of CL-H1T</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="236612"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>ACP-103 to Treat Parkinson's Disease</ProtocolTitle><Sponsor>National Institute of Neurological Disorders and Stroke</Sponsor><StudyType>Interventional</StudyType><Trial id="6093"/><TrialStartDate>2004-06-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Refractory Anxiety</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="31331"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="49">Breast tumor</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine for MDD, Cognition, and Systemic Inflammatory Biomarkers</ProtocolTitle><Sponsor>University of Miami</Sponsor><StudyType>Interventional</StudyType><Trial id="249225"/><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1932">Catatonic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1932">Catatonic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65680"/><TrialStartDate>2010-04-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Sumatriptan 100 mg Tablets Under Fasting Conditions</ProtocolTitle><Sponsor>Ranbaxy Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="50346"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Sumatriptan Succinate Tablets 100 mg in Fed Conditions</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="200966"/><TrialStartDate>2005-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Cross-over, Pharmacokinetic and Pharmacodynamic Study to Investigate Any Interaction Between Pizotifen and GR-43175C</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153746"/><TrialStartDate>1989-06-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Single-Dose, Two-Period, Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a Trexima (Sumatriptan 85 mg and Naproxen Sodium 500 mg) Tablet Compared With an Imitrex (Sumatriptan) 100 mg Tablet</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152012"/><TrialStartDate>2006-02-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, placebo-controlled, randomized study to evaluate CNS effects of sumatriptan rizatriptan in healthy female volunteers</ProtocolTitle><Sponsor>Centre for Human Drug Research</Sponsor><StudyType>Interventional</StudyType><Trial id="111397"/><TrialStartDate>2002-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Sumatriptan 100 mg Tablets Under Fed Conditions</ProtocolTitle><Sponsor>Ranbaxy Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="100324"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="9">Aggression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of a Triptan in the Treatment of Hostility and Aggression Among Convicts With a Psychiatric Treatment Order</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><Trial id="21469"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym/><ProtocolTitle>ACP-103 to Treat Parkinson's Disease</ProtocolTitle><Sponsor>National Institute of Neurological Disorders and Stroke</Sponsor><StudyType>Interventional</StudyType><Trial id="6093"/><TrialStartDate>2004-06-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder</ProtocolTitle><Sponsor>University of Pennsylvania</Sponsor><StudyType>Interventional</StudyType><Trial id="329002"/><TrialStartDate>2018-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Comparing the Therapeutic Efficacy and Safety of DA-9701 With Domperidone in Patients With Parkinson's Disease</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="285330"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym>B-ACE</ProtocolAcronym><ProtocolTitle>Buspirone in the Treatment of 2 to 6 Year Old Children With Autistic Disorder</ProtocolTitle><Sponsor>Wayne State University</Sponsor><StudyType>Interventional</StudyType><Trial id="50498"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2774">Hypoprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia</ProtocolTitle><Sponsor>Genovate Biotechnology Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="14198"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="36247"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1A">Phase 1a Clinical</DevStatus><Drug id="14131">LY-315535</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1269">Functional bowel disorder</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, single rising dose, phase Ia study to evaluate the safety and tolerability of LY-315535, a potential treatment for functional bowel disorders</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="19673"/><TrialStartDate>1997-11-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="226">Nausea</Indication><ProtocolAcronym/><ProtocolTitle>Study to Test a Marketed Product in the Treatment of Migraine-Associated Nausea</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="13995"/><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="260">Peripheral vascular disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2164">Rosacea</Indication><ProtocolAcronym/><ProtocolTitle>PACAP-38 Induced Headache and Rosacea-like Symptoms in Patients With Rosacea</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373775"/><TrialStartDate>2018-11-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Tolerability of Lu-AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="83220"/><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Vortioxetine (Lu-AA21004) in Treating Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35057"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>SToP-C</ProtocolAcronym><ProtocolTitle>Substance Misuse To Psychiatric Disorders for Cannabis</ProtocolTitle><Sponsor>The University of Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="334943"/><TrialStartDate>2018-07-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2425">Frontotemporal dementia</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2940">Tic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized, controlled clinical trial</ProtocolTitle><Sponsor>Shiraz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="210938"/><TrialStartDate>2014-01-13 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2940">Tic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder</ProtocolTitle><Sponsor>New York University School of Medicine, US</Sponsor><StudyType>Interventional</StudyType><Trial id="20591"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="75382">carbidopa + levodopa + buspirone (oral, spinal cord injury), Nordic Life Sciences Pipeline</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1258">Spinal cord injury</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (Spinalon) in Patients With Chronic Spinal Cord Injury</ProtocolTitle><Sponsor>Nordic Life Science Pipeline Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="83109"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Effects on Alcohol Drinking and Craving</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="74595"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym>NALAPZ</ProtocolAcronym><ProtocolTitle>An Exploratory Study of Naltrexone Plus Aripiprazole for Alcohol Dependence</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="57156"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2158">Pseudoobstruction</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)</ProtocolTitle><Sponsor>Johnson &amp; Johnson, Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="36415"/><TrialStartDate>2008-11-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1943">Psychiatric symptom</Indication><ProtocolAcronym/><ProtocolTitle>A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="344862"/><TrialStartDate>2018-05-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="127">Stomach tumor</Indication><ProtocolAcronym>SMW</ProtocolAcronym><ProtocolTitle>Efficacy Study of a Low Volume of Water Intake and Mosapride for Endoscopy in Patients With Subtotal Gastrectomy</ProtocolTitle><Sponsor>Inje University</Sponsor><StudyType>Interventional</StudyType><Trial id="74284"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic properties of lorcaserin in subjects with renal impairment</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42192"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Thorough Corrected QT Interval (QTc) Study To Evaluate Possible Effects of Prucalopride on Electrocardiography (ECG) Parameters</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="55430"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>33+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1105">Scleroderma</Indication><ProtocolAcronym>PCTS</ProtocolAcronym><ProtocolTitle>Pragmatic Clinical Trials in Scleroderma</ProtocolTitle><Sponsor>University of West London</Sponsor><StudyType>Interventional</StudyType><Trial id="349233"/><TrialStartDate>2018-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1948">Asperger syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>SFBRI</ProtocolAcronym><ProtocolTitle>Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia</ProtocolTitle><Sponsor>Louisiana State University</Sponsor><StudyType>Interventional</StudyType><Trial id="36222"/><TrialStartDate>2003-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)</ProtocolTitle><Sponsor>Louisiana State University</Sponsor><StudyType>Interventional</StudyType><Trial id="35138"/><TrialStartDate>2003-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PAFIP3_3Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: Three-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="292671"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1279">Panic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in Bipolar Disorder With Co-morbid Lifetime Panic or Generalized Anxiety Disorder (GAD)</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="68728"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15073">FK-960</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A pharmacokinetic study of FK-960 in healthy volunteers</ProtocolTitle><Sponsor>Fujisawa Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52009"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="358334"/><TrialStartDate>2018-11-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="150606"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the efficacy and safety of tezampanel compared to sumatriptan in the treatment of acute migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="41049"/><TrialStartDate>2003-06-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>BD-CAEL</ProtocolAcronym><ProtocolTitle>CAE Plus LAI in Individuals With Bipolar Disorder at Risk for Treatment Non-adherence</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="327471"/><TrialStartDate>2018-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Between Single Administration of ASC-01 (Aripiprazole/Sertraline Combination Drug) and Concomitant Single Administration of Aripiprazole and Sertraline, and Food Effect on Pharmacokinetics of ASC-01 in Healthy Male Adults</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="319613"/><TrialStartDate>2017-11-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open, randomized, conducted in two phases, cross-sectional study of drug bioequivalence of Pipzol tablets 10 mg (Alembic Pharmaceuticals Limited, India) and Abilify tablets 10 mg (Bristol-Myers Squibb Company Manufacturing, Puerto Rico) with a single dose on an empty stomach in healthy volunteers</ProtocolTitle><Sponsor>Alembic Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="213967"/><TrialStartDate>2014-10-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics</ProtocolTitle><Sponsor>Janssen Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="191093"/><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90513">YL-0919</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Hydroxypyridone Hydrochloride Tablets I Clinical Trial Food Effects</ProtocolTitle><Sponsor>Institute of Pharmacology and Toxicology Academy of Military Medical Sciences PLA, Zhejiang Huahai Pharmaceutical Group Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="294861"/><TrialStartDate/><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Rebalancing the Serotonergic System in Cocaine Dependence</ProtocolTitle><Sponsor>McLean Hospital Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="310897"/><TrialStartDate>2018-10-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="96279">sumatriptan (autoinjector, migraine), Promius Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>RESTOR</ProtocolAcronym><ProtocolTitle>DFN-11 Injection in Episodic Migraine With or Without Aura</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="242272"/><TrialStartDate>2015-09-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="235">Nicotine dependence</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled trial to evaluate the efficacy of sertraline and buspirone combination in non-depressed smokers</ProtocolTitle><Sponsor>Federal University of Rio Grande do Sul</Sponsor><StudyType>Interventional</StudyType><Trial id="66078"/><TrialStartDate>2006-08-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym>IBS-5HT-MOT</ProtocolAcronym><ProtocolTitle>Effect of 5-HT4 receptor agonist on sensorimotor rectosigmoid function in patients with irritable bowel syndrome (IBS)</ProtocolTitle><Sponsor>Tohoku University</Sponsor><StudyType>Interventional</StudyType><Trial id="93677"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="108460">meloxicam + rizatriptan (fixed-dose combination/oral, migraine), Axsome</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>MOMENTUM</ProtocolAcronym><ProtocolTitle>Maximizing Outcomes in Treating Acute Migraine</ProtocolTitle><Sponsor>Axsome Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="320888"/><TrialStartDate>2019-03-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="80985"/><TrialStartDate>2000-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A fully counterbalanced, randomised within-subject, double-blinded, placebo-controlled, cross-over study to investigate the effects of aripiprazole and haloperidol on brain activation during working memory in healthy volunteers</ProtocolTitle><Sponsor>King's College London</Sponsor><StudyType>Interventional</StudyType><Trial id="261477"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP2_3Y</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: Three-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="237668"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PREVENT</ProtocolAcronym><ProtocolTitle>Secondary Prevention of Schizophrenia. A randomized, controlled trial</ProtocolTitle><Sponsor>University of Cologne</Sponsor><StudyType>Interventional</StudyType><Trial id="228171"/><TrialStartDate>2007-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of effectiveness of Risperdal Consta compared to Abilify over a two-year period in patients with schizophrenia</ProtocolTitle><Sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="21111"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Comparison of Risperidone and Aripiprazole for Treatment of Patirnts With Methamphetamine-Associated Psychosis</ProtocolTitle><Sponsor>Central South University</Sponsor><StudyType>Interventional</StudyType><Trial id="116522"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in L-dopa-Induced Dyskinesias: A One-year Open-label Pilot Study</ProtocolTitle><Sponsor>Universita degli Studi di Roma La Sapienza</Sponsor><StudyType>Interventional</StudyType><Trial id="147082"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="21671"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2954">Weight gain</Indication><ProtocolAcronym/><ProtocolTitle>1/2-MC4R Genotype and Pediatric Antipsychotic Drug-Induced Weight Gain</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="126918"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="201">Liver disease</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="66878"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2520">Insulin resistance</Indication><ProtocolAcronym/><ProtocolTitle>Improving Diabetes Risk Factors in Mexican-American Persons With Schizophrenia by Switching to Ziprasidone</ProtocolTitle><Sponsor>University of Texas Health Science Center San Antonio</Sponsor><StudyType>Interventional</StudyType><Trial id="5089"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="63849"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1929">Borderline personality disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in the Treatment of Borderline Personality Disorder</ProtocolTitle><Sponsor>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Sponsor><StudyType>Interventional</StudyType><Trial id="33030"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Evaluation of Histamine, CGRP and VIP as Markers for Activation of Trigeminal and Parasympathetic Nerve Fibers</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="58817"/><TrialStartDate>2004-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, crossover, double-blind, dose-finding, placebo-controlled study to evaluate the hemodynamic and electrocardiographic effect of almotriptan in healthy volunteers</ProtocolTitle><Sponsor>Hammersmith Medicines Research</Sponsor><StudyType>Interventional</StudyType><Trial id="110562"/><TrialStartDate>2001-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-954 in Healthy Adult Participants</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><Trial id="373163"/><TrialStartDate>2019-03-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="80">Coronary artery disease</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="230579"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="96279">sumatriptan (autoinjector, migraine), Promius Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>RESTOR</ProtocolAcronym><ProtocolTitle>DFN-11 Injection in Episodic Migraine With or Without Aura</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="242272"/><TrialStartDate>2015-09-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP2_3Y</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in Treatment of First Episode Psychosis: Three-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="237668"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Switching Outpatients with Bipolar or Schizoaffective Disorders and Substance Abuse from Their Current Antipsychotic to Aripiprazole</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="147788"/><TrialStartDate>2003-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone as a Candidate Medication for Methamphetamine Abuse</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><Trial id="126742"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of Oral Sumatriptan for the Acute Treatment of Migraine in Children and Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="59826"/><TrialStartDate>2009-09-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Investigation of Vascular Inflammation in Migraine Using Molecular Nano-imaging and Black Blood Imaging MRI</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="240769"/><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="299935"/><TrialStartDate>2017-05-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study to assess the changes in bone turnover biomarkers after aripiprazole treatment in patients with psychiatric disorders</ProtocolTitle><Sponsor>University of Alberta</Sponsor><StudyType>Interventional</StudyType><Trial id="254667"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="67578">mosapride citrate (dyspepsia, sustained release), Daewoong</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical Trials to Compare Mosapride Bioavailability Between DWJ-1252 and Mosapride Medicine</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="65188"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type</ProtocolTitle><Sponsor>First Teaching Hospital of Tianjin University of Traditional Chinese Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="203644"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Psychotherapy and Pharmacotherapy on Anxiety</ProtocolTitle><Sponsor>Tabriz University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="121673"/><TrialStartDate>2012-06-04 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="164016"/><TrialStartDate>2013-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment of Schizophrenia or Schizoaffective Disorder in Hospitalized Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35469"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34898"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Ziprasidone Study for Psychosis Treatment in Adolescents</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="33934"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="275883"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>Kahn</ProtocolAcronym><ProtocolTitle>Investigation of the efficacy of ziprasidone versus olanzapine in the management of recent-onset psychosis; A flexible-dose, parallel-group, double-blind study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="20969"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A crossover, double-blind, randomized study was to evaluate the pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine in healthy subjects</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="109265"/><TrialStartDate>1999-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym>PAMS</ProtocolAcronym><ProtocolTitle>Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder</ProtocolTitle><Sponsor>University of Maryland</Sponsor><StudyType>Interventional</StudyType><Trial id="34878"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3283">Cannabis dependence</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone Treatment for Marijuana Dependence</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="50749"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess the Pharmacokinetics, Safety, and Tolerability of Pimavanserin in Adolescents with Psychiatric Disorders</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="360393"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan on the Heart in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="332637"/><TrialStartDate>2011-09-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1926">Trichotillomania</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Aripiprazole in Trichotillomania</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><Trial id="59143"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62606">CL-H1T</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="226">Nausea</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effects of Galantamine and Buspirone on Serotonergic/Cholinergic Imbalance of Depression and its Related Abnormalities in Sleep Structure of Healthy Female Subjects</ProtocolTitle><Sponsor>University of Ottawa</Sponsor><StudyType>Interventional</StudyType><Trial id="243360"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, placebo-controlled study determining whether prucalopride would augment secondary peristalsis in gastroesophageal reflux disease patients with ineffective esophageal motility</ProtocolTitle><Sponsor>Hualien Tzu Chi Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="336520"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>ACES 255</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="65921"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Therapy for Reducing Comorbid Substance Abuse</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="33105"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>Depression-Anx Trial</ProtocolAcronym><ProtocolTitle>An Antidepressant Medications from Treatment Initiation for Depressive Disorder with Anxiety Symptoms: A Prospective Comparative Study</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="282448"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Antidepressant Medication Plus Donepezil for Treating Late-Life Depression</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="20631"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Mixed Depression</ProtocolTitle><Sponsor>Kurdistan University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="130604"/><TrialStartDate>2012-12-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2085">Dysphagia</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the effect of aripiprazole on the steady-state pharmacokinetics of escitalopram or venlafaxine in subjects with depressive or anxiety disorders</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="77979"/><TrialStartDate>2007-05-02 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, parallel-group study of haloperidol or aripiprazole for the treatment of Anxiety-Depressed Attack</ProtocolTitle><Sponsor>Warakukai Medical Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="345320"/><TrialStartDate>2018-02-06 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5111">lesopitron</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, randomized, double-blind, parallel, placebo and lorazepam-controlled, phase II, single-center, outpatient study to evaluate the safety and efficacy of lesopitron in a patients with anxiety history</ProtocolTitle><Sponsor>Laboratorios Dr Esteve SA</Sponsor><StudyType>Interventional</StudyType><Trial id="56262"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>RESOLVE3</ProtocolAcronym><ProtocolTitle>Major Depressive Disorder With Mixed Features - Extension</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80317"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Tadospirone Citrate on Symptom Resolution of Patients With Functional Dyspepsia - A Double-blind Placebo-Controlled trial</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="163796"/><TrialStartDate>2005-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3010">Colonoscopy</Indication><ProtocolAcronym/><ProtocolTitle>Free-residue Nutrients for the Bowel Preparation of Colon Capsule Endoscopy</ProtocolTitle><Sponsor>Xijing Hospital of Digestive Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="270493"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="129">Gastrointestinal disease</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor) given subcutaneously in patients undergoing elective partial colectomies</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19104"/><TrialStartDate>2008-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym>OC-DDI</ProtocolAcronym><ProtocolTitle>A randomized, placebo-controlled, two-period, crossover study to evaluate the effect of lurasidone HCl on oral contraceptive pharmacokinetics in healthy female subjects</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="42271"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2954">Weight gain</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole as an Adjunct to Atypical Antipsychotics for Weight Reduction and Improvement in Metabolic Profile</ProtocolTitle><Sponsor>Institute Of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="277982"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="584">Lipid metabolism disorder</Indication><ProtocolAcronym/><ProtocolTitle>Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia</ProtocolTitle><Sponsor>Genovate Biotechnology Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="14198"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2954">Weight gain</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin for Preventing Weight Gain Among Smokers</ProtocolTitle><Sponsor>Mayo Clinic, Minnesota</Sponsor><StudyType>Interventional</StudyType><Trial id="224774"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive Disorder: A Double-Blind, Placebo-Controlled Study</ProtocolTitle><Sponsor>Universita' Degli Studi Di Messina</Sponsor><StudyType>Interventional</StudyType><Trial id="144492"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Aripiprazole Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder</ProtocolTitle><Sponsor>Imam General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="101816"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Dyspepsia - Buspiron</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="119454"/><TrialStartDate>2005-06-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="668">Muscle weakness</Indication><ProtocolAcronym>EMILI</ProtocolAcronym><ProtocolTitle>Evaluating Muscle Weakness Improvement With Lorcaserin in ICU</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="237506"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="2647">BMS-181100</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I/II, open-label study to evaluate the safety and tolerance of BMS-181100 in schizophrenic patients</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="50441"/><TrialStartDate>1991-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>University of Malaya</Sponsor><StudyType>Interventional</StudyType><Trial id="95891"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A compassionate protocol of ziprasidone for patients who had successfully completed a previous ziprasidone study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="89310"/><TrialStartDate>2000-07-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open extension study to assess the safety and tolerability of oral ziprasidone in patients who have successfully completed a previous ziprasidone study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88878"/><TrialStartDate>2002-05-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, multicenter, 6-week, open-label, non-comparative, flexible-dose study to evaluate the efficacy, safety and tolerability of oral ziprasidone in the treatment of acute exacerbation of schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86402"/><TrialStartDate>2002-09-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, 40-week, double-blind study, followed by a double-blind continuation trial up to 156 additional weeks to evaluate the efficacy and treatment outcomes of ziprasidone versus haloperidol for the treatment of patients with schizophrenia</ProtocolTitle><Sponsor>University of California San Diego</Sponsor><StudyType>Interventional</StudyType><Trial id="68780"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ZEISIG</ProtocolAcronym><ProtocolTitle>A 12-week, prospective, flexible-dose, multicenter, open-label observational clinical study to assess the efficacy, safety and tolerability of ziprasidone for the treatment of patients with schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Universitätsklinikum Hamburg-Eppendorf</Sponsor><StudyType>Interventional</StudyType><Trial id="67211"/><TrialStartDate>2005-11-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, three-way crossover study to evaluate the influence of a high-fat meal on the pharmacokinetics and pharmacodynamics of ziprasidone in healthy male volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53492"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>STAR-1</ProtocolAcronym><ProtocolTitle>Use of Galantamine and CDP-Choline (Citicoline) to Treat Adults with Schizophrenia</ProtocolTitle><Sponsor>Georgetown University</Sponsor><StudyType>Interventional</StudyType><Trial id="36353"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial</ProtocolTitle><Sponsor>Central Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="35792"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34982"/><TrialStartDate>2001-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>ME-2112 Phase III</ProtocolTitle><Sponsor>Meiji Seika Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="224196"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Impact of Aripiprazole (Abilify) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><Trial id="210228"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>7</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind Trial With Six Antipsychotic Drugs for Schizophrenia</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="206129"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes</ProtocolTitle><Sponsor>Veterans Medical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="18217"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>TAAS</ProtocolAcronym><ProtocolTitle>Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia</ProtocolTitle><Sponsor>Guangzhou Psychiatric Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="168968"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>EUFEST</ProtocolAcronym><ProtocolTitle>The European First Episode Schizophrenia Trial (EUFEST): Comparison Of Outcome In First Episode Schizophrenia With Different Low Dose Antipsychotic Drug Regimens</ProtocolTitle><Sponsor>AstraZeneca plc, Pfizer Inc, Sanofi SA, The European Group for Research in Schizophrenia (EGRIS)</Sponsor><StudyType>Interventional</StudyType><Trial id="146760"/><TrialStartDate>2002-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open Clinical Study To Evaluate The Combination of Clozapine and Ziprasidone in Treatment-Resistant Schizophrenia</ProtocolTitle><Sponsor>Hannover Medical School</Sponsor><StudyType>Interventional</StudyType><Trial id="144270"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>Zip Ad</ProtocolAcronym><ProtocolTitle>Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="74716"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study evaluating the cardiovascular safety of ziprasidone</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53571"/><TrialStartDate>2001-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66130"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="362864"/><TrialStartDate>2018-12-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Adjunctive Ziprasidone in the Treatment of Bipolar I Depression</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33937"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment Optimization For Bipolar I Disorder, Manic Or Mixed Phase</ProtocolTitle><Sponsor>Guangzhou Psychiatric Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="144912"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, safety and efficacy study of gepirone in patients with generalized anxiety disorder (GAD)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45902"/><TrialStartDate>1997-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind Trial of Low- and High-Dose Ranges of Gepirone-ER Compared With Placebo in the Treatment of Depressed Out Patients</ProtocolTitle><Sponsor>Pharmacology Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="153349"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, single dose study to determine the pharmacokinetics of naratriptan in male and female adolescent (12 to 17 years old) migraine subjects outside a migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78535"/><TrialStartDate>1996-05-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, single-blind, ascending dose, randomized, three-period study to evaluate the safety and pharmacokinetic (PK) profile of naratriptan in healthy male volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78515"/><TrialStartDate>1994-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, phase I, randomized, two-way crossover study to determine the absolute bioavailability of oral GR-85548A in healthy subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78288"/><TrialStartDate>1994-07-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, double-dummy, crossover, multi-attack, outpatient study to compare the patient preference of naratriptan with naproxen in patients dissatisfied with simple analgesics in the treatment of acute migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77300"/><TrialStartDate>1999-02-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, four-period, crossover study to evaluate the pharmacokinetics and safety of naratriptan in healthy male volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77131"/><TrialStartDate>1994-05-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A dose-ranging, late phase II study to evaluate the safety and efficacy of tandospirone for the treatment of neurosis</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="50252"/><TrialStartDate>1992-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of DWJ-1252 in the Treatment of Functional Dyspepsia (PART 2)</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="301316"/><TrialStartDate>2017-04-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Study on Post Evaluation After Listing of Qizhi Weitong Granules</ProtocolTitle><Sponsor>Xiyuan Hospital China Academy Of Chinese Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="298072"/><TrialStartDate>2017-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A clinical study to evaluate the efficacy and safety of acotiamide in indian adult patients with functional dyspepsia-post prandial distress syndrome</ProtocolTitle><Sponsor>Hetero Group</Sponsor><StudyType>Interventional</StudyType><Trial id="256693"/><TrialStartDate>2016-03-26 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of mosapride plus esomeprazole combination therapy in patients with gastroesophageal reflux disease</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="384371"/><TrialStartDate>2019-07-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Investigation of the Efficacy of Esomeprazole for 8 Weeks to the Proton Pomp Inhibitor (PPI)-Resistant Gastroesophageal Reflux Disease (GERD) Patients</ProtocolTitle><Sponsor>National Hospital Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="159225"/><TrialStartDate>2013-08-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4274">roxindole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open-label trial to assess the efficacy of roxindole in schizophrenic patients</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><Trial id="48839"/><TrialStartDate>1992-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="678">Neuropathy</Indication><ProtocolAcronym>XENOX</ProtocolAcronym><ProtocolTitle>XENOX – Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45807"/><TrialStartDate>2002-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1089">Neurotoxicity drug-induced</Indication><ProtocolAcronym/><ProtocolTitle>An exploratory study to evaluate the efficacy of xaliproden in eliminating chemotherapy-induced neuropathy in patients with colorectal cancer</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45808"/><TrialStartDate>2007-02-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1089">Neurotoxicity drug-induced</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Efficacy of Xaliproden (SR-57746A) in Preventing the Neurotoxicity of Oxaliplatin/5FU/LV Chemotherapy</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41370"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, double-dummy, randomized, placebo-controlled, four-way crossover study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77167"/><TrialStartDate>1996-02-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Muticenter, Post-Marketing Surveillance Study To Evaluate Safety And Efficacy Of Sumatriptan In Patients With Migraine and Cluster Headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="73796"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Neuropeptides in the Humane Intra- og Extracerebral Circulation</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="57922"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Open-label Trial on the efficacy and Tolerability of Sumatriptan in Cluster Headache</ProtocolTitle><Sponsor>Christian-Albrechts-University Kiel</Sponsor><StudyType>Interventional</StudyType><Trial id="107976"/><TrialStartDate>1998-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Migraine Treatment Satisfaction With Treximet Versus Concomitant Two Aleve and Imitrex</ProtocolTitle><Sponsor>Wesley Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="81562"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, randomized, double-blind, placebo-controlled, parallel group, two-attack, outpatient study to determine if naratriptan was able to treat migraine headaches in subjects with a history of poor response to sumatriptan</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77212"/><TrialStartDate>1997-09-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, double-blind, two-attack, cross-over outpatient study to compare the efficacy, safety and tolerability of oral naratriptan with oral sumatriptan in the acute treatment of migraine in patients susceptible to headache recurrence</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77197"/><TrialStartDate>1995-09-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>SAMS</ProtocolAcronym><ProtocolTitle>A prospective, double-blind, randomized, placebo-controlled trial to evaluate the efficacy of sumatriptan for the prevention of acute mountain sickness (AMS)</ProtocolTitle><Sponsor>University of Tehran</Sponsor><StudyType>Interventional</StudyType><Trial id="66340"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Neuropeptides in the Humane Intra- og Extracerebral Circulation</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="57922"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Sumatriptan and Placebo Injection on Cilostazol Induced Headache</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="328480"/><TrialStartDate>2017-11-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, placebo-controlled, post-approval study of ZEMBRACE SymTouch(sumatriptan injection)for the treatment of acute migraine headache</ProtocolTitle><Sponsor>Promius Pharma LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="319549"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of sumatriptan and propofol VS Sumatriptan and placebo in acute migraine</ProtocolTitle><Sponsor>Shahid Sadoughi University of Medical Sciences and Health Services</Sponsor><StudyType>Interventional</StudyType><Trial id="293881"/><TrialStartDate>2014-09-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Parallel-Group Study of a Second 100 mg Oral Dose of GR43175C in the Acute Treatment of a Migraine Attack and of a Further 100 mg Dose in Treating Headache Recurrence</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="152483"/><TrialStartDate>1990-09-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind Study to Compare Oral GR-43175-C With Oral Cafergot (Ergotamine + Caffeine) in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="150864"/><TrialStartDate>1989-01-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Open, Additional Treatment With GR43175C by Subcutaneous Injection for Patients Participating in Protocol S2BT02</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="150859"/><TrialStartDate>1988-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14043"/><TrialStartDate>2006-06-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Preference for Triptans in Migraine Patients: A Randomized, Open-Label, Crossover Prospective Study</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><Trial id="125981"/><TrialStartDate>2010-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess an Auto-injector Being Used to Treat a Migraine Attack</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="113745"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of Effects of Metoclopramide Versus Sumatriptan on Migraine Headache</ProtocolTitle><Sponsor>Isfahan University of medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="110407"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Double-blind, Multicenter, Placebo-controlled, Randomized Study to Evaluate the Efficacy of Zolmitriptan and Sumatriptan in Patients with Migraine</ProtocolTitle><Sponsor>Centre Hospitalier Universitaire de Rangueil</Sponsor><StudyType>Interventional</StudyType><Trial id="110125"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, comparative, crossover, double-blind, multicenter, placebo-controlled study to assess the tolerability and efficacy of diclofenac versus sumatriptan in migraine patients</ProtocolTitle><Sponsor>Glaxo Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="106088"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TSM</ProtocolAcronym><ProtocolTitle>Drug and Non-Drug Treatment Of Severe Migraine</ProtocolTitle><Sponsor>Ohio University</Sponsor><StudyType>Interventional</StudyType><Trial id="102773"/><TrialStartDate>2001-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4710">zalospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, double-blind study to assess the efficacy and safety of zalospirone, a potential treatment for anxiety disorder</ProtocolTitle><Sponsor>American Home Products Holdings (UK) Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52533"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym>ZINCH</ProtocolAcronym><ProtocolTitle>Intranasal Zolmitriptan is Effective And Well Tolerated In Acute Cluster Headache</ProtocolTitle><Sponsor>AstraZeneca plc</Sponsor><StudyType>Interventional</StudyType><Trial id="143515"/><TrialStartDate>2003-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MATRIX(Migrainer Assess TRiptane eXamination)</ProtocolTitle><Sponsor>University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><Trial id="132785"/><TrialStartDate>2010-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Patient Preference Study of Frovatriptan Versus Zolmitriptan for The Acute Treatment of Migraine</ProtocolTitle><Sponsor>Laboratorio Guidotti SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="116962"/><TrialStartDate>2007-06-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>A pivotal, phase III study of eltoprazine in adults with attention deficit hyperactivity disorder (ADHD)</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="321611"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Efficacy and Safety of Eltoprazine HCl for Treating Levodopa-induced Dyskinesia in Parkinson's Disease Patients</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="229269"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of Rizatriptan in the Treatment of Acute Attacks of Post-Traumatic Headache in US Military Troops (Maxalt)</ProtocolTitle><Sponsor>Henry M Jackson Foundation for the Advancement of Military Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="75139"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Preference for Triptans in Migraine Patients: A Randomized, Open-Label, Crossover Prospective Study</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><Trial id="125981"/><TrialStartDate>2010-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to assess the efficacy of rizatriptan in migraine patients</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="115932"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>REFRESH</ProtocolAcronym><ProtocolTitle>RP-5063 in Subjects With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc, Sristek Clinical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="83188"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Safety and Tolerability in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="77405"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>13</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PRIDE</ProtocolAcronym><ProtocolTitle>A 15-Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated</ProtocolTitle><Sponsor>Janssen Scientific Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="68045"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>HeartAriQue</ProtocolAcronym><ProtocolTitle>Heart Rate Changes in Schizophrenic and Bipolar Patients Under the Medication of Aripiprazole and Quetiapine</ProtocolTitle><Sponsor>Taichung Veterans General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="63409"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="48288"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A single-blind, randomized, exploratory pharmacological neuroimaging study on effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="384676"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled, Cross-Over Trial of Aripiprazole</ProtocolTitle><Sponsor>North Suffolk Mental Health Association</Sponsor><StudyType>Interventional</StudyType><Trial id="35458"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="34910"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>APEX 241</ProtocolAcronym><ProtocolTitle>Aripiprazole Open-Label, Safety and Tolerability Study</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34106"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regimen</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="337764"/><TrialStartDate>2018-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="32883"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Optimal Treatment for Treatment-resistant Schizophrenia</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="274620"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Enhancing Recovery in Early Schizophrenia</ProtocolTitle><Sponsor>Central Institute of Mental Health, Mannheim</Sponsor><StudyType>Interventional</StudyType><Trial id="274611"/><TrialStartDate>2017-04-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PAFIP3_1Y</ProtocolAcronym><ProtocolTitle>Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: One-Year Follow-Up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238547"/><TrialStartDate>2014-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Open, crossover, randomized, single dose, two-treatments, two-periods and two-sequences bioequivalence study of two pharmaceutical preparations of Aripiprazole 10 mg tablets in healthy Mexican population under fasting conditions</ProtocolTitle><Sponsor>Hetlabs Mexico, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="231919"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PLACID</ProtocolAcronym><ProtocolTitle>Comparison of treatment with inhaled loxapine and an injected drug to treat patients with schizophrenia or bipolar disorder and who are seriously agitated</ProtocolTitle><Sponsor>Ferrer Internacional SA</Sponsor><StudyType>Interventional</StudyType><Trial id="226539"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>7</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind Trial With Six Antipsychotic Drugs for Schizophrenia</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="206129"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Remediation of Schizophrenia Sensory Gating Deficit With Aripiprazole</ProtocolTitle><Sponsor>New Mexico VA Healthcare System</Sponsor><StudyType>Interventional</StudyType><Trial id="174832"/><TrialStartDate>2003-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device 1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161124"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Triple Tracer PET Study to Evaluate the Differential Effects of Aripiprazole on D(2), 5-HT(2), and 5-HT(1A) Receptor Occupancy in Patients With Schizophrenia</ProtocolTitle><Sponsor>University of Toronto</Sponsor><StudyType>Interventional</StudyType><Trial id="146616"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, randomized, open-label, flexible-dose study of perospirone versus aripiprazole for the treatment of schizophrenia in Japanese patients</ProtocolTitle><Sponsor>Kansai Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="125813"/><TrialStartDate>2013-01-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, controlled study comparing aripiprazole and olanzapine in the treatment of individuals with schizophrenia in an inpatient clinical setting</ProtocolTitle><Sponsor>Government Medical College, Chandigarh</Sponsor><StudyType>Interventional</StudyType><Trial id="124087"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute, Sichuan Otsuka Pharmaceutical Co., Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="331075"/><TrialStartDate>2018-04-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled study to evaluate the safety and efficacy of aripiprazole in patients with acute mania</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52079"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Late Life Bipolar Disorder</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="34175"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-Week Open-Label Treatment of Refractory Bipolar Depression</ProtocolTitle><Sponsor>University of Texas Health Science Center San Antonio</Sponsor><StudyType>Interventional</StudyType><Trial id="33920"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Therapy for Reducing Comorbid Substance Abuse</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="33105"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Examination of the Relations with Sleep Disturbance and the Prognosis for the Bipolar Disorder</ProtocolTitle><Sponsor>St Marianna University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="138294"/><TrialStartDate>2012-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness Of Aripiprazole Augmentation Therapy In Patients With Bipolar Depression Who Do Not Respond To Mood Stabilizers: A Randomized, Double-Blind, Placebo-Controlled Study</ProtocolTitle><Sponsor>Kansai Medical University, University of Occupational &amp; Environmental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="127116"/><TrialStartDate>2012-08-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of adding aripiprazole to lithium therapy in children and adolescents with BPD</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="125625"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><Trial id="50074"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="32455"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole effect in the treatment of mania</ProtocolTitle><Sponsor>University of Social Welfare and Rehabilitation Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="301904"/><TrialStartDate>2015-10-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym>AWARE 274</ProtocolAcronym><ProtocolTitle>Safety and Tolerability Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="80341"/><TrialStartDate>2011-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="314057"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52591"/><TrialStartDate>2009-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week prospective open-label multicenter study for treatment of patients with chronic or recurrent major depressive disorder with Aripiprazole augmentation</ProtocolTitle><Sponsor>Dongguk University, Korea Otsuka Pharmaceuticals, Soonchunhyang University, Sungkyunkwan University</Sponsor><StudyType>Interventional</StudyType><Trial id="164203"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Phase IIIb, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease</ProtocolTitle><Sponsor>Ever Progressing System Pte Ltd, UCB Pharma GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="97482"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>ROADMAP</ProtocolAcronym><ProtocolTitle>Effect of Rotigotine on Motor Symptoms in Patients With Advanced Parkinson's Disease (PD) With Motor Fluctuations and Symptoms of Gastrointestinal Dysfunction</ProtocolTitle><Sponsor>UCB Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="85053"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="7121"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label, Extension Trial to Assess the Safety and Tolerability of Long-Term Treatment of Rotigotine in Subjects With Idiopathic Parkinson's Disease</ProtocolTitle><Sponsor>Schwarz Pharma SpA, UCB BIOSCIENCES GmbH, UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6662"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled Study for SPM-962 in Early Parkinson's Disease Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="6116"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>PREFER</ProtocolAcronym><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled study designed to evaluate the safety and efficacy of rotigotine in patients with advanced-stage idiopathic Parkinson's disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="51540"/><TrialStartDate>2004-10-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Adhesiveness of two Different Rotigotine Patches Used for the Treatment of Parkinson's Disease</ProtocolTitle><Sponsor>UCB BIOSCIENCES GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="350511"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>DOLORES</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-associated Pain</ProtocolTitle><Sponsor>UCB BIOSCIENCES GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="161362"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym>ENCORE</ProtocolAcronym><ProtocolTitle>Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome</ProtocolTitle><Sponsor>UCB BIOSCIENCES GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="81707"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study to evaluate the efficacy of Neupro for treatment of patients with idiopathic restless legs syndrome or Willis-Ekbom disease</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="133444"/><TrialStartDate>2013-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="2527">Fibromyalgia</Indication><ProtocolAcronym/><ProtocolTitle>Study in Healthy Volunteers to Prove That Two Rotigotine Patches Have Equivalent Ingredient Delivery to the Body</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="52878"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="63181"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="69515"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>A real-world clinical trial to evaluate the safety and to evaluate the effect of bedtime administration of Addyi in the management of risk of syncope and severe hypotension in healthy premenopausal women</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="374422"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study to assess the efficacy and safety of eletriptan in migraine patients</ProtocolTitle><Sponsor>University of Malaya</Sponsor><StudyType>Interventional</StudyType><Trial id="116196"/><TrialStartDate>2003-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, multicenter, placebo-controlled, randomized study on the safety and efficacy of eletriptan versus zolmitriptan in migraine</ProtocolTitle><Sponsor>Imperial College London</Sponsor><StudyType>Interventional</StudyType><Trial id="115191"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, placebo-controlled, dose-finding study to assess the efficacy of eletriptan in migraine patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="109670"/><TrialStartDate>2000-04-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PEARL 3</ProtocolAcronym><ProtocolTitle>Lurasidone HCL - A 6-Week, Phase III Study of Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35671"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PEARL 3 Extension</ProtocolAcronym><ProtocolTitle>Lurasidone HCl- A Long-Term Phase III Study of Patients With Chronic Schizophrenia</ProtocolTitle><Sponsor>FUNDACION ESPANOLA PARA EL DESARROLLO DE LA NEUROMETRIA, Sumitomo Chemical Co Ltd, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="35670"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PEARL 1</ProtocolAcronym><ProtocolTitle>Lurasidone HCl: A Phase III Study of Patients With Acute Schizophrenia</ProtocolTitle><Sponsor>FUNDACION ESPANOLA PARA EL DESARROLLO DE LA NEUROMETRIA, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35468"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35027"/><TrialStartDate>2002-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia</ProtocolTitle><Sponsor>Bukwang Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="332604"/><TrialStartDate>2018-04-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pediatric Schizophrenia Efficacy and Safety Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="148184"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Low-Dose - High-Dose Study</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="118456"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Autism Study</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="148198"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression</ProtocolTitle><Sponsor>Cephalon Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="181649"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment) Of Menstrual Migraine</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="55520"/><TrialStartDate>2005-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vilazodone for Treatment of Geriatric Depression</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><StudyType>Interventional</StudyType><Trial id="87996"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison Of Two Anti-Depressant Drugs In Major Depressive Disorder</ProtocolTitle><Sponsor>Government Medical College, Jammu</Sponsor><StudyType>Interventional</StudyType><Trial id="328275"/><TrialStartDate>2015-12-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="228801"/><TrialStartDate>2015-05-02 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="222914"/><TrialStartDate>2015-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A clinical trial study of two drugs Vilazodone Hydrochloride 40 mg od and Fluoxetine Hydrochloride 20 mg od in patients with major depressive disorders</ProtocolTitle><Sponsor>MSN Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="166941"/><TrialStartDate>2014-01-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A multinational, double-blind, placebo-controlled study to evaluate the efficacy and safety of tegaserod in patients with irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19730"/><TrialStartDate>1999-11-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, randomized trial to evaluate the efficacy and safety and tolerability of tegaserod in patients with irritable bowel syndrome</ProtocolTitle><Sponsor>Royal North Shore Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="114147"/><TrialStartDate>2003-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial of tegaserod in healthy volunteers</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19834"/><TrialStartDate>2002-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A trial of tegaserod in patients with irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19717"/><TrialStartDate>1998-09-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study of tegaserod in patients with constipation associated irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19711"/><TrialStartDate>2002-10-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, parallel-group, placebo-controlled, ascending-dose study to evaluate the tolerability, pharmacokinetics and pharmacodynamics of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19849"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, crossover design study of tegaserod in gastroesophageal reflux disease patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19779"/><TrialStartDate>2005-05-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, multicenter, open-label, crossover trial to assess patient preference for almotriptan or rizatriptan for the treatment of moderate/severe migraine attacks</ProtocolTitle><Sponsor>Hospital General Yagüe</Sponsor><StudyType>Interventional</StudyType><Trial id="66613"/><TrialStartDate>2006-03-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, retrospective study of almotriptan versus rizatriptan in patients with migraine in Spain</ProtocolTitle><Sponsor>University of Valencia</Sponsor><StudyType>Interventional</StudyType><Trial id="113890"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-blind, Multicenter, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Tolerability of Almotriptan in the Acute Treatment of Multiple Migraine Attacks</ProtocolTitle><Sponsor>Servicio de Neurología</Sponsor><StudyType>Interventional</StudyType><Trial id="109540"/><TrialStartDate>2000-07-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="14178">LY-334370</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled, parallel-group clinical trial to evaluate the safety and efficacy of LY-334370 for the treatment of patients with acute migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="76323"/><TrialStartDate>2001-10-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Study to Investigate Prucalopride versus Polyethylene Glycol 3350 on Colon Activity</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="95008"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Improving Bowel Preparation for the Colon Capsule</ProtocolTitle><Sponsor>Queen's University</Sponsor><StudyType>Interventional</StudyType><Trial id="89837"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Study of Prucalopride in Participants With Chronic Constipation(Resolor)</ProtocolTitle><Sponsor>Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="66101"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label, single dose, pharmacokinetic study of prucalopride in pediatric patients with functional fecal retention (FFR) prucalopride</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="58961"/><TrialStartDate>2009-06-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effect of PEG, Bisacodyl and Prucalopride on Colonic Motility in Healthy Subjects</ProtocolTitle><Sponsor>University Hospital, Gasthuisberg</Sponsor><StudyType>Interventional</StudyType><Trial id="312396"/><TrialStartDate>2012-12-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym>PRUCALOC</ProtocolAcronym><ProtocolTitle>A Clinical Study to Evaluate Efficacy and Tolerability of Prucalopride in Indian Adult Patients With Chronic Functional Constipation</ProtocolTitle><Sponsor>Hetero Group</Sponsor><StudyType>Interventional</StudyType><Trial id="279010"/><TrialStartDate>2016-11-14 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride (Resolor) in patients with opioid-induced constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19100"/><TrialStartDate>2008-05-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Prucalopride to Treat Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18438"/><TrialStartDate>1998-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Evaluate the Efficacy and Safety of R093877 in Patients With Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18414"/><TrialStartDate>1996-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, randomized trial to evaluate the efficacy and tolerability of prucalopride in patients with constipation due to spinal cord injury</ProtocolTitle><Sponsor>Aarhus University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="112571"/><TrialStartDate>2002-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>EMD-128130 for the Treatment of Parkinson's Disease</ProtocolTitle><Sponsor>National Institute of Neurological Disorders and Stroke</Sponsor><StudyType>Interventional</StudyType><Trial id="6045"/><TrialStartDate>2001-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>PADDY-O</ProtocolAcronym><ProtocolTitle>An Open-Label, Multicenter, Multinational, Phase III Follow-Up Study to Investigate the Long-Term Safety and Efficacy of Sarizotan HCl 1 mg bid in Patients With Parkinsons Disease Suffering From Treatment-Associated Dyskinesia</ProtocolTitle><Sponsor>Merck KGaA</Sponsor><StudyType>Interventional</StudyType><Trial id="143076"/><TrialStartDate>2005-09-08 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, pilot phase I study to evaluate dopamine D2 receptor occupancy after multiple oral administration of DU-127090 to healthy male volunteers, using 11C-raclopride by means of position emission tomography (PET)</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41463"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Bifeprunox in Patients With Schizophrenia</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34925"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Comparing the Affect of Bifeprunox Versus Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34838"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Bifeprunox in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34499"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34636"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="19955">VML-670</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="369">Male sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIa, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy of VML-670 in patients with sexual dysfunction</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="55878"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>The Vermeer study</ProtocolAcronym><ProtocolTitle>Pardoprunox and pramipexole for treatment of patients with early Parkinson disease</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6808"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Ascending Dose Tolerability/Safety of SLV-308 for the Treatment of Parkinson's Disease</ProtocolTitle><Sponsor>Abbott Healthcare Products BV</Sponsor><StudyType>Interventional</StudyType><Trial id="6136"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>A phase III, pivotal, randomized, double-blind, placebo-controlled study, evaluating the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="314710"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="386216"/><TrialStartDate>2019-06-06 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine</ProtocolTitle><Sponsor>University of Alabama at Birmingham</Sponsor><StudyType>Interventional</StudyType><Trial id="86638"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treximet in the Prevention and Modification of Disease Progression in Migraine</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="75121"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Three-Period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a Trexima (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by Imitrex (Sumatriptan Succinate)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="50760"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14077"/><TrialStartDate>2004-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Menstrual Migraine Treatment With Treximet (Formerly Known as Trexima)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14015"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Buspar on Depressive Symptom Improvement and Neuroprotection in Patients With Anxiety Disorder</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="85450"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, randomized, placebo-controlled trial to evaluate the efficacy of buspirone for the treatment of anxiety in opioid-dependent patients</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="72136"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Measurement of the Hippocampal Theta Rhythm From the Outer Ear Canal</ProtocolTitle><Sponsor>University of Manitoba</Sponsor><StudyType>Interventional</StudyType><Trial id="381148"/><TrialStartDate>2019-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Pilot Study of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum Disorders</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="329271"/><TrialStartDate>2018-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [(11)C]-(+)-PHNO PET Study in Humans</ProtocolTitle><Sponsor>University of Toronto</Sponsor><StudyType>Interventional</StudyType><Trial id="249480"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone in ADHD</ProtocolTitle><Sponsor>Shahid Beheshti University</Sponsor><StudyType>Interventional</StudyType><Trial id="123736"/><TrialStartDate>2007-02-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A Single-Dose, Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age</ProtocolTitle><Sponsor>Eisai Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="225268"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Double-blind, Randomized, parallel-group Pilot Study of 12-week Duration to Assess the Short-term Safety and Tolerability of Lorcaserin Plus Two Doses of Immediate-release Phentermine-HCl Compared With Lorcaserin Alone in Overweight and Obese Adults</ProtocolTitle><Sponsor>Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161232"/><TrialStartDate>2013-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>REVIVE</ProtocolAcronym><ProtocolTitle>A Study of Vortioxetine (Lu-AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="83119"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Placebo-controlled, Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu-AA21004) in Acute Treatment of Major Depressive Disorder in Adults</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="67185"/><TrialStartDate>2010-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Vortioxetine (Lu-AA21004) in the Prevention of Relapse of Major Depressive Episodes</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="34966"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine in Patients With Major Depressive Disorder and Coronary Artery Disease</ProtocolTitle><Sponsor>Thomas Jefferson University</Sponsor><StudyType>Interventional</StudyType><Trial id="230579"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder</ProtocolTitle><Sponsor>The Medical Research Network</Sponsor><StudyType>Interventional</StudyType><Trial id="216250"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of PRX-03140 for the Treatment of Alzheimer's Disease</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="3894"/><TrialStartDate>2005-07-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Phase II, Randomized, Placebo-Controlled Study of ATI-7505 in Patients With Chronic Idiopathic Constipation</ProtocolTitle><Sponsor>Procter &amp; Gamble Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17614"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Formulation Study of Vabicaserin</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="58340"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="78364"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-Term Treatment in Patients With Chronic Stable Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="44774"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Cariprazine (RGH-188) in the Treatment of Patients With Acute Mania</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="29374"/><TrialStartDate>2007-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="47594"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled study to evaluate the safety and pharmacokinetics of single escalating doses of APD-125, a potential treatment for insomnia</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7319"/><TrialStartDate>2004-12-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53651">ATHX-105</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A phase I trial to evaluate the safety, tolerability and pharmacokinetics of ATHX-105 for potential treatment of obesity</ProtocolTitle><Sponsor>Athersys Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36253"/><TrialStartDate>2008-09-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1269">Functional bowel disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82214"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="284368"/><TrialStartDate>2017-02-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Food-Effect Study in Healthy Subjects</ProtocolTitle><Sponsor>CoLucid Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="209891"/><TrialStartDate>2015-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="55455">zonisamide + bupropion (obesity), Orexigen</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Zonisamide SR plus bupropion SR combination therapy in subjects with obesity</ProtocolTitle><Sponsor>Orexigen Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19441"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Study to Compare NP-101 (Sumatriptan Iontophoretic Transdermal Patch) With Three Formulations of Imitrex</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53833"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetic, and Tolerability Study of Zecuity in Adolescent Subjects With a History of Acute Migraine</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="253573"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>NP101-011</ProtocolAcronym><ProtocolTitle>Phase I, Open-Label, Single-Dose, Randomized, Four-Way, Crossover Study to Compare the PK of NP-101 With Oral Imitrex (50 mg) in Migraine Subjects During an Acute Migraine Attack and a Non-Migraine Period</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23206"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="57473">revexepride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym>SPD557-206</ProtocolAcronym><ProtocolTitle>Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="82474"/><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="57748">NXN-188 (oral), NeurAxon</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Safety and Effectiveness of NXN-188 for the Acute Treatment of Migraine Attacks With Aura</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="51255"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57748">NXN-188 (oral), NeurAxon</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, multi-center, double-blind, placebo-controlled, parallel-group study of NXN-188 in patients with migraine</ProtocolTitle><Sponsor>NeurAxon Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="25748"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="83185"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial of Motilitone on Gastric Motor Function in Healthy Volunteers</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="96772"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Multicenter Clinical Study of RP-5063</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="154091"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="60663">buspirone + melatonin (depression), BrainCells</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="23028"/><TrialStartDate>2008-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to &lt; 13 Years Old) With Central Nervous System Disorders</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="313836"/><TrialStartDate>2017-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>STEP 210</ProtocolAcronym><ProtocolTitle>Multicenter, Open-label, Safety and Tolerability Study</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="89519"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Pilot Dose-Response Biomarker Study of Brexpiprazole Treatment in PTSD</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="275839"/><TrialStartDate>2017-04-25 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="161390"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for Bipolar Depression</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="328722"/><TrialStartDate>2017-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="313284"/><TrialStartDate>2017-10-24 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>ORION</ProtocolAcronym><ProtocolTitle>Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77638"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="37124"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Argo</ProtocolAcronym><ProtocolTitle>Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="124201"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym>MINT</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Metoclopramide Nasal Spray Solution in Diabetic Patients With Gastroparesis</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54347"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="63318">metoclopramide (optimized intranasal formulation, diabetic gastroparesis), Marina/Questcor/Evoke</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="3203">Diabetic gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis</ProtocolTitle><Sponsor>Evoke Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="165653"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="91207"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>PK Study of Aripiprazole IM Depot for Chinese Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="313005"/><TrialStartDate>2018-08-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1B">Phase 1b Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase Ib, randomized, multicenter, double-blind, placebo-controlled, 20-week study to assess safety, tolerability and pharmacokinetics ALKS-9070 in patients with schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78932"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study Of Aripiprazole Lauroxil (Also Known As ARISTADA) In Subjects With Schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="249170"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="73740">sumatriptan (intranasal, migraine), Promius Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="R">Registered</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Efficacy and Safety Study of DFN-02</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="267560"/><TrialStartDate>2016-07-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia</ProtocolTitle><Sponsor>Eisai Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="82229"/><TrialStartDate>2010-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="76079">mosapride + probiotics (oral, IBS), Hanmi</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea</ProtocolTitle><Sponsor>Hanmi Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="84969"/><TrialStartDate>2011-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>ADAM</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Long-Term Safety of M-207 in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="312554"/><TrialStartDate>2017-11-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81094">F-17464</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>FAST</ProtocolAcronym><ProtocolTitle>F-17464 in Acute Schizophrenia Trial</ProtocolTitle><Sponsor>Pierre Fabre SA</Sponsor><StudyType>Interventional</StudyType><Trial id="192777"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="280061"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="84360">testosterone + buspirone hydrochloride (oral, hypoactive sexual desire disorder), Emotional Brain</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1276">Female sexual dysfunction</Indication><ProtocolAcronym>Lybridos PoC</ProtocolAcronym><ProtocolTitle>A double blind, randomized, cross-over, placebo-controlled, pilot study to investigate the subjective and physiological efficacy and safety of Lybridos in healthy female subjects with female sexual dysfunction</ProtocolTitle><Sponsor>Emotional Brain BV</Sponsor><StudyType>Interventional</StudyType><Trial id="121241"/><TrialStartDate>2009-01-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87714">dihydroergotamine (nasal, migraine), Satsuma Pharmaceuticals</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Study the PK and Safety of Single-Doses of STS-101, DHE Injection and Nasal Spray in Healthy Subjects</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373407"/><TrialStartDate>2018-09-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87742">aripiprazole (transdermal patch, psychiatric disorder), Aequus Pharmaceuticals/Corium</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>A multi dose, proof of concept clinical trial to evaluate the bioavailability and safety of aripiprazole transdermal patch for the treatment of psychiatric disorder</ProtocolTitle><Sponsor>Aequus Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="284651"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="90560">lorcaserin hydrochloride (extended-release, obesity), Arena/Eisai</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Real-World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity</ProtocolTitle><Sponsor>Novo Nordisk A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="366135"/><TrialStartDate>2019-01-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym>STABIL-B</ProtocolAcronym><ProtocolTitle>Sequential Therapy for the Treatment of Severe Bipolar Depression</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="280467"/><TrialStartDate>2018-01-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="102333">sumatriptan succinate + acetylsalicylic acid, Vivid</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="200529"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="104885">dihydroergotamine (buccal transmucosal film, migraine), Klaria Pharma</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A study of dihydroergotamine for the potential treatment of migraine</ProtocolTitle><Sponsor>Klaria Pharma Holding Ab</Sponsor><StudyType>Interventional</StudyType><Trial id="324988"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial Analyzing Effects of Prokinetic Drug on the Blood Glucose in Patients With Type 2 Diabetes</ProtocolTitle><Sponsor>Third Military Medical University of the Chinese PLA</Sponsor><StudyType>Interventional</StudyType><Trial id="246088"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the safety and efficacy of aripiprazole in preventing relapse of a mood episode in recently manic- or mixed-episode patients with bipolar I disorder stabilized on aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52030"/><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="48288"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="371510"/><TrialStartDate>2019-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Children and Adolescents With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34110"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19210"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1279">Panic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder</ProtocolTitle><Sponsor>Siyan Clinical Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="225102"/><TrialStartDate>2015-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence study, single oral dose, randomized, balanced, open, two-treatments, two-sequences, two-routes, two-periods, crossed, Eletriptan Bromhydrate 40 mg tablets covered by Cadila Healthcare Limited in relation to RELPAX (Eletriptan Bromhydrate ) 40 mg coated tablets from Pfizer, SA de CV, in healthy adult subjects of both genders under fasting conditions</ProtocolTitle><Sponsor>Zydus-Cadila Group</Sponsor><StudyType>Interventional</StudyType><Trial id="347688"/><TrialStartDate>2017-08-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Prospective, randomized, open, crossover comparison in healthy subjects to establish bioequivalence of Eletriptan 80 mg tablets of Landsteiner Scientific, SA de CV versus Eletriptan 80 mg tablets: Relpax of Pfizer, SA de CV</ProtocolTitle><Sponsor>Landsteiner Scientific Sa De Cv</Sponsor><StudyType>Interventional</StudyType><Trial id="164499"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A Prospective, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Effects Of The Addition Of Mosapride To Gastroesophageal Reflux Disease Patients On Proton Pump Inhibitor</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="162792"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="69">Renal failure</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Varying Degrees of Renal Impairment on the Single Dose Pharmacokinetic Profile of Orally Administered Lurasidone: A Phase I Study</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="158469"/><TrialStartDate>2008-10-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Buspirone in Opiate Withdrawal</ProtocolTitle><Sponsor>National Institute on Drug Abuse</Sponsor><StudyType>Interventional</StudyType><Trial id="34839"/><TrialStartDate>2002-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1933">Undifferentiated schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Single-dose, randomized, balanced, open-label, two-treatments, two-cross-over periods, oral bioequivalence study of Zolmitriptan 2.5mg orodispersible tablets (Synthon México, SA de CV) compared with administration of Zomig Rapimelt (Zolmitriptan de 2.5 mg) in orodispersible tablets (AstraZeneca, SA de CV) in healthy adult subjects of both genders under fasting conditions</ProtocolTitle><Sponsor>Synthon Mexico S.A. de C.V.</Sponsor><StudyType>Interventional</StudyType><Trial id="313501"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine for Post-traumatic Stress Disorder</ProtocolTitle><Sponsor>University of Miami</Sponsor><StudyType>Interventional</StudyType><Trial id="249309"/><TrialStartDate>2016-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, multicenter, cross-over, comparative, Italian study to compare the efficacy of frovatriptan and zolmitriptan in the treatment of patients with migraine with aura</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="118990"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47204">sumatriptan (sublingual, migraine, NovaMist), Suda</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A four-arm, crossover, pharmacokinetic study designed to compare the pharmacokinetics of two doses of sumatriptan oral spray with Imitrex tablets in healthy male volunteers under fasting conditions</ProtocolTitle><Sponsor>NovaDel Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="60145"/><TrialStartDate>2006-09-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the effect of obesity on the pharmacokinetics of the serotonergic antidepressant vortioxetine</ProtocolTitle><Sponsor>Tufts University</Sponsor><StudyType>Interventional</StudyType><Trial id="340043"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1050">Hallucination</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="317606"/><TrialStartDate>2017-09-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4838">flesinoxan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I crossover, randomized, placebo-controlled study comparing the pharmacokinetics of two doses of DU-29894 with flesinoxan, sulpride, haloperidol and placebo in healthy volunteers</ProtocolTitle><Sponsor>Abbott Healthcare Products BV</Sponsor><StudyType>Interventional</StudyType><Trial id="50117"/><TrialStartDate>1995-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="129">Gastrointestinal disease</Indication><ProtocolAcronym>J-FOCUS</ProtocolAcronym><ProtocolTitle>A multicenter, randomized, open-label, omeprazole-controlled, parallel-group study to evaluate the safety and efficacy of famotidine, mosapride and teprenone in patients with upper gastrointestinal symptoms</ProtocolTitle><Sponsor>Japan Dyspepsia Society</Sponsor><StudyType>Interventional</StudyType><Trial id="94617"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="90560">lorcaserin hydrochloride (extended-release, obesity), Arena/Eisai</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3283">Cannabis dependence</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin for Cannabis Use Disorder</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="350630"/><TrialStartDate>2019-04-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6094"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and  Depression</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="334705"/><TrialStartDate>2018-03-09 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13960"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vilazodone for Separation Anxiety Disorder</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="163095"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Phase I, Open-label, Randomized, Three-way, Incomplete Crossover Study to Evaluate the Bioavailability of Different Dose Combinations of Sumatriptan Succinate and Naproxen Sodium 500 mg in Healthy Volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="183618"/><TrialStartDate>2004-01-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A prospective, open, randomized, crossover study of comparative pharmacokinetics and bioequivalence of the drug sumatriptan tablets, film-coated 100 mg (OOO "Ozone", Russia), in comparison with the drug Imigran, coated tablets, 100 mg ("GlaxoSmithKline Pharmaceuticals SA ", Poland)</ProtocolTitle><Sponsor>Atoll LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="176328"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="156143"/><TrialStartDate>2003-09-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An Open-label, Randomized, Two-way Crossover, Bioequivalence Study Between Sumatriptan Succinate Kit Product (STATdose) and Ampoule Product in Healthy Japanese Male Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="154198"/><TrialStartDate>2003-10-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Determine Whether Flunarizine Has Any Effect on the Pharmacokinetics and Pharmacodynamics of Oral G-43175C in Healthy Subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="150343"/><TrialStartDate>1989-03-13 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open-label, safety, pharmacokinetic, single-dose study to evaluate the excretion of a 6 mg sc dose of sumatriptan into breast milk</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="118429"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym>Depression-Anx Trial</ProtocolAcronym><ProtocolTitle>An Antidepressant Medications from Treatment Initiation for Depressive Disorder with Anxiety Symptoms: A Prospective Comparative Study</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="282448"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>The role of buspirone in LIDs in patients with Parkinson's disease.</ProtocolAcronym><ProtocolTitle>The role of Buspirone in attenuating involuntary movements (Dyskinesias) in patients with Parkinson's disease</ProtocolTitle><Sponsor>Imperial College London</Sponsor><StudyType>Interventional</StudyType><Trial id="375494"/><TrialStartDate>2015-05-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>The Role Of Striatal Serotonergic Terminals In L-Dopa Induced-Dyskinesia In Parkinsons Disease Patients: An In Vivo Positron Emission Tomography (PET) Study</ProtocolTitle><Sponsor>Imperial College London</Sponsor><StudyType>Interventional</StudyType><Trial id="119148"/><TrialStartDate>2008-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>A 8-week, randomized, double-blind, placebo-controlled, safety and efficacy study of aripiprazole in the treatment hyperprolactinemia in  patients with schizophrenia</ProtocolTitle><Sponsor>Inje University</Sponsor><StudyType>Interventional</StudyType><Trial id="68133"/><TrialStartDate>2006-07-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Ziprasidone in Major Depression</ProtocolAcronym><ProtocolTitle>A Pilot Study - Ziprasidone Used as an Adjunctive Therapy in Patients with Major Depressive Disorder: Impact on Symptoms and Functional Disability</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="140741"/><TrialStartDate>2008-01-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of 7 Day Prucalopride Administration in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="344627"/><TrialStartDate>2018-06-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism</ProtocolTitle><Sponsor>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Sponsor><StudyType>Interventional</StudyType><Trial id="33118"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, parallel-controlled, open-label study to evaluate the efficacy and safety of adjunctive tandospirone in patients with major depressive disorder and high level of anxiety symptoms</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="341599"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Opened, two-period, two treatments, two sequences, crossover, randomized, single-dose of two oral preparations of ziprasidone 40 mg (40 mg ziprasidone capsules, Actavis PTC versus Geodon, Laboratorios Pfizer Ltda) in healthy volunteers with food effect</ProtocolTitle><Sponsor>Allergan plc</Sponsor><StudyType>Interventional</StudyType><Trial id="216268"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole and Topiramate on Free-Choice Alcohol Use</ProtocolTitle><Sponsor>National Institute on Alcohol Abuse and Alcoholism</Sponsor><StudyType>Interventional</StudyType><Trial id="52721"/><TrialStartDate>2007-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1490">Sleep apnea</Indication><ProtocolAcronym/><ProtocolTitle>An Interventional, Double-blind, Cross-over, Randomized Study to Determine the Efficacy of Buspirone on Central Apneas in Patients With Systolic Heart Failure</ProtocolTitle><Sponsor>Scuola Superiore Sant'Anna di Pisa</Sponsor><StudyType>Interventional</StudyType><Trial id="342258"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1105">Scleroderma</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)</ProtocolTitle><Sponsor>Laiko General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="222096"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, randomized, double-blind, placebo-controlled, parallel-group, single-attack study to determine the onset of efficacy of a new formulation of sumatriptan tablets 50 and 100 mg in treatment of subjects with acute migraine with and without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87179"/><TrialStartDate>2003-10-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Study of Oral Eletriptan (40 and 80 mg), Oral Sumatriptan (25 and 50 mg) and Placebo</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161722"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Phase III clinical trial of a combination of MGV-5 and AS-4370 as pretreatment for barium enema X-ray radiography</ProtocolTitle><Sponsor>EA Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="97761"/><TrialStartDate>2007-08-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical Trials to Compare Mosapride Bioavailability Between DWJ-1252 and Mosapride Medicine</ProtocolTitle><Sponsor>Daewoong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="65188"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Pilot Study to Determine the Relative Bioavailability of Mosapride 5 mg From Two Candidate Formulations of GR-107719B Relative to One 5 mg Tablet of Reference Mosapride Citrate (Gasmotin) in Healthy Adult Human Subjects Under Fasting Conditions</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="210894"/><TrialStartDate>2014-02-03 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Prucalopride Subjects With Renal Impairment</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="90490"/><TrialStartDate>1997-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1948">Asperger syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="90513">YL-0919</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>To Explore the Effective Doses, and to Assess the Safety and Efficacy of Hypidone Hydrochloride Tablets</ProtocolTitle><Sponsor>Shanghai Synergy Pharmaceutical Sciences Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="360096"/><TrialStartDate>2018-11-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, double-blind, multicenter, 4-week, placebo-controlled study to evaluate the safety and efficacy of aripiprazole and risperidone in hospitalized patients with a DSM-IV diagnosis of schizophrenia and schizoaffective disorder with acute relapse</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="52038"/><TrialStartDate>2001-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Therapy for Reducing Comorbid Substance Abuse</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="33105"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety</ProtocolTitle><Sponsor>University of Medicine and Dentistry of New Jersey</Sponsor><StudyType>Interventional</StudyType><Trial id="31470"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled trial of blonanserin versus aripiprazole in psychotic disorder</ProtocolTitle><Sponsor>Fujita Health University, Hospital of St Cross, The Jindai Hospital, The Okehazama Hospital, Toyota Memorial Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="156063"/><TrialStartDate>2013-07-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Triple Tracer PET Study to Evaluate the Differential Effects of Aripiprazole on D(2), 5-HT(2), and 5-HT(1A) Receptor Occupancy in Patients With Schizophrenia</ProtocolTitle><Sponsor>University of Toronto</Sponsor><StudyType>Interventional</StudyType><Trial id="146616"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label Trial to Evaluate the Efficacy and Tolerability of Aripiprazole in Patients With Schizophrenia and Schizoaffective Disorders</ProtocolTitle><Sponsor>Ranbaxy Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="144391"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="90560">lorcaserin hydrochloride (extended-release, obesity), Arena/Eisai</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years</ProtocolTitle><Sponsor>Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="319212"/><TrialStartDate>2017-09-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="279">Pruritus</Indication><ProtocolAcronym/><ProtocolTitle>Sumatriptan and Ondansetron in Treatment of Spinal Anesthesia-Induced Pruritus</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="308759"/><TrialStartDate>2017-05-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="60">Central nervous system disease</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82214"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Based on PEEG and PET Study of Anxiolytic Treatment to Improve Cognitive Function in Patients With Alzheimer Disease</ProtocolTitle><Sponsor>Zhejiang Provincial People's Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="298289"/><TrialStartDate>2017-05-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of risperidone and buspirone in treatment of problem behaviors in children with PKU</ProtocolTitle><Sponsor>Hamadan University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="315252"/><TrialStartDate>2012-04-17 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A study to evaluate the bioavailability of combo formulation, each of its components and currently marketed versions of the components in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="156143"/><TrialStartDate>2003-09-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Geodon in Weight Loss Study for Bipolar Disorders</ProtocolTitle><Sponsor>Stanford University</Sponsor><StudyType>Interventional</StudyType><Trial id="35111"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3399">ipsapirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study to assess the behavioral and neuroendocrine effects of the 5-HT1A receptor partial agonist ipsapirone in patients with seasonal affective disorder and healthy control subjects</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="108065"/><TrialStartDate>1999-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open-label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100 mg on the Pharmacokinetics of Aripiprazole When Coadministered to Healthy Subjects</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="69945"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study to assess pharmacokinetic parameters, tolerability and safety of aripiprazole in healthy volunteers</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52120"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Bosiqing and Abilify Under Fasting/Fed Condition</ProtocolTitle><Sponsor>Chengdu Kanghong Pharmaceutical Group Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="306932"/><TrialStartDate>2017-06-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Magnetic Resonance Spectroscopy Study to Evaluate Atypical Antipsychotic Drug Treatment in First-Episode Patients with Early Onset Schizophrenia</ProtocolTitle><Sponsor>No 91 hospital of PLA</Sponsor><StudyType>Interventional</StudyType><Trial id="231069"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Change in Brain Metabolism and Cognitive Function by Aripiprazole</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="188142"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym>OSMITTER</ProtocolAcronym><ProtocolTitle>Substudy of the Accuracy of Ingestible Event Marker (IEM) Detection by the Medical Information Device 1 (MIND1)</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="178378"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An Open-Label, Dose-Finding Study To Assess Efficacy Of Aripiprazole In Healthy Volunteers</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="111462"/><TrialStartDate>2002-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="213936"/><TrialStartDate>2014-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><Trial id="239368"/><TrialStartDate>2015-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Examination Of Large Intestine Contraction Patterns By Mosapride Citrate For Irritable Bowel Syndrome (IBS, Constipation Type) Using a Capsule Endoscope</ProtocolTitle><Sponsor>Nagoya University Graduate School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="151128"/><TrialStartDate>2008-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Properties of Lu-AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="90635"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="374194"/><TrialStartDate>2019-03-18 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan (LY-573144) Over Four Migraine Attacks</ProtocolTitle><Sponsor>Eli Lilly &amp; Co, Eli Lilly &amp; Co of India Inc, Eli Lilly SA</Sponsor><StudyType>Interventional</StudyType><Trial id="353496"/><TrialStartDate>2019-06-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Short-Term Tolerability of a Nonazapirone Selective Serotonin 1A Agonist in Adults With Generalized Anxiety Disorder: A 28-Day, Open-Label Study</ProtocolTitle><Sponsor>Mount Sinai School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="146879"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, One-Year Clinical Outcome Study To Assess The Efficacy And Safety of Aripiprazole as A First Choice Of Treatment in Patients with First Episode of A Psychotic Disorder</ProtocolTitle><Sponsor>McGill University</Sponsor><StudyType>Interventional</StudyType><Trial id="264275"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Efficacy of Adjunctive Lithium Treatment for the Treatment of Psychotical Mania</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="190612"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate The Effect Of Aripiprazole for Drug-Induced Psychosis in Parkinson Disease</ProtocolTitle><Sponsor>University of Florida College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="144979"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="472">Hypothermia</Indication><ProtocolAcronym/><ProtocolTitle>Dexmed/Buspirone Synergism on Shivering</ProtocolTitle><Sponsor>Cleveland Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="54882"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="57473">revexepride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Adsorption, Metabolism and Excretion (AME) of Single-Dose Radiolabeled SPD-557 in Volunteers</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="108955"/><TrialStartDate>2013-03-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373929"/><TrialStartDate>2018-07-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym>TWIST</ProtocolAcronym><ProtocolTitle>Sumatriptan as Treatment for Post-traumatic Headache</ProtocolTitle><Sponsor>University of Washington</Sponsor><StudyType>Interventional</StudyType><Trial id="131070"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="123">Fragile X syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Fragile X Syndrome</ProtocolTitle><Sponsor>Indiana University</Sponsor><StudyType>Interventional</StudyType><Trial id="7040"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym>ACCORD</ProtocolAcronym><ProtocolTitle>Evaluate the Safety and Efficacy of TD-5108, a 5-HT4 Agonist in Chronic Constipation</ProtocolTitle><Sponsor>Innoviva Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="17884"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="9">Aggression</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="295506"/><TrialStartDate>2017-02-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, open-label, uncontrolled, preliminary study to explore the efficacy of ziprasidone add-on pharmacotherapy on clinical symptoms and cognitive functioning in patients with treatment-resistant obsessive-compulsive disorder receiving serotonin reuptake inhibitors</ProtocolTitle><Sponsor>Policlin University</Sponsor><StudyType>Interventional</StudyType><Trial id="256255"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33782"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>ZAC</ProtocolAcronym><ProtocolTitle>Improving Metabolic Parameters of Antipsychotic Child Treatment With Ziprasidone, Aripiprazole, and Clozapine</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="170060"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, randomized study to compare the 12-month effectiveness of olanzapine, quetiapine, risperidone and ziprasidone versus haloperidol in  antipsychotic-naive patients with a first-episode psychosis</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="118703"/><TrialStartDate>2012-12-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1931">Hebephrenic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34895"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, placebo-controlled, randomized study to evaluate whether sumatriptan modifies gastric size after 500 ml of water in dyspeptic subjects and normal subjects</ProtocolTitle><Sponsor>Universita Degli Studi G D`Annunzio Chieti</Sponsor><StudyType>Interventional</StudyType><Trial id="111136"/><TrialStartDate>2002-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Frovatriptan as Prophylactic Treatment of Cluster Headache, a Multicenter, Placebo-Controlled, Randomized, Double-Blind, Prospective, Phase III Parallel-Group Trial Comparing Frovatriptan with Placebo</ProtocolTitle><Sponsor>Berlin-Chemie AG, The Menarini Group</Sponsor><StudyType>Interventional</StudyType><Trial id="117049"/><TrialStartDate>2006-11-06 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure</ProtocolTitle><Sponsor>TEMPVA Research Group, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="22997"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>PERSIST</ProtocolAcronym><ProtocolTitle>Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77684"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>ELICE_BD</ProtocolAcronym><ProtocolTitle>Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients</ProtocolTitle><Sponsor>Japan National Institute Of Mental Health, National Center Of Neurology &amp; Psychiatry, University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="257654"/><TrialStartDate>2017-05-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="234069"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Study of Oral Eletriptan (40 and 80 mg), Oral Sumatriptan (25 and 50 mg) and Placebo</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161722"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19411"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Migraine Study in Adolescent Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45654"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of liver-discharging and heat-clearing therapy for fire derived from stagnation of liver-QI type of generalized anxiety disorder and its influence on inflammatory cytokines</ProtocolTitle><Sponsor>Beijing Anding Hospital, Capital Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="316495"/><TrialStartDate>2017-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym>TACGAD</ProtocolAcronym><ProtocolTitle>Tandospirone Citrate in the Treatment of Patients With Generalized Anxiety Disorder</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88192"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Single-center, single-dose pharmacokinetics study of vilazodone in healthy Mexican adult volunteers</ProtocolTitle><Sponsor>Forest Research Institute, Inc.</Sponsor><StudyType>Interventional</StudyType><Trial id="217413"/><TrialStartDate>2014-05-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="112">Endocrine disease</Indication><ProtocolAcronym/><ProtocolTitle>Study of Bioequivalence for Costa Rica Between the Lorcaserine Protein Chlorhydrate of Gutis Limited and Belviq of Arena Pharmaceuticals, As a Reference Medicine</ProtocolTitle><Sponsor>Gutis Farmacéutica</Sponsor><StudyType>Interventional</StudyType><Trial id="382476"/><TrialStartDate>2018-09-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan for the Treatment of Migraine in Patients With Previous Poor Response or Tolerance to Oral Sumatriptan</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161569"/><TrialStartDate>1999-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, prospective, multicenter, non-comparative, open-label study to determine the tolerability, safety and efficacy of ziprasidone in pre-treated or untreated subjects with schizophrenia or schizoaffective disorders, over 12 weeks with an extension phase of up to 6 months for tolerability and safety</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86059"/><TrialStartDate>2001-07-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>ZEISIG</ProtocolAcronym><ProtocolTitle>A 12-week, prospective, flexible-dose, multicenter, open-label observational clinical study to assess the efficacy, safety and tolerability of ziprasidone for the treatment of patients with schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Universitätsklinikum Hamburg-Eppendorf</Sponsor><StudyType>Interventional</StudyType><Trial id="67211"/><TrialStartDate>2005-11-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 24-h Time Course of Striatal Dopamine D2 Receptor Occupancy of Ziprasidone: A PET Study</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="45729"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PROACTIVE</ProtocolAcronym><ProtocolTitle>Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36294"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36285"/><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Tolerability of Switching to Ziprasidone From Other Antipsychotics</ProtocolTitle><Sponsor>Bronx Psychiatric Center</Sponsor><StudyType>Interventional</StudyType><Trial id="35153"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Effects of Ziprasidone for the Treatment of Schizophrenia or Schizoaffective Disorder in Patients Who Were Switched From Other Antipsychotic Drugs</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34897"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34753"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Clinical effect of cross titration of anti-psychotics with ziprasidone in schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="20968"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1948">Asperger syndrome</Indication><ProtocolAcronym>PAIRS</ProtocolAcronym><ProtocolTitle>Study of Aripiprazole to Treat Children and Adolescents With Autism</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="30965"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59896">brilaroxazine hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>REFRESH</ProtocolAcronym><ProtocolTitle>RP-5063 in Subjects With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Reviva Pharmaceuticals Inc, Sristek Clinical Research</Sponsor><StudyType>Interventional</StudyType><Trial id="83188"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence Study of Brexpiprazole Orally Disintegrating Tablets (ODT) 2 mg</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="375971"/><TrialStartDate>2019-03-27 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>The Pharmacokinetics and Safety of Brexpiprazole Tablets in Chinese Healthy Subjects</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="359293"/><TrialStartDate>2019-04-24 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan in Healthy Japanese and Caucasian Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="345630"/><TrialStartDate>2018-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan in Healthy Japanese and Caucasian Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="345630"/><TrialStartDate>2018-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan and Propranolol in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="311349"/><TrialStartDate>2017-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Comparison Between Frovatriptan Plus Different Treatment Regimens of Dexketoprofen (25 and 37.5 mg) and Frovatriptan Alone in the Acute Treatment of Migraine Without Aura and Migraine With Aura Attacks</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="135638"/><TrialStartDate>2009-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="684">Nutritional disorder</Indication><ProtocolAcronym/><ProtocolTitle>TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><Trial id="333934"/><TrialStartDate>2018-08-25 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym/><ProtocolTitle>Gene-by-Stress Interactions in Intervention Studies Significance</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="284338"/><TrialStartDate>2018-05-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1273">Barretts esophagus</Indication><ProtocolAcronym/><ProtocolTitle>The role of Qing-gan-jian-pi decoction treatment of Barrett's esophagus and the influence of the expression of CDX2, P38MAPK</ProtocolTitle><Sponsor>Xi 'an Hospital of Traditional Chinese Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="210738"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1950">Conduct disorder</Indication><ProtocolAcronym/><ProtocolTitle>Trial of Aripiprazole in the Treatment of CD in Adolescents</ProtocolTitle><Sponsor>University of Iowa</Sponsor><StudyType>Interventional</StudyType><Trial id="31508"/><TrialStartDate>2004-11-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym>DOLORES</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-associated Pain</ProtocolTitle><Sponsor>UCB BIOSCIENCES GmbH</Sponsor><StudyType>Interventional</StudyType><Trial id="161362"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62606">CL-H1T</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Study the PK and Safety of Single-Doses of STS-101, DHE Injection and Nasal Spray in Healthy Subjects</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373407"/><TrialStartDate>2018-09-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, parallel-group study of haloperidol or aripiprazole for the treatment of Anxiety-Depressed Attack</ProtocolTitle><Sponsor>Warakukai Medical Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="345320"/><TrialStartDate>2018-02-06 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Towards Neurobiology-based Diagnosis and Treatment of Affective Disorders</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="314057"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism</ProtocolTitle><Sponsor>University of Ottawa</Sponsor><StudyType>Interventional</StudyType><Trial id="205695"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="19216"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3676">Ischemic stroke</Indication><ProtocolAcronym>EuroHYP-1</ProtocolAcronym><ProtocolTitle>Cooling Plus Best Medical Treatment Versus Best Medical Treatment Alone for Acute Ischemic Stroke</ProtocolTitle><Sponsor>St. James's Hospital, Universitatsklinikum Erlangen, University of Erlangen-Nurnberg Medical School</Sponsor><StudyType>Interventional</StudyType><Trial id="121883"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Phase I Trial of PRX-00023 in Healthy Male Volunteers</ProtocolTitle><Sponsor>Predix Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="143881"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes</ProtocolTitle><Sponsor>Loyola University of Chicago</Sponsor><StudyType>Interventional</StudyType><Trial id="345848"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="104883">sumatriptan (buccal transmucosal film, migraine), Klaria Pharma</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Study the Efficacy and Safety of KL-00119 in Healthy Volunteers</ProtocolTitle><Sponsor>CTC Clinical Trial Consultants</Sponsor><StudyType>Interventional</StudyType><Trial id="284987"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3150">Social phobia</Indication><ProtocolAcronym>SAD</ProtocolAcronym><ProtocolTitle>Geodon in Social Anxiety Disorder</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="32572"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Ziprasidone Study for Psychosis Treatment in Adolescents</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="33934"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="129">Gastrointestinal disease</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Prior to Small Bowel Capsule Endoscopy</ProtocolTitle><Sponsor>University of British Columbia</Sponsor><StudyType>Interventional</StudyType><Trial id="263746"/><TrialStartDate>2016-07-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open-label, single-dose, multicenter study to evaluate the effect of varying degrees of hepatic impairment on the safety, tolerability, and pharmacokinetics of lurasidone in healthy and hepatically impaired subjects</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="81484"/><TrialStartDate>2011-03-03 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="651">Cancer</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study  designed to evaluate safety, efficacy and pharmacological actions of AVI-4557 at different doses in healthy human volunteers</ProtocolTitle><Sponsor>Sarepta Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="39297"/><TrialStartDate>2001-09-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1084">Psychomotor disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, dose-escalation, safety and pharmacokinetic study of ACP-103 in healthy volunteers</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7649"/><TrialStartDate>2003-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, multicenter, placebo-controlled, randomized, safety, efficacy study of buspirone in patients with depression</ProtocolTitle><Sponsor>Göteborg University</Sponsor><StudyType>Interventional</StudyType><Trial id="109278"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Comparison of Aripiprazole and Risperidone Augmentation in Selective Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Single-Blind, Randomized Study</ProtocolTitle><Sponsor>Yüzüncü Yil Üniversitesi</Sponsor><StudyType>Interventional</StudyType><Trial id="145299"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1950">Conduct disorder</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Assess the Pharmacokinetics, Safety, Tolerability of Oral Brexpiprazole in Children (6 to &lt; 13 Years Old) With Central Nervous System Disorders</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="313836"/><TrialStartDate>2017-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="989">Colorectal tumor</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Mosapride Citrate on the Quality and Tolerance of Colonic Lavage: a Double-blind, Randomized Study</ProtocolTitle><Sponsor>Aichi Cancer Center Hospital and Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="137934"/><TrialStartDate>2009-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>SWITCHCore</ProtocolAcronym><ProtocolTitle>A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="67260"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Digoxin Drug-Drug Interaction With Lurasidone HCl</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="64678"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, 8-week, multicenter, open-label, non-comparative, switch study to determine the efficacy and safety of ziprasidone in patients with chronic schizophrenia, after switching therapy from other antipsychotics</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86455"/><TrialStartDate>2002-01-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, multicenter, open-label, non-comparative, switch study to determine the efficacy and safety of ziprasidone in patients with acute exacerbation of schizophrenia, after switching therapy from other antipsychotics</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86403"/><TrialStartDate>2002-04-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety With Ziprasidone in First-episode Psychosis</ProtocolTitle><Sponsor>Chonbuk National University</Sponsor><StudyType>Interventional</StudyType><Trial id="67917"/><TrialStartDate>2010-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A head-to-head trial comparing iloperidone with ziprasidone to evaluate the potential effect of iloperidone in patients with schizophrenia</ProtocolTitle><Sponsor>Novartis Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42159"/><TrialStartDate>2002-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Neurocognitive Effects of Ziprasidone: Relationship to Working Memory and Dopamine Blockade</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36285"/><TrialStartDate>2002-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Energy Homeostasis Under Treatment With Atypical Antipsychotics</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><Trial id="35778"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ZODIAC</ProtocolAcronym><ProtocolTitle>Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35124"/><TrialStartDate>2002-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="35025"/><TrialStartDate>2001-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability of Ziprasidone in Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34604"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>TAILOR</ProtocolAcronym><ProtocolTitle>An experimental study comparing discontinuation with maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or schizophrenia-like psychosis without psychotic symptoms</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="298863"/><TrialStartDate>2017-03-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the functional and structural brain changes associated with the cognitive processing of emotional visual stimuli in schizophrenic patients after treatment with ziprasidone</ProtocolTitle><Sponsor>Universite De Montreal</Sponsor><StudyType>Interventional</StudyType><Trial id="298077"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>11</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>LLS-ICP</ProtocolAcronym><ProtocolTitle>Evaluating the Efficacy of a Late-Life Schizophrenia Integrated Care Pathway to Treat Acute Psychotic Symptoms</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="240159"/><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Antipsychotics and Gene Expression in Soft Tissues</ProtocolTitle><Sponsor>Medical University of Vienna</Sponsor><StudyType>Interventional</StudyType><Trial id="192590"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, Placebo-Controlled Trial To Evaluate The Effect Of Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder in the Ziprasidone Study Group</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="145236"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate The Effects of Oral Ziprasidone and Oral Haloperidol on QTc Interval in Patients with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Pfizer Global Research &amp; Development</Sponsor><StudyType>Interventional</StudyType><Trial id="144272"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>On the question of Neuroleptic-Induced Metabolic Syndrome. Study 2: Fat Distribution and Specific Hormonal Parameters. Comparison between the metabolic syndrome of vulnerable and non-vulnerable patients from the schizophrenic group</ProtocolTitle><Sponsor>Medical University of Graz</Sponsor><StudyType>Interventional</StudyType><Trial id="132530"/><TrialStartDate>2006-01-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, three-way crossover study to evaluate the influence of a high-fat meal on the pharmacokinetics and pharmacodynamics of ziprasidone in healthy male volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53492"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone Pharmacokinetics Using a Reduced Food Effect Formulation Compared to Pharmacokinetics From Commercial Capsules</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="40981"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in Pediatric Bipolar Disorder</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="34191"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for the Treatment of Generalized Anxiety in Patients With Bipolar Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="32536"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>ZOOM</ProtocolAcronym><ProtocolTitle>Ziprasidone And Olanzapine's Outcomes In Mania</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="31498"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="275883"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment and Outcome of Early Onset Bipolar Disorder</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System, The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="34477"/><TrialStartDate>2002-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, double-blind, placebo-controlled, oral sumatriptan-controlled, randomized, three attack, parallel-group, outpatient study to determine the efficacy, safety and tolerability of oral naratriptan in the acute treatment of migraine headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78579"/><TrialStartDate>1995-07-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, phase I, randomized, four-way cross-over study to evaluate the dose proportionality of oral GR-85548A pharmacokinetics in healthy female volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78093"/><TrialStartDate>1994-01-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, open-label, single arm, three-attack study to determine the percentage of subjects who preferred naratriptan to their usual non-triptan migraine therapy after treating three migraines with naratriptan</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77520"/><TrialStartDate>2000-04-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, randomized, double-blind, double-dummy, active-placebo controlled, parallel group, multi-attack, outpatient study to evaluate the efficacy and safety of oral naratriptan compared with oral naproxen sodium on migraine-related quality of life</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77172"/><TrialStartDate>1997-10-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, placebo-controlled, two-way crossover study to investigate whether alcohol has an effect on the safety, tolerability, pharmacokinetics or pharmacodynamics of GR-85548</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77154"/><TrialStartDate>1994-04-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="128">Gastritis</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy of mosapride on oesophageal 24-h acid reflux variables in patients with gastro-esophageal reflux disease (GERD) symptoms</ProtocolTitle><Sponsor>Dainippon Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19373"/><TrialStartDate>1998-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="376">Gastric motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study to evaluate the effect of mosapride on gastric motility in patients with diabetic autonomic neuropathy</ProtocolTitle><Sponsor>Dainippon Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="19487"/><TrialStartDate>1992-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled study to compare the safety and efficacy of omeprazole plus a prokinetic, mosapride, to omeprazole alone for the potential treatment of non-erosive reflux disease</ProtocolTitle><Sponsor>Hyogo College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="74693"/><TrialStartDate>2011-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Efficacy of Omeprazole plus Mosapride Combination Therapy versus Omeprazole Monotherapy in Patients with Proton Pump Inhibitor-Refractory Gastroesophageal Reflux Disease: a randomized, controlled trial</ProtocolTitle><Sponsor>Rajavithi Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="379083"/><TrialStartDate>2016-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)</ProtocolTitle><Sponsor>Alizyme plc</Sponsor><StudyType>Interventional</StudyType><Trial id="18134"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="212">Motor neurone disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, placebo-controlled study to evaluate the safety and efficacy of xaliproden in patients with amyotrophic lateral sclerosis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45816"/><TrialStartDate>1997-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="212">Motor neurone disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, placebo-controlled study to evaluate the safety and efficacy of xaliproden in combination with riluzole in patients with amyotrophic lateral sclerosis</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="45813"/><TrialStartDate>1997-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of A Hydro-Alcoholic Solution of Sumatriptan Administered Sublingually in The Treatment of an Attack of Cluster Headache, at A Dose of 2, 4 or 6 mg Determined by The First Part of Study 'Dose-Ranging'</ProtocolTitle><Sponsor>Unither Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="117108"/><TrialStartDate>2007-09-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, placebo-controlled, two-attack crossover, inpatient study to evaluate the safety and efficacy of sc GR-43175C (6 mg) in patients with cluster headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="113755"/><TrialStartDate>1989-08-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel group, single-attack, outpatient study to evaluate efficacy and safety of sumatriptan 50 mg tablets versus placebo in the treatment of self-described and/or physician-diagnosed sinus headaches that meet International Headache Society (IHS) criteria for migraine headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="88030"/><TrialStartDate>2001-11-02 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, randomized, double-blind, placebo-controlled, parallel-group, single-attack, outpatient study to evaluate the efficacy, safety and tolerability of sumatriptan fast disintegrating tablets (FDT) 50 and 100 mg versus placebo during the mild pain phase of a migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87952"/><TrialStartDate>2002-10-10 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, cross-over, multiattack, outpatient study to evaluate the relation of migraine recurrence and anxiety-depressive symptoms in patients treated with sumatriptan</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87839"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, open-label, randomized, controlled, two-period, partly cross-over study to evaluate the safety, clinical efficacy, economic impact and quality of life of sumatriptan nasal spray (20 mg) compared to patient’s customary treatment in acute migraine attacks in a workplace setting</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87789"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, randomized, double-blind, placebo-controlled, parallel-group, single-attack, outpatient study to evaluate the safety and efficacy of two dose levels (5 and 20 mg) of sumatriptan nasal spray in the acute treatment of a single migraine attack in adolescent migraineurs (12 to 17 years of age)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87774"/><TrialStartDate>2002-04-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, Danish, randomized, multicenter, placebo-controlled, double-blind, parallel-group, single attack, outpatient study to evaluate the safety and the effect of sumatriptan 50 mg versus placebo in migraine patients with 6 to 11 attacks per year, taken during the mild phase of a migraine attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87704"/><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety Tolerability and Pharmacokinetics of ALD-403</ProtocolTitle><Sponsor>Alder Biopharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86589"/><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled, parallel group, single-attack, inpatient study to compare the efficacy and safety of oral naratriptan with that of oral sumatriptan and placebo in the acute treatment of migraine headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78081"/><TrialStartDate>1993-10-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-dose, double-blind, multicenter study to evaluate the efficacy and safety of almotriptan in patients with migraine</ProtocolTitle><Sponsor>King's College London</Sponsor><StudyType>Interventional</StudyType><Trial id="74142"/><TrialStartDate>2002-07-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, two-way crossover out-patient study to evaluate the efficacy and safety of nasal sumatriptan in treatment of migraine attacks of children and adolescents</ProtocolTitle><Sponsor>University of Helsinki</Sponsor><StudyType>Interventional</StudyType><Trial id="71204"/><TrialStartDate>1999-09-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate the pharmacokinetics and bioequivalence of sumatriptan delivered via the intraject system</ProtocolTitle><Sponsor>Zogenix Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="18493"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open Design Study to Evaluate the Safety of Rectal Dosing With Sumatriptan (25 mg and Optional 25 mg Dose for Headache Recurrence) in the Acute Treatment of All Migraine Attacks Over a 12 Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="173417"/><TrialStartDate>1994-01-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II, In-patient, Open-label, Pilot Study to Assess Efficacy and Safety of Oral GR-43175C for the Acute Treatment of Migraine in Adolescents</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="157339"/><TrialStartDate>1991-04-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Drug Use Investigation for Imigran Intranasal (Sumatriptan)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="149345"/><TrialStartDate>2003-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Imitrex Injection on Work Place Productivity Loss Due to migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="149188"/><TrialStartDate>1995-04-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial of Eletriptan to Treat Acute Migraine Attacks in Adult Patients</ProtocolTitle><Sponsor>Intas Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="133437"/><TrialStartDate>2010-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial to Study the Effects of Almotriptan Oral Tablets in Patients With Migraine Headache</ProtocolTitle><Sponsor>MSN Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="133279"/><TrialStartDate>2010-12-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative trial to evaluate the effect of zolmitriptan or sumatriptan for treatment of migraine</ProtocolTitle><Sponsor>Konstantopoulio GENERAL HOSPITAL OF NEA IONIA - PATISION</Sponsor><StudyType>Interventional</StudyType><Trial id="114816"/><TrialStartDate>2003-01-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Open-labeled Study to Evaluate One-year Tolerability and Efficacy of Sumatriptan Nasal Spray in Adolescents with Migraine</ProtocolTitle><Sponsor>Cleveland Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="110764"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Dose-finding, Double-blind, Multicenter, Placebo-controlled, Randomized Study To Evaluate Safety, Efficacy And Early Clinical Experience With Subcutaneous Naratriptan In The Acute Treatment Of Migraine</ProtocolTitle><Sponsor>Glaxo Wellcome Research and Development Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="107426"/><TrialStartDate>1998-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label study to assess the tolerability of sumatriptan in migraine patients</ProtocolTitle><Sponsor>Glaxo Wellcome Biopharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="106085"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Cross-over, Patient Preference Study of Frovatriptan Versus Zolmitriptan for the Acute Treatment of Migraine</ProtocolTitle><Sponsor>The Menarini Group</Sponsor><StudyType>Interventional</StudyType><Trial id="117269"/><TrialStartDate>2007-06-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, multicenter, randomized study to evaluate the efficacy and tolerability of zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine</ProtocolTitle><Sponsor>Rangueil hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="113402"/><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, placebo-controlled, randomized study evaluating patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110457"/><TrialStartDate>2001-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym>Duphar</ProtocolAcronym><ProtocolTitle>A randomized, double-blind, placebo and baseline-controlled, multi-center,  parallel-group study of eltoprazine in demented elderly patients with disruptive behaviour</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="248440"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Eltoprazine on Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in Adults: a Double-Blind, Multiple Dose, Crossover, Safety and Preliminary Efficacy Trial</ProtocolTitle><Sponsor>Amarantus BioScience Holdings Inc, PsychoGenics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="172412"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5125">buspirone (transdermal), BMS/Elan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>An 8-week, open-label, phase II study to evaluate the tolerability and efficacy of buspirone in children with Attention Deficit Hyperactivity Disorder (ADHD)</ProtocolTitle><Sponsor>Elan Corp plc</Sponsor><StudyType>Interventional</StudyType><Trial id="54411"/><TrialStartDate>1997-06-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>Rinotama</ProtocolAcronym><ProtocolTitle>Rizatriptan 10 mg RPD in the Treatment of Acute Migraine</ProtocolTitle><Sponsor>Univeristat Duisburg-Essen</Sponsor><StudyType>Interventional</StudyType><Trial id="63670"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-Autonomic Symptoms</ProtocolTitle><Sponsor>IRCCS San Raffaele</Sponsor><StudyType>Interventional</StudyType><Trial id="54179"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="39008"/><TrialStartDate>2009-03-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Maxalt 10 mg Plus Caffeine 75 mg in the Acute Treatment of Migraine Headache</ProtocolTitle><Sponsor>Diamond Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="191913"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Tolerability of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine</ProtocolTitle><Sponsor>Diamond Headache Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="14021"/><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Study to Test an Approved Product in the Early Treatment of Migraine</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="13934"/><TrialStartDate>2004-10-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Single-Dose Study to Evaluate the Pediatric Palatability of Maxalt Oral Disintegrating Tablets</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="117498"/><TrialStartDate/><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Crossover, Patient Preference Study of Frovatriptan Versus Rizatriptan for The Acute Treatment Of Migraine</ProtocolTitle><Sponsor>The Menarini Group</Sponsor><StudyType>Interventional</StudyType><Trial id="117052"/><TrialStartDate>2007-04-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, randomized, double-blind, comparative, crossover study to evaluate the effect of rizatriptan versus ergotamine/caffeine in migraine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="115463"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, naturalistic study to assess the efficacy of rizatriptan on migraine treatment outcomes in triptan-naive patients</ProtocolTitle><Sponsor>Merck &amp; Co Inc, Montefiore Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="111186"/><TrialStartDate>2001-03-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, placebo-controlled, randomized study evaluating patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110457"/><TrialStartDate>2001-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, open-label extension study to evaluate the long-term safety and efficacy of aripiprazole in patients who completed the 10-week acute phase of the study CN138005 ST and for whom continued treatment was indicated for psychotic symptoms associated with dementia of the Alzheimer’s type</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="79709"/><TrialStartDate>2000-08-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Comparison of Aripiprazole versus Risperidone in Attention Deficit Hyperactivity Disorder</ProtocolTitle><Sponsor>Shaheed Beheshti Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="155193"/><TrialStartDate>2012-02-29 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Aripiprazole and Ziprasidone Among Schizophrenic Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>University of Malaya</Sponsor><StudyType>Interventional</StudyType><Trial id="95891"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label study to evaluate the safety, tolerability and pharmacokinetics of aripiprazole and carbamazepine coadministration in patients with schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="80620"/><TrialStartDate>2000-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>8</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>12-Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults with Schizophrenia who have been Recently Discharged from an Inpatient Psychiatric Hospital</ProtocolTitle><Sponsor>Ortho-McNeil Janssen Scientific Affairs, LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="69767"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Standard Comprehensive Intervention to Treat First-episode Schizophrenia</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="63676"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Open-Label Rollover Study</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="61419"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>STEP 203</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="55677"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 4-week, double-blind, multicenter, Active- and placebo-controlled, phase III study to evaluate the safety and efficacy of aripiprazole when compared with either haloperidol or placebo in hospitalized patients with a DSM-IV diagnosis of acute relapse, schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="51215"/><TrialStartDate>2000-05-16 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 26-week, randomized, double-blind, multicenter to evaluate the safety and efficacy of aripiprazole when compared to olanzapine in patients with acute relapse of schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="51154"/><TrialStartDate>2003-05-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Metabolic Signatures and Biomarkers in Schizophrenia</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="36306"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>8</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CATIE</ProtocolAcronym><ProtocolTitle>Schizophrenia Trial</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="36183"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The New Strategy for Pharmacological Treatment in Peoples With Schizophrenia</ProtocolTitle><Sponsor>Inje University</Sponsor><StudyType>Interventional</StudyType><Trial id="35807"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Comparing Patients Taking Olanzapine and Patients Taking Aripiprazole on Learning of Vocational Skills</ProtocolTitle><Sponsor>University of Texas Health Science Center San Antonio</Sponsor><StudyType>Interventional</StudyType><Trial id="35461"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Adjunctive Treatment of Aripiprazole in Schizophrenic Patients</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35267"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34986"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Aripiprazole on Patients With Metabolic Syndrome</ProtocolTitle><Sponsor>US Department of Veterans Affairs</Sponsor><StudyType>Interventional</StudyType><Trial id="34597"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34547"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Treatment of Prodromal Patients</ProtocolTitle><Sponsor>Yale University</Sponsor><StudyType>Interventional</StudyType><Trial id="33981"/><TrialStartDate>2004-02-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>REMEDY</ProtocolAcronym><ProtocolTitle>Assessing approaches aimed at improving sexual functioning</ProtocolTitle><Sponsor>Imperial College Healthcare NHS trust</Sponsor><StudyType>Interventional</StudyType><Trial id="336942"/><TrialStartDate>2018-05-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="33453"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in the Treatment of Patients With Schizophrenia and Symptoms of Obsessive Compulsive Disorder (OCD)</ProtocolTitle><Sponsor>Jamaica Hospital Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="33315"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Abilify Therapy for Reducing Comorbid Substance Abuse</ProtocolTitle><Sponsor>Creighton University</Sponsor><StudyType>Interventional</StudyType><Trial id="33105"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="32452"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety</ProtocolTitle><Sponsor>University of Medicine and Dentistry of New Jersey</Sponsor><StudyType>Interventional</StudyType><Trial id="31470"/><TrialStartDate>2004-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence</ProtocolTitle><Sponsor>Denver Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="23479"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ASPIRE</ProtocolAcronym><ProtocolTitle>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21269"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ESCAPE Study</ProtocolAcronym><ProtocolTitle>Effect on cognitive function of a treatment with aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19410"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>BETA</ProtocolAcronym><ProtocolTitle>Broad effectiveness: Study with aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19395"/><TrialStartDate>2002-05-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study of Pregnenolone Augmentation Targeting Cognitive Symptoms in Persistently Symptomatic Patients With Schizophrenia</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="189291"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="18219"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Aripiprazole in Patients With Schizophrenia or Bipolar Disorder</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="172452"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Research of the Variance on Patients With Schizophrenia Treated With Aripiprazole on Hyperprolactinemia Induced by Risperidone or Paliperidone</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="171572"/><TrialStartDate>2012-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="171461"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>TAAS</ProtocolAcronym><ProtocolTitle>Tandospirone Combined With Atypical Antipsychotic Drugs in Schizophrenia</ProtocolTitle><Sponsor>Guangzhou Psychiatric Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="168968"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of Aripiprazole 10, 15 or 20 mg/day for the Treatment of Patients With Acute Exacerbations of Schizophrenia</ProtocolTitle><Sponsor>Duke University Medical Center, John Umstead Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="145482"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, 8-week trial to Evaluate the Effect of Aripiprazole on Cognition in the Treatment of Patients With Schizophrenia</ProtocolTitle><Sponsor>Munich University of Applied Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="144407"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, 8-week, multicenter, parallel-group, randomized, flexible-dose study of aripiprazole versus haloperidol for patients with schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>unknown</Sponsor><StudyType>Interventional</StudyType><Trial id="143510"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>TADS-J</ProtocolAcronym><ProtocolTitle>Treatment Alternatives for Drug-naive Schizophrenia in Japan</ProtocolTitle><Sponsor>Japanese Society of Clinical Neuropsychopharmacology</Sponsor><StudyType>Interventional</StudyType><Trial id="140379"/><TrialStartDate>2009-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Research over Schizophrenia Patients (Both on First Episode And Recurrence) About its Efficacy And Influence on Cognitive Function</ProtocolTitle><Sponsor>Kyoto University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="140001"/><TrialStartDate>2009-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="134886"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>On the question of Neuroleptic-Induced Metabolic Syndrome. Study 2: Fat Distribution and Specific Hormonal Parameters. Comparison between the metabolic syndrome of vulnerable and non-vulnerable patients from the schizophrenic group</ProtocolTitle><Sponsor>Medical University of Graz</Sponsor><StudyType>Interventional</StudyType><Trial id="132530"/><TrialStartDate>2006-01-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>JUMPs</ProtocolAcronym><ProtocolTitle>Long-Term Study on Discontinuation Rate, Resolution/Remission and Improvement in Social Functioning Rate Associated with Atypical Antipsychotic Medications in Patients with Schizophrenia</ProtocolTitle><Sponsor>Mebix Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="124647"/><TrialStartDate>2012-07-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CALPET01</ProtocolAcronym><ProtocolTitle>A Comparative, Randomized, Parallel-Group Study With PET in Newly Diagnosed Schizophrenic Patients Treated With Aripiprazole and Risperidone</ProtocolTitle><Sponsor>Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañon</Sponsor><StudyType>Interventional</StudyType><Trial id="118030"/><TrialStartDate>2007-05-11 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders</ProtocolTitle><Sponsor>Cambridge Health Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="31007"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym>PAIRS</ProtocolAcronym><ProtocolTitle>Study of Aripiprazole to Treat Children and Adolescents With Autism</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="30965"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="23291"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym>BAART</ProtocolAcronym><ProtocolTitle>Biomarkers in Autism of Aripiprazole and Risperidone Treatment</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="191238"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Aripiprazole in the Treatment of Autism</ProtocolTitle><Sponsor>University of Social Welfare and Rehabilitation Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="130219"/><TrialStartDate>2012-09-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, placebo-controlled, double-blind trial to study the safety and efficacy of aripiprazole in the treatment of methamphetamine dependence and associated psychosis</ProtocolTitle><Sponsor>University of Malaya</Sponsor><StudyType>Interventional</StudyType><Trial id="149516"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of aripiprazole in patients with acute mania</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="52072"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="34174"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>SMART-M</ProtocolAcronym><ProtocolTitle>Abilify in Bipolar Disorder for 24 Weeks Treatment Effectiveness</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="33960"/><TrialStartDate>2007-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>SMART-A</ProtocolAcronym><ProtocolTitle>Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="33958"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-Controlled, Pilot Study To Evaluate Aripiprazole as Adjunct to a Mood Stabilizer and Citalopram in Bipolar Depression</ProtocolTitle><Sponsor>Charite Universitaetsmedizin Berlin</Sponsor><StudyType>Interventional</StudyType><Trial id="146395"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole (Abilify) in Children With Symptoms of Mania</ProtocolTitle><Sponsor>University Hospitals Of Cleveland</Sponsor><StudyType>Interventional</StudyType><Trial id="34590"/><TrialStartDate>2004-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="32452"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="80099"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3514">Postnatal depression</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole and Resistant Postpartum Depression</ProtocolTitle><Sponsor>Lawson Health Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="78821"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3514">Postnatal depression</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>ACES 256</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder (MDD)</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65940"/><TrialStartDate>2010-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>IRL GREY</ProtocolAcronym><ProtocolTitle>Incomplete Response in Late Life Depression: Getting to Remission</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="53821"/><TrialStartDate>2009-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, open-label, controlled study to evaluate the efficacy of Low and high-dose aripiprazole augmentation in patients with major depressive disorder</ProtocolTitle><Sponsor>Fukushima Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="383503"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>DIMES</ProtocolAcronym><ProtocolTitle>Digital Medicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373941"/><TrialStartDate>2019-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="263970"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="15435"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Extension Trial From Late Phase II of SPM-962 in Advanced Parkinson's Disease Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88834"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Study in Healthy Volunteers to Prove That Two Rotigotine Patches Have Equivalent Ingredient Delivery to the Body</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="52878"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess Pharmacokinetic Profiles of LY-03003 and Neupro</ProtocolTitle><Sponsor>Luye Pharma Group Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="359124"/><TrialStartDate>2018-11-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Study in Healthy Volunteers to Prove That Two Rotigotine Patches Have Equivalent Ingredient Delivery to the Body</ProtocolTitle><Sponsor>UCB SA</Sponsor><StudyType>Interventional</StudyType><Trial id="52878"/><TrialStartDate>2008-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 28-Week, Safety, Extension Study of Flibanserin to Treat Pre-menopausal and Post-menopausal Women With Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Boehringer Ingelheim Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="65602"/><TrialStartDate>2010-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="33109"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the safety and efficacy of eletriptan for the treatment of adolescent patients with migraine</ProtocolTitle><Sponsor>Nova Southeastern University (NSU)</Sponsor><StudyType>Interventional</StudyType><Trial id="68443"/><TrialStartDate>2006-12-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>ACTMigraine</ProtocolAcronym><ProtocolTitle>ACT Therapy for HF Migraine</ProtocolTitle><Sponsor>Fondazione IRCCS Istituto Neurologico Carlo Besta</Sponsor><StudyType>Interventional</StudyType><Trial id="332221"/><TrialStartDate>2018-03-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia</ProtocolTitle><Sponsor>Badan Pendidikan Psikiatri Hospital, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88215"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 12-Week, Open-Label Extension Study in Patients With Schizophrenia</ProtocolTitle><Sponsor>Spanish Foundation for Neurometrics Development, Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="86070"/><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Rifampin Drug-Drug Interaction Study With Lurasidone HCl</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64677"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>JEWEL</ProtocolAcronym><ProtocolTitle>A 6-Week Study Looking at the Effectiveness and Safety of Lurasidone in Acutely Psychotic Subjects With Schizophrenia</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="262277"/><TrialStartDate>2017-03-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial of Lurasidone in Treatment of Schizophrenia</ProtocolTitle><Sponsor>Sumitomo Pharmaceuticals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="163009"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Rifampin Drug-Drug Interaction Study With Lurasidone HCl</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64677"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>NRX-GLX</ProtocolAcronym><ProtocolTitle>NRX101 Glx Biomarker Validation Study</ProtocolTitle><Sponsor>NeuroRx Inc, New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="326023"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="98930"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>PERSIST</ProtocolAcronym><ProtocolTitle>Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77684"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine</ProtocolTitle><Sponsor>Endo Health Solutions Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14075"/><TrialStartDate>2001-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Crossover Patient Preference Study of Frovatriptan Versus Rizatriptan for the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="117175"/><TrialStartDate>2007-05-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88790"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>10+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82270"/><TrialStartDate>2011-12-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness Study of Vilazodone to Treat Depression and to Discover Genetic Markers Associated With Response</ProtocolTitle><Sponsor>Genaissance Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34541"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Double-Blind Treatment of Major Depressive Disorder With Vilazodone</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><Trial id="100828"/><TrialStartDate>2013-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="22878"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, open-label, two-phase, five-period crossover study to evaluate the pharmacokinetics of tegaserod in healthy subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19860"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, parallel-group, placebo-controlled, ascending-dose study to evaluate the tolerability, pharmacokinetics and pharmacodynamics of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19849"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study of tegaserod in patients with constipation associated irritable bowel syndrome</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19711"/><TrialStartDate>2002-10-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>An open label study of tegaserod in patients with irritable bowel syndrome and constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19702"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled parallel-group, phase I, pharmacodynamic study  of tegaserod in healthy volunteers</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19845"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>An open label study of tegaserod in patients with irritable bowel syndrome and constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19702"/><TrialStartDate>2003-05-17 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, multicenter trial of tegaserod in women with irritable bowel syndrome (IBS) with constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19583"/><TrialStartDate>2004-11-10 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Study of Effect of Tegaserod on Small and Large Bowel Transit by Scintigraphic Method</ProtocolTitle><Sponsor>Hospital Authority,Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="18430"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>The Role of Tegaserod Therapy in the Management of Dyspeptic Symptoms in Female Patients on Proton Pump Inhibitors for the Treatment of Heartburn</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="56774"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42498"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Tegaserod on Mechanical Sensitivity of the Esophagus and Stomach in Patients With Heartburn and Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="20936"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, phase II, multi-center, double-blind, placebo-controlled study of tegaserod in patients with functional dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19832"/><TrialStartDate>2002-05-20 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, cross-over trial of tegaserod in patients with functional heartburn</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19795"/><TrialStartDate>2005-05-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, crossover design study of tegaserod in dyspepsia patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19786"/><TrialStartDate>2005-05-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>The Effects of Tegaserod Versus Placebo on Whole Gut Transit Time in Patients With Chronic Constipation and Dyspepsia</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18705"/><TrialStartDate>2006-01-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, open-label, two-phase, five-period crossover study to evaluate the pharmacokinetics of tegaserod in healthy subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19860"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, cross-over study of tegaserod in gastroesophageal reflux disease patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19791"/><TrialStartDate>2005-05-18 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Comparison between Resolor and lactulose</ProtocolTitle><Sponsor>University Malaya Medical Centre</Sponsor><StudyType>Interventional</StudyType><Trial id="377914"/><TrialStartDate>2019-03-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Phase I/IIa Trial of YH-12852 in Healthy Subjects and Patients With Functional Constipation</ProtocolTitle><Sponsor>Yuhan Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="239544"/><TrialStartDate>2015-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Effects of prucalpride  on colonic transit in patients with chronic constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19093"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and safety study of prucalopride for the treatment of chronic constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18669"/><TrialStartDate>1998-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Prucalopride for the Treatment of Patients With Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18668"/><TrialStartDate>1998-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Study of Prucalopride for the Treatment of Elderly Patients With Chronic Constipation</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="18440"/><TrialStartDate>1998-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="16564">sarizotan hydrochloride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>PADDY 1</ProtocolAcronym><ProtocolTitle>Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment Associated Dyskinesia</ProtocolTitle><Sponsor>Merck KGaA, Merck Pharma SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="6134"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, pilot phase I study to evaluate dopamine D2 receptor occupancy after multiple oral administration of DU-127090 to healthy male volunteers, using 11C-raclopride by means of position emission tomography (PET)</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41463"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Abbott Healthcare Products BV</Sponsor><StudyType>Interventional</StudyType><Trial id="1370"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Bifeprunox in Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="35167"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34996"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Twice-Daily Titration Study of Bifeprunox in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34635"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, dose-escalation, safety and pharmacokinetic study of ACP-103 in healthy volunteers</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7649"/><TrialStartDate>2003-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, placebo-controlled study assessing the effectiveness of ACP-103 for the treatment of side effects associated with schizophrenia treatment</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="43962"/><TrialStartDate>2004-09-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36021"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, dose-escalation, safety and pharmacokinetic study of ACP-103 in healthy volunteers</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7649"/><TrialStartDate>2003-06-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Ictal and Interictal Inflammatory Markers in Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc, Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="67103"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="38094">ibipinabant</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>BMS-646256 in obese and overweight type 2 Diabetics</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="5138"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A 12-month, open-label study to assess overall safety (including pulmonary and cardiovascular) of dihydroergotamine at 6 and 12 months</ProtocolTitle><Sponsor>MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="66346"/><TrialStartDate>2010-05-11 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="93597"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Buspirone and Ritaline in the treatment of ADHD</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="152104"/><TrialStartDate>2010-04-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44411">dihydroergotamine mesylate</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Study the PK and Safety of Single-Doses of STS-101, DHE Injection and Nasal Spray in Healthy Subjects</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373407"/><TrialStartDate>2018-09-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="47204">sumatriptan (sublingual, migraine, NovaMist), Suda</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multi-center, open-label, active-controlled, dose-ranging study to compare the efficacy and safety of three different doses of sumatriptan oral spray with sumatriptan oral tablets in migraine patients with documented slow response to sumatriptan tablets</ProtocolTitle><Sponsor>NovaDel Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="60242"/><TrialStartDate>2008-09-04 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym>BLOOM</ProtocolAcronym><ProtocolTitle>Behavioral Modification and Lorcaserin for Overweight and Obesity Management</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38929"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Real-World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity</ProtocolTitle><Sponsor>Novo Nordisk A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="366135"/><TrialStartDate>2019-01-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Low Level Laser Treatment (LLLT) and Lorcaserin for Weight Management</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="185149"/><TrialStartDate>2014-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Lu-AA21004 in treating generalized anxiety disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23036"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>FOCUS</ProtocolAcronym><ProtocolTitle>Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="80249"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu-AA21004) in Long-term Treatment of Major Depressive Disorder in Adults</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="75799"/><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="362684"/><TrialStartDate>2018-12-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Lu-AA21004 in the Treatment of Subjects With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34992"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes</ProtocolTitle><Sponsor>Loyola University of Chicago</Sponsor><StudyType>Interventional</StudyType><Trial id="345848"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Vortioxetine (Lu-AA21004) in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23330"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="214756"/><TrialStartDate>2014-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="48739">PRX-3140</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Safety and efficacy of novel 5HT4 partial agonist PRX-03140 for the treatment of Alzheimers disease</ProtocolTitle><Sponsor>EPIX Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="40342"/><TrialStartDate>2006-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="OL">Outlicensed</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, multiple-ascending dose, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability and pharmacokinetics of naronapride in healthy volunteers</ProtocolTitle><Sponsor>ARYx Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77600"/><TrialStartDate>2011-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate pharmacokinetics, safety and tolerability of Cariprazine in adolescent subjects with schizophrenia compared to adults</ProtocolTitle><Sponsor>Gedeon Richter Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="292530"/><TrialStartDate>2017-01-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine for Bipolar I Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63809"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>10+</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82270"/><TrialStartDate>2011-12-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Efficacy of a Fixed-Dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="252333"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>Subjective study to assess the efficacy of APD-125 in patients with sleep maintenance insomnia</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="16697"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="52893">clavulanic acid (extended-release, depression/Parkinson's disease), Rexahn</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder</ProtocolTitle><Sponsor>Rexahn Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="73671"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="53257">aripiprazole (intramuscular), Otsuka/BMS</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19202"/><TrialStartDate>2002-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="53257">aripiprazole (intramuscular), Otsuka/BMS</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of aripiprazole in comparision with lorazepam in the treatment of acute agitation in patients with a diagnosis of bipolar I disorder, manic or mixed</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="48308"/><TrialStartDate>2003-11-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Phase II Study of Velusetrag in Diabetic or Idiopathic Gastroparesis</ProtocolTitle><Sponsor>Theravance Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="96663"/><TrialStartDate>2012-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54699">temanogrel</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3258">Acute coronary syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Dose-escalation, Repeated and Single Oral Dosing Study</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="227143"/><TrialStartDate>2015-03-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Phase I, Open-Label, Single-Dose Study to Compare the Pharmacokinetics of NP-101 Healthy Volunteers</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="57182"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56714">PF-885706</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-Esophageal Reflux Disease (GERD)</ProtocolTitle><Sponsor>Pfizer Inc, Pfizer Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="23086"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="57473">revexepride</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD-557 on Reflux Parameters in Refractory GERD Patients</ProtocolTitle><Sponsor>Shire plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78064"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Demonstrate the Efficacy and Safety of Motilitone</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="117434"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TARGET</ProtocolAcronym><ProtocolTitle>Safety and Efficacy of a Single-Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine</ProtocolTitle><Sponsor>Optinose US Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="81963"/><TrialStartDate>2011-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="90372"/><TrialStartDate>2012-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A multicenter, open-label, clinical pharmacology study for comparative investigation of the pharmacokinetics, tolerability, and safety of three types of brexpiprazole (OPC-34712) once-weekly (QW) formulation administered as single oral doses in patients with schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="340924"/><TrialStartDate>2018-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="131668"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62606">CL-H1T</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="110">Emesis</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter Open-label Study Investigating the Pharmacokinetics and Safety of Aripiprazole IM Depot Formulation (OPC-14597 IMD) During Repeated Administration by Injection Into the Deltoid Muscle in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="208552"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Open-label, Multicenter Trial to Investigate the Pharmacokinetics of Aripiprazole IM Depot Fornulation (OPC-14597-IMD) by Repeated Dosing in Patients with Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="101227"/><TrialStartDate>2011-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>ATLAS</ProtocolAcronym><ProtocolTitle>Open-Label Study to Evaluate the Effectiveness of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="95371"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Long-term Safety Study of ALKS-9072 (Also Known as ALKS-9070)</ProtocolTitle><Sponsor>Alkermes plc, Syneos Health Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88627"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Efficacy and Safety of ALKS-9072 (Also Known as Aripiprazole Lauroxil, ALKS-9070, or ARISTADA) in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="82261"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Aripiprazole Lauroxil in Subjects with Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="249326"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="218809"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="193004"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>RESTART</ProtocolAcronym><ProtocolTitle>PF-04995274 and Emotional Processing in Treatment Resistant Depression</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="338568"/><TrialStartDate>2018-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="67509">SUVN-D4010</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects</ProtocolTitle><Sponsor>Suven Life Sciences Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="286240"/><TrialStartDate>2017-01-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="71845">aripiprazole + escitalopram</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A randomized study to evaluate the efficacy of augmentation therapy of aripiprazole with escitalopram in patients with co-occurrence of depression and alcohol dependence</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="154027"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="87714">dihydroergotamine (nasal, migraine), Satsuma Pharmaceuticals</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C1">Phase 1 Clinical</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I Study to Study the PK and Safety of Single-Doses of STS-101, DHE Injection and Nasal Spray in Healthy Subjects</ProtocolTitle><Sponsor>Satsuma Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373407"/><TrialStartDate>2018-09-11 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="90560">lorcaserin hydrochloride (extended-release, obesity), Arena/Eisai</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Belviq XR in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years</ProtocolTitle><Sponsor>Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="319212"/><TrialStartDate>2017-09-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="106222">lorcaserin (Dravet syndrome), Epygenix Therapeutics</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="5614">Dravet syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A safety and efficacy study of lorcaserin in the treatment of patients with Dravet syndrome</ProtocolTitle><Sponsor>Epygenix Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="298855"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="80360"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym>BRAC</ProtocolAcronym><ProtocolTitle>Study of Buspirone for Relapse-Prevention in Adults With Cocaine Dependence</ProtocolTitle><Sponsor>University of Cincinnati</Sponsor><StudyType>Interventional</StudyType><Trial id="89188"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>DIMES</ProtocolAcronym><ProtocolTitle>Digital Medicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373941"/><TrialStartDate>2019-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="34199"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>APEX 241</ProtocolAcronym><ProtocolTitle>Aripiprazole Open-Label, Safety and Tolerability Study</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34106"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>APOLLO</ProtocolAcronym><ProtocolTitle>A Study of Abilify Tablet (Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="328310"/><TrialStartDate>2018-02-22 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Investigative Study of the Safety and Efficacy of Long-Term Administration of Aripiprazole in Combination With Mood Stabilizer for the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="31463"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Bipolar Disorder and Alcohol Use Disorder</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="273220"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Patients With Acute Bipolar Mania</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19401"/><TrialStartDate>2004-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Pilot Study of comparative bioavailability between two oral formulations of cinitapride administered as 1 mg tablets in healthy volunteers under fasting conditions</ProtocolTitle><Sponsor>Ultra Laboratories, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="197216"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, open-label, single dose, phase 1 study to evaluate the safety, tolerability, food effect, and pharmacokinetic characteristics of DA-9701 in healthy volunteers</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="315382"/><TrialStartDate>2017-05-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical Study To Assess Bioequivalence of eletriptan 80 mg Tablets In Healthy Volunteers, eletriptan versus Relpax</ProtocolTitle><Sponsor>Landsteiner Scientific Sa De Cv</Sponsor><StudyType>Interventional</StudyType><Trial id="219904"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="810">Esophagitis</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Treatment for Refractory Gastroesophageal Reflux Disease</ProtocolTitle><Sponsor>Universitaire Ziekenhuizen Leuven</Sponsor><StudyType>Interventional</StudyType><Trial id="353800"/><TrialStartDate>2018-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="87907">OMS-210</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3863">Diarrhea predominant irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Parallel-Group Study to Compare the Safety and Efficacy of Two Dose Levels of OMS-210 With Placebo in the Treatment of Patients With Diarrhea Predominant Irritable Bowel Syndrome</ProtocolTitle><Sponsor>LOTUS Pharmaceutical Co Ltd (JAPAN)</Sponsor><StudyType>Interventional</StudyType><Trial id="142444"/><TrialStartDate>2010-10-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="400">Hypersomnia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for treating patients with delayed sleep phase syndrome and hypersomnolence disorder</ProtocolTitle><Sponsor>Akita University</Sponsor><StudyType>Interventional</StudyType><Trial id="314591"/><TrialStartDate>2016-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="82058">YH-12852</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3797">Gastrointestinal motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH-12852 After Oral Administration in Healthy Male Subjects</ProtocolTitle><Sponsor>Yuhan Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="137804"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="15">Amnesia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, parallel study to probe the implications of the partial D2 receptor agonist actions of aripiprazole within the dorsolateral prefrontal cortex during working memory in healthy volunteers</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="259593"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label, Safety Study of Pimavanserin in Parkinson's Disease Patients</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="84300"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1932">Catatonic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34895"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, two-way, cross-over, in-patient study to assess the safety and potential pharmacokinetic interaction of sumatriptan and clarithromycin when co-administered to healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87856"/><TrialStartDate>2000-06-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Fasting Study of Sumatriptan Succinate Tablets 100 mg to Imitrex Tablets 100 mg</ProtocolTitle><Sponsor>Mylan Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="189833"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym>PG-OCT</ProtocolAcronym><ProtocolTitle>Open-Label, Pharmacokinetic-Pharmacogenetic Study on Polymorphisms in the Organic Cation Transporter OCT1</ProtocolTitle><Sponsor>University Medical Center Goettingen</Sponsor><StudyType>Interventional</StudyType><Trial id="171413"/><TrialStartDate>2013-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym>SToP-C</ProtocolAcronym><ProtocolTitle>Substance Misuse To Psychiatric Disorders for Cannabis</ProtocolTitle><Sponsor>The University of Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="334943"/><TrialStartDate>2018-07-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for the Long-term Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="358334"/><TrialStartDate>2018-11-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Study of Two Fixed-Doses of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimers Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="134389"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="177">Hyperprolactinemia</Indication><ProtocolAcronym/><ProtocolTitle>Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="164012"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, crossover study to assess the efficacy of tegaserod in healthy volunteers</ProtocolTitle><Sponsor>University Hospital, Gasthuisberg</Sponsor><StudyType>Interventional</StudyType><Trial id="115671"/><TrialStartDate>2003-11-13 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A Bicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DA-9701 in Patients with Minimal Change Esophagitis</ProtocolTitle><Sponsor>Severance Hospital, Yonsei University College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="209078"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, double-dummy, randomized, placebo-controlled, four-way crossover study to investigate the effect of subcutaneous sumatriptan on the safety, pharmacodynamics and pharmacokinetics of oral naratriptan in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77167"/><TrialStartDate>1996-02-07 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Tandospirone, Amlodipine and Their Combination in Adults With Hypertension and Anxiety</ProtocolTitle><Sponsor>Chongqing Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="353222"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Acute Prucalopride Administration in Healthy Volunteers</ProtocolTitle><Sponsor>University of Oxford</Sponsor><StudyType>Interventional</StudyType><Trial id="372348"/><TrialStartDate>2017-02-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine versus Sertraline in Mexicans</ProtocolTitle><Sponsor>Universidad Juarez Autonoma de Tabasco</Sponsor><StudyType>Interventional</StudyType><Trial id="383778"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>ViBiD</ProtocolAcronym><ProtocolTitle>Vortioxetine add-on Treatment Improves the Symptoms in Patients With Bipolar Depression</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="347676"/><TrialStartDate>2018-08-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym>Depression-Cog Trial</ProtocolAcronym><ProtocolTitle>An Antidepressant Medications from Treatment Initiation for Depressive Disorder with Cognitive Impairment: A Prospective Comparative Study</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="282235"/><TrialStartDate>2016-11-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine as adjunctive treatment of schizophrenia</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="319958"/><TrialStartDate>2017-11-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, randomized study to evaluate anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="112807"/><TrialStartDate>2002-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>A Trial To Evaluate Switching Outpatients with Bipolar or Schizoaffective Disorders and Substance Abuse from Their Current Antipsychotic to Aripiprazole</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="147788"/><TrialStartDate>2003-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Single-Attack and Inpatient Study to Evaluate the Efficacy and Safety of Five Dose Levels of Sumatriptan Suppositories (6, 12.5, 25, 50 and 100 mg) in the Acute Treatment of Migraine With and Without Aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="206851"/><TrialStartDate>1992-10-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, double-blind, placebo-controlled, randomized study for the comparison of eletriptan (40 to 80 mg) and oral sumatriptan (50 to 100 mg) for the treatment of acute migraine in sumatriptan-naive patients</ProtocolTitle><Sponsor>Memorial University</Sponsor><StudyType>Interventional</StudyType><Trial id="109744"/><TrialStartDate>1999-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for Severe Conduct and Other Disruptive Behavior Disorders</ProtocolTitle><Sponsor>Albert-Ludwigs-Universität Freiburg</Sponsor><StudyType>Interventional</StudyType><Trial id="31334"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, Double-Blind, Parallel Study Determining Efficacy Of Tandospirone Citrate On L-DOPA-Induced Dyskinesia in Patients With Parkinson's Disease</ProtocolTitle><Sponsor>Hirosaki University Graduate School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="146691"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Double-blind, placebo-controlled, crossover study to evaluate the effect of a novel prokinetic drug, prucalopride, on bowel function and gastrointestinal transit in healthy volunteers</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19053"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3599">Dysphoria</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy and safety of intermittent prophylactic treatment with oral naratriptan in women with pre-menstrual dysphoria</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78592"/><TrialStartDate>2000-03-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Switch Study of Existing Atypical Antipsychotics to Bifeprunox</ProtocolTitle><Sponsor>Solvay Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35593"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment of Schizophrenia or Schizoaffective Disorder in Hospitalized Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35469"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="35450"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Anticonvulsant Mood Stabilizers, Antipsychotic Drugs and the Insulin Resistance Syndrome</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="34910"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><Trial id="146370"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan (LY-573144) Over Four Migraine Attacks</ProtocolTitle><Sponsor>Eli Lilly &amp; Co, Eli Lilly &amp; Co of India Inc, Eli Lilly SA</Sponsor><StudyType>Interventional</StudyType><Trial id="353496"/><TrialStartDate>2019-06-20 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia</ProtocolTitle><Sponsor>Taoyuan Mental Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="44097"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="677">Neurological disease</Indication><ProtocolAcronym/><ProtocolTitle>Monocentric, Open, Randomized study of Two-treatments, Two-periods, Two-sequences, Crossed, to Evaluate the Bioequivalence of Two po Formulations in Dispersible tablets, after the Administration of a Single Dose Equivalent to 5 mg of Zolmitriptan (Product provided by Exeltis Pharma Mexico, Test medicine versus Zomig Rapimelt, product of Astrazeneca, SA de CV, reference medicine) in Healthy Fasting Volunteers</ProtocolTitle><Sponsor>Investigación Farmacológica y Biofarmacéutica SAPI de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="381745"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="242">Esophageal disease</Indication><ProtocolAcronym>IEMPru</ProtocolAcronym><ProtocolTitle>Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study</ProtocolTitle><Sponsor>University of Calgary</Sponsor><StudyType>Interventional</StudyType><Trial id="308271"/><TrialStartDate>2017-10-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Ziprasidone Study for Psychosis Treatment in Adolescents</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="33934"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism</ProtocolTitle><Sponsor>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Sponsor><StudyType>Interventional</StudyType><Trial id="33118"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2083">Dumping syndrome</Indication><ProtocolAcronym/><ProtocolTitle>The effect of Motilitone to Gastric Emptying time in patients with Distal Gastrectomy</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="385322"/><TrialStartDate>2018-04-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="14473"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole for Bipolar Depression</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="328722"/><TrialStartDate>2017-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Examining the Effects of Antipsychotic Medications on Insulin Sensitivity</ProtocolTitle><Sponsor>Veterans Medical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="54493"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Evaluation of palatability of gummi drugs</ProtocolTitle><Sponsor>Hamamatsu University School of Medicine, Shizuoka University</Sponsor><StudyType>Interventional</StudyType><Trial id="275454"/><TrialStartDate>2015-10-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A 8-week, parallel-group, open-label, randomized study to compare the efficacy and safety of olanzapine versus aripiprazole in the management of Borderline Personality Disorder (BPD)</ProtocolTitle><Sponsor>University of Social Welfare and Rehabilitation Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="239061"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A PET Study in Healthy Volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="170368"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot study to evaluate the bioequivalence of aripiprazole in healthy male volunteers. Abilify, Bristol-Myers Squibb de Mexico, S. de RL de CV versus Aripiprazole Ultra Laboratories, SA de CV, 15 mg tablets</ProtocolTitle><Sponsor>Ultra Laboratories, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="164593"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Frovatriptan Versus Zolmitriptan in the Treatment of Migraine With or Without Aura, a Patient Preference Study</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="117172"/><TrialStartDate>2007-03-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="533">Mood disorder</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone Versus Sertraline/Haloperidol in Psychotic Depression</ProtocolTitle><Sponsor>Duke University</Sponsor><StudyType>Interventional</StudyType><Trial id="36489"/><TrialStartDate>2003-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Effect of tegaserod on gastric emptying in patients with diabetic gastroparesis</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="9410"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Randomized Trial of Mosapride versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome</ProtocolTitle><Sponsor>American University of Beirut Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="25323"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Neuropeptides in the Humane Intra- og Extracerebral Circulation</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="57922"/><TrialStartDate>2007-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Bioequivalence Study of the Lu-AA21004 20 mg and 2 x 10 mg Tablets</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="329734"/><TrialStartDate>2018-02-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="110">Emesis</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy and Safety of Oral CL-H1T in the Treatment of Acute Migraine Pain</ProtocolTitle><Sponsor>Charleston Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="373716"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride Versus Placebo in Gastroparesis</ProtocolTitle><Sponsor>Universitaire Ziekenhuizen Leuven</Sponsor><StudyType>Interventional</StudyType><Trial id="236159"/><TrialStartDate>2011-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="91166">vortioxetine (modified release capsules, depression), H Lundbeck</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="181875"/><TrialStartDate>2014-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1066">Spleen disease</Indication><ProtocolAcronym/><ProtocolTitle>Clinical observation of Pingwei capsule in treating functional dyspepsia with liver stagnation and spleen deficiency and its effect on CCK, ghrelin</ProtocolTitle><Sponsor>Affiliated Hospital of Gansu University of Chinese Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="372403"/><TrialStartDate>2014-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="35268"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Combination of Aripiprazole and Antidepressants in Psychotic Major Depression</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="33974"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>EDIPP</ProtocolAcronym><ProtocolTitle>Early Detection and Intervention for the Prevention of Psychosis</ProtocolTitle><Sponsor>Maine Medical Center Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="33594"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Risperidone versus Aripiprazole in amphetamine induced psychotic disorder</ProtocolTitle><Sponsor>Kermanshah University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="308422"/><TrialStartDate>2012-09-22 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind study to explore the longitudinal effect of treatment with second-generation antipsychotics on functional connectivity of the striatum during the resting state in patients experiencing a first episode of psychosis</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="223025"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>FACT</ProtocolAcronym><ProtocolTitle>Fluoxetine Versus Aripiprazole Comparative Trial</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="222658"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="1264"/><TrialStartDate>2000-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, single-blind, cross-over study to evlauate the safety and pharmacokinetics of gepirone in healthy male volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45045"/><TrialStartDate>1990-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Sumatriptan and Placebo on Cilostazol Induced Headache</ProtocolTitle><Sponsor>Danish Headache Center</Sponsor><StudyType>Interventional</StudyType><Trial id="234069"/><TrialStartDate>2015-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym>BBS</ProtocolAcronym><ProtocolTitle>Remediation of Age-related Cognitive Decline: Vortioxetine and Cognitive Training</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="311695"/><TrialStartDate>2016-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Cognitive Dysfunction in MDD Patients</ProtocolTitle><Sponsor>Zaporizhzhya Medical Academy of Postgraduate Education</Sponsor><StudyType>Interventional</StudyType><Trial id="301563"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3774">Sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="100958"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of the Potent Cytochrome P-450 3A4 (CYP3A4) Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-954 in Healthy Adult Participants</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="300311"/><TrialStartDate>2017-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="9">Aggression</Indication><ProtocolAcronym>SERENE</ProtocolAcronym><ProtocolTitle>Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="282172"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treatment With Ziprasidone for Schizophrenia Patients With Obsessive Compulsive Disorder (OCD)</ProtocolTitle><Sponsor>Sheba Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="33142"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open, randomized clinical trial involving Haloperidol, Olanzapine, Quetiapine, Risperidone, and Ziprasidone in first episode never-treated psychosis</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="267866"/><TrialStartDate>2002-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Use of Intramuscular Ziprasidone for the Control of Acute Psychosis or Agitation in an Inpatient Geriatric Population</ProtocolTitle><Sponsor>University of Toledo</Sponsor><StudyType>Interventional</StudyType><Trial id="145657"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="119">Epilepsy</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone Therapy for Localized Epilepsy</ProtocolTitle><Sponsor>National Institute of Neurological Disorders and Stroke</Sponsor><StudyType>Interventional</StudyType><Trial id="83428"/><TrialStartDate>2011-11-22 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole to Reduce Cocaine Relapse</ProtocolTitle><Sponsor>University of Kentucky</Sponsor><StudyType>Interventional</StudyType><Trial id="34066"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1931">Hebephrenic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Patient-Centered Collaborative Care for Preventing Post-Traumatic Stress Disorder After Traumatic Injury</ProtocolTitle><Sponsor>The National Institute of Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="23007"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>COMPASS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura</ProtocolTitle><Sponsor>Avanir Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="90303"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A phase IIIb, randomized, double-blind, placebo-controlled, parallel-group, single-attack study to determine the onset of efficacy of a new formulation of sumatriptan tablets 50 and 100 mg in treatment of subjects with acute migraine with and without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87179"/><TrialStartDate>2003-10-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>Eletriptan versus Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161688"/><TrialStartDate>1996-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Phase I Functional Magnetic Resonance Imaging (fMRI) Pharmacodynamic Studies of Compounds for Opioid Use Disorder and Cocaine Use Disorder</ProtocolTitle><Sponsor>Virginia Commonwealth University</Sponsor><StudyType>Interventional</StudyType><Trial id="297959"/><TrialStartDate>2015-07-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1519">Ileus</Indication><ProtocolAcronym/><ProtocolTitle>Prucalopride in Postoperative Ileus</ProtocolTitle><Sponsor>University of Auckland</Sponsor><StudyType>Interventional</StudyType><Trial id="277782"/><TrialStartDate>2017-10-25 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym>MEAC</ProtocolAcronym><ProtocolTitle>Metabolic Effects of Antipsychotics in Children</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="181395"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14054"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1931">Hebephrenic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="97">Diabetes mellitus</Indication><ProtocolAcronym/><ProtocolTitle>Improving Diabetes Risk Factors in Mexican-American Persons With Schizophrenia by Switching to Ziprasidone</ProtocolTitle><Sponsor>University of Texas Health Science Center San Antonio</Sponsor><StudyType>Interventional</StudyType><Trial id="5089"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1930">Paranoid schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65680"/><TrialStartDate>2010-04-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1930">Paranoid schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34895"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blind study to evaluate the safety and efficacy of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder (GAD)</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="65641"/><TrialStartDate>2010-02-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3020">motilide, Kitasato/Shimizu/Takeda</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A study to evaluate the effect of motilide on the human interdigestive gastrointestinal tract</ProtocolTitle><Sponsor>Kitasato Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="20120"/><TrialStartDate>1993-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia</ProtocolTitle><Sponsor>Research Foundation for Mental Hygiene Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="97708"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="353">Cognitive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open, Randomized Trial Of The Effect Of Aripiprazole Versus Risperidone On Social Cognition In Schizophrenia</ProtocolTitle><Sponsor>Universitair Medisch Centrum Utrecht </Sponsor><StudyType>Interventional</StudyType><Trial id="142289"/><TrialStartDate>2005-12-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, phase IIIb, multicenter, open-label, randomized, parallel-group, flexible-dose study to evaluate the efficacy of im/oral ziprasidone compared to haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86719"/><TrialStartDate>2002-03-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 6-week, double-blind, active-controlled, safety and efficacy study of ziprasidone, compared to olanzapine in hospitalized patients with schizophrenia and schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53560"/><TrialStartDate>2001-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, placebo-controlled, randomized study to evaluate CNS effects of sumatriptan rizatriptan in healthy female volunteers</ProtocolTitle><Sponsor>Centre for Human Drug Research</Sponsor><StudyType>Interventional</StudyType><Trial id="111397"/><TrialStartDate>2002-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="233">Neurodegenerative disease</Indication><ProtocolAcronym/><ProtocolTitle>Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="349386"/><TrialStartDate>2018-07-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="568">Colon disease</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the efficacy, safety and tolerability of prucalopride (Resolor) given subcutaneously in patients undergoing elective partial colectomies</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="19104"/><TrialStartDate>2008-05-21 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1948">Asperger syndrome</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders</ProtocolTitle><Sponsor>Cambridge Health Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="31007"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Study to Evaluate Pharmacokinetics, Safety, and Tolerability Ildong COL-144 Tablet in Korean Healthy Volunteers</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="379462"/><TrialStartDate>2019-08-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan in Healthy Elderly Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="326499"/><TrialStartDate>2018-01-25 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1175">Motion sickness</Indication><ProtocolAcronym/><ProtocolTitle>Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="7069"/><TrialStartDate>2006-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Buspirone Hydrochloride 30 mg Tablets, Non-Fasting</ProtocolTitle><Sponsor>Teva Pharmaceuticals USA Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="194956"/><TrialStartDate>2001-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Diindolylmethane in Healthy Volunteers</ProtocolTitle><Sponsor>National Cancer Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="185235"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Antidepressants on the Treatment for Korean Major Depressive Disorder Patients</ProtocolTitle><Sponsor>Ministry of Health &amp; Welfare, Korea</Sponsor><StudyType>Interventional</StudyType><Trial id="58247"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Augmentation Therapy in Treatment-Resistant Depression</ProtocolTitle><Sponsor>Albert-Ludwigs-Universität Freiburg</Sponsor><StudyType>Interventional</StudyType><Trial id="34601"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="298650"/><TrialStartDate>2017-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>RESOLVE 1</ProtocolAcronym><ProtocolTitle>Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80300"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect and safety of ziprasidone compared to other atypical anti-psychotic drug in schizophrenic patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21120"/><TrialStartDate>2001-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>Kahn</ProtocolAcronym><ProtocolTitle>Investigation of the efficacy of ziprasidone versus olanzapine in the management of recent-onset psychosis; A flexible-dose, parallel-group, double-blind study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="20969"/><TrialStartDate>2003-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1932">Catatonic schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3010">Colonoscopy</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of mosapride citrate with a split dose of PEG + ascorbic acid for bowel preparation in elderly patients</ProtocolTitle><Sponsor>Korea United Pharm Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="322125"/><TrialStartDate>2017-11-21 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1971">Schizophreniform disorder</Indication><ProtocolAcronym>PAFIP2</ProtocolAcronym><ProtocolTitle>Comparative Study of Aripiprazole, Quetiapine and Ziprasidone in the Treatment of First Episode Non-affective Psychosis</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="217461"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2954">Weight gain</Indication><ProtocolAcronym/><ProtocolTitle>1/2-MC4R Genotype and Pediatric Antipsychotic Drug-Induced Weight Gain</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="126918"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate pharmacokinetics, safety and tolerability of Cariprazine in adolescent subjects with schizophrenia compared to adults</ProtocolTitle><Sponsor>Gedeon Richter Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="292530"/><TrialStartDate>2017-01-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym>BUSPARK</ProtocolAcronym><ProtocolTitle>Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson Disease</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><Trial id="247246"/><TrialStartDate>2016-06-17 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="368">Movement disorder</Indication><ProtocolAcronym>BUS-PD</ProtocolAcronym><ProtocolTitle>Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia</ProtocolTitle><Sponsor>Oregon Health Sciences University</Sponsor><StudyType>Interventional</StudyType><Trial id="244179"/><TrialStartDate>2016-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="90560">lorcaserin hydrochloride (extended-release, obesity), Arena/Eisai</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants</ProtocolTitle><Sponsor>Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="349964"/><TrialStartDate>2018-08-07 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Augmentation therapy comparison in refractory obsessive-compulsive disorder with aripiprazole versus risperidone</ProtocolTitle><Sponsor>Kashan University of Medical Sciences and Health Services</Sponsor><StudyType>Interventional</StudyType><Trial id="294001"/><TrialStartDate>2013-04-21 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Aripiprazole Augmentation in SSRI-Refractory OCD With Poor Insight</ProtocolTitle><Sponsor>Hyogo College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="119243"/><TrialStartDate>2012-01-01 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="109472">sumatriptan (migraine, ZENEO), Crossject</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>A bioequivalence study of sumatriptan in the treatment of facial algia and acute migraine</ProtocolTitle><Sponsor>Crossject</Sponsor><StudyType>Interventional</StudyType><Trial id="330220"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>Switch Ext</ProtocolAcronym><ProtocolTitle>A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="67269"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2460">Neurobehavioral disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD)</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19411"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2686">bromerguride</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I study to evaluate the safety, pharmacokinetics and pharmacodynamics of bromerguride in healthy male volunteers</ProtocolTitle><Sponsor>Bayer Schering Pharma AG</Sponsor><StudyType>Interventional</StudyType><Trial id="55739"/><TrialStartDate>1986-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, open-label, multicenter, non-comparative study to determine the tolerability, safety, and efficacy of ziprasidone (Geodon) in treatment of subjects with schizophrenia or schizoaffective disorder who were ineffectively treated with antipsychotic agents</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86686"/><TrialStartDate>2002-11-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, open-label, randomized, multicenter, parallel-group, 3-months pilot study to determine the best option for transitioning from amisulpride to ziprasidone therapy in subjects receiving amisulpride for chronic or subchronic schizophrenia or schizoaffective disorders</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86319"/><TrialStartDate>2001-04-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="85624"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Identifying Predictors of Response to Antipsychotics Using a Treatment Algorithm</ProtocolTitle><Sponsor>University of Sao Paulo</Sponsor><StudyType>Interventional</StudyType><Trial id="62081"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, randomized, double-blind, dose-ranging, haloperidol-controlled, exploratory study evaluating safety and efficacy of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53489"/><TrialStartDate>1998-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Ziprasidone on Glucose and Plasma Lipids in Diabetes II and Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Manhattan Psychiatric Center</Sponsor><StudyType>Interventional</StudyType><Trial id="4761"/><TrialStartDate>2003-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PROACTIVE</ProtocolAcronym><ProtocolTitle>Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36294"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating The Safety, Tolerability, And Efficacy Of Switching From Quetiapine To Ziprasidone</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="35810"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34898"/><TrialStartDate>2004-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34891"/><TrialStartDate>2004-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2A">Phase 2a Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Tolerability of Oral Ziprasidone in Children and Teens With Psychotic Disorders</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34753"/><TrialStartDate>2003-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Safety and Efficacy of ASP-4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication</ProtocolTitle><Sponsor>Astellas Pharma Global Development Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="343094"/><TrialStartDate>2018-07-13 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Efficacy And Safety Of Intramuscular Ziprasidone For Three Days In Patients With Psychotic Agitation</ProtocolTitle><Sponsor>Beijing Hui-Long-Guan Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="275883"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>AP Project</ProtocolAcronym><ProtocolTitle>Dose reduction or switch to ziprasidone followed by clozapine therapy: what works better in a long stay schizophrenia group?</ProtocolTitle><Sponsor>Universiteit Utrecht</Sponsor><StudyType>Interventional</StudyType><Trial id="270203"/><TrialStartDate>2007-07-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Open-Label Ziprasidone Study for Psychosis Treatment in Adolescents</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="33934"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 21-day, phase III, multicenter, in-patient, randomized, double-blind, placebo-controlled, safety and efficacy study of ziprasidone in patients with acute bipolar mania</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="53553"/><TrialStartDate>2002-04-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="176229"/><TrialStartDate>2014-05-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Association Between Anxiety and Bipolar I Disorder in Randomized, Placebo-Controlled, Maintenance Study of Ziprasidone Combined With Mood Stabilizer</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="147988"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3203">gepirone (extended release), Fabre Kramer</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Relapse Prevention with Gepirone ER in Outpatients with Major Depression</ProtocolTitle><Sponsor>Brown University</Sponsor><StudyType>Interventional</StudyType><Trial id="153208"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase IV, Randomized, Double-Blind, Placebo-Controlled, Parallel Group To Evaluate The Safety And Efficacy Of Oral Naratriptan 1 mg Twice Daily as Prophylactic Treatment for Menstrually-Associated Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78597"/><TrialStartDate>2000-04-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, multicenter, post-marketing surveillance study to monitor the safety of Naramig in Korean subjects according to the prescribing information</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78547"/><TrialStartDate>2001-03-26 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled, parallel group, single-attack, inpatient study to compare the efficacy and safety of oral naratriptan with that of oral sumatriptan and placebo in the acute treatment of migraine headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="78081"/><TrialStartDate>1993-10-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, two-period, crossover study to determine the effect of food on the pharmacokinetics of oral naratriptan tablets in healthy female volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77250"/><TrialStartDate>1995-07-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, prospective, randomized, double-blind, placebo-controlled, parallel group, two-attack, outpatient study to determine if naratriptan was able to treat migraine headaches in subjects with a history of poor response to sumatriptan</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77212"/><TrialStartDate>1997-09-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>Ateneia</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine</ProtocolTitle><Sponsor>Ache Laboratorios Farmaceuticos SA</Sponsor><StudyType>Interventional</StudyType><Trial id="108509"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3619">tandospirone</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled trial to evaluate the safety and efficacy of tandospirone augmentation in patients with major depressive disorder</ProtocolTitle><Sponsor>Keio University</Sponsor><StudyType>Interventional</StudyType><Trial id="73839"/><TrialStartDate>2003-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C0">Phase 0 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical observation of Pingwei capsule in treating functional dyspepsia with liver stagnation and spleen deficiency and its effect on CCK, ghrelin</ProtocolTitle><Sponsor>Affiliated Hospital of Gansu University of Chinese Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="372403"/><TrialStartDate>2014-01-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym>MARS</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of UI05MSP015CT in Functional Dyspepsia</ProtocolTitle><Sponsor>Korea United Pharm Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="306090"/><TrialStartDate>2014-11-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Clinical study of Shuganjieyuejiaonang joint Mosapride Citrate Dispersible Tablets for the treatment of functional dyspepsia: a multi-center, randomized, double-blind, placebo controlled clinical trial</ProtocolTitle><Sponsor>Shanghai Jiao Tong University</Sponsor><StudyType>Interventional</StudyType><Trial id="288963"/><TrialStartDate>2016-09-15 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-Label Comparison of PPIs and H2-Receptor Antagonists Plus Prokinetics For Dysmotility-Like Dyspepsia</ProtocolTitle><Sponsor>Moriguchi Keijinkai Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="173358"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Lansoprazole Versus Mosapride for Functional Dyspepsia</ProtocolTitle><Sponsor>Lotung Poh-Ai Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="12815"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Tokyo University Omeprazole versus Gasmotin (mosapride) plus Omeprazole Study</ProtocolTitle><Sponsor>The University of Tokyo Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="149260"/><TrialStartDate>2007-10-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4474">xaliproden</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>Study of Xaliproden (SR-57746A) in Patients With Mild-to-Moderate Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><StudyType>Interventional</StudyType><Trial id="2407"/><TrialStartDate>2003-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A Crossover; Double-blind; Placebo-controlled; Randomized study to assess the efficacy of sumatriptan in cluster headache</ProtocolTitle><Sponsor>University of Turin</Sponsor><StudyType>Interventional</StudyType><Trial id="115872"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Prochlorperazine Versus Imitrex for Acute Migraine in the Emergency Department</ProtocolTitle><Sponsor>Naval Medical Center, Portsmouth</Sponsor><StudyType>Interventional</StudyType><Trial id="92417"/><TrialStartDate>2007-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, single-attack, outpatient study to evaluate the efficacy and tolerability of oral sumatriptan 25, 50, and 100 mg tablets for a single moderate or severe headache in adults diagnosed with migrainous disorder</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87972"/><TrialStartDate>2002-08-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, double-blind, placebo-controlled, parallel-group, outpatient, single attack study to evaluate the safety and efficacy of sumatriptan tablets 50 and 100 mg versus placebo during a migraine headache at the first sign of pain</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87867"/><TrialStartDate>2000-07-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, randomized, multicenter, single-blind, cross-over study to evaluate the efficacy and safety of sumatriptan 25 mg suppositories compared to naproxen 500 mg suppositories in the acute, early treatment of migraine in patients suffering from nausea and/or vomiting during their attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87843"/><TrialStartDate>2001-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, single-center, placebo-controlled, double-blind, randomized, two-period, cross-over, outpatient study to evaluate the efficacy and tolerability of sumatriptan nasal spray 10 mg for the acute treatment of migraine in children suffering from refractory migraine with/without aura</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87710"/><TrialStartDate>2000-02-14 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Muticenter, Post-Marketing Surveillance Study To Evaluate Safety And Efficacy Of Sumatriptan In Patients With Migraine and Cluster Headache</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="73796"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Three-Period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a Trexima (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by Imitrex (Sumatriptan Succinate)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="50760"/><TrialStartDate>2008-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Bioavailability Study of Omexa Sumatriptan Versus Imitrex in Healthy Volunteers</ProtocolTitle><Sponsor>Targia Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="278686"/><TrialStartDate>2016-03-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Two Dose Levels (10 and 20 mg) of Intranasal Sumatriptan in the Acute Treatment of Migraine Attack</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="204241"/><TrialStartDate>1993-10-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Acetaminophen, Aspirin and Caffeine With Sumatriptan in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="176338"/><TrialStartDate>2010-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>MATRIX(Migrainer Assess TRiptane eXamination)</ProtocolTitle><Sponsor>University of Tsukuba</Sponsor><StudyType>Interventional</StudyType><Trial id="132785"/><TrialStartDate>2010-01-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>KSPN Migraine</ProtocolAcronym><ProtocolTitle>Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="115495"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A comparative, crossover, double-blind, placebo-controlled, randomized study evaluating patient satisfaction with rizatriptan versus other triptans: Direct head-to-head comparisons</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110457"/><TrialStartDate>2001-10-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, randomized, cross-over trial of a dual-release formulation of oral ketoprofen in the acute treatment of migraine attacks</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris</Sponsor><StudyType>Interventional</StudyType><Trial id="73999"/><TrialStartDate>2002-06-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TRXvUsualTrptn</ProtocolAcronym><ProtocolTitle>Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?</ProtocolTitle><Sponsor>The Cleveland Clinic Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="64858"/><TrialStartDate>2009-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Preference for Triptans in Migraine Patients: A Randomized, Open-Label, Crossover Prospective Study</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><Trial id="125981"/><TrialStartDate>2010-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, two-period, two-way crossover study in healthy male and female subjects to compare safety, pharmacokinetics and bioequivalence of rizatriptan with Maxalt-MLT</ProtocolTitle><Sponsor>IntelGenx Technologies Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="87945"/><TrialStartDate>2012-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of Multiple Attacks of Acute Migraine</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="54709"/><TrialStartDate>1995-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Rizatriptan 5 and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="54675"/><TrialStartDate>1995-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Preference Trial with Rizatriptan 10 mg and Ibuprofen 400 mg in Migraine Patients In the General Practice</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="286458"/><TrialStartDate>2005-03-23 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Rizatriptan for Episodic Dizziness in Vestibular Migraine</ProtocolTitle><Sponsor>University of California Los Angeles</Sponsor><StudyType>Interventional</StudyType><Trial id="230238"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Two Rizatriptan Prescribing Portions for Treatment of Migraine</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="14040"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Crossover Patient Preference Study of Frovatriptan Versus Rizatriptan for the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="117175"/><TrialStartDate>2007-05-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, comparative, double-blind, multicenter, placebo-controlled study to assess the safety and efficacy of rizatriptan and naratriptan in patients with  moderate/severe migraine headache</ProtocolTitle><Sponsor>Ignatius Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="107809"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>TSM</ProtocolAcronym><ProtocolTitle>Drug and Non-Drug Treatment Of Severe Migraine</ProtocolTitle><Sponsor>Ohio University</Sponsor><StudyType>Interventional</StudyType><Trial id="102773"/><TrialStartDate>2001-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A prospective, multicenter, open-label study to evaluate the safety and effectiveness of aripiprazole in the treatment of a broad range of patients with schizophrenia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="96275"/><TrialStartDate>2011-09-14 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind study to compare the safety and efficacy of flexible doses of aripiprazole with perphenazine for the treatment of patients with treatment-resistant schizophrenia</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co, Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="83048"/><TrialStartDate>2000-08-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, randomized trial to compare the efficacy of aripiprazole with risperidone on measures of anhedonia and subjective well-being in patients with schizophrenia</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="78554"/><TrialStartDate>2011-03-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Comparison Study of LY-2140023 and Aripiprazole in Schizophrenia Patients</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="76073"/><TrialStartDate>2011-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of LY-2140023 in Schizophrenia Patients With Prominent Negative Symptoms</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="63506"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 52-week study to evaluate the safety and efficacy of aripiprazole when compared to haloperidol in patients with acute relapse of schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="51199"/><TrialStartDate>2002-05-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>DIMES</ProtocolAcronym><ProtocolTitle>Digital Medicine Study for Adults With Schizophrenia, Bipolar I Disorder, or Major Depression Currently Using Aripiprazole</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="373941"/><TrialStartDate>2019-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="371510"/><TrialStartDate>2019-01-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CHAT</ProtocolAcronym><ProtocolTitle>Randomized Evaluation of the Effectiveness of Clozapine and Aripiprazole Versus Clozapine and Haloperidol in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Universita di Verona</Sponsor><StudyType>Interventional</StudyType><Trial id="36225"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Augmentation for Clozapine-Treated Patients With Refractory Schizophrenia</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="35451"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="35450"/><TrialStartDate>2006-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>BETA</ProtocolAcronym><ProtocolTitle>A Study of Aripiprazole in the Management of Patients With Schizophrenia in the General Psychiatric Practices</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34546"/><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Diagnosis and Treatment of Depression Based on Biological Evidence of Dopamine Reward Pathway</ProtocolTitle><Sponsor>Peking University</Sponsor><StudyType>Interventional</StudyType><Trial id="298650"/><TrialStartDate>2017-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>5</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment</ProtocolTitle><Sponsor>Shanxi Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="250546"/><TrialStartDate>2013-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of the Impact of Aripiprazole (Abilify) Once Monthly Versus Standard of Care Oral Antipsychotic Medications on Changes in Brain Structure and Metabolism</ProtocolTitle><Sponsor>University of Utah</Sponsor><StudyType>Interventional</StudyType><Trial id="210228"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>CONSTATRE</ProtocolAcronym><ProtocolTitle>A Study of Relapse Prevention and the Effectiveness of Long-Acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schiozaffective Disorder</ProtocolTitle><Sponsor>Janssen-Cilag International NV (BE)</Sponsor><StudyType>Interventional</StudyType><Trial id="20998"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Effectiveness of Switching Antipsychotics to Aripiprazole or Blonanserin and Plasma Monoamine Metabolites Levels in Patients With Schizophrenia</ProtocolTitle><Sponsor>Fukushima Medical University</Sponsor><StudyType>Interventional</StudyType><Trial id="178192"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>A-BLAS</ProtocolAcronym><ProtocolTitle>A Comparison of Medication Adherence of Blonanserin and Aripiprazole in Schizophrenic Patients: a Multicenter, Randomized, Open-label Study</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd, University of Occupational &amp; Environmental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="166234"/><TrialStartDate>2012-02-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, controlled trial of blonanserin versus aripiprazole in psychotic disorder</ProtocolTitle><Sponsor>Fujita Health University, Hospital of St Cross, The Jindai Hospital, The Okehazama Hospital, Toyota Memorial Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="156063"/><TrialStartDate>2013-07-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Pilot Study to Evaluate the Improvement in Social Competence in Schizophrenic Patients Using a Performance-Based Measure Using Virtual Reality</ProtocolTitle><Sponsor>Severance Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="153077"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Randomized, Switch-Over Study of Two Fixed Doses (10/15 mg) of Aripiprazole To Evaluate Its Safety and Efficacy in the Treatment of Indian Schizophrenic Patients</ProtocolTitle><Sponsor>Vidyasagar Institute of Mental Health, Neuro &amp; Allied Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="148151"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole, an Antipsychotic With a Novel Mechanism of Action, and Risperidone versus Placebo in Patients With Schizophrenia and Schizoaffective Disorder</ProtocolTitle><Sponsor>University of California Irvine</Sponsor><StudyType>Interventional</StudyType><Trial id="146370"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Pilot Study of Aripiprazole in Schizophrenia Patients With Cocaine Dependence</ProtocolTitle><Sponsor>University of Denver</Sponsor><StudyType>Interventional</StudyType><Trial id="145093"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A 26-Week, Prospective Study to Evaluate the Long-Term Efficacy and Safety of Aripiprazole in Patients with Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder</ProtocolTitle><Sponsor>Seoul National University College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="144495"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial of Aripiprazole in Treating First-episode Schizophrenia</ProtocolTitle><Sponsor>Korea University</Sponsor><StudyType>Interventional</StudyType><Trial id="144390"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Controlled Clinical Comparison of Perospirone and Aripiprazole Considering the Drug Susceptibility Gene</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd, Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="142285"/><TrialStartDate>2010-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Efficacy and Safety of Aripiprazole</ProtocolTitle><Sponsor>Samsung Medical Center (SMC)</Sponsor><StudyType>Interventional</StudyType><Trial id="174686"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>An Study of Aripiprazole in the Treatment of Methamphetamine Dependence</ProtocolTitle><Sponsor>Central South University</Sponsor><StudyType>Interventional</StudyType><Trial id="116515"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Treatment of Bipolar Depression</ProtocolTitle><Sponsor>Indiana University School of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="34178"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym>ABLE</ProtocolAcronym><ProtocolTitle>Abilify in Bipolar Disorder for Long-Term Effectiveness</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="33954"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar Disorder</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="32455"/><TrialStartDate>2003-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Children and Adolescents With Bipolar Disorder and ADHD</ProtocolTitle><Sponsor>Federal University of Rio Grande do Sul</Sponsor><StudyType>Interventional</StudyType><Trial id="31579"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study to investigate the effects of switching to aripiprazole from current atypical antipsychotics on subsyndromal symptoms and tolerability in patients with bipolar disorder</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="275720"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in the Treatment of Patients With Acute Symptoms in Bipolar Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19201"/><TrialStartDate>2002-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Trial of Aripiprazole in Autism Spectrum Disorders</ProtocolTitle><Sponsor>Cambridge Health Alliance</Sponsor><StudyType>Interventional</StudyType><Trial id="31007"/><TrialStartDate>2006-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym>PAIRS</ProtocolAcronym><ProtocolTitle>Study of Aripiprazole to Treat Children and Adolescents With Autism</ProtocolTitle><Sponsor>University of North Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="30965"/><TrialStartDate>2006-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1947">Pervasive child developmental disorder</Indication><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of aripiprazole when administered as a 15 mg orally disintegrating tablet relative to a 15 mg commercial tablet in healthy male and/or female subjects under fasting condition</ProtocolTitle><Sponsor>Korea Otsuka Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="244133"/><TrialStartDate>2012-08-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Patients With Acute Mania</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="19400"/><TrialStartDate>2004-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1957">Mania</Indication><ProtocolAcronym>AMAZE</ProtocolAcronym><ProtocolTitle>A Placebo-controlled, Double-blind Study of The Efficacy And Safety of Aripiprazole For the Treatment of Acute Manic or Mixed Episodes in Asian Patients With Bipolar i Disorder</ProtocolTitle><Sponsor>National Hospital Organization</Sponsor><StudyType>Interventional</StudyType><Trial id="144135"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2941">Tourette syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Tourette's Syndrome</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="331071"/><TrialStartDate>2018-05-02 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>PAMS</ProtocolAcronym><ProtocolTitle>Side Effect Study of Antipsychotic Medicines to Treat Childhood Bipolar Disorder</ProtocolTitle><Sponsor>University of Maryland</Sponsor><StudyType>Interventional</StudyType><Trial id="34878"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of 8 Weeks, Open-Label Aripiprazole as Augmentation Therapy in Bipolar II Disorder</ProtocolTitle><Sponsor>Bristol-Myers Squibb Co</Sponsor><StudyType>Interventional</StudyType><Trial id="134718"/><TrialStartDate>2004-01-08 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="3514">Postnatal depression</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="3609">Agitation</Indication><ProtocolAcronym/><ProtocolTitle>Comparative study of the pharmacokinetics and bioequivalence of drugs "Mirium Tablets 10 mg" ("Sinton Spain SL", owner of the registration certificate of JSC "Grindeks", Latvia) and Abilify Tablets 10 mg ("Bristol-Myers Squibb Company Manufacturing" Puerto Rico)</ProtocolTitle><Sponsor>Grindeks, Publiska Akciju Sabiedriba</Sponsor><StudyType>Interventional</StudyType><Trial id="247044"/><TrialStartDate>2015-11-24 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Extension Trial From Phase II/III of SPM-962 in Early Parkinson's Disease Patients</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="88760"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, double-blind, placebo-controlled, phase II study designed to evaluate the safety and efficacy of rotigotine in patients with early-stage Parkinson's disease</ProtocolTitle><Sponsor>Aderis Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="51461"/><TrialStartDate>2002-11-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term, Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome</ProtocolTitle><Sponsor>UCB Biosciences Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="83492"/><TrialStartDate>2011-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="1774">Restless legs syndrome</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome of Unknown Cause</ProtocolTitle><Sponsor>UCB Biopharma SPRL</Sponsor><StudyType>Interventional</StudyType><Trial id="358887"/><TrialStartDate>2018-12-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Flibanserin on the Pre-and Post-menopausal Female Brain</ProtocolTitle><Sponsor>University of Chicago</Sponsor><StudyType>Interventional</StudyType><Trial id="260655"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Zolmitriptan Nasal Spray Versus Eletriptan in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>California Medical Clinic for Headache</Sponsor><StudyType>Interventional</StudyType><Trial id="74173"/><TrialStartDate>2008-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics of Two Eletriptan Oral Formulations Given With and Without Water and the Commercial Tablet Formulation Given With Water</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="50199"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Eletriptan for the Treatment of Migraine in Subjects Unsuccessfuly Treated With Nonsteroidal Anti-Inflammatory Drugs</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14083"/><TrialStartDate>2002-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial of Eletriptan to Treat Acute Migraine Attacks in Adult Patients</ProtocolTitle><Sponsor>Intas Pharmaceuticals Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="133437"/><TrialStartDate>2010-05-29 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Comparison of Preference for Triptans in Migraine Patients: A Randomized, Open-Label, Crossover Prospective Study</ProtocolTitle><Sponsor>Kitasato University</Sponsor><StudyType>Interventional</StudyType><Trial id="125981"/><TrialStartDate>2010-02-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, efficacy and tolerability of eletriptan in treatment of migraine</ProtocolTitle><Sponsor>Alfred Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="112777"/><TrialStartDate>2002-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A multicentre, randomized, double-blind, placebo-controlled, comparative study to evaluate the safety, efficacy, and tolerability of oral eletriptan and ergotamine plus caffeine in the acute treatment of migraine</ProtocolTitle><Sponsor>Universitat Duisburg Essen</Sponsor><StudyType>Interventional</StudyType><Trial id="112749"/><TrialStartDate>2002-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Dose-response study of SM-13496 in patients with schizophrenia</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="96173"/><TrialStartDate>2005-09-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Extended Use Study</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd, Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="82983"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>PEARL</ProtocolAcronym><ProtocolTitle>Schizophrenia Maintenance</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80886"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and tolerability study of drug to treat schizophrenia</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="34498"/><TrialStartDate>2002-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Lurasidone HCl in Subjects With Schizophrenia</ProtocolTitle><Sponsor>Standard Chemical &amp; Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="324973"/><TrialStartDate>2018-01-03 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Pediatric Open-Label, Extension Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="148804"/><TrialStartDate>2013-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym>PREVAIL 2</ProtocolAcronym><ProtocolTitle>Lurasidone - A 6-Week Study of Patients With Bipolar I Depression (Monotherapy)</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="49922"/><TrialStartDate>2009-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase III Study of SM-13496 in Patients With Bipolar I Depression</ProtocolTitle><Sponsor>Sumitomo Dainippon Pharma Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="161679"/><TrialStartDate>2014-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>MAM</ProtocolAcronym><ProtocolTitle>Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals</ProtocolTitle><Sponsor>Scott and White Hospital &amp; Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="20544"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9022">frovatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Patient Preference Study of Frovatriptan Versus Zolmitriptan for The Acute Treatment of Migraine</ProtocolTitle><Sponsor>Laboratorio Guidotti SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="116962"/><TrialStartDate>2007-06-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy Study of Vilazodone and Discovering Genetic Markers Associated With Response in Patients With Major Depressive Disorder</ProtocolTitle><Sponsor>Pharmacology Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="34551"/><TrialStartDate>2006-02-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Vilazodone in Major Depressive Disorder</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86328"/><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A study comparing vilazodone with escitalopram in terms of efficacy, safety and onset of action in patients with depression</ProtocolTitle><Sponsor>Government Medical College, Latur</Sponsor><StudyType>Interventional</StudyType><Trial id="369531"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, parallel-group, placebo-controlled, ascending-dose study to evaluate the tolerability, pharmacokinetics and pharmacodynamics of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19849"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A phase II study of tegaserod in constipation-predominant irritable bowel syndrome patients</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19715"/><TrialStartDate>1998-09-06 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A trial to evaluate the long-term safety and tolerability of tegaserod in patients with chronic constipation</ProtocolTitle><Sponsor>Novartis Pharmaceuticals Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="19636"/><TrialStartDate>2004-05-19 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, phase III trial of tegaserod in patients with constipation predominant irritable bowel syndrome (C-IBS)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19602"/><TrialStartDate>1999-10-22 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy, Safety and Tolerability of Tegaserod in Patients With Chronic Constipation</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18713"/><TrialStartDate>2004-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Assess the Efficacy, Safety and Tolerability of Tegaserod Alone and in Combination With Omeprazole Given Orally in Patients With Symptoms of Symptomatic Gastroesophageal Reflux Disease (sGERD)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="42634"/><TrialStartDate>2004-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, open-label, two-phase, five-period crossover study to evaluate the pharmacokinetics of tegaserod in healthy subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19860"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, randomized, parallel-group, placebo-controlled, ascending-dose study to evaluate the tolerability, pharmacokinetics and pharmacodynamics of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19849"/><TrialStartDate>1997-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>Assessment of the Effects of Tegaserod in the Management of Gastroesophageal Reflux Disease (GERD) in Patients With Incomplete Response to Proton Pump Inhibitors (PPIs)</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="18799"/><TrialStartDate>2003-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, placebo-controlled study to evaluate the efficacy and tolerability of almotriptan in migraine patients who respond poorly to sumatriptan</ProtocolTitle><Sponsor>Universitat Duisburg Essen</Sponsor><StudyType>Interventional</StudyType><Trial id="69797"/><TrialStartDate>2005-08-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A One-Year Study in Adolescents to Assess the Long-Term Safety of Almotriptan Malate When Treating Their Migraine Headaches</ProtocolTitle><Sponsor>Janssen-Ortho Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13996"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>AEGIS</ProtocolAcronym><ProtocolTitle>A Study of the Effectiveness and Safety of Almotriptan Versus Placebo in the Treatment of Migraine Headache</ProtocolTitle><Sponsor>Janssen-Ortho Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13952"/><TrialStartDate>2004-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Potential Impact (Benefit) of Preventative Treatment With Topamax on the Effectiveness of Axert in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>Janssen-Ortho Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13951"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label, Multicenter Study To Assess Safety And Efficacy Of Almotriptan In Migraine</ProtocolTitle><Sponsor>Universidad de Santander</Sponsor><StudyType>Interventional</StudyType><Trial id="110909"/><TrialStartDate>2001-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15265">OPC-14523</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, placebo-controlled, phase II study to assess the efficacy and safety of VPI-013 in patients with major depressive disorder</ProtocolTitle><Sponsor>Vela Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="55448"/><TrialStartDate>2006-04-05 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy Study of Prucalopride to Treat Chronic Intestinal Pseudo-Obstruction (CIP)</ProtocolTitle><Sponsor>Johnson &amp; Johnson, Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="36415"/><TrialStartDate>2008-11-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="395">Gastrointestinal function disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Prucalopride on Gastroesophageal Reflux, Esophageal Motility and Gastric Emptying in Healthy Volunteers</ProtocolTitle><Sponsor>Academic Medical Center, University of Amsterdam</Sponsor><StudyType>Interventional</StudyType><Trial id="122160"/><TrialStartDate>2011-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Single-Dose, Pharmacokinetics of Prucalopride in Pediatric Subjects, With Functional Fecal Retention</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="90498"/><TrialStartDate>1998-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>M-0001 Effects on Oral Contraceptive Plasma Levels</ProtocolTitle><Sponsor>Shire-Movetis NV</Sponsor><StudyType>Interventional</StudyType><Trial id="62869"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A head-to-head study to compare the safety, tolerability and efficacy of Movicol versus prucalopride in women with chronic constipation</ProtocolTitle><Sponsor>Norgine BV</Sponsor><StudyType>Interventional</StudyType><Trial id="135798"/><TrialStartDate>2013-05-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-blind, Placebo-controlled Study Of Prucalopride In Patients With Constipation Without A Rectal Evacuation Disorder</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="110443"/><TrialStartDate>2001-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Patient-Reported Outcomes in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Abbott Laboratories, Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="36286"/><TrialStartDate>2005-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Bifeprunox in Patients With Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="21266"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Placebo-Controlled, Quetiapine-Referenced, Multicenter Study of the Long-Term Bifeprunox Efficacy, Safety and Tolerability in Patiens With Stable Schizophrenia</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="132803"/><TrialStartDate>2007-03-13 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, pilot phase I study to evaluate dopamine D2 receptor occupancy after multiple oral administration of DU-127090 to healthy male volunteers, using 11C-raclopride by means of position emission tomography (PET)</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="41463"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="22806">piclozotan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease</ProtocolTitle><Sponsor>Daiichi Sankyo Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="8245"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>The Mondriaan study</ProtocolAcronym><ProtocolTitle>SLV-308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="6812"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Double-Blind Study To Evaluate The Effect of Pardoprunox, a New Partial Dopamine Agonist, in Early Parkinsons Disease</ProtocolTitle><Sponsor>Abbott Healthcare Products BV</Sponsor><StudyType>Interventional</StudyType><Trial id="146686"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="24202">pardoprunox</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An Extension of the Van Gogh Study</ProtocolTitle><Sponsor>AbbVie Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="143432"/><TrialStartDate>2008-03-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trail To Evaluate Pimavanserin, a Serotonin(2A) Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>Vanderbilt University</Sponsor><StudyType>Interventional</StudyType><Trial id="146074"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13960"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo-controlled, crossover study to assess the reduction of haloperidol-induced side effects by ACP-103</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7650"/><TrialStartDate>2005-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>Sub-Sero</ProtocolAcronym><ProtocolTitle>The Sub-Sero Study</ProtocolTitle><Sponsor>Koebenhavns Universitet</Sponsor><StudyType>Interventional</StudyType><Trial id="385459"/><TrialStartDate>2020-01-31 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ENHANCE-1</ProtocolAcronym><ProtocolTitle>Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="279886"/><TrialStartDate>2016-10-31 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="PNA">Phase Not Applicable</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A 52-week, open-label extension study to assess the long-term safety and tolerability of pimavanserin</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="378491"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="29493">adoprazine</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Multiple Ascending Dose in Schizophrenia Patients</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="36603"/><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>'Completeness of Response' Following Treatment With Treximet for Migraine</ProtocolTitle><Sponsor>Clinvest</Sponsor><StudyType>Interventional</StudyType><Trial id="54231"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-Month Period</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="36247"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Trexima and Relpax Gastric Scintigraphy Inside and Outside a Migraine</ProtocolTitle><Sponsor>POZEN Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14046"/><TrialStartDate>2006-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A drug-interaction study assessing the effects of CYP3A4 inhibition on the pharmacokinetics of Levadex (MAP-0004, orally inhaled DHE) in healthy subjects</ProtocolTitle><Sponsor>MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="78532"/><TrialStartDate>2011-06-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Tolerability Study of MAP-0004 in Smoking and Non-Smoking Adult Volunteers</ProtocolTitle><Sponsor>Allergan Inc, MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="70494"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="148">Headache</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure</ProtocolTitle><Sponsor>Allergan Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="64984"/><TrialStartDate>2010-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET</ProtocolTitle><Sponsor>Centre for Addiction and Mental Health</Sponsor><StudyType>Interventional</StudyType><Trial id="93597"/><TrialStartDate>2012-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, double-blind, balanced, cross-over study to evaluate the effect of lesopitron on pupil diameter and oral temperature compared to buspirone in healthy male subjects</ProtocolTitle><Sponsor>Laboratorios Dr Esteve SA</Sponsor><StudyType>Interventional</StudyType><Trial id="56274"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="34">Attention deficit hyperactivity disorder</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone in ADHD</ProtocolTitle><Sponsor>Kerman Neuroscience Research Center</Sponsor><StudyType>Interventional</StudyType><Trial id="122221"/><TrialStartDate>2010-09-10 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="46857">naluzotan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="119">Epilepsy</Indication><ProtocolAcronym/><ProtocolTitle>PRX-00023 Therapy in Localization-Related Epilepsy</ProtocolTitle><Sponsor>National Institute of Neurological Disorders and Stroke</Sponsor><StudyType>Interventional</StudyType><Trial id="74028"/><TrialStartDate>2011-01-07 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47202">zolmitriptan (intranasal), AstraZeneca</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Study of M-207 at Two App Sites With Intranasal Zolmitriptan 2.5 mg in Healthy Volunteers</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="357027"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym>TULIP</ProtocolAcronym><ProtocolTitle>To assess the effect of lorcaserin hydrochloride on energy metabolism and food intake</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="42245"/><TrialStartDate>2008-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients</ProtocolTitle><Sponsor>Kanion and Huawe Medicine Co, Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="357868"/><TrialStartDate>2018-12-06 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Addressing Post Cessation Weight Gain</ProtocolTitle><Sponsor>Mayo Clinic Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="226533"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine (Lu-AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction</ProtocolTitle><Sponsor>Takeda Development Center Americas, Inc, Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="77862"/><TrialStartDate>2011-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Randomized, Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu-AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="38975"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>VESPA</ProtocolAcronym><ProtocolTitle>Vortioxetine in the Elderly Versus Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment</ProtocolTitle><Sponsor>Azienda Ospedaliera Universitaria Integrata Di Verona</Sponsor><StudyType>Interventional</StudyType><Trial id="363997"/><TrialStartDate>2019-02-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="280161"/><TrialStartDate>2016-12-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Vortioxetine for Menopausal Depression</ProtocolTitle><Sponsor>Massachusetts General Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="210052"/><TrialStartDate>2015-06-12 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49840">naronapride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1243">Gastroesophageal reflux</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, multiple-ascending dose, randomized, double-blind, placebo-controlled trial to assess the safety, tolerability and pharmacokinetics of naronapride in healthy volunteers</ProtocolTitle><Sponsor>ARYx Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="77600"/><TrialStartDate>2011-05-08 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Formulation Study of Vabicaserin</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="58340"/><TrialStartDate>2009-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating SCA-136 Tolerability With Dose Titration and Food</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="37274"/><TrialStartDate>2006-12-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating the Safety and Tolerability of SCA-136 in Healthy Japanese and Non-Japanese Female Subjects</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34844"/><TrialStartDate>2007-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="49984">vabicaserin</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety, Pharmacokinetic and Pharmacodynamic Study in Healthy Male Japanese Subjects</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="34606"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia</ProtocolTitle><Sponsor>Mitsubishi Tanabe Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="88658"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65680"/><TrialStartDate>2010-04-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy,Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study of Cariprazine Capsules 6 mg in Schizophrenia or Bipolar Disorder I Patients</ProtocolTitle><Sponsor>AXIS Clinicals Limited, Aurobindo Pharma Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="354246"/><TrialStartDate>2018-09-21 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34895"/><TrialStartDate>2008-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="51405">cariprazine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine for Mania</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="63704"/><TrialStartDate>2010-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="750">Insomnia</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, placebo-controlled, double-blind study to evaluate the safety and pharmacokinetics of escalating daytime doses of APD-125, a potential treatment for insomnia</ProtocolTitle><Sponsor>Arena Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7336"/><TrialStartDate>2005-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="52239">nelotanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="1050">Hallucination</Indication><ProtocolAcronym/><ProtocolTitle>Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder</ProtocolTitle><Sponsor>Axovant Gene Therapies Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="268946"/><TrialStartDate>2016-10-20 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="53651">ATHX-105</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blinded, placebo-controlled trial to evaluate the safety, efficacy, tolerability and pharmacokinetics of ATHX-105 in healthy overweight subjects</ProtocolTitle><Sponsor>Athersys Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36235"/><TrialStartDate>2007-07-25 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="53651">ATHX-105</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>A Short-Term Study to Examine the Effects of ATHX-105 Phosphate on Weight Loss and Safety</ProtocolTitle><Sponsor>Athersys Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23328"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="54688">velusetrag</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym>DIGEST</ProtocolAcronym><ProtocolTitle>The Diabetic and Idiopathic Gastroparesis Efficacy, Safety and Tolerability study</ProtocolTitle><Sponsor>Theravance Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="213523"/><TrialStartDate>2014-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="PR">Pre-registration</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>CoLucid Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14056"/><TrialStartDate>2006-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="55455">zonisamide + bupropion (obesity), Orexigen</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="238">Obesity</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Different Combinations of Zonisamide CR Plus Bupropion SR to Treat Uncomplicated Obesity</ProtocolTitle><Sponsor>Orexigen Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="40174"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>NP101-009</ProtocolAcronym><ProtocolTitle>An Open-Label Study to Evaluate the Safety of NP-101 in the Treatment of Acute Migraine Over 12 Months</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="38408"/><TrialStartDate>2009-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>NP101-008</ProtocolAcronym><ProtocolTitle>An Open-Label Study to Evaluate the Safety of NP-101 in the Treatment of Acute Migraine Over 12 Months</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="36005"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym>PREDICT</ProtocolAcronym><ProtocolTitle>The Efficacy and Tolerability of NP-101 Patch in the Treatment of Acute Migraine</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="23207"/><TrialStartDate>2009-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Compare PK and Bioavailability of Two NP-101 Patches With Oral Imitrex in Healthy Adults</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="178045"/><TrialStartDate>2009-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="55707">sumatriptan (transdermal patch, SmartRelief), NuPathe</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="S">Suspended</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I, Open-label, Single-dose Study of Zecuity to Assess Safety, Pharmacokinetics and Tolerability in Adolescents with a History of Migraine Attacks</ProtocolTitle><Sponsor>NuPathe Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="160983"/><TrialStartDate>2013-09-23 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="56729">PF-217830</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Dose-Response Study to Evaluate Safety, Efficacy, and Pharmacokinetics of PF-00217830 Compared With Placebo in Acute Exacerbation of Schizophrenia</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21173"/><TrialStartDate>2007-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="58635">piromelatine</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3147">Open angle glaucoma</Indication><ProtocolAcronym/><ProtocolTitle>Treatment of piromelatine in patients with ocular hypertension or primary open angle glaucoma</ProtocolTitle><Sponsor>Neurim Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="327251"/><TrialStartDate>2016-09-19 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Bicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of DA-9701 in Patients with Minimal Change Esophagitis</ProtocolTitle><Sponsor>Severance Hospital, Yonsei University College of Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="209078"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, single-blind, 2-week proof of concept study to compare the quality of life in subjects receiving DA-9701 and mosapride</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="17642"/><TrialStartDate>2008-03-20 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="3797">Gastrointestinal motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Phase I, Multiple Intravenous Dose Study to Examine Safety, Tolerability and PK of Intravenous TD-8954, a 5-HT4 Receptor Agonist, in Healthy Subjects</ProtocolTitle><Sponsor>Theravance Biopharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="89317"/><TrialStartDate>2012-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Bioavailability Study to Compare OptiNose Sumatriptan With Imitrex in Healthy Subjects</ProtocolTitle><Sponsor>OptiNose AS</Sponsor><StudyType>Interventional</StudyType><Trial id="83918"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60691">sumatriptan (low-dose intranasal, migraine), OptiNose/AVANIR</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A phase I, pharmacokinetic and efficacy study of intranasal sumatriptan, administered using an OptiNose device, in migraine sufferers</ProtocolTitle><Sponsor>OptiNose AS</Sponsor><StudyType>Interventional</StudyType><Trial id="64435"/><TrialStartDate>2008-04-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Dose-finding Trial of OPC-34712 in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="81526"/><TrialStartDate>2011-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="80360"/><TrialStartDate>2011-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A Study Evaluating the OPC-34712 in Subjects With Normal Hepatic Function and Hepatically Impaired Subjects</ProtocolTitle><Sponsor>Otsuka Holdings Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="74887"/><TrialStartDate>2010-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>STEP 203</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 and Aripiprazole for Treatment of Acute Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="55677"/><TrialStartDate>2009-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Brexpiprazole in the Treatment of Schizophrenia</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="373398"/><TrialStartDate>2019-05-05 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Subjective assessment of brexpiprazole with acute schizophrenia</ProtocolTitle><Sponsor>Fujita Health University</Sponsor><StudyType>Interventional</StudyType><Trial id="348831"/><TrialStartDate>2018-06-15 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Trial to Evaluate the Short-term Safety and Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="303053"/><TrialStartDate>2017-06-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Assess Brexpiprazole Versus Placebo for the Treatment of Acute Manic Episodes Associated With Bipolar I Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="310103"/><TrialStartDate>2017-10-04 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Anti-depressant Discontinuation in Treatment Resistant Depression</ProtocolTitle><Sponsor>University of Louisville</Sponsor><StudyType>Interventional</StudyType><Trial id="365306"/><TrialStartDate>2019-02-28 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Brexpiprazole (OPC-34712) trial in the treatment of adults with major depressive disorder and irritability</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="207968"/><TrialStartDate>2014-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>Sirius</ProtocolAcronym><ProtocolTitle>Study of the Safety and Efficacy of Fixed-dose Brexpiprazole (OPC-34712) as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder With and Without Anxious Distress</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="206263"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="63557">relenopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of YKP-10811 in Subjects With Irritable Bowel Syndrome With Constipation</ProtocolTitle><Sponsor>SK Chemicals Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="177029"/><TrialStartDate>2013-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="63557">relenopride</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II Study to Evaluate Pharmacodynamics of YKP-10811 in Patients With Chronic or Functional Constipation</ProtocolTitle><Sponsor>SK Biopharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="84504"/><TrialStartDate>2012-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ARRIVE- EU</ProtocolAcronym><ProtocolTitle>Open-label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole</ProtocolTitle><Sponsor>Otsuka America Pharmaceutical Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="83955"/><TrialStartDate>2012-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ARRIVE US</ProtocolAcronym><ProtocolTitle>Open-Label Study to Compare Hospitalization Rates of Schizophrenic Patients Treated With Oral Antipsychotics Versus IM Depot Aripiprazole</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="80768"/><TrialStartDate>2011-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="64328">aripiprazole (intramuscular depot, schizophrenia), Otsuka/H Lundbeck</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym>ASPIRE</ProtocolAcronym><ProtocolTitle>Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd, Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="21269"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="65523">aripiprazole (extended-release intramuscular, LinkeRx, schizophrenia), Alkermes</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>An Extension of a Long-term Safety Study of ALKS-9072 (Also Known as ALKS-9070)</ProtocolTitle><Sponsor>Alkermes plc</Sponsor><StudyType>Interventional</StudyType><Trial id="145351"/><TrialStartDate>2013-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="66046">PF-04995274</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="DX">Discontinued</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="68565"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="74357">cinitapride tartrate</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy and Safety of Cinitapride in Functional Dyspepsia</ProtocolTitle><Sponsor>Highnoon Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="151817"/><TrialStartDate>2009-07-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="77208">Zolmitriptan (transdermal patch, ZP Patch technology, migraine/cluster headache), Zosano Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="DR">Discovery</HighestDevStatusForInd><Indication id="73">Cluster headache</Indication><ProtocolAcronym/><ProtocolTitle>A Phase II clinical study of Qtrypta in patients with cluster headaches</ProtocolTitle><Sponsor>Zosano Pharma Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="373744"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81696">SEP-363856</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="C2">Phase 2 Clinical</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="159401"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="89741">cinitapride + omeprazole (extended release, capsule, dyspepsia/GERD), Cadila Healthcare</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NDR">No Development Reported</HighestDevStatusForInd><Indication id="432">Dyspepsia</Indication><ProtocolAcronym/><ProtocolTitle>A Clinical Trial To Study The Effects Of Two Drugs, Fixed Dose Combination Capsules Of Omeprazole and Cinitapride ER And Omeprazole Capsules In Patients With Non-Ulcer Dyspepsia (NUD) Or Gastroesophageal Reflux Disease (GERD)</ProtocolTitle><Sponsor>Cadila Pharmaceuticals (EA) Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="160046"/><TrialStartDate>2009-04-18 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="96279">sumatriptan (autoinjector, migraine), Promius Pharma</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="L">Launched</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>Pilot Study of DFN-11 Injection in Medication Overuse Headache</ProtocolTitle><Sponsor>Dr Reddy's Laboratories Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="243746"/><TrialStartDate>2015-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Drug id="108460">meloxicam + rizatriptan (fixed-dose combination/oral, migraine), Axsome</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="C3">Phase 3 Clinical</HighestDevStatusForInd><Indication id="210">Migraine</Indication><ProtocolAcronym/><ProtocolTitle>A pharmacokinetic, randomized and parallel-group study to evaluate AXS-07 (MoSEIC meloxicam and rizatriptan) for the acute treatment of migraine</ProtocolTitle><Sponsor>Axsome Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="362250"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Combination of Mosapride and DPP-4 Inhibitor on Plasma Concentration of Incretin Hormones</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="201872"/><TrialStartDate>2014-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety of SPD-417 Combined With Other Psychotropic Medications in the Treatment of Bipolar I Disorder</ProtocolTitle><Sponsor>Validus Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="35044"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Aripiprazole in Patients With a History of Bipolar Disorder</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="34510"/><TrialStartDate>2000-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Comparison Trial of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="31462"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84108">NLX-112</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3923">Diabetic peripheral neuropathy</Indication><ProtocolAcronym>BEST</ProtocolAcronym><ProtocolTitle>A Dose-Finding Study of Efficacy and Safety of F-13640 in Patients With Moderate to Severe Painful Peripheral Diabetic Polyneuropathy</ProtocolTitle><Sponsor>Pierre-Fabre Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="188408"/><TrialStartDate>2009-07-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open study on the safety and efficacy of eletriptan in healthy volunteers</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110907"/><TrialStartDate>2001-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole Augmentation of Antidepressants in PTSD</ProtocolTitle><Sponsor>Durham VA Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="45468"/><TrialStartDate>2007-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1935">Post traumatic stress disorder</Indication><ProtocolAcronym/><ProtocolTitle>An Open-Label Study of the use of Aripiprazole in the Treatment of Chronic Post Traumatic Stress Disorder</ProtocolTitle><Sponsor>Austin Health</Sponsor><StudyType>Interventional</StudyType><Trial id="137096"/><TrialStartDate>2006-03-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3010">Colonoscopy</Indication><ProtocolAcronym/><ProtocolTitle>Efficacy of Prucalopride Plus Polyethylene Glycol in Bowel Preparation for Colonoscopy</ProtocolTitle><Sponsor>Shandong University</Sponsor><StudyType>Interventional</StudyType><Trial id="261728"/><TrialStartDate>2016-06-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="735">Toxicity</Indication><ProtocolAcronym>PREPARE</ProtocolAcronym><ProtocolTitle>Preemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions</ProtocolTitle><Sponsor>Leiden University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="292330"/><TrialStartDate>2017-03-20 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="243">Opiate dependence</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone for Opioid Tapering</ProtocolTitle><Sponsor>Johns Hopkins University</Sponsor><StudyType>Interventional</StudyType><Trial id="339117"/><TrialStartDate>2018-05-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>A Trial to Study of the Effects of Eletriptan 40 mg on Mild vs Moderate to Severe Pain Intensity of Migraine</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="13793"/><TrialStartDate>2005-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Clinical study to determine bioequivalence between two medicinal products for oral administration of Zolmitriptan in 2.5 mg dispersible tablets in healthy female volunteers under fasting conditions</ProtocolTitle><Sponsor>Productos Científicos, S.A. de C.V.</Sponsor><StudyType>Interventional</StudyType><Trial id="302807"/><TrialStartDate>2016-08-08 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Bioequivalence,Bioavailability</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Prospective, randomized, open-label, cross-over, comparative study to establish the bioequivalence of Zolmitriptan 2.5 mg dispersible tablets (Laboratorios PISA, SA de CV) versus Zomig Rapimelt (Astrazeneca, SA de CV)</ProtocolTitle><Sponsor>Pisa Laboratorios, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="302222"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A study to evaluate the effects of zolmitriptan (Zomig) on psychomotor performance alone and in combination with diazepam in healthy volunteers</ProtocolTitle><Sponsor>Zeneca Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="105861"/><TrialStartDate>1998-09-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8549">flibanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, placebo and positive-controlled (zopiclone), four-way crossover study to evaluate the safety and efficacy of flibanserin in healthy premenopausal women</ProtocolTitle><Sponsor>Sprout Pharmaceuticals</Sponsor><StudyType>Interventional</StudyType><Trial id="216551"/><TrialStartDate/><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3194">Delusion</Indication><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>A phase III, pivotal, randomized, double-blind, placebo-controlled study, evaluating the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="314710"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Remifentanil analgesia during labor and decreasing maternal respiratory depression with mosapride</ProtocolTitle><Sponsor>Kurashiki Central Hospital, Kyoto University, Mitsubishi Kyoto Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="276950"/><TrialStartDate>2016-06-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2400">Dyspnea</Indication><ProtocolAcronym/><ProtocolTitle>Buspirone in Reducing Shortness of Breath in Patients With Cancer</ProtocolTitle><Sponsor>University of Rochester</Sponsor><StudyType>Interventional</StudyType><Trial id="38423"/><TrialStartDate>2002-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1050">Hallucination</Indication><ProtocolAcronym>HARMONY</ProtocolAcronym><ProtocolTitle>A phase III, pivotal, randomized, double-blind, placebo-controlled study, evaluating the efficacy and safety of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="314710"/><TrialStartDate>2017-10-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="90">Dementia</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="198402"/><TrialStartDate>2014-06-11 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14253"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>An open-label, extension study of ACP-103 in patients with Parkinson's disease and treatment-induced psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="7645"/><TrialStartDate>2006-03-23 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="25148">pimavanserin</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym/><ProtocolTitle>A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis</ProtocolTitle><Sponsor>ACADIA Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="6117"/><TrialStartDate>2007-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Randomized, double-blind, placebo-controlled study of vilazodone's efficacy, safety, and biomarkers of response in major depressive disorder (MDD)</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="15425"/><TrialStartDate>2008-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, open-label, randomized, two-period, crossover study to evaluate the safety, tolerability and pharmacokinetics of the 3 mg STATdose administered 2 h after a single Imitrex 100 mg tablet relative to two 6 mg STATdose injections administered 1 h apart in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87721"/><TrialStartDate>2003-07-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, single-dose, open-label, randomized, three-way crossover, pilot study to evaluate the relative bioavailability of two newly formulated fast disintegrating sumatriptan 50 mg tablets versus the currently marketed sumatriptan 50 mg tablets in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87622"/><TrialStartDate>2001-10-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioequivalence,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, single-center, single-dose, open-label, randomized, two-period, crossover study to evaluate the safety, pharmacokinetics and bioequivalence of fast disintegrating sumatriptan 100 mg tablet dissolved in water compared to the currently marketed sumatriptan 100 mg tablet administered in the fasted state to healthy male and female subjects</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="87603"/><TrialStartDate>2002-09-26 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan When Given With Sumatriptan in Healthy Participants</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="316099"/><TrialStartDate>2017-10-17 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, placebo-controlled, pharmacokinetics and safety study of ascending doses of GR-43175C administered subcutaneously to healthy male volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="156978"/><TrialStartDate>1988-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Randomized, Open-label, Cross-over Trial To Determine the Effect of Food on the Pharmacokinetics of Oral GR-43175C</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153597"/><TrialStartDate>1988-10-05 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetics and Tolerability of Lu-AA21004 in Child and Adolescent Patients With Depressive or Anxiety Disorder</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="83220"/><TrialStartDate>2012-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="65">Stroke</Indication><ProtocolAcronym/><ProtocolTitle>Dopamine Agonist for Hemispatial Neglect and Motor Deficit Post Stroke</ProtocolTitle><Sponsor>University College London</Sponsor><StudyType>Interventional</StudyType><Trial id="11086"/><TrialStartDate>2010-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>A 12-week, Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="347113"/><TrialStartDate>2018-10-12 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="802">Stomach disease</Indication><ProtocolAcronym/><ProtocolTitle>Early effects of oral administrations of omeprazole with mosapride on intragastric pH</ProtocolTitle><Sponsor>Yokohama City University</Sponsor><StudyType>Interventional</StudyType><Trial id="302287"/><TrialStartDate>2009-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>European Ancestry</Ancestry><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1930">Paranoid schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacogenetic study to assess safety and the associations between polymorphisms of dopaminergic, serotonergic, and glutamatergic system-related genes with adverse events in schizophrenia treatment: comparison study of ziprasidone, olanzapine and perazine</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="221363"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="5024">eltoprazine</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3483">Parkinsons disease dementia</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Study of Oral Eltoprazine for Treatment of Levodopa-Induced Dyskinesias (LID) in a Levodopa Challenge-Dose Setting in Parkinsons Disease</ProtocolTitle><Sponsor>PsychoGenics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="142028"/><TrialStartDate>2010-10-06 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10091">tegaserod</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A randomized, open-label, cross-over study to evaluate the pharmacokinetics of tegaserod in healthy male subjects</ProtocolTitle><Sponsor>Novartis AG</Sponsor><StudyType>Interventional</StudyType><Trial id="19854"/><TrialStartDate>1999-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="255">Parkinsons disease</Indication><ProtocolAcronym>PASS-GI</ProtocolAcronym><ProtocolTitle>Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms</ProtocolTitle><Sponsor>Seoul National University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="261289"/><TrialStartDate>2016-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym>CAMELLIA-TIMI</ProtocolAcronym><ProtocolTitle>A Study to Evaluate the Effect of Long-term Treatment With Belviq (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors</ProtocolTitle><Sponsor>Eisai Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="165000"/><TrialStartDate>2014-01-24 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="84108">NLX-112</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3211">Cancer pain</Indication><ProtocolAcronym/><ProtocolTitle>Proof of Concept Study of the Efficacy and Tolerability of a 4-Week Treatment With F-13640 in Patients in Whom the Adaptation of Opioid Therapy of Cancer Pain Has Failed. A Prospective, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study</ProtocolTitle><Sponsor>Pierre Fabre SA</Sponsor><StudyType>Interventional</StudyType><Trial id="118414"/><TrialStartDate>2007-09-24 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1585">Syndrome X</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes</ProtocolTitle><Sponsor>Veterans Medical Research Foundation</Sponsor><StudyType>Interventional</StudyType><Trial id="18217"/><TrialStartDate>2006-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>MBRP + Vortioxetine versus MBRP on Preventing Relapse in Chronic MA Users</ProtocolTitle><Sponsor>Central South University</Sponsor><StudyType>Interventional</StudyType><Trial id="369154"/><TrialStartDate>2019-04-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle</ProtocolTitle><Sponsor>Medical University of Vienna</Sponsor><StudyType>Interventional</StudyType><Trial id="44319"/><TrialStartDate>2005-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Bioequivalence</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Bioequivalence study of ziprasidone 40 mg capsule from Laboratory Raam de Sahuayo, SA de CV versus Geodon 40 mg capsule from Pfizer, SA de CV, in healthy research subjects of both genders</ProtocolTitle><Sponsor>RAAM Sahuayo Laboratory, SA de CV</Sponsor><StudyType>Interventional</StudyType><Trial id="219981"/><TrialStartDate/><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="25">Anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>Clinical Trial With Ziprasidone for the Treatment of Psychiatric Pathology Associated to Alcoholism</ProtocolTitle><Sponsor>Fundacio Privada I Institut De Recerca De L'Hospital De La Santa Creu I Sant Pau</Sponsor><StudyType>Interventional</StudyType><Trial id="33118"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="11">Alcoholism</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole for Bipolar Disorder and Alcohol Use Disorder</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="273220"/><TrialStartDate>2016-11-30 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2B">Phase 2b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>ANODYNE-2</ProtocolAcronym><ProtocolTitle>Oral ALLOD-2 versus Oral Sumatriptan and versus Placebo in the Acute Treatment of Migraine With Associated Nausea</ProtocolTitle><Sponsor>Allodynic Therapeutics LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="301738"/><TrialStartDate>2017-06-27 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, General Practice Study to Compare GR-43175 With Paracetamol and Metoclopramide in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="153845"/><TrialStartDate>1991-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Comparison of pharmacokinetics between immediate-release tablets and controlled-release tablets of mosapride citrate</ProtocolTitle><Sponsor>Korea United Pharm Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="360954"/><TrialStartDate>2012-02-06 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>6</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="65">Stroke</Indication><ProtocolAcronym>IF-STROKE</ProtocolAcronym><ProtocolTitle>Optimizing Early Enteral Nutrition in Severe Stroke</ProtocolTitle><Sponsor>Xijing Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="281247"/><TrialStartDate>2017-01-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Pilot study of comparative bioavailability between two drugs for oral administration of Lorcaserin Hydrochloride in prolonged-release tablets with 20 mg in healthy subjects under feeding conditions</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="336722"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym>Belviq PK</ProtocolAcronym><ProtocolTitle>Pharmacokinetic Study of Belviq in Adult Korean Volunteers</ProtocolTitle><Sponsor>Il Dong Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="141559"/><TrialStartDate>2013-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="57">Cardiovascular disease</Indication><ProtocolAcronym/><ProtocolTitle>The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia</ProtocolTitle><Sponsor>University of Pittsburgh</Sponsor><StudyType>Interventional</StudyType><Trial id="8781"/><TrialStartDate>2004-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents</ProtocolTitle><Sponsor>National Taiwan University Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="36310"/><TrialStartDate>2007-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>7</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PROACTIVE</ProtocolAcronym><ProtocolTitle>Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy</ProtocolTitle><Sponsor>North Shore Long Island Jewish Health System</Sponsor><StudyType>Interventional</StudyType><Trial id="36294"/><TrialStartDate>2006-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="179">Hyperthyroidism</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, single-blinded, placebo-controlled study to evaluate the effect of antidopaminergic treatment with aripiprazole, haloperidol, and reserpine on psychopathology and motor symptoms in healthy volunteers</ProtocolTitle><Sponsor>Deutsche Forschungsgemeinschaft (DFG), Rheinisch-Westfaelische Technische Hochschule Aachen</Sponsor><StudyType>Interventional</StudyType><Trial id="83817"/><TrialStartDate>2011-03-11 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>MONONOFU</ProtocolAcronym><ProtocolTitle>A Study Lasmiditan (LY-573144) in a Single Migraine Attack in Japanese Participants With Migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="382167"/><TrialStartDate>2019-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="29493">adoprazine</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Safety and Tolerability of Ascending Multiple Dose of SLV-313 in Schizophrenia Patients</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="36604"/><TrialStartDate>2008-01-31 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="29493">adoprazine</Drug><Endpoint>Safety</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study Evaluating Multiple Ascending Dose in Schizophrenia Patients</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="36603"/><TrialStartDate>2008-02-29 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>HAMLETT</ProtocolAcronym><ProtocolTitle>Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuation/dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="376186"/><TrialStartDate>2019-04-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym>BESST</ProtocolAcronym><ProtocolTitle>Buspirone for Early Satiety and Symptoms of Gastroparesis</ProtocolTitle><Sponsor>National Institute of Diabetes, Digestive and Kidney Diseases</Sponsor><StudyType>Interventional</StudyType><Trial id="346475"/><TrialStartDate>2019-06-15 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="320">Tardive dyskinesia</Indication><ProtocolAcronym/><ProtocolTitle>An open-label study of buspirone in the treatment of tardive dyskinesia</ProtocolTitle><Sponsor>University of Washington</Sponsor><StudyType>Interventional</StudyType><Trial id="108354"/><TrialStartDate>1993-06-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="93">Depression</Indication><ProtocolAcronym/><ProtocolTitle>Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism</ProtocolTitle><Sponsor>University of Ottawa</Sponsor><StudyType>Interventional</StudyType><Trial id="205695"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Telcagepant (MK-0974) Long-term, Safety Study in Adult Participants With Acute Migraine</ProtocolTitle><Sponsor>Laboratoires Merck Sharp &amp; Dohme Chibret SA, Merck &amp; Co Inc, Merck Sharp &amp; Dohme Corp, Merck Sharp &amp; Dohme SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="13922"/><TrialStartDate>2007-02-21 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Open-Label, Placebo-Controlled, Parallel-Group Study in Healthy Volunteers to Evaluate the Effects of Two Single MT-400 or Naproxen Sodium Tablets</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="46328"/><TrialStartDate>2007-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="299">Schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>A phase II/III, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of buspirone added to risperidone as augmentation therapy in patients with chronic schizophrenia</ProtocolTitle><Sponsor>Tehran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="72646"/><TrialStartDate>2006-04-20 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="59050">DA-9701</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Therapeutic effects of Motilitone in patient with constiptation</ProtocolTitle><Sponsor>Dong-A ST Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="245914"/><TrialStartDate>2015-11-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym>MBD</ProtocolAcronym><ProtocolTitle>NRX-101 for Moderate Bipolar Depression and Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325291"/><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3117">Suicidal ideation</Indication><ProtocolAcronym/><ProtocolTitle>NMDA Antagonists in Bipolar Depression</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="121831"/><TrialStartDate>2013-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Safety and Potential Pharmacokinetic Drug-Drug Interaction Between Armodafinil and Aripiprazole in Healthy Adult Subjects</ProtocolTitle><Sponsor>Teva Pharmaceutical Industries Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="238257"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym/><ProtocolTitle>Treating Caregiver Depression to Improve Childhood Asthma: Impact and Mediators</ProtocolTitle><Sponsor>University of Texas Southwestern Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="263970"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4736">zolmitriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A double-blind, randomized, multicenter, cross-over, comparative, Italian study to compare the efficacy of frovatriptan and zolmitriptan in the treatment of patients with migraine with aura</ProtocolTitle><Sponsor>Istituto Lusofarmaco D`Italia SpA</Sponsor><StudyType>Interventional</StudyType><Trial id="118990"/><TrialStartDate>2012-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="47504">lorcaserin</Drug><Endpoint>Bioequivalence,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="655">Metabolic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Study of Bioequivalence for Costa Rica Between the Lorcaserine Protein Chlorhydrate of Gutis Limited and Belviq of Arena Pharmaceuticals, As a Reference Medicine</ProtocolTitle><Sponsor>Gutis Farmacéutica</Sponsor><StudyType>Interventional</StudyType><Trial id="382476"/><TrialStartDate>2018-09-22 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects</ProtocolTitle><Sponsor>H Lundbeck A/S</Sponsor><StudyType>Interventional</StudyType><Trial id="175282"/><TrialStartDate>2014-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>MONONOFU</ProtocolAcronym><ProtocolTitle>A Study Lasmiditan (LY-573144) in a Single Migraine Attack in Japanese Participants With Migraine</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="382167"/><TrialStartDate>2019-05-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym>SPARTAN</ProtocolAcronym><ProtocolTitle>Three Doses of Lasmiditan (50, 100 and 200 mg) Compared to Placebo in the Acute Treatment of Migraine</ProtocolTitle><Sponsor>CoLucid Pharmaceuticals Inc, Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="246340"/><TrialStartDate>2016-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A single-blind, randomized, exploratory pharmacological neuroimaging study on effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia</ProtocolTitle><Sponsor>University Medical Center Groningen</Sponsor><StudyType>Interventional</StudyType><Trial id="384676"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>5</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Chinese First Episode Schizophrenia's Optimal Dynamic Antipsychotic Treatment Regimen</ProtocolTitle><Sponsor>Shanghai Mental Health Center</Sponsor><StudyType>Interventional</StudyType><Trial id="337764"/><TrialStartDate>2018-10-01 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>5</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>SToP-S</ProtocolAcronym><ProtocolTitle>Substance Misuse To Psychosis for Stimulants</ProtocolTitle><Sponsor>Li Ka Shing Faculty of Medicine, The University of Hong Kong</Sponsor><StudyType>Interventional</StudyType><Trial id="335058"/><TrialStartDate>2019-06-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, placebo-controlled, double-blind trial to study the safety and efficacy of aripiprazole in the treatment of methamphetamine dependence and associated psychosis</ProtocolTitle><Sponsor>University of Malaya</Sponsor><StudyType>Interventional</StudyType><Trial id="149516"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>Aripiprazole in Patients With Psychosis Associated With Parkinson's Disease</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Development and Commercialization Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="14253"/><TrialStartDate>2003-07-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="472">Hypothermia</Indication><ProtocolAcronym>HICHV</ProtocolAcronym><ProtocolTitle>Hypothermia In Conscious Healthy Volunteers: a feasibility trial</ProtocolTitle><Sponsor>Emcools-Emergency Medical Cooling Systems AG</Sponsor><StudyType>Interventional</StudyType><Trial id="151201"/><TrialStartDate>2011-03-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="17515">bifeprunox</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3114">Bipolar I disorder</Indication><ProtocolAcronym/><ProtocolTitle>Pharmacokinetic Effects of Bifeprunox and Valproate in Bipolar I</ProtocolTitle><Sponsor>Solvay SA</Sponsor><StudyType>Interventional</StudyType><Trial id="34111"/><TrialStartDate>2005-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3774">Sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Effect of aripiprazole in treatment of sexual dysfunction due to antidepressants</ProtocolTitle><Sponsor>Mazandaran University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="292780"/><TrialStartDate>2015-11-22 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Trial to Explore Symptomatic Therapy for Application Site Reaction to SPM-962 in Healthy Subject</ProtocolTitle><Sponsor>Otsuka Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="100156"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Bioavailability,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open, randomized, crossover, single-dose study to evaluate the safety, tolerability and effect of food intake on the bioavailability of almotriptan in healthy volunteers</ProtocolTitle><Sponsor>Almirall Prodesfarma SA</Sponsor><StudyType>Interventional</StudyType><Trial id="68933"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A crossover, open, randomized study on the safety and efficacy of moclobemide and almotriptan in healthy volunteers</ProtocolTitle><Sponsor>Pharmacia &amp; Upjohn Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110766"/><TrialStartDate>2001-05-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>An open-label study of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers</ProtocolTitle><Sponsor>Pharmacia &amp; Upjohn Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="110327"/><TrialStartDate>2001-02-28 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="59234">RQ-00000010</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of RQ-00000010, and the compound's effects on gastric emptying in healthy subjects</ProtocolTitle><Sponsor>RaQualia Pharma Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="97239"/><TrialStartDate>2012-06-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Mass Balance, Pharmacokinetics (PK), Metabolism and Excretion of TAK-954 Containing Microtracer ([14C]-TAK-954) in Healthy Male Participants</ProtocolTitle><Sponsor>Takeda Oncology</Sponsor><StudyType>Interventional</StudyType><Trial id="336739"/><TrialStartDate>2018-04-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="60292">TAK-954</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study to Evaluate the Effect of Hepatic Impairment on the Single-Dose Pharmacokinetics (PK) of Intravenous (IV) TAK-954</ProtocolTitle><Sponsor>Takeda Pharmaceutical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="312197"/><TrialStartDate>2017-11-09 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym>PAFIP2_nc1Y</ProtocolAcronym><ProtocolTitle>Neurocognitive Effectiveness in Treatment of First-episode Non-affective Psychosis: One-year Follow-up</ProtocolTitle><Sponsor>Fundacion Marques de Valdecilla</Sponsor><StudyType>Interventional</StudyType><Trial id="238915"/><TrialStartDate>2005-10-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="282">Psychotic disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Comparative, Multicenter, Open-labeled, Randomized Study to Evaluate the Safety and Efficacy of Intramuscular Ziprasidone Compared with Intramuscular Haloperidol in the Treatment of Acute Psychosis</ProtocolTitle><Sponsor>Sterkfontein Hospital</Sponsor><StudyType>Interventional</StudyType><Trial id="109571"/><TrialStartDate>2000-12-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym>MOMENTUM</ProtocolAcronym><ProtocolTitle>Maximizing Outcomes in Treating Acute Migraine</ProtocolTitle><Sponsor>Axsome Therapeutics Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="320888"/><TrialStartDate>2019-03-04 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1933">Undifferentiated schizophrenia</Indication><ProtocolAcronym/><ProtocolTitle>Safety and Efficacy of Cariprazine in Patients With Schizophrenia</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="65682"/><TrialStartDate>2010-04-23 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="48119">vortioxetine hydrobromide</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="14">Alzheimers disease</Indication><ProtocolAcronym/><ProtocolTitle>The effect of Brintellix as antidepressant for Alzheimer's disease</ProtocolTitle><Sponsor>Hallym University Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="385315"/><TrialStartDate>2017-03-09 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="76">Cocaine addiction</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence</ProtocolTitle><Sponsor>Denver Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="23479"/><TrialStartDate>2008-08-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="423">Autism</Indication><ProtocolAcronym/><ProtocolTitle>Ziprasidone in Children With Autism: A Pilot Study</ProtocolTitle><Sponsor>Drexel University</Sponsor><StudyType>Interventional</StudyType><Trial id="43596"/><TrialStartDate>2002-02-28 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>4</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym/><ProtocolTitle>18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder</ProtocolTitle><Sponsor>New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="375923"/><TrialStartDate>2019-02-07 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>A Double-blind, Placebo-controlled, Parallel Study To Evaluate the Safety and Efficacy of 25, 50 and 100 mg Sumatriptan and Placebo in Subjects with Acute Migraine Attacks</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="202177"/><TrialStartDate>1989-09-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="4491">sumatriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3680">Migraine without aura</Indication><ProtocolAcronym/><ProtocolTitle>An Open-label Study Of Sumatriptan In Treating Migraine With Unilateral Cranial Autonomic Symptoms</ProtocolTitle><Sponsor>Universita degli Studi di Roma La Sapienza</Sponsor><StudyType>Interventional</StudyType><Trial id="113929"/><TrialStartDate>2003-04-30 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="39491">dihydroergotamine (migraine, Tempo-inhaled/oral), Allergan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo</ProtocolTitle><Sponsor>Allergan Inc, MAP Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="69963"/><TrialStartDate>2010-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1+</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3235">naratriptan</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A phase I, randomized, double-blind, four-way crossover, inpatient study to evaluate the safety, pharmacodynamics and pharmacokinetics of naratriptan and dihydroergotamine in healthy volunteers</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="77132"/><TrialStartDate>1995-09-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry>Japanese Ancestry</Ancestry><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>A randomized, pharmacokinetic study to evaluate the effect of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese psychiatric patients</ProtocolTitle><Sponsor>University of the Ryukyus</Sponsor><StudyType>Interventional</StudyType><Trial id="238524"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="207">Psychiatric disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Research of Aripiprazole Treatment for the Behavioral Symptoms in Subjects With Pervasive Developmental Disorders</ProtocolTitle><Sponsor>Faculty of Medical Sciences, University of Fukui</Sponsor><StudyType>Interventional</StudyType><Trial id="119058"/><TrialStartDate>2011-10-01 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1937">Generalized anxiety disorder</Indication><ProtocolAcronym/><ProtocolTitle>A placebo-controlled, efficacy study of venlafaxine XR, compared to buspirone in patients with generalized anxiety disorder</ProtocolTitle><Sponsor>Wyeth</Sponsor><StudyType>Interventional</StudyType><Trial id="50670"/><TrialStartDate>1998-07-15 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2039">Hypoactive sexual desire disorder</Indication><ProtocolAcronym/><ProtocolTitle>A Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study to Investigate the Differences Between the Combined Administration of 0.5 mg Sublingual Testosterone and 10 mg Buspirone and 10 mg Buspirone Administration Alone in Women With Hypoactive Sexual Desire Disorder</ProtocolTitle><Sponsor>Emotional Brain BV</Sponsor><StudyType>Interventional</StudyType><Trial id="118001"/><TrialStartDate>2012-08-24 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="8715">eletriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Comparative Study of Oral Eletriptan (40 and 80 mg), Oral Sumatriptan (25 and 50 mg) and Placebo</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="161722"/><TrialStartDate>1996-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="837">Non-insulin dependent diabetes</Indication><ProtocolAcronym/><ProtocolTitle>Pfizer/IVGTT/Ziprasidone/Olanzapine</ProtocolTitle><Sponsor>Washington University in St Louis</Sponsor><StudyType>Interventional</StudyType><Trial id="3580"/><TrialStartDate>2000-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>An open extension study to assess the safety and tolerability of oral ziprasidone in patients who have successfully completed a previous ziprasidone study</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88878"/><TrialStartDate>2002-05-12 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="2860">ziprasidone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>A phase IV, open-label, multicenter, non-comparative study to determine the tolerability, safety, and efficacy of ziprasidone (Geodon) in treatment of subjects with schizophrenia or schizoaffective disorder who were ineffectively treated with antipsychotic agents</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="86686"/><TrialStartDate>2002-11-15 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="5328">rizatriptan</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Double-blind; Placebo-controlled; Randomized study to assess the safety and efficacy of Rizatriptan in healthy subjects</ProtocolTitle><Sponsor>Merck Research Laboratories</Sponsor><StudyType>Interventional</StudyType><Trial id="108707"/><TrialStartDate>2000-02-29 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry>Asian Ancestry</Ancestry><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="62001">brexpiprazole</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>The Pharmacokinetics, Tolerability and Safety of Brexpiprazole in Healthy Chinese Subjects</ProtocolTitle><Sponsor>Otsuka Beijing Research Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="359297"/><TrialStartDate>2019-04-07 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="54812">lasmiditan</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate</ProtocolTitle><Sponsor>Eli Lilly &amp; Co</Sponsor><StudyType>Interventional</StudyType><Trial id="315841"/><TrialStartDate>2017-10-16 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Randomized Trial of Mosapride versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome</ProtocolTitle><Sponsor>American University of Beirut Medical Center</Sponsor><StudyType>Interventional</StudyType><Trial id="25323"/><TrialStartDate>2008-09-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Electroacupuncture for the Treatment of Functional Constipation</ProtocolTitle><Sponsor>Huazhong University of Science and Technology</Sponsor><StudyType>Interventional</StudyType><Trial id="107223"/><TrialStartDate>2013-02-28 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>4+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy,Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Effects of Ginseng and Ginkgo on Drug Disposition in Man</ProtocolTitle><Sponsor>National Center for Complementary and Alternative Medicine</Sponsor><StudyType>Interventional</StudyType><Trial id="168223"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3774">Sexual dysfunction</Indication><ProtocolAcronym/><ProtocolTitle>Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo</ProtocolTitle><Sponsor>Forest Laboratories Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="179384"/><TrialStartDate>2014-03-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7971">rotigotine (transdermal patch, Parkinson's/restless legs syndrome), UCB</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="20">Pain</Indication><ProtocolAcronym/><ProtocolTitle>Study to Assess Dopamine Receptor Modulation With Rotigotine to Enhance Morphine Analgesia in the Dental Model</ProtocolTitle><Sponsor>East Carolina University</Sponsor><StudyType>Interventional</StudyType><Trial id="184287"/><TrialStartDate>2014-11-30 00:00:00</TrialStartDate><TrialStatus>Not yet recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2+</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="653">Bipolar disorder</Indication><ProtocolAcronym/><ProtocolTitle>Saxenda in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)</ProtocolTitle><Sponsor>The Lindner Center of HOPE</Sponsor><StudyType>Interventional</StudyType><Trial id="299143"/><TrialStartDate>2017-04-26 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="15716">prucalopride</Drug><Endpoint>Safety,Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3797">Gastrointestinal motility disorder</Indication><ProtocolAcronym/><ProtocolTitle>Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH-12852 After Oral Administration in Healthy Male Subjects</ProtocolTitle><Sponsor>Yuhan Corp</Sponsor><StudyType>Interventional</StudyType><Trial id="137804"/><TrialStartDate>2013-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="97846">cycloserine + lurasidone (bipolar depression, suicidality), NeuroRx</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3115">Bipolar II disorder</Indication><ProtocolAcronym>MBD</ProtocolAcronym><ProtocolTitle>NRX-101 for Moderate Bipolar Depression and Suicidal Ideation</ProtocolTitle><Sponsor>NeuroRx Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="325291"/><TrialStartDate>2019-01-01 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Safety</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="404">Constipation</Indication><ProtocolAcronym/><ProtocolTitle>Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)</ProtocolTitle><Sponsor>Alizyme plc</Sponsor><StudyType>Interventional</StudyType><Trial id="18134"/><TrialStartDate>2006-04-30 00:00:00</TrialStartDate><TrialStatus>Terminated</TrialStatus></Row><Row><Ancestry/><ArmCount>3</ArmCount><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="4898">Major depressive disorder</Indication><ProtocolAcronym>NRX-GLX</ProtocolAcronym><ProtocolTitle>NRX101 Glx Biomarker Validation Study</ProtocolTitle><Sponsor>NeuroRx Inc, New York State Psychiatric Institute</Sponsor><StudyType>Interventional</StudyType><Trial id="326023"/><TrialStartDate>2018-11-01 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>Migraine Study in Adolescent Patients</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="45654"/><TrialStartDate>2008-12-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="31482">sumatriptan + naproxen sodium, Pernix/Old API Wind-down</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="3679">Migraine with aura</Indication><ProtocolAcronym/><ProtocolTitle>A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2)</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><StudyType>Interventional</StudyType><Trial id="14054"/><TrialStartDate>2006-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="44364">buspirone</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Serotonin 1A Agonists and Cognition in Schizophrenia</ProtocolTitle><Sponsor>Northwestern University</Sponsor><StudyType>Interventional</StudyType><Trial id="35790"/><TrialStartDate>2003-01-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2593">Miosis</Indication><ProtocolAcronym/><ProtocolTitle>A study to evaluate whether aripiprazole affects pupil contraction and its relationship with pharmacokinetics and pharmacogenetics in healthy volunteers</ProtocolTitle><Sponsor>Hospital Universitario de La Princesa</Sponsor><StudyType>Interventional</StudyType><Trial id="368162"/><TrialStartDate/><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="4211">renzapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="2100">Gastroparesis</Indication><ProtocolAcronym/><ProtocolTitle>A phase II, 12-week, pivotal trial to identify the best dose of renzapride in the treatment of patients with gastroparesis</ProtocolTitle><Sponsor>EndoLogic LLC</Sponsor><StudyType>Interventional</StudyType><Trial id="339701"/><TrialStartDate/><TrialStatus>Planned</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="192">Irritable bowel syndrome</Indication><ProtocolAcronym/><ProtocolTitle>Effects of Aripiprazole on Irritable Bowel Syndrome (IBS)</ProtocolTitle><Sponsor>Poursina Hakim Clinic</Sponsor><StudyType>Interventional</StudyType><Trial id="294588"/><TrialStartDate>2017-04-04 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="NS">Phase not specified</DevStatus><Drug id="10524">almotriptan</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="178">Hypertension</Indication><ProtocolAcronym/><ProtocolTitle>A crossover, double-blind, placebo-controlled, randomized study to investigate the cardiovascular effects of almotriptan, a 5-hydroxytryptamine 1B/1D agonist, in treated patients with hypertension</ProtocolTitle><Sponsor>Pfizer Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="114704"/><TrialStartDate>2002-03-31 00:00:00</TrialStartDate><TrialStatus>Status not specified</TrialStatus></Row><Row><Ancestry/><ArmCount>2</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="7781">aripiprazole</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="468">Obsessive compulsive disorder</Indication><ProtocolAcronym/><ProtocolTitle>The Comparison of Aripiprazole and Quetiapine Augmentation Between Selective Serotonin Reuptake Inhibitors in Refractory Obsessive-Compulsive Disorder</ProtocolTitle><Sponsor>Mashhad University of Medical Sciences</Sponsor><StudyType>Interventional</StudyType><Trial id="169784"/><TrialStartDate>2013-05-22 00:00:00</TrialStartDate><TrialStatus>No longer recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C2">Phase 2 Clinical</DevStatus><Drug id="9943">vilazodone</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="588">Drug dependence</Indication><ProtocolAcronym/><ProtocolTitle>Vilazodone Treatment for Marijuana Dependence</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><StudyType>Interventional</StudyType><Trial id="86371"/><TrialStartDate>2012-08-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C3">Phase 3 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1519">Ileus</Indication><ProtocolAcronym/><ProtocolTitle>Mouth Dissolving Mosapride Tables Enhance Post Cesarean Gut Recovery</ProtocolTitle><Sponsor>Benha University</Sponsor><StudyType>Interventional</StudyType><Trial id="333708"/><TrialStartDate>2018-04-01 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C4">Phase 4 Clinical</DevStatus><Drug id="3658">mosapride</Drug><Endpoint>Safety,Efficacy</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1519">Ileus</Indication><ProtocolAcronym>ILEUS</ProtocolAcronym><ProtocolTitle>Effect of Mosapride on Postoperative Ileus in Patients Undergoing Colorectal Surgery</ProtocolTitle><Sponsor>Hospital Italiano de Buenos Aires</Sponsor><StudyType>Interventional</StudyType><Trial id="171836"/><TrialStartDate>2015-12-31 00:00:00</TrialStartDate><TrialStatus>Recruiting</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Safety,Pharmacokinetics</Endpoint><EndpointReached>Y</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Lurasidone Pediatric Pharmacokinetics Study</ProtocolTitle><Sponsor>Sunovion Pharmaceuticals Inc</Sponsor><StudyType>Interventional</StudyType><Trial id="88405"/><TrialStartDate>2012-06-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="8732">lurasidone</Drug><Endpoint>Pharmacokinetics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>N</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication id="1257">Schizoaffective disorder</Indication><ProtocolAcronym/><ProtocolTitle>Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl</ProtocolTitle><Sponsor>Sumitomo Chemical Co Ltd</Sponsor><StudyType>Interventional</StudyType><Trial id="172841"/><TrialStartDate>2009-05-31 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row><Row><Ancestry/><ArmCount>1</ArmCount><DevStatus id="C1">Phase 1 Clinical</DevStatus><Drug id="81094">F-17464</Drug><Endpoint>Pharmacokinetics,Pharmacodynamics</Endpoint><EndpointReached>N</EndpointReached><HasHealthyVolunteers>Y</HasHealthyVolunteers><HighestDevStatusForInd id="NS">PHASE NOT SPECIFIED</HighestDevStatusForInd><Indication/><ProtocolAcronym/><ProtocolTitle>Brain Imaging Study of F-17464</ProtocolTitle><Sponsor>Pierre Fabre SA</Sponsor><StudyType>Interventional</StudyType><Trial id="91984"/><TrialStartDate>2012-11-30 00:00:00</TrialStartDate><TrialStatus>Completed</TrialStatus></Row></Rowset>